SA98180918A - Nucleic acid and amino acid sequences relating to hellcobacter pylori and vaccine compositions thereof - Google Patents

Abstract

«Nucleic and amino acid sequences related to H. Pylori bacteria» and vaccine formulations including «Summary» The present invention relates to the description of pure or reconstituted preparations of H. pylori polypeptide as well as the description of nucleic acids that encode polypeptides. Note that H.Pylori bacteria peptides are useful for diagnostic and vaccine formulations

Description

A

H. pylori is an amino acid related to bacteria EIS “H. pylori sequences 1 and their vaccine compositions” Full description A: Background of the invention Pylori is a Gram-negative, microphilic bacterium” 116112002016: Pylori The L: for air in the form of letter 5 was discovered and cultured from a human gastric biopsy sample as stated in (Warren, J.R and B. Marshall (1983) Lancet 1 : 1273 - 1275 ; and Marshall et al. M. (1984) Microbios Lett. 25:83-88). ° Strongly linked to chronic gastritis and 'HPylori' bacteria: duodenal ulcers. (As reported in (Rathbone et al, (1986) Gut 27 : 635 - 641) Moreover; Evidence is increasing for a pathological role for B. 11.7101 in non-ulcer indigestion, in gastric ulcer disease, and in Candida 0: gastric tumor as reported in Ua ad (Blaser M. J, (1993) Trends Microbiol, 1 : 255-260) Note that the transmission of bacteria occurs through the mouth, and the risk of infection increases with age, as stated in (Taylor, D.N. and M.J. Blaser (1991) Epidemiol. Rev 13: 42-50).\o Infectious sputum is human and creates an infection in it that usually lasts "H.Pyori" bacteria colonize for decades. Given that the infection with the "11.597011" bacterium is spread all over the developed countries, I have not forgotten about f the globe. The percentage of people infected with this bacteria is in the adult population, while the percentage of people infected with this bacteria in countries is 70.

v The population over the age of twenty years as the developing sue rate is .79 of: stated in (Hopkins R.J. and J.G Morris (1994) Am. J. Med. 97: 265-277). The bacterial factors needed to colonize the infectious environment, and the relative viability of the bacterium, are poorly understood. Examples of oa yall overcoming the body's defense for this © Factors of that supposed ability include the following: urease enzyme, an enzyme that can play a role in: gastric acid as mentioned in (PH) adjusting the pH

Eaton et al., (1991) Infection. Immunol., 59: 2470-2475; Ferrcoro R.L. and A.LEE (1991)

Microb ECol. Health Dis. 4: 121 - 134; Labigne et al., (1991) J. BacteriO 1. 173: \. 1920 - 1931). Bacterial flagellum proteins are responsible for movement across the stigma. As stated in ( Hazell et al., (1986) l.Inf. dis. 153 : 658 - 663 Leying et al., (1992) Mo/,

Microbiol. 6 : 2863 - 2874 and Haas et al., (1993) Mol. Microbiol. 8: 753-760); \e A bacterial toxin that induces the formation of internal cavities in epithelial cells: VacA: As reported in Schmitt W. and R. Haas, (1994) Molecular Microbiol. 12 (2): 307-319); Multiple stomach specific tissue adhesions. As stated in Boren et al., (1993) Science 262 1892 - 1895; Evans et al., (1993) J. Bacteriol. Y. 175: 674 - 683; and Falk et al., (1993) Proc. Nat. / Acad. SCi. 90 2035-203). Multiple available at the present time eradicate infections of bacteria, Ladle, and there are factors: “in the laboratory” (in the glass tube) as stated in, “H.Pyori” (Huesca et, al., (1993) > Zbl. Bakt. 280 : 244 - 252; Hopkins, R.J. and J. 6

Morris, supra). Yo

¢ However, many of these treatments are less than optimally effective in the 'body organism' because of bacterial resistance, and because of the altered drug distribution; And because the patient did not pled] or because the drug was not available, he had enough growth (Hopkins R.J. and J.G.

Morrissura) and combined antibiotic treatment with Bismuth 0 is part of the standard diet used to treat H. pyorn as reported in Malfertheiner, P. and J.

E.

DoMinguez - Munoz (1993) Clinical therapeutics 15 ) ‎Supp.

B:37-48). Recently, the combination of proton pump inhibitors and one antibiotic showed efficacy in fibrosis of duodenal ulcer disease. As stated in: (Malfer theiner, P. and J.

E.

Dominguez, Munoz Swpra) and on Ja LT that methods using antibiotic agents can involve the problem of creating bacterial strains that are resistant to these agents as reported in: Hopkins, R.

J. and J. 6. Morris, supra). Design of modern vaccines that can prevent infection with this bacteria. In the bob (lower stomach mouth), and other related genes, their products, and their uses, including nucleic acids and peptides of the present invention.

0 The benefit of diagnosing and treating H. pylori bacteria located in the bob (lower stomach mouth) and treating other types of any H. pylori bacteria. These mentioned acids and peptides can be used to detect the presence of H.Pylori bacteria in the stomach microbiota “H.Pylori” 1 and the presence of any other types of spiral bacteria in a sample, and they can also be used in

0 Examined compounds for the ability to interfere with the life cycle of H. pylori bacteria or to prevent infection with this bacterium “H. Pylori”. More specifically, “This invention describes combinations of nucleic acids identical to the coding sequences of the proteins of bacteria “11.5710” containing surface or secreted proteases or portions thereof which are capable of

0 Splicing of mRNA from "117100" proteins to prevent translocation or protein transformation. It also describes methods for producing "1157103" proteins or fragments thereof using Galas peptides and DNA (deoxyribonucleic acid) recombination techniques. This also describes the invention of antibodies and nucleic acids useful as probes for detecting infection with "11.7103" bacteria.

,. Treatment of infection with bacteria "11.5101" within the scope of this invention. Type "HPYloA" antibacterial antigens form? Vertical graph describing the antibody standard in the mucous membranes of rats

,. After grafting it with antibacterial antigens "11.5710" type Y.

appearance ? : a vertical graph describing J of the ! © J for immunizing I for my treatment of rat (ny) ron with bacteria “11.3101” with specific antigens dissolved in a buffer of “1150158”. Figure 3 Las Ni vertical drawing describing | to fortify | For my treatment O 13 yall aqueous bacteria “H.Pylori” generates specific antigens dissolved in a buffer containing DOC 0. Fig. 00 : 1 describes the alignment of the amino acid sequence in part of the I sequence of the five protea of “HPYlOM” bacteria (described by the single-letter amino acid code, E: indicated on the N-terminal to C-terminal; left to right) Fig. 1 : describes the P-alignment of the amino acid sequence in part of the 1-sequence of the four T0 proteins of bacterium "1152100" (described by the single-letter amino acid code; (C-terminal J) N-terminal “left to right” . Fig. 1: Bacteria "1127108" (depicted in a single-letter amino acid symbol - shown as Ne C-terminal J) terminal ~~ Vo ; left to right).

v : Description | For more details, an essentially pure or recombinant preparation of all the invention describes an aly with an appearance. The present invention also includes VE: a polypeptide “11.5710” with a reference number with a sequence “HPylor” as well. Essentially pure nucleic acid coded for polypeptide 0 with reference number VE: such nucleic acid is present in sequence reference number 1: . The peptide sequences of "11.0210" according to gl madd described herein are contained in the sequence list, and nucleic acids encoding polypeptides of the invention are contained in the sequence list. another look; The invention describes an essentially pure nucleic acid that encodes (encodes) poly

, 79 : bacterial peptide "11.7101" containing an amino acid sequence with reference number 0 . In another aspect, the invention describes an essentially pure nucleic acid encoding a polypeptide of bacteria “11.7103” containing an amino acid sequence with reference number: 71, such as . It contains a nucleotide with a retrograde sequence number: ? (sus acid

VO in another look; The invention describes a nucleic acid based on Sas, a polypeptide of bacteria “H.Pylori” containing an amino acid sequence with reference number Wi, such as a nucleic acid containing a nucleotide sequence with reference number: 4. another look; The invention describes an essentially purifying nucleic acid encoding a polypeptide of bacteria “11.7101” containing an amino acid sequence with the number m VA: aa as

,. 0: nucleic acid containing a nucleotide sequence from a sequence with reference number 0. in another way; The invention describes an essentially pure nucleic acid encoding a polypeptide: bacterium “11.5108” containing an amino acid sequence of a reference numbered sequence

A

. 0: As nucleic acid including a nucleotide of a reference number sequence. VA (encodes) Poly Sash In another aspect, the invention describes essentially pure nucleic acid a bacterium peptide “11.5710” containing an amino acid sequence of sequence number: reference: .4, such as nucleic acid including a nucleotide sequence From a sequence with a reference number

Yo SAD polypeptide in another aspect “The invention describes essentially pure nucleic acid: a bacterium “1171011” containing an amino acid sequence of a reference number sequence. 8 : As nucleic acid including a nucleotide sequence of a sequence with reference number “AD” in another form;, the invention describes an essentially pure nucleic acid encoding a polypeptide

AY: bacterium "11517100" containing an amino acid sequence of sequence with reference number 0 . 5: As a nucleic acid containing a nucleotide sequence of a sequence with a reference number presenting another manifestation, the invention describes an essentially pure nucleic acid encoding a polypeptide: bacterium "11.7101" ;, containing an amino acid sequence of a sequence with a reference number

Not as a nucleic acid containing a nucleotide sequence from a reference-numbered sequence, AY, of another appearance; The invention describes an essentially pure nucleic acid encoding a polypeptide NO: of sequence with reference number ial bacteria “1115710” containing an acid sequence 11: such as nucleic acid containing a nucleotide sequence of sequence with reference number , AS In another aspect, the invention describes an essentially pure nucleic acid encoding a polypeptide: bacterium "11108" containing an amino acid sequence of sequence with a reference number

NY: as a nucleic acid containing a nucleotide sequence of sequence with reference number AoYL in another aspect, the invention describes an essentially pure nucleic acid encoding a polypeptide containing an amino acid sequence of sequence number “H.Pylon” bacteria

Reference AT: As nucleic acid comprising a nucleotide sequence of the sequence with reference number AY In another aspect, the invention describes an essentially pure nucleic acid encoding a polypeptide of bacteria "1137100" containing an amino acid sequence of the sequence with reference number:

NE: as acid 5080 (containing a nucleotide sequence of a sequence with reference number VA 0 showing another manifestation; the invention describes an essentially pure nucleic acid; encoding a polypeptide

AA: contains an amino acid sequence from the sequence with reference number "H Pylori" bacteria. 01: such as nucleic acid containing a nucleotide sequence of a reference number sequence in another appearance; The invention describes an essentially pure nucleic acid encoding a polypeptide

AS: Bacteria "11.5103" containing an amino acid sequence of Pasture Sequence No. 0 . 11: As a nucleic acid containing a nucleotide sequence of a reference sequence number in another form, the invention describes an essentially pure toric acid encoding a polypeptide

Aut from reference sequence number Saal bacteria "11.2101" containing an acid sequence. 17 : Such as nucleic acid containing a nucleotide sequence of reference sequence No. VO with a GAT appearance The invention describes a basically pure nucleic acid rum polypeptide "11,10" containing an amino acid sequence of reference sequence No. 40: , Such as nucleic acid containing a nucleotide sequence of reference sequence number: 8. Another manifestation;, The invention describes purified nucleic acid on a base mutation encoding a bacterium polypeptide "11.7101" containing an amino acid sequence of reference sequence number: ,. 19 : As nucleic acid containing a nucleotide sequence of reference sequence number AYYL in another form, the invention describes an essentially pure nucleic acid encoding a polypeptide

AF: Bacteria "11.7101" containing an amino acid sequence from reference sequence no.

A. Like a nucleic acid containing a nucleotide sequence from a reference sequence with the number: .? . another look; The invention describes an essentially pure nucleic acid encoding a bacterial polypeptide “11.7101” containing an amino acid sequence of reference sequence number AL such as nucleic acid containing a nucleotide sequence of reference sequence number: ?. 0 in another look; The invention describes essentially pure nucleic acid encoding a bacterium “H.Pylori” polypeptide containing an amino acid sequence of reference sequence number: A0 such as nucleic acid containing a nucleotide sequence of reference sequence number: ?? . In the form of SAT;, the invention describes essentially pure nucleic acid; Encoding a bacterial polypeptide "11.0101" containing an amino acid sequence of reference sequence number AN 0 such as nucleic acid containing a nucleotide sequence of reference sequence number: ?? . In terms of “SAT” the invention describes essentially pure nucleic acid encoding a polypeptide of “H.Pylori” bacterium containing an amino acid sequence of reference sequence No. ;? . another look; The invention describes essentially pure nucleic acid encoding polypeptide 0 bacteria: 110710" containing an amino acid sequence of reference sequence number AN, such as nucleic acid containing a nucleopeptide sequence of reference sequence number: YO in another appearance, The invention describes an essentially pure nucleic acid encoding a polypeptide of bacterium:11710" containing a nucleotide sequence of sequence reference number:1. HAT appears; The invention describes an essentially pure sus acid encoding an amino acid sequence Ye of sequence reference number: 01, as nucleic acid containing a nucleotide sequence of reference sequence number: 7? .

AR

another; The invention describes an essentially pure nucleic acid encoding a polypeptide alias: bacterium “11.1103” containing an amino acid sequence of reference sequence number; Such as nucleic acid containing a nucleotide sequence of reference number 1: /?. in another form; The invention describes an essentially pure nucleic acid encoding a polypeptide 0: of bacteria “11.7101” containing an amino acid sequence of sequence reference number: ; Such as nucleic acid containing a nucleotide sequence of sequence reference number 01 Y4. The invention describes an essentially purified nucleic acid encoding a SAT polypeptide with appearance: bacterium “11.7100” containing an amino acid sequence of sequence reference number 0 : ; As nucleic acid containing a nucleotide sequence of sequence reference number 01"00 in another aspect; the invention describes an essentially pure nucleic acid encoding a polypeptide: bacterium "11.5110" containing an amino acid sequence of sequence reference number 9 04, such as nucleic acid containing a nucleotide sequence of a reference sequence numbered: 1?, in the form of SAT, the invention describes an essentially pure gust acid encoding a polypeptide of bacteria "11.7101" containing an amino acid sequence of a reference sequence numbered: , For example, nucleic acid containing a nucleotide sequence of reference sequence number: ??.. In appearance HAT The invention describes an essentially pure nucleic acid encoding a polypeptide: containing an amino acid sequence of sequence with reference number “HPylon” bacteria 00: Such as a nucleic acid containing a nucleotide sequence of a sequence with a reference number VY Red

\Y with an AT appearance The invention describes an essentially pure nucleic acid encoding a bacterium “H.Pylori” polypeptide containing an amino acid sequence of sequence reference number : 04 ; such as nucleic acid containing a nucleotide sequence of sequence with reference number: YO in another appearance; The invention describes a substantially pure nucleic acid encoding a polypeptide: of bacteria “117100” containing an amino acid sequence of sequence reference number 0. Such as nucleic acid comprising a nucleotide sequence of a sequence with reference number: 16?, 4 In another aspect, the invention describes an essentially pure nucleic acid encoding a polypeptide

Av. Bacteria "11.5100" containing an amino acid sequence from the sequence with a reference number. such as nucleic acid containing a nucleotide sequence of sequence with reference number: 7?0 in another appearance; The invention describes a virtually pure nucleic acid encoding a bacterial polypeptide “11.3103” containing an amino acid sequence of sequence with reference number: WD as nucleic acid including a nucleotide sequence of reference sequence number: CYA in another appearance “The invention describes acid Virtually pure nucleic acid encoding a bacterial polypeptide “H.Pylori” containing an amino acid sequence of reference sequence No. MWY: Ex. Nucleic acid including nucleotide sequence of reference sequence No.: 4? The invention is a virtually pure nucleic acid encoding a polypeptide of bacteria "1117103" containing an amino acid sequence of a reference sequence: such as a nucleic acid containing a nucleotide sequence of a reference sequence No. 117: headquarters

L.E. .? In appearance AT, the invention describes pure nucleic acid on an actual live cell encoding a bacterium polypeptide “11.7107” containing an amino acid sequence of reference sequence number: VME as nucleic acid containing a nucleotide sequence of reference sequence number: 41.

VY

In another aspect, the invention describes a virtually pure nucleic acid encoding a bacterial polypeptide such as, 119: containing an amino acid sequence of reference sequence number “H.Pylor”

EY: a nucleotide containing a nucleotide sequence of a reference sequence number “In another aspect, the invention describes a virtually pure nucleic acid encoding a bacterial polypeptide such as, 116: containing an amino acid sequence reference number “HPylori” 0 . Nucleic acid comprising a nucleotide sequence of a reference sequence number: ?; In another aspect, the invention describes a virtually pure nucleic acid encoding a polypeptide: bacterium “11.7100” containing an amino acid sequence of a reference number sequence. 5:; such as nucleic acid containing a nucleotide sequence from a sequence with a reference number MWY in another appearance; The invention describes a virtually pure nucleic acid encoding a bacterial polypeptide 0 terminal containing an amino acid sequence of reference sequence number: 118; “H.Pylori”. 56: Such as nucleic acid including a nucleotide sequence of a reference sequence number in another appearance;

CEN a nucleic acid including a nucleotide sequence of a reference sequence No. Vo encodes a polypeptide las The invention describes a pure nucleic acid in the form of “GAT” with appearance: bacterium “11.1030” containing an amino acid sequence of reference sequence No. ‎ . as toric acid containing a nucleotide sequence of sequence reference number: 7; VY. The invention describes a virtually pure nucleic acid encoding a bacterium “SAT” polypeptide of appearance , 01 containing an amino acid sequence of sequence reference number “11.5210” YX. . 88: Like a nucleic acid containing a nucleotide sequence from a sequence with a reference number

In another aspect, the invention describes a virtually pure nucleic acid encoding a polypeptide of bacteria,; 1: containing an amino acid sequence of a reference number sequence “]]. . . 5: such as nucleic acid containing a nucleotide sequence of Reference-numbered sequence “HLPylori” In another aspect, the invention describes a virtually pure nucleic acid that encodes a polypeptide as an acid, WY: containing an amino acid sequence of a reference-numbered sequence °

Nuclear containing nucleotide sequence of sequence with reference number: 0. In another aspect “the invention describes a virtually pure nucleic acid encoding a polypeptide of bacteria “H.Pylori” containing an amino acid sequence of reference number: AYE as nucleic acid containing a nucleotide sequence of sequence reference number: 00: .

0 in another look; The invention describes a virtually pure nucleic acid encoding a bacterial polypeptide “11.5710” containing an amino acid sequence of sequence reference number: 0, such as nucleic acid containing a nucleotide sequence of sequence reference number “LOY:” in another aspect; The invention describes an essentially strong nucleic acid encoding a bacterium polypeptide “11.7101” containing an amino acid sequence of the reference number sequence:

ATT 0 as nucleic acid containing a nucleotide sequence of sequence with reference number LOY: in appearance GAT The invention describes a virtually pure nucleic acid encoding a bacteriophage polypeptide “7” containing an amino acid sequence of sequence reference number: 7, such as A nucleic acid containing a nucleotide sequence of a reference sequence number: 4. Another manifestation “The invention describes a virtually pure nucleic acid encoding a bacterial polypeptide

¥. "11.7100" contains an amino acid sequence of reference sequence number: 14, such as nucleic acid containing a nucleotide sequence of reference sequence number: 99 .

\o In another aspect, the invention describes a virtually pure nucleic acid encoding a bacterial polypeptide such as WA: containing an amino acid sequence of reference sequence number “H.Pylori”. 96: nucleic acid containing a nucleotide sequence of sequence With a reference number The invention describes an actually protective nucleic acid that encodes a polypeptide of bacteria AT with the appearance of , 7.: containing an amino acid sequence of the reference number "11.100" 0. Like a nucleic acid including a nucleotide sequence of the sequence Reference No.: LA In another aspect, the invention describes a virtually pure nucleic acid encoding a polypeptide of bacteria such as , 171 containing an amino acid sequence of reference sequence No. "H.Pylori"

OA: nucleic acid containing a nucleotide sequence from a reference number sequence of 0 with another appearance; The invention describes a virtually pure nucleic acid encoding a bacterial polypeptide “H Pylori” containing an amino acid sequence of reference sequence number: APY as a nucleic acid including a nucleotide sequence of sequence reference number: 94. With the appearance of GAT the invention describes acid Essentially pure nucleic acid; a bacterium polypeptide encodes “11.1103” containing an amino acid sequence of sequence with reference number: .0 : as nucleic acid including a nucleotide sequence of reference sequence number ATT NO The invention describes substantially pure nucleic acid GAT polypeptide with appearance ATE encodes bacterium "11.7108" containing an amino acid sequence of a reference sequence 60: a nucleic acid containing a nucleotide sequence of a sequence number with another appearance, the invention describes a virtually pure nucleic acid Encodes a polypeptide of bacteria, 35: containing an amino acid sequence of sequence reference number “112100” YX. Like nucleic acid, including a nucleotide sequence of sequence reference number: 67 ;

Other glia;, The invention describes a substantially pure nucleic acid encoding a bacterium polypeptide “11.5108” containing an amino acid sequence of sequence reference number: 1; Like a nucleic acid containing a nucleotide sequence from a reference sequence number: 17. In terms of HAT the invention describes an essentially pious nucleic acid; encodes a polypeptide

: Containing an amino acid sequence of reference sequence number "HPylori" bacterium 0. 14: Like a nucleic acid containing a nucleotide sequence from a reference sequence number, 177, in another appearance; The invention describes a virtually pure nucleic acid encoding a bacterial polypeptide such as WA: containing an amino acid sequence of reference sequence number "111". 19: A nucleic acid containing a nucleotide sequence from a sequence with a reference number

In another aspect, the invention describes a virtually pure nucleic acid encoding a bacterium polypeptide “H.Pylori® containing an amino acid sequence of sequence reference number: 79, as nucleic acid including a nucleotide sequence of sequence reference number: 6 In another aspect, the invention describes an essentially pure nucleic acid encoding a polypeptide of bacterium “117101” containing an amino acid sequence of the reference number sequence:

VEL VO Like a nucleic acid containing a sequence of reference number: 14. , Like a nucleic acid containing a nucleotide sequence of a reference number: 17 . In the “SAT” appearance, the invention describes a virtually pure nucleic acid encoding a polypeptide of the bacterium “H.Pylori” containing an amino acid sequence of reference sequence number: 150, as nucleic acid including a nucleotide sequence of reference sequence number: 18.

.* in another look; The invention describes a virtually pure nucleic acid encoding a polypeptide of bacteria “H.pylori” containing an amino acid sequence of reference sequence number: 7, as nucleic acid including a nucleotide sequence of sequence reference number: 19.

7 For the appearance of the HAT;, the invention describes a virtually pure nucleic acid encoding a polypeptide of the bacterium “H.Pylori” containing an amino acid sequence of sequence with reference number: 157, such as nucleic acid including a nucleotide sequence of sequence with reference number: 0. .

Z | In the form of HAT, the invention describes a virtually pure toric acid encoding a bacterial polypeptide

HoPylor | 0 containing an amino acid sequence from Seq reference number: 46 ; Like a nucleic acid containing a nucleotide sequence of its reference number sequence 1: . In the “HAT” form, the invention describes a physically strong nucleic acid encoding a polypeptide of “Ho Pylori” bacteria containing an amino acid sequence of sequence reference number: 49; as a nucleic acid including a nucleotide sequence of sequence reference number: 7.

In another aspect, the invention describes a virtually pure nucleic acid encoding a polypeptide of “Ho Pylori” bacteria containing an amino acid sequence of reference sequence number: 1476, as nucleic acid including a nucleotide sequence of sequence reference number: 7. But Particularly preferred is an isolated nucleic acid that includes a nucleotide sequence encoding a bacterial cell envelope polypeptide of type "11.5710" or part thereof.

0 nucleic acid is selected in the group formed by the sequence with reference number: 7; Sequence numbered YO , From sequence referenced EA : Sequence referenced : 1 , Sequence referenced : 01 ; sequence with reference number: #8; The sequence with the reference number: 717, the sequence with the reference number: 1 ; Sequence with reference number: 74 , Sequence with reference number: 08 ; serial reference number: 8;

YL Sequence with reference number VR Sequence with reference number YA: Sequence with reference number: .? PR Sequence with reference number: IS Sequence with reference number: 0;* Sequence with reference number: 0 , Sequence with reference number: 08 , Sequence with reference number:

VA

14: The sequence with the reference number: 47, the sequence with the reference number. 0 Reference numbered sequence , 11 : referenced sequence EA : referenced sequence Referenced sequence : nah , 17 : referenced sequence , 00 : reference The sequence with the reference number: © , the sequence with the reference number: 6 , the sequence with the number ' . 49 : Sequence with reference number Ph 11 : Reference 6 : Sequence with reference number 0 is a bacterial cell envelope polypeptide of type "0M1171" or SAT fragment embodiment; Or part thereof “HPylori” is a polypeptide of the inner cell membrane of bacteria encoded by the DNA selected from the group composed of the sequence with . 48: reference number: 7, the sequence with the reference number: 19, the sequence with the reference number; A bacterial cell envelope polypeptide of type "11.5100" or SAT fragment with embodiment 0 of a part encoded by "HPylor" thereof is an outer membrane polypeptide of bacteria: by nucleic acid selected from the group composed of the sequence with Reference: Sequence with reference: 40, Sequence with reference: 01, Sequence with reference: AY, Sequence with reference: 7; 17: Reference: 9? , the reference-numbered sequence the reference-numbered sequence: 4? , sequence ref: 09 , sequence ref 0: 8 , sequence ref: 14 , sequence ref: 8 ; sequence ref: 0X: sequence ref: .? , sequence with reference number : 04 , sequence with reference number : 81 , sequence with reference number : 08 ; sequence with reference number : PIES : sequence with reference number , 0 : sequence with reference number ; 10: sequence with reference number PE: sequence with reference number FR 14: reference. 70: the reference-numbered sequence

in another embodiment; The outer membrane polypeptide of “HPylori” bacteria or of the “ce” fragment is a polypeptide “11.9101” containing a terminal phenylalanine residue and a terminal tyrosine group in the form of © or its parts encoded by nucleic acid selected from the group consisting of sequence with reference number 0: ; Sequence with 0 reference: ?4, Sequence with reference number: PRT, sequence with reference number: 47; Sequence with reference number: ,11 Sequence with reference number 0: . In yet another embodiment, the outer membrane polypeptide of bacteria “11.5710” or part thereof is a polypeptide of bacteria “HPYlOM” containing a terminal ethylalanine residue or a portion of it encoded by the nucleic acid selected from the set of 0 sequence With the reference number: 16, the sequence with the reference number: 49, the sequence with the reference number: 9? , the sequence with the reference number: ? , the sequence with the reference number: no ; Sequence with reference number : 74 , Sequence with reference number : PET Sequence with reference number : 8 , Sequence with reference number : 19 PR Sequence with reference number : 78 , Sequence with reference number : 7 , Sequence with reference number :? , sequence with reference number 1 : 04 , sequence with reference number : 01 ; The sequence with the reference number: 98. But the preferred form of pals is an isolated nucleic acid containing a nucleotide sequence encoding a polypeptide The from bacteria 11.9101 of part is . Such nucleic acid is selected from the group formed by the sequence with the reference number: VY, the sequence with the reference number: ?? , sequence with reference number 00: , sequence with reference number: ? ; Sequence with reference number: 4 PR Sequence with reference number: 4 , Sequence with reference number: AY Sequence with reference number: ?? , the sequence with reference number: 4? , the sequence with the reference number: 01?, the sequence with the reference number: ?? . Sequence with reference number: 4? , serial numbered reference 1: PR sequence numbered

Y.

Reference: 78, the sequence with the reference number: 4, the sequence with the reference number: 49; Sequence reference number: PET Sequence reference number: 46 , Sequence number

Reference: 59 , sequence with reference number OF: ; sequence with reference number: 54; Sequence with reference number PR 0: Sequence with reference number: 17; numbered sequence

0 reference: 67 , the sequence with the reference number: 68 , the sequence with the reference number: 16 ; The sequence with the reference number: 17, the sequence with the reference number: 68. Particularly preferred is an isolated nucleic acid containing a nucleotide sequence encoding a cellular polypeptide of Bacterium 11.1031 or part thereof. Such DNA is selected from the set made up of the sequence with reference number 11; numbered sequence

0 Reference 19: ; The sequence with the reference number: .? , the sequence with the reference number: ?? ; Sequence Reference: YE Sequence Reference: 1 ; sequence with reference number: 1, sequence with reference number: 27, sequence with reference number: 9; The sequence with the reference number: 60 , the sequence with the reference number: 64 , the sequence with the reference number: 14 , the sequence with the reference number: ./, the sequence with the reference number: 77 .

V0 and particularly preferred is Bacteria cell envelope polypeptide 11.5103 isolated or purified or part thereof; Where the polypeptide is selected from the group consisting of: the sequences, each of which includes a reference number from the following reference numbers CAS AYN LAA VA etc Ka Lakhla GAY h

YL in another embodiment;, being a HoPlor cell membrane polypeptide or part thereof a membrane polypeptide Als of Bacterium 11.108 or part thereof selected from the group

Consisting of sequences, each of which includes a reference number of the following numbers: 76

analyzer

in another embodiment; The polypeptide of bacteria cell envelope 11.0107 part of is a

An outer membrane peptide of H.plori bacteria, or part thereof, selected from set 0 of sequences each containing one of the following reference numbers: 849

TAKE CLICK HERE TO LOW NO AYA CANT TAKE YOUR VY ON ALL THROUGH TO ALL WL AVL ON AY. cA

In another embodiment, the polypeptide is an outer membrane of bacterium 11.5910 or part thereof

It is a bacterial polypeptide 11.5103 containing a terminal residue of phenylalanine A and a terminal tyrosine group in the form of 0 or 3 parts selected from the I of group

Consisting of sequences, each of which includes a reference number

The following: No place for no other

In another embodiment, the polypeptide is an outer membrane of B. 1157103 or part thereof

It is a polypeptide with pH1157108 containing a terminal residue of the Vo-althene filament or a dia fragment selected from the set of sequences that each includes

Including a reference number from the following reference numbers: 45 without a solution

Why don't you leave all the workers for a tireless situation?

Preferred in pad form is a polypeptide secreted from B. 1137105 isolated or purified.

or the Ls fraction where is a polypeptide selected from | for group | It is composed of the YS sequences, each of which takes a reference number from the following reference numbers: Ft16.301.

To roll as long as you unscrew all the lamellas, all the lamellas, all the AMA JK

You eat all of our ATA ATA files

YY

Bacteria cellular polypeptide : 11.3710 isolated or repurified or sa 0 which is particularly preferred where the polypeptide is selected from the set of sequences Ge part ECD VOU of which each sequence takes a reference number from the following reference numbers : Fah

VET NETL VEY. The present invention relates to any member or individual fragment of a bacteriophage polypeptide-3 or to a nucleic acid encoding such member or fragment of the previously defined groups of poly Bacteria peptides: 11.10. In another aspect, “the invention describes nucleic acids capable of binding mRNA from bacteria 3. Such a nucleic acid is able to act as an antisense nucleic acid for the purpose of controlling the transmission or transformation of mRNA from bacteria: 11710. Another feature describes a nucleic acid that is able to bind specifically to the DNA of bacteria3. Note that these nucleic acids are referred to here as complements and have utility as sensors and as retention reagents. another look; The invention demonstrates an embodiment system containing an open-read structure corresponding to the Vo nucleic acid of Bacteria 11579108 . The DNA also contains a control sequence that corresponds to any intended host. Note that the embodiment system is useful in making polypeptides match the nucleic acid of HPylori bacteria. In another aspect, the invention highlights a cell transferred with an embodiment system for the production of H.Pylori polypeptides. 0 in another look; The invention highlights a method for generating antibodies against Streptococcus 1 polypeptides that are capable of binding; In the form of esd bacteria polypeptides

YY

. H.Pylorn and such antibodies have their usefulness as reagents for immunoassays to evaluate grimaces. H.Pylori and distribution of specific antigens for bacteria Y | In another aspect, the invention shows a method of generating vaccines to immunize a person against bacteria, and the method of immunization includes immunizing a person with a bacterial polypeptide. 11.1710 0 at least one of the present invention, such as a polypeptide surfactant or a polypeptide. H.Pylori Secreted Peptide; Or an effective protein thereof, and a pharmaceutically acceptable carrier. And such vaccines. Preventive benefits l/s have therapeutic benefits in another aspect; The present invention provides a method for generating a vaccine containing a modified heterogeneous polypeptide such as a surfactant polypeptide or HPylo polypeptide of bacteria 0. secreted or active protein thereof; and a pharmaceutically acceptable carrier. The invention demonstrates a method for evaluating a compound such as a polypeptide; To find out its ability to bind to a bacterial polypeptide, this method includes: contacting the candidate compound with a bacterial polypeptide 3 and determining the extent to which the compound can bind or interact with a bacterial polypeptide 11.710: Ae, and therefore the compounds that bind to bacteria: 11710 are the pathogens . HPylor as catalysts or fluids for the bacterial life cycle. These calibrations can be performed in the laboratory (glass tube) or in the body of a living organism. In another way; The invention demonstrates a method for evaluating a compound; Such as a polypeptide, such as part of a polypeptide of an incubating cell, to see its ability to bind with the nucleic acid of Y bacteria. (deoxyribonucleic acid; or RNA or DNA, such as acids,.

ve ribonucleic acid). This method includes: contacting the candidate compound with nucleic acid of bacterium 11.7105 and determining the extent to which the compound can bind or interact with the polypeptide of bacterium 1157108. Therefore, compounds that are associated with bacteria are 11359103. It is for the bacterial life cycle. These Like candidates can be performed as catalysts or as catalysts. Tests ex vivo or in vivo 0 The invention highlights polypeptides of bacteria 1117108, preferably a formulation that is virtually purified from

HPylori Polypeptide Bacteria 11.9103; or a recombinant polypeptide from bacteria and in preferred embodiments: the polypeptide has biological activity, and the polypeptide has an amino acid sequence homologous or homologous to .716 that no;00 or 7A. NEVA, 8A, or 748 with an amino acid sequence of the invention contained in the list of sequences. Preferably include a sequence match of 7710 with an amino acid sequence of the invention contained in the sequence list; Most preferably, it shall include a sequence match ranging from 7497-794 to an amino acid sequence of the invention contained in the sequence list. It is also preferable that the polypeptide contains 1 amino acid sequence that has the same basic availability as the same amino acid sequence of the invention included in the sequence list. It is preferable that the polypeptide be at least co 8.7.0 ...0 s of amino acid residues in length, and it is preferable that the polypeptide contain at least Ve, more preferable, Yo more and more preferable 00.0000 At least or Vou is a contiguous amino acid residue of the invention contained in the sequence list. 00 In another preferred embodiment 0 the invention includes an amino acid sequence that differs in sequence conformity by about -77 to about 7/4 from the amino acid sequences of bacteria:11.5710 of the invention included in the sequence list.

Yo in preferred embodiments: is a bacterial polypeptide 11.5101 encoded by nucleic acid of the listed invention, or by a nucleic acid containing 40b, 44/t, 78% homology to the nucleic acid of the listed invention » 78. ZA . 010. 7/1. the least. in serial list in HPylon acid sequence in preferred embodiment; The polypeptide © differs significantly from the sequence of the invention listed in ASTIN co YL YN amino at residue fragments formed where the polypeptide Ja appears on the sequence list. But the differences, on any bacteria 11.9103 biological activity of bacteria: 11.5710 such as polypeptide retention occurs in the form of HPylor bacteria: 11.5910 biological activity of polypeptide bacteria. Natural 0 Polypeptide contains all or part of the Wade acid sequence in embodiments of the Amity Listed Invention fused; In my interpretation; for the remaining 'O' DNA segments from an extra amino acid; Preferably for the remaining parts encoded by related to genetic factors that encode DNA or ? related to genetic factors; for . The sequence of the invention included in Sequence Listing 1 and in other preferred embodiments the Bacterial polypeptide 11.7108 is a solute recombinant protein containing a first Bacterial polypeptide fragment:11.5910 and on a second polypeptide fragment such as a second containing polypeptide fragment An amino acid sequence unrelated to bacteria 11.5710 and the second polypeptide fragment can be, for example, the linker or DNA catalyst domain of the sf domain, “glutathione-S-transferase” of

for the polymerase. In a preferred embodiment the molten protein may be used in an assay. Polypeptides of the invention include those polypeptides that ans as a result of successive transcription events. As a result of the successive RNA splicing events; As a result of el Sl © transformational and post-translational recombinant, the invention also includes an immunogenic component containing at least one HPylon bacteriological polypeptide in a heterogeneous preparation with the immunogenic component being able to elicit an immune response specific to a bacteriophage polypeptide 11.7103 such as a humoral response , an antibody response or a cellular response. In preferred embodiments the immunogenic component contains at least 0 immunogenic determinant of the serially listed polypeptide of the invention. In another aspect, the invention provides a truly pure nucleic acid containing a nucleotide sequence encoding a polypeptide of bacterium 11.7105. In preferred embodiments: the encoded polypeptide has biological activity, and the encoded polypeptide contains an amino acid sequence identical in ratio 0716 70/6 745 745 07456 754 or 745 with the amino acid sequence of the invention included in the sequence list, and the encoded polypeptide contains Basically an amino acid sequence. The same amino acid sequence of the invention included in the list of sequences and the encoded polypeptide is approximately 0.77.0069 0..., or .09 amino acids in length, and the encoded polypeptide also includes at least 0, preferably at least Ve More preferred Yo at least YL preferred more and more .5 at least 00. 1 , or You are conjugated amino acids of the invention listed in the sequence list. In preferred embodiments: the nucleic acid of the invention is the one listed for sequence.

Yv. with the amino acid sequence of the invention listed in the sequence list in a preferred embodiment “the encoded polypeptide :11.710 differs (such as varies by an amino acid substitution, addition or deletion of at least one remaining portion of an amino acid) in one or more of the portions remaining for sequence 000072701 an amino acid sequence at | is where : Ja shows the invention listed by the sequence . But the differences are at 0

Jia HPylor Polypeptide Bacteria 11.0710 Encoded Biological Activity for Bacteria

H.Pylori enzyme retention bacteria 11.2710 encoded biological activity of bacteria. naturally occurring in preferred embodiments the encoded polypeptide contains all or part of the sequence of an amino acid of the invention listed in the sequence list fused and in an interpretive framework to the remaining 0 or 5 DNA fragments of an additional amino acid; Preferably for the remaining parts encoded by the genetic factor that encodes the DNA sequence ? related to genetic factors. The invention listed for sequence contains an HPylori sequence in preferred embodiments will contain bacterium nucleic acid such as at least one transcriptional promoter or transcriptional promoter sequence; regulatory pls 1 render or sequence the Jiao gene 11.7710 Operationally linked to a bacterial gene sequence. Bacteria 11.7101 suitable for embodiment in a recombinant host cell and in another embodiment after; The nucleic acid encoding the bacterium polypeptide of the invention is hybridized, under strict conditions, to a probe nucleic acid corresponding to at least 3 of the eight consecutive chlorotides of the invention listed in the sequence list, more preferably 0

Ya

. At least one consecutive nucleotide of the invention listed in the sequence list 11 corresponds to, preferably more than ; that matches with .? At least one consecutive nucleotide of the invention included in the sequence list, and it is more preferable that it matches .5 nucleotides. A succession of the invention listed in Sequence Table 0 in a preferred embodiment; Nucleic acid encodes a peptide that differs by at least one amino acid residue from the sequences of the invention included in the list of sequences. In the Judie embodiment, the tRNA differs by at least one nucleotide from the nucleotide sequence of the invention included in the sequence list that encodes amino acids of the invention listed in the sequence list. 0 in the appearance of SAT. The invention includes: a vector containing nucleic acid encoding a different bacterium polypeptide 11.2710 or a different bacterium polypeptide 11.7101 as described herein and a host cell infected with the vector; And a method for producing HPylori recombinant polypeptides or bacterial polypeptides: 11.9710 different, including Jie cell culture by la culture, and HPylor bacteria isolation or bacterial polypeptide isolation. Isolation from the cell or from a different cell culture medium Jia HPylori 0 The invention is a purified recombinant nucleic acid containing a match with what 5c in another appearance in the role of the number of the shelf of the sqn 4 with the sequence of the invention listed in . The list of sequences contains a oligonucleotide (Tagan oligome). The invention also provides a purified probe or YL nucleotide. The oligonucleotide contains a region of nucleotide sequence that hybridizes under strict conditions to A sequence nucleotides of the sense or antisense sequence of the invention included in the sequence list; Or mutants (mutants) of them occur naturally. in

Ya favorite avatars; The probe or grader has a rating group attached to it. This ¢ ER Ie (0 for blink Ls) can be a radioisotope 'compound of haan 1 descriptor group and less than A' and/or an enzyme cofactor. Preferably, the oligonucleotide should be at least nucleotides in length. The invention also provides. POLY TPR PRINS SO IPR Bacteria peptide 11.0710 isolate encoded with an amino acid hybridized under 0 hybridization conditions. P. 5) DNA DNA included in the list of sequences, polypeptide, add DNA or RNA, as well as amino acids such as Id of choice I, according to the invention. This includes nucleic acids with double filaments, in addition to containing fuses. coding and antisense singular; From which the HPylor genome sequences were arranged, a bacterial strain was placed: (related to the group of genetic factors) cascading sequences in Americon Type Culture Collection (ATCC # 55679, deposited by Genome Ther a reutic, Cor Poration, 100 Beaver street, Waltham, MA 02154) as strain HP-J99. The invention also includes: allelic changes, natural mutants, mutants

O | 2 high Lk strains hybridized under induced DNA conditions with 0 acid-encoded proteins Vo: (For definitions of high and low stringency, see Current Protocols in Molecular Biology, John wiley & Sons, New York, 1989, 6.3.1 - 6.3.6 and 6.4.1-6.4.10,) The antiserum la coli is bound 3 times by antiserum | dada for reference here and poly | X. An active site or Lala, H.Pylori bacteria polypeptides for the binding domain of bacterial polypeptides: 11.5910 The invention also includes parts that are preferably biologically active parts, these parts and other polypeptides referred to

Here as homologues or heterogeneous polypeptide HPylori bacteria. The putative functions of several polypeptides of Streptococcus :11210 have been determined according to the invention as shown in Table 1. Accordingly, uses of HPylor bacterial polypeptides based on these defined functions, in addition to other functions as described herein, fall within the scope of the invention. Furthermore it . The present invention includes HPylon bacterial polypeptides distinct from what is shown in Table 1 following la, including H.Pylori cell envelope proteins and 11.7910 “elas pally” secreted proteins of H.Pylori bacteria. 0 also. Note that members of these groups were exposed by research 31.81 to homogeneity and by research on individual secretion or hoof protein transmembrane. The polypeptides bound by significant conformation to the polypeptides of Table 1 are also considered to be arranged in the pattern of isomers shown in Table 1 .

1 Table Z 0 AA N M

AT Inner membrane Ta09s752.c3.96 | 25 - 78 82000020 | [

AZT final residue

Bepiio0s_seesarsz 21 1# 7] 89 5:50 “slashing” 2 + 88

YY

1 affiliated lodge SS terminal tyrosine cluster [ASVahomolgy |] 020806015083195 8-8 | 17] 0

Ad Other cel envelope proteins 04cpTi202 20415937 225 |B] 79] 04eeTTT08 3906963 17 | 5] Tg] [5 SECRETEDPROTENS | — — 052e30220_14570443 2 04 | ©] #7] 06cp30603 2772578 146 | 73] 8g] hp8p22217 23564012 5 | Be] 13]

C OTHER CELLULAR PROTENS

os] 23 - A hp2p10272_34042518_f1_2 hp5e15211_25411557_c1_22 hp5p15641_3907968_f1_3 | 26) 99] 60] 133] ‎hp6p10509_14642217_c2_17 ' ‎hp6p80503_20964382_f2_11 | 69] 142] hp7e10192_5917593_f1_2 hp6p10509_14642217_c3_25 au 3 for 1 : "01" 5 . - . - PO] wl Lale 3 in Gedo: “01” represents a sequence with a nucleotide reference number. And “aa” represents a sequence with an amino acid reference number. Definitions:

0 The terms “purified polypeptide”, “isolated polypeptide” and “pure L-reaction preparation of a polypeptide” are used interchangeably. bad . It is preferable, pls, to other proteins, lipids, and amino acids in which it occurs in a form

ا 4 0 - . . PE is normal. It is preferable that the polypeptide be separated from substances such as: antibodies or

0 origin of the gel » Joa polyacrylamide, used to purify it. preferably; That the polypeptide constitutes at least Veco Yeo 82 or 039780 Bla of purified I preparation and preferably ¢ that contains | For a product: I have enough peptide for the serum, C, aal, and C-chain protein, at least, for a night microgram | ¢ of | Lili peptides ¢ have at least 0.000 milligrams of polyurea L. Fa Ee is not added, so 0 indicates

\o The terms “purified polypeptide,” “isolated polypeptide,” and “a preparation purified from nature or produced by DNA recombinant techniques [alas] are as described herein.

Ye, for example, is an “isolated” or “purified” protein or a biologically active protein thereof that is essentially free of cellular material or of any other contaminating proteins from a cell or from a source of chemical precursors or from tissue derived Sad Of it bacteria protein: 11.710, or chemical free or from other chemicals when it is chemically synthesized. Also, the term “really free of cellular substance” includes preparations of the protein of bacteria 1157103, in which the protein is separated from the cellular components of cells isolated from or produced from them by a recombinant method. one embodied; The term “already acellular free” includes preparations of Bacteroides :11.0710 , including less than .77 (dry weight) of non-bacterial protein :11.5710 , (herein referred to as “contaminated protein” preferably less of AST less than .77 of non-bacterial protein :11.5710 , and still preferred LAST 0 most preferred of all, less than I <I 1159108 about +73 of non-bacterial protein of about 70 non-bacterial protein :11710 , And when a bacterial protein is produced by recombination, it is preferable a, or the production of a biologically active protein 1 also, basically, to be free from a culture medium, that is, to represent its culture medium, and the most preferred of all is about, 7101 Less than LAST Preferably 0. loa Less than 1 Less than 7/9 of the volume of the protein preparation The term “virtually free of chemical precursors or other chemicals” also includes protein preparations Bacteria : 11.0710 in which the protein is separated from precursors or other chemicals from those involved in protein synthesis.In one embodiment, the term “virtually free of precursors or other chemicals” includes Y. Preparations of B Rutin bacteria: 11.0710, containing less than 77 (dry weight)

¢ Yo from precursor chemicals or from bacteria chemicals other than HPylorl, preferably more, less than 0. Precursor chemicals or bacteria chemicals other than HPylon, preferably more; Less than /01 of chemical precursors or bacteria chemicals other than: 115710, and the most preferred of all; Less than about 70 probiotics or bacteria chemicals other than –HPylori © indicates a cell purifying preparation; In a plant or animal case, it refers to the preparation of cells in the body of a living organism and not to a healthy whole plant or animal. In the case of cultured cells or in the case of microbial cells, alae consists of a preparation of 701 on JY. Preferably 75 of the cells concerned, the purified, isolated or pure DNA, such as DNA, is virtually pure (terms used here on commutative syntax) is a nucleic acid that is one or both of the following 0. that: is not directly tangential to both of the coding sequences with which it is in direct contact with the I-chlad of two sequences 1 of two I-coding sequences of which it is directly in contact (i.e., Langa ] (spots at the tip * and the other at the tip?) in the group of naturally occurring genetic factors (all GASH) from which DNA is derived; Or actually devoid of the term V0, for example. recombinant DNA incorporated into a vector such as being incorporated into an independent replicating plasmid, into a virus ¢, or into genomic DNA at the start of | Noa 2 or in SSOI | K) 1 ' 3 | gn] that exists as a Jada molecule (as cDNA or as a fragment of DNA obtained by PCR or by restriction endonuclease processing) independent of other DNA sequences. Also, the pure DNA actually includes the DNA of H. Pylori bacteria.

The term “Contig” “Mas” as used herein is a Touic acid Shas, a continuous extension of a sequence related to a group of genetic factors of an organism. Nuclear encoding polypeptide This region can represent part of the coding 0 sequence or an entire sequence and can be extended from one codon (the basic one of the autosomal codon) position to position or from a start codon to an end codon.

z As used herein, the term “coding sequenee” is a nucleic acid transcribed as messenger RNA and/or transformed into a polypeptide when placed under appropriate regulatory control of the sequences. A coding sequence can contain

0 0 without limitation to RNA 0 Synthetic DNA 0 and to recombinant nucleic acid sequences. The term “00100160601” “complement or sequel” to nucleic acid as used herein refers to an antiparallel sequence or to an antisense sequence that participates in Watson-Crick base-pairing with sequence 1 of the original .

VO 'gene product' means a protein or synthetic RNA encoded by a gene. As sa used here, 'Probe' refers to 0 nucleic acid or to A peptide or other chemical entity that binds specifically to a molecule of interest Typically, the probes are associated with, or able to bind to, a distinctive tag.

Y. is a detectable chemical moiety. Typically distinctive signs

Gal includes radioactive isotopes; photoreactive and photoreactive fractions, fluorophores, enzymes, precipitating agents; amplified sequences; And the like. On a similar shift referred to nucleic acid; or a peptide or any chemical entity that binds specifically to a molecule of interest and stabilizes such a molecule as a “capture ligand”.

0 Typical Availability Retention bonds bond with or are capable of bonding with supports such as nitrocellulose, glad, nylon membranes, beads, particles, and the like. The specification of the hybridization depends on conditions such as the base pair composition of the nucleotides, the temperature, and the salt concentration of the reaction. These conditions are identified by a person of ordinary skill in the art using routine empirical tests.

0 Homologous refers to sequence similarity or to the identity and sequence identity between two polypeptides or between two nucleic acid molecules. And when the site in both the comparative sequences is occupied by the same base or a sub-unit of an amino acid compound, such as: when a site in each of the two H molecules is occupied by two adenines, then the molecules are identical at that site. The percentage of homogenization is between

dae of two sequences is a function of the number of homogeneous sites common to the two sequences, divided by Vo of sites in two sequences proportional or 01, for example if the + of Nx of the compared sites is identical. Then the two sequences are 0.71 symmetric. For example, it shares a symmetry of .70. In general, TATGGC Jiy ATTGCC conducts DNA sequences. A comparison is when two sequences line up to give maximum symmetry

Y. The nucleic acids are subject to hybridization with each other, when a strand of nucleic acid can heat up and cool down with the other nucleic acid under specific conditions of intensity. Note that the intensity of the hybridization is determined by: (1) The temperature at which the hybridization is performed

Ya

and// or ghusl at that time; and (b) the ionic strength and polarity of the hybridization and washing solutions. Crossing requires that the two nucleic acids contain complementary sequences, depending on the intensity of cross-crossing. But the mismatch is tolerable. Typically, hybridization is required at 19 °C; that (SSC X . 50 such as a solution of Tulle two sequences of intensity the two sequences are essentially exactly the same as required by the conditions of intensity © at a temperature C) and conditions of low intensity (such as SSC Xe medium ( For example, at 19 °C) © Complementary Total Less Matching SSC Xe e.g. a solution of .yen hybridization sequences 19.R ye concentration is 1R gram molecular concentration of sodium chloride SSC XY ). ) molar sodium stearate 0 A favorite non-deterministic example of strict hybridization conditions is hybridization in chloride solution at about £0 °C, followed by (SSC) sodium stearate/6X sodium stearate at ‎ 19 - 0. On SDS 7.01 R SSC X,Y with one or more washes in solution. C The terminology is peptides; Proteins, polypeptides used herein are Vo-interchangeable (that is, one can be used in place of the other). As used here, the term “surface protein” refers to all surfaces that attach to proteins such as inner and outer membrane proteins; proteins attached to the cell wall; And secreted proteins, and a polypeptide containing biological activity for bacteria: 115710 if it contains Y.

Ya

on one property; or on two properties; it is preferable to HAST properties from the following properties:

. If he can, when it is embodied in the context of infection or infection with bacteria: (1) 11.10

to raise; Or mediates the binding of bacteria: 11.710 to a cell “(7) to ensure enzymatic activity or structural regulatory functional properties of the protein of bacteria 11.57108, 0 (*) that

0 The gene that it encodes was able to rescue a fatal mutation in the gene of HPylor bacteria “(8) if it was

immune generator in the body. Also, the polypeptide contains biological activity, whether it is Tobias or a thin agonist of the polypeptide, which includes one of the aforementioned properties.

As for a biologically active part; Or symmetric, it is a part that contains activity, whether in the glass tube or in vivo, which is its characteristic, polypeptides of HPylori bacteria

0 of the invention included in the list of sequences, or characteristic of bacterial polypeptides

HoPylori; Other naturally occurring » such as one or more biological activity than described

here. But especially preferred are parts that exist in the living body, such as parts that originate from something

After the course of transcriptional operations or that arise from the transformation of the 1188 18 cascade links. The parts include those parts that are embodied in self cells or in endogenous sex cells

1 In addition to those cells produced in embodiment systems such as: produced in CHO and Lan cells

Peptides such as polypeptides of bacteria 119108 express Yass to different parts of

molecule. Then it is part of bacteria: 11.5710 or similar bacteria: 11.5910

It is a part that shows biological activity in any biological test for the activity of 11.7108 bacteria and the most preferred of all is a part or similar that includes 701 preferably that includes 7.

0 is preferred over those containing .71 .77 ZAC 0 or .79 or more of the activity of B. 3 in any of the tests whether in vitro (in vitro); or in vivo.

t. Homologs can differ from naturally occurring polypeptides from bacteria in an amino acid sequence or in ways that do not involve a sequence, or both. conversion or methylation), or in phosphorylation (transformation or conversion with phosphorus) or in carboxylation (conversion or conversion with carboxylate), or in conversion 0 or glycol treatment, but preferred homologues include bacterial polypeptides (or active parts of those whose sequences differ from H.Pylor aberrant sequences by one or more conservative amino acid substitutions Deletions or insertions that do not impair the biological activity of bacterial polypeptides Amino acid substitution alge Includes protective substitutions , in the manner of H.Pylori 0: one with another with similar properties such as substitutions within the following groups valine, glycine, glycine, valine, valine, isoleucine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, Serine, threonine, lysine, arginine: tyrosine, and can be prepared D Protective substitutions in light of the following table, 0 » and phenylalanine

1 1 Conservative amino acid substitutions table

For Amino Acid Replace with any of

Arginine R D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, lle,

D-Met, D-Ile, Orn, D-Om

D-Asn, Asp, D-Asp, Glu, D-Glu, Gin, D-GIn

Aspartic Acid M D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln

D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr

Guuamine [Q| D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp 1 Glutamic Acid D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-GIn 1-116, Val , D-Val, Leu, D-Leu, Met, D-Met

D-Leu, Val, D-Val, Leu, D-Leu, Met, D-Met -1 Lysine K D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-

Met, Ile, D-Ile, Orn, D-Om

D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val 1 Phenylalanine F D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, trp, d-trp,

Trans-3,4, or 5-phenylproline, cis-3,4, or 5-phenylproline

Proline D-Pro, L-I-thioazolidine-4-carboxylic acid, D-or L-1- oxazolidine-4-carboxylic acid

Serine S D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O),

D-Met(O), L-Cys, D-Cys

Threonine T D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(0),

D-Met(O), Val, D-Val

D-Tyr, Phe, D-Phe, L-Dopa, His, D-His

D-Val, Leu, D-Leu, lle, D-Ile, Met. D-met

In other homologues falling within the Gls of the invention, those homologues that include modifications that increase the stability of the peptide, and such homologues may contain, for example. contains one or more non-peptide bonds (replaces peptide bonds) in a peptide sequence. Also included within the Glas of the invention are: homologues that contain residual parts 1 instead of L-amino acids than those that occur naturally such as amino acids = I or amino acids that do not occur naturally or synthetic amino acids such as β-amino acids or Lila Amino Acids; and cyclic symmetries. And as oa is used here;

0 Typically to have at least 40 residual parts, preferably about ve residual length usually. Fragments of HPylor bacteria polypeptides can be generated by methods known to those skilled in this field. The ability of the candidate fraction to exhibit biological activity of the HPylor polypeptide can also be evaluated by methods known to those skilled in this field as described here.

0 Also within the scope of the invention are HPylor bacterial polypeptides containing residual fractions that are not required for the biological activity of the peptide or that result from delivery of an alternative mRNA; Or on the facts of the process of the replacement protein process. The term “immunogenic component” as it is used here is a sham; Such as the polypeptide of bacteria 117100 or similar or part thereof capable of eliciting a humoral immune response

,. In combination with a helper of and/or cellular in a single brood animal 0 The term “antigenic component” as used herein is a moiety such as a polypeptide

HPylori, or a cognate, or part thereof, capable of binding a sufficiently high level Lally-specific antibody to form a detectable antigen-antibody complex.

M. As ga is used here, the term “transgene” means a toui-acid (encoding a single polypeptide or AST, for example) that is wholly or partially heterodimeric; That is, it is alien to the animal

The epigenee or the cell that is presented with PEPIN or is inconsistent with a gene developed from the inside of an animal through a genetic or from a cell of those in which it is presented and is designed to be inserted or is already included in the gene (group of genetic factors) of the cell in a way that changes the genome of the cell In which it is included (such as being inserted at a site different from the normal gene site, or if its insertion leads to disruption).

0 can contain across a gene (containing chromosomes in which one or more Slo genes are naturally or synthetically fused) may contain one or more regular transcriptional sequences and any other nucleic acid such as introns, which may be necessary for perfect expression of the selected nucleic acid;, with all being attached to the selective nucleic acid, and may include a promotional sequence 0.

Vo As used herein, the term “transgenic cell” refers to a cell containing The trans gene can be introduced into the cell directly or indirectly

Y. This is by producing it in a precursor of the cell, or by a studied genetic (genetic) treatment, such as its production by the method of transforming a cell qualified for that 1, or by means of a small injection, or by infection with a recombinant virus. This molecule can be combined with

Chromosome 1, or it can be a repeat of the DNA in a way outside the chromosomes. As for the term “antibody” as used here, its use means that it contains de parts of it that are specifically reactive with polypeptides of bacteria: 11710. As ga uses Ls, the term “cell specific promoter” means a sequence of DNA ° that performs the task of a promoter 0 i.e. regulates the embodiment of the selected DNA sequence in LA its type of tissue. The aforementioned term also implies so-called “permeable” inducers that regulate the expression of selected DNA, mainly in a single tissue; And his embodiment caused in other copies as well. The term baad, as used herein, refers to a baad of a non-abnormal type 0 of Jin's embodiment. It also contains: the embodiment of non-abnormal levels; i.e. above or below incarnation; It contains an embodiment pattern that differs from the violent species in terms of the time or journey at which the gene is expressed, such as if it is increased or decreased expression (compared to that of the violent species) at a predetermined evolutionary time period or stage; or is a type of embodiment different from embodiment of the violent (or savage) type No for a low embodiment (compared to embodiment of the violent type) in a predetermined cell type or tissue type; with respect to conductivity size, amino acid sequence, or post-translational modification; Or biological activity of the transcribed polypeptide 1 or be stretched from an embodiment different from the type of the aggressive type with regard to the effect of the environmental stimulus or the external cellular stimulus YL on the expression of the gene such as if the bad Whe is from an increased or decreased expression (compared to the expression of the virulent type In the presence of an increase or decrease in the strength of the stimulus or stimulus. As used here, the term "host cells" and other similar terms denote

0 microorganism or on normalized cell lines cultured as mononuclear cell entities, refers to cells that can become or have been used as excipients for a recombinant vector or have been used as excipients for a recombinant vector or for another vector; and contain the progeny of the original cell to which the infection was infected (i.e., infection of a cell with nucleic acid of an isolated virus Followed by complete virus production in the gel). © It is understood that the offspring of a single parental cell may not necessarily be completely identical in the total DNA sequence or in the set of genetic factors with the original father, as a result of an accident or as a result of the studied transformation. and as used herein; The term "control sequence" refers to a nucleic acid containing a base sequence that is recognized by the host organism in order to perform the expression of the encoded sequences 0 aligned with it. Tle showed that the nature of such control sequences varies according to the host organism and differs in early nucleation, and such sequences generally contain inducers; at the ribosomal binding sites; It contains initializers and in some cases contains actuators and differs also in eukaryotic organisms. Usually such sequences include inducers, primers and in some cases include reinforcers. The use of the term control sequence means that it contains all the components necessary to be present for embodiment, and it can also contain additional components of those whose presence is necessary for the embodiment; It may also contain additional components from those whose presence would be useful, such as leading sequences. As used herein, the term “connected to an operational or practical change” denotes .? Chains connected or linked to perform their tasks in the manner assigned to them.

For example, a control sequence is linked to a coding sequence by means of a ligand in such a way that the embodiment of the coding sequence is achieved under conditions compatible with the control sequence and with the incubating cell. Metabolism of a substance as used herein means any manifestation of the activity of a function

° to organize the material. The metabolism of a substance also includes modifications, such as covalent and non-covalent modifications of the substance, just as the metabolism of a substance includes covalent or non-covalent modifications; of those that are induced by the substance in other substances.” The metabolism of the substance also includes the occurrence of changes in the distribution of that substance. Its independence also includes the changes of the substance in the distribution of other substances.

0 The term "sample" as used herein refers to a biological sample such as tissue or such fluid isolated from an individual (including without limitation Jean's plasma, spinal fluid, AL fluid, tears, saliva and tissue sections) or To a sample of the components of a cell culture in a glass tube, in addition to referring to the aforementioned term for samples taken from the environment. The invention practice will use traditional technical methods of chemistry

VO molecular biology, from microbiology, from recombinant DNA, from ple immunology, from those within the skill of the field, unless otherwise noted. Such methods are fully described in the field literature. See eg: Sambrook; fretch; Maniats in the book “Molecular Cloning” Laboratory Booklet Edition An (15449), and see “cloning or cloning of DNA folders or (ed. D. N. Glover;

1580 AD), see little nucleotide synthesis” (ed. M. J. Gibbet (PVA) and “acid hybridization (gust) ([ed. P. D. Himes and S. H. Higgins 1544 AD), and see the series “Methods” ale Enzymes (Academic Press). Especially the "Volumes No. 194 and No. 199 (Woo Editions)

and Grossman), and see “A Practical PCR-A Approach” (McPherson eds.; Kirk and Taylor, Achham). -1 Isolation of nucleic acids from bacteria: 11.5710 and their uses: Sequence of bacteria: 11.710 Genome (related to the group of genetic factors): © This invention provides nucleotide sequences from the group of factors inherited from 83 bacteria, which includes a series of DNA sequences from DNA lignocellulosic from bacterium 3; The following detailed description provides oligonucleotide sequences from H.Pylon, how to obtain the sequences, how to define ORFs and protein-encoding sequences, and how to use the detected HPylo-0 sequences in ways that include therapeutic and prophylactic uses. . In addition, (Sar) series was used as a database for identification and comparison of medically important sequences in these bacteria strains and in other strains. To determine the genome sequence of bacteria: 112910, DNA was isolated from a strain of H.Pylori (ATCC # 55679 depsited by Genome Therapeutics Cor Pobation, 100 Beaver stereet yo Waltham M.A. 02154) and were mechanically sheared by Atomic (313,91) to an average size of ?Kb and after volume fractionation by gel electrophoresis, the sections were bluntly terminated, and bound with adapter oligonucleotides, and cloned to a different vector from

M. type PmPX (Rice et al.; in “Abstractions of the Meeting of Genome Planning and Sequencing Action” Cold Spring Harbor; NY NAL 0/10 - 5/11 p. (Village). The invention (Americas No. 147.1) 4) and R145.170) Collected DNA was extracted from cultures and subjected to chemical or enzymatic sequencing, and the chain reactions (i.e., the procedure or work of the sequences) were resolved by electrophoresis, and the products were transferred and covalently linked by nylon membranes, and finally , the tranny-sequence_lea 0 series of a few distinct nucleotides complementary to the "188" (discriminatory) sequences present in the different village stenosis vectors were hybridized. In this way, a huge number of sequences from one set of chain interactions can be obtained. Noting that the procedures Clones and sequences are described in greater detail in the examples, and reads of each individual sequence obtained with this method were aggregated using FALCON software. ™ (Church et al.; 0 1544 pm; “Automated DNA Sequencing and Analysis”, ed. bad ; Venter Academic Press) and according to PHRAP (P.Green, Abstracts of DOE Hnman Genome Program Contractor- Grantee Work shop V, Jan. 1996 p. 157), the average tangent length was about £-Y 160. Various methods have been used to arrange the tangents in order to obtain a continuous sequence

£4 represents the total genome of HPylori bacteria. Synthetic oligonucleotides were also designed to be complementary to the sequences at the 0 end of each tangent. These few nucleotides can be hybridized to genomic DNA sequences of Bacterium:11.5710, in lambda phage vectors or into plasmid transducers to select 0-questions containing sequences that correspond to linking regions between individual tangents. Such wonders are then used to isolate the template DNA—the same few nucleotides are used as primers in a polymerase chain reaction (PCR) to amplify the splicing fragments; at which the nucleotide sequence is determined. The sequences of HPylori bacteria were also analyzed for the presence of (ORFS) containing at least 0.18 oligonucleotides. As a result of the analysis of ORFs based on Ramoz's readings, it should be understood that such ORFs may not be Gulbis with the ORF. L-polypeptide 1,177,108 bacteria, naturally occurring. These ORFs can include initiation codons indicating the initiation of the synthesis of a naturally occurring polypeptide protein from bacteria: 11.5710, and such initiation codons within the ORFs provided here (V0) can be defined by those with normal skill in the relevant field. The resulting ORF and polypeptides, HPYlO, are encoded within the scope of this invention. For example. In the ORFs, a codon can be identified such as 8106 or such as GUG (encoding methionine or valine), which is part of the signal to initiate protein synthesis. The ORF can be modified

0, to be compatible with a naturally occurring polypeptide from H.Pylori bacteria. It also specifies a coding term for | predicted by effort evaluation | to encrypt for such | for sequences with 'eal': Borodovsky and Mcl nineh 1993, Com.

Chem. 17: 123) GENEMARK™ 0 » Other nucleic acids of bacteria “H.Pylori”. Nucleic acids from this invention 1 can be obtained directly from the DNA of a 11.0 strain of bacteria referenced above using polymerase chain reaction (PCR). ) See: "PCR, A Practical Approach" (McPherson, Quirke and Taylor, eds.

(IRL press, Oxford, UK, 1991) 0 for more details on PCR The high reliability of PCR can be used to ensure a reliable copy of DNA prior to embodiment. Moreover, the reliability of amplified products can be checked by conventional series methods. Also, clones carrying the desired sequences in this invention can be obtained by scintillation screening of the sequences by means or by hybridization of synthetic oligodendrocyte probes with filter promoters of Vo chain clones or plaques as is known in the art; For example, see: (Sambrook et al., Molecular Cloning, Alaboratory Manual 2nd edition, 1989, Cold Spring Harbor Press Ny). It is also possible to obtain nucleic acids encoding polypeptides of H Pylori bacteria from the H pylori chain. cDNA according to the transcripts described here. cDNA YL encoding a polypeptide of HPylor bacteria can be obtained; By isolating the mRNA IS from a suitable strain, double primers can then be prepared from two strands of the total mRNA. And yet

0) That cDNAG can be inserted into a suitable plasmid or into a viral vector such as (a bacterophage) using any of several known techniques. Genes encoding polypeptides of bacterium 1,157,100 can also be cloned, using polymerase chain reaction techniques according to the nucleotide sequence information provided by the invention. © According to the law, nucleic acids can be DNA or RNA. Note that the preferred nucleic acids of the invention are included in the list of sequences. The nucleic acids of the invention can also be chemically synthesized using standard technical methods. Various methods for the chemical cyclization of polyroxynucleotides are well known and from lias solid-phase synthesis; which; Like peptide synthesis, it has been automated in commercially available DNA syntheses (see eg Itacura et al. in USPt. £500, £8 and Carruthers et al. in USPt. 77. 2.44” and Itacura in Patent U.S. Patent No. VAT .£58 and No. IRA 2.17, incorporated herein by way of citation and reference). Nucleic acids isolated or synthesized according to the advantages of the present invention are useful V0 and useful as probes; as primers; as retention ligands as antisense genes and for the development of transcription systems for the synthesis of proteins and peptides identical to such sequences; sing Benefits to name a few. and as sensors. Or as primers, retaining ligands, or as anti-puall agents The acid Bale gus! These uses are described in detail with the AST later.

oy: Probes. Nucleic acid isolated or synthesized according to the sequence of the invention included in the sequence list can be used as a probe to detect B. :11.5710 and with sequence information.

Described above in the Jal usage, sequences of 20 tkledtide or

0 more, which provides the desired comprehensiveness and exclusivity with respect to HPylori ; However, occasional nucleic acids are likely to be encountered during hybridization conditions. It is more preferable that the sequence contain at least .7 = .4 nucleotides to convey the stability of the hybridization product formed between the probe and the respective target molecules. It is difficult to synthesize sequences of more than 1,000 nucleotides, but they can be generated by various methods

0 Art for DNA Recombinant. Individuals skilled in this field will readily realize that nucleic acids for use as probes can be provided with a label to facilitate detection of a cross product. An isolated nucleic acid or Slate according to the sequence of the invention included in the sequence list may also be useful as probes for detecting regions similar in structure (particularly the genes of

(Walaa VO) from other strains of Helicobactor using appropriate stringent cross-crossing conditions as described herein. Holding ligands: for use as a holding ligand; link

,. Stadt's toric acid is well known YL if the nucleic acid containing twenty nucleotides or more is in the sequence of the invention

0 Listed for sequencing Useful for separating the DNA of HPYlor bacteria from their respective DNA and from other organisms. Nucleic acid containing twenty or more peptides in the sequences of the invention included in the list of sequences may also have utility in separating other Helicobacter genera from each other and from

0 other memberships. But he prefers; The sequence should include at least twenty peptides in order to convey the stability of the hybridization product formed between the probe and the target molecules bound. It is difficult to synthesize sequences longer than 1,000 nucleotides in length; But its generation is possible by DNA recombinant techniques. graders:

0 Isolated goss acid or Glas according to the sequences described here has a usefulness as a precursor to amplify the nodic acid of bacteria: 11.5210, and such nucleic acids can contain Laine as a primer to amplify nucleic acids in other strains of Helicobacter . For polymerase chain reaction (PCR) and its techniques, it includes sequences

Vo nucleic acids V0 = 01 wld tekelotide from the sequences of the invention included in the list of sequences is useful in linking with suitable enzymes and with reagents for the purpose of HA copies of the nucleic acid of bacteria 11.7105, but it is more preferred that the sequence include twenty nucleotides or HAST To transfer the stability of the hybridization product formed between the primer and the reduced target molecules. Noting that the binding conditions of primers of more than 100 takleotides are more difficult

XY. Control it to get the specification. High-temperature PCR can be used to ensure of

A reliable copy of DNA before embodiment. In addition, “inflated products can be examined by conventional chain methods. adil can be used in diagnostic tests. GLASSY contains specific sequences including genes from other strains of B. 117108; and/or from other strains of

Helicobacter 0 transcripts can also be combined in a cloning and transfection sequence to generate polypeptides identical to the nucleic acid synthesized by PCR, as described in more detail here. Antisense: containing nucleic acid or hybrid nucleic acid derivatives isolated or synthesized according to

The sequences described here have a usefulness as antisense agents to prevent the expression of genes of bacteria: 11.5710, and these sequences also have benefits as antisense agents that prevent the expression of genes of other species of Helicobacter. with one embodiment; A nucleic acid or its derivative corresponding to the nucleic acids of bacteria :11.5710 , is loaded into a suitable JS such as a liposome or a bacteriophages for presentation

Ve in bacterial cells. For example, any nucleic acid containing twenty nucleotides or more is able to bind to the nucleic acid of RNA bacteria. It is preferable that the antisense nucleic acid consist of 0. nucleotide or more to provide the necessary stability for the crossbreeding product from naturally occurring non-occurring nucleic acid, bacterial nucleic acid and/or bacterial messenger RNA.

Y. It is difficult to synthesize a nucleic acid containing a sequence of more than 0.01 nucleotides in

00 length, but it can be generated by recombinant DNA techniques. Note that the methods of loading antisense nucleic acid into liposomes are known in the field as shown by US Patent No. 87 5 £56 issued in December YY pVAAL by the inventor Papagopolos and others. ° 11. Embodimentation of deoxyribonucleic acids from H. pylori Toui acid isolated or synthesized according to the sequences described in this paper has the benefit of generating polypeptides. It is also possible to clone the nucleic acid from the invention provided in the list of sequences or parts of the said nucleic acid that encode active proteins of 11.0710 polypeptides, in suitable vectors or in vectors 0 used to isolate nucleic acid. The isolated DNA combines with suitable DNA bonds and is transcribed into a suitable vector. Also, the assignment of a specific gene or the task of a genetic modulator can be verified by expression in a bacterial strain under conditions in which the activity of the gene product(s) characterized by the gene or by the genetic operator in question can be measured. And in a qualitative way. 0 Alternatively 0 gene product can be mass produced in an exemplary strain for use as an antigen, as a synthetic reagent; for synthetic studies; etc. This embodiment can be accomplished in a variable strain that lacks the activity of the gene to be examined; Or in a strain that does not produce the same product or genetic products. And this Goby on other strains of Helicobacter and on other bacterial strains - Macle Campy 1 Corynebacterium . Norcardia « E.Coli labacter 0 , and genus Streptomyces . In some cases, the incubator will use the natural agitated embodiment of Helicobacter, while in other cases it will be of

01 necessary to drive the gene with an inducible sequence from the Jha (carboxylic organism) inducible E.

coli beta-galactosidase to express or to embody in (E.Coli) and to embody a gene repressor using the natural promoter of 0, then it can be used

Method as follows: A restriction fragment containing the gene of interest is cloned side by side

0 together with its associated natural promoter and regulatory sequences (determined using DNA-sequencing data) in an appropriate recombinant plasmid containing a working repeat origin in the incubating organism and an appropriate selectable indicator. This can be accomplished by a number of procedures known to those skilled in the art. It is most preferable to accomplish this by clipping the plasmid and the part to be cloned

. With the same restriction enzyme to produce compatible ends that can be linked in order to bring the two pieces together 0 and the recombinant plasmid is presented or introduced to the incubating organism by, for example; tag on the plasmid. The embodiment of the product of Gene is also discovered. desirable by using a special test to produce that gene

VO In the case where the gene requires a different promoter, the gene body (the coding sequence) is specifically biomarked and cloned into a suitable expression plasmid. This bles wy can be accomplished by multiple ways Sais OSH very easily by amplifying the PCR of a specific part and linking it in an expression plasmid after treating the PCR product with a restriction enzyme or baxotomy to create suitable ends for cloning.

XY. A suitable host cell for expressing a gene can be an LF or a prokaryotic cell. For example, the polypeptide of bacteria 11.7103 can be embodied in bacterial LA such as ov yeast - or mammalian cells such as ovary 0 cells (baculovirus). Cells of E.coli insects, knowing that the cells of his incubator are other hosts. (CHO) MY CHARGE 1 (RAT RATTON) us god . Jl is known to those skilled in 'and embodiment in normal nucleus cells such as mammalian cells' yeasts, or cells can lead to the formation of disulfide bonds IR VAR TEU insects to a partial glycocilia 0 of an internal chain of a peptide product Reconciliation An example of a render vector is in

Baldari. et al., (1987) as reported in PYepsecl, including 0. S.cervisisae: yeasts: and 0183788 as stated in Embo J. 6: 229 - 234) (Schultz et al., (1987) Gene 54: 113 - 123). (Invitrogen Corporation, san Diego, CA) p XES2 and \. LMA insects are available to express proteases of Baculovirus and also include vectors: pAC chain L (SFq cells) in culture (Smith et al., (1983) Mol. Cell Biol. 3: 2156 - 2165): As stated in pVL and the series (LUCKOW, 11 pt. and Summers, M.D., (1989) Virology 170: 31-39) \o : As stated in COS and on For the whole used cells

Gluzmam, Y., (1981) Cell 23 : 175 - 182): in combination with such vectors as 00018 as reported in Araffo, A. and Seed, B., (1987) proc. Natl ACad. Sci. UsA 84: 8573 - 8577) (dhfr - chinese Hamster) for transient amplification/embodiment in mammalian cells; while 00 cells are used as reported in pMT2PC with counterpoises as OV ary cHO (Kaufman et al. (1987) (EMBo J. 6: 187-195).

oA to mammalian cell DNA for stable amplification/expression in mammalian cells. A carrier can be introduced by conventional techniques such as calcium phosphate or as co-precipitation of . "electroporation" Ji. sf; DEAE-infection with coxanesane 0 Calcium chloride 0: Appropriate methods for transforming host cells can be found in the reference (Sambrook et al. (molecular cloning : A Labora' tory Manu al, 2 nd Edition, Cold °

Spring Harbor Laboratory Press (1989), . : And in other references such as the books of prokaryotic laboratories in 1 AH. 15 By Lyall embodiment transition, the embodiment is carried out in molten or non-melted induction. Fusion vectors usually add a number of amino acids to the target gene embodied. These NH, 0-terminal amino acids are often referred to as a reporter group. And such a group, NH, the amino terminal with A, increases the solubility of the target protein (10: correspondence or news) serves two purposes, helping to purify the recombinant protein, the target, by doing it (Y recombinant, and It often occurs, in fusion embodiment vectors, the .FY site with a ligand task in purifying the lysosome or solvent cleavage of the protein at the contact of the newsgroup and the target recombinant protein Yo to open the way for the separation of the target recombinant protein from the group. news after fusion protein culturation, and such enzymes and their discriminating sequences are thrombin and enterokines, and also include Xa expression vectors containing epistatic factor

PMAL including (Amrad Corp. Melbourne Anstralia (pGEX) typical fusion PRITS including (New England Biolabs, Beverly, MA) from: sf. fusion (glutathione S-trans ferase) Fusible (Pharmacia, Piscataway, N J)

04 (maltose E binding protein), or fusion protein ©, respectively, of the target recombinant protein. One of the preferred news groups is the “poly (His) group that can be fused to the amino or carboxy ends of the protein, which makes the recombinant fusion protein easily purifiable by chromatographic chelate. 0 Inducible non-fusional embodiment vectors include pTrec as reported: (Amann et al., (1988) Gene 69:301 - 315); It includes PETIA as stated in: (Studier et al., Gene Expression Technology: Me thods in En2ymology 185, Academic Press, san Diego, California (1990) 60-89). Ola RNA polymerase from a hybrid promoter 0 fusion plac in ©0117 » Expression of target genes within PETIA relies on transcription from an intermediate T7gnlo-lacO fusion promoter mediated by a co-encapsulated caprosian RNA polymerase ( T7gnl). This viral polymerase is all mediated by incubating strains BL21(DE3)¢ or (DE3) 11145174 of the A latent prophage lamida A suse 17801 under the transcriptional control of an inducer and an anamnesis. For example, 0. A Lala cell infected with a nucleic acid vector directing expression of a nucleotide sequence encoding the polypeptide of bacterium 117101 can be cultured under suitable conditions that allow expression of the polypeptide to occur. The polypeptide can be secreted and isolated from the cell mixture and from a medium containing the peptide. Alternatively, the polyβ-peptide can be captured in cytoplasm and the cells are harvested INTC PRR, and the protein is isolated.

Seeds of cells contain incubator cells, culture media and other by-products. Tate that culture media suitable for cell culture are well known in the field. The polypeptides of the invention can be isolated from cell culture media, from incubating cells 1 or from

1 Both using techniques known in the art for the purification of C-containing proteins

0 ion exchange chromatography, gel filtration chromatography; microarray 0 electrophoresis (migration of particles suspended in an electric field), affinity purification of specific antibodies to such polypeptides; In addition, and in many situations; Polypeptides can be produced by chemical fission of an autoprotein Jia (trypsinase digest) and the fission products can then be purified by standard technical methods.

0 and in Ula membrane-bound proteins, they can be isolated from a host cell by contacting a membrane-bound protein fraction with a detergent that forms a soluble complex; Where the membrane-bound protein is no longer immersed in the membrane part and becomes soluble to an extent that allows it to be isolated micro- and morphologically from the membrane part. Several different criteria are also used to choose a suitable detergent to make these compounds soluble, for example,. There is an important advantage is the ability of the cleaner to

Vo 11.7101 bacteriophage protein solubilization, within the membrane fraction on a denaturant in the lower bounds of the membrane bound protein to reinstate it upon protein reconstitution. There is another important characteristic when selecting a detergent, which is the critical concentration of the micelle (electrified body in a colloidal substance) (CMO) of the detergent in that the selected detergent is preferred to include a high CMC value that allows for easy removal after reconstitution, and there is an AIG property Must

Y. It should be taken into account when selecting a detergent, which is its phobicity (i.e. its lack of affinity for liquids). It is typical availability; The membrane-attached proteins are Tua phobic, and therefore phobic detergents, such as the Triton series, are useful for dissolving repellent proteins or

Hydrophobic. Also, there is another property, Tals of a detergent, which is the ability of the detergent to remove the protein of bacteria 11.5710, within a lower protein-protein interaction, which facilitates additional purification. The fifth property of a detergent that must be taken into consideration is the charge of the detergent. E Maas, if there is a desire to use ion exchange resins in the dated purification process, it is preferable that the detergent be an uncharged detergent. Note that the chromatographic techniques that can be used in the final purification step are known in the field and include hydrophobic reactions, lectin affinity, ion exchange, dye affinity; and immune intimacy. 0 One of the strategies to enlarge the embodiment of bacterial peptide 11.5710, recombinant in E.Coli is to embody the protein in an incubating bacterium with the ability to assimilate the cleavage of the recombinant protein in a proteolytic manner according to what was stated in: (Gottesman, S., Gene Expression Technology - methods in Enzymology 185,

Academic Press, san Digo, California (1990) 119 - 128) 0 Another strategy is to alter the DNA encoding the bacterium peptide 3. To include it in an embodiment vector so that the individual codons for each amino acid are those used preferentially in embodied proteins at a high level of 2.00 according to: (Wada et al., (1992) NUC. ACids Res. 20: 2111-2118) Ys and such alteration of nucleic acids of the invention can be carried out by standard technical methods of DNA synthesis.

Various acids can be synthesized for the chemically well-known chemical synthesis of polydeoxynucleotides, including solid-phase synthesis; Like peptide synthesis; It has been fully automated in commercially available DNA synthetases (see e.g. Itacura et al. in US Patent No. 2.49/99 and Capothers et al. in USPt. £5604, 0 and Itacura US Patents No. 47/R1.)2.VY and VY. 5 ? for the Arias are compact here for reference and reference). 1 HPylori bacteria polypeptides: This invention includes polypeptides isolated from bacteria 11.7101, encoded by the genome sequences of HPylori bacteria disclosed by, including polypeptides 0 of the invention included in the list of sequences, preferably at least polypeptides of the invention 0 parts remaining of an amino acid in length. And using the DNA sequence information provided in this research; The amino acid sequences of the polypeptides covered by the invention can be deduced using methods well known in this field. It will be understood that it is possible to isolate a total nucleic acid encoding polypeptide 1 of bacteria: 11.5710, and identify it based on the ORF or parts thereof, She for the purpose of charging a polymerase chain reaction with genomic DNA of bacteria 11.7101, as a calibrator; Followed by the amplified or amplifier output series. The polypeptides of the invention can be isolated from bacteria cells: 11.0710, of virulent, virulent or variable type, or isolated from organisms of different composition or from XY.Lo cells) including, but not limited to: bacteria cells, pronoun cells , cells

ol pda (plant cells and mammalian cells) in which HPylor bacterium nucleic acid was introduced and lysed. Further, polypeptides can be part of recombinant fuse-1 proteins. Galas polypeptides of bacteria:11.0710, according to the invention, can also be chemically processed using commercially available Gage procedures such as those referred to herein. 17- Matching of nucleic acids encoding vaccine components and targets of active agents against H.pylori bacteria: The revealed genomic sequence of HPylon bacteria includes parts directing the synthesis of RNA and polypeptides, in addition to the synthesis of repetitive origins 0 inducers and types Others are from regular sequences, and from internal constituent acids. The invention also includes citric acids that encode components of immunogens from vaccines and targets of active agents against HPylor bacteria. Lise matching of the mentioned immunogens included in determining the functions of the disclosed sequences can be achieved using a variety of methods. Non-restrictive examples of such methods are briefly described below. Vo Similarity to Known Sequences: A computer-assisted comparison of the detected B. 1159103 sequences with previously mentioned sequences in a commonly available database is useful in identifying a functional HPylon amino acid and Hom peptide sequences. It will also be understood that the sequences that encode a protein, such as its lg JSS comparison, have a high degree of sequence similarity between two proteins (eg more than .8 - .£3) at the amino acid level, indicating that the two proteins also contain some degree

From Glass Functional; Such as, for example, among the enzymes found in pal “DNA synthesis” or the synthesis of a cell wall. And such as proteins present in Tql , or in cell division , G . 0 In addition, several structural features of special protein classes and associations with their respective group sequences have been identified such as eg; binding domains of nucleotides; And for (DNA 0) and metal ions, and other small molecules; sites for covalent modifications such as phosphorylation; acylation and the like; HI and sites for protein-protein interactions; and these complex sequences can be completely short and thus can represent only a part of a sequence encoding a total protein. Matching such a feature to a Bacterium 3 sequence is useful in defining the function of the encoded protein and useful in identifying useful targets for antibacterial drugs. , and for surface proteins, including 0 transmembrane-repellent secretion-domain signal peptides, and of note: 11.5710 bacteria proteins; defined as containing putative Vo-signal sequences and/or transmembrane domains, useful as heterogeneous components From vaccines “Identification of essential genes” The nucleic acids that encode proteins essential for the growth or vitality of bacteria: 11710 are preferred drug targets.3 genes can be tested for their association I with biological or organism by testing the effect of deletion of YL and / RAO Tear off genes, i.e. the so-called «Battaa Genes, using techniques known to those skilled in the field concerned. In this method, basic fairies can be defined.

qo : Specific strain sequences HPylor is believed to be because of the evolutionary relationship between the different strains of bacteria , Bacterial sequences : 11.5710 , disclosed at the present time are useful in identifying 0 and/or in distinguishing between previously known strains and strains Recent strains of bacteria Other strains of bacteria: 11.0710, show at least GU as H.Pylori is believed to have at least .77 sequence similarity to the newly revealed sequence. Systemic and routine analyzes of sequences of strains of bacteria: 11.5710, derived from samples containing DNA, are heard, and compared to the current modern sequence, with the definition of sequences that can be used to distinguish between strains in addition to those common with lS HPylori 0 strains of bacteria. in one embodiment; The invention provides nucleic acids that include tentacles; And sequences of peptides and polypeptides discriminate between the different strains of bacteria 11.7105, and specific components of the strains can be defined functionally by their ability to elicit or interact with . 11.5710: Antibodies that selectively differentiate one or more strains of bacteria; The invention provides nucleic acids including probes; HAT peptide sequences are represented by Vo, but they are not HPylor and polypeptides common or common to all strains of bacteria. Existing in other bacterial genera: “Qualitative example: identification of candidate protein antigens for the development of an antibody and a vaccine.” The selection of candidate protein antigens for the development of a vaccine can be derived from acids

ORF'S nuclear nuclei encoding polypeptides of bacteria: 11.5710; Or, Al cannot be parsed

For known similarities with membrane proteins or with other exported proteins, they were analyzed using the discriminant analysis described by Klein et al.: (Klein, P., Kanehsia M., and DeLisi, C. 1985 Bioch mica et Biophysica Acta 815, . 476). 0 468 to predict membrane proteins or export (exogenous) proteins. Similarity searches can be performed using the BLAST algorithm (bead) located in the Wisconsin sequence Analysis Package (Genetic Computer Group, University Research park, 575 Science Drive, Madison, WI 53711) to compare each amino acid sequence of an ORF. And the sequences of the data bank showed a mark of 0, the probability of Jus on the probability that this sequence was found by chance in the database and represented by a significant similarity (such as lower odds than 1-1171 that the similarity is caused only by random coincidence) with membrane proteins or with antigen export proteins anti-protein for vaccine development. It can provide possible activities for the genes of 117100 bacteria, based on the similarity of the Vo sequence to cloned or cloned bodies of other organisms. 1 can be used for discriminant analysis (Klein, etal, supra) to test ORF sequences. This ratio uses the essential information contained in the amino acid sequence of the ORF and compares it with the information derived from the properties of a known membrane protein and a source protein. This comparison predicts which gh protein will be exported and which bound or cellular plasma membrane. Thus, the amino acid sequences of the ORF defined as export or membrane bound proteins by this calculation are wv antigens. A protein for the development of a vaccine, and surface-exposed outer membrane proteins represent the best antigens to provide a protective immune response against bacteria: 113710, and among the calculation methods that can be used to help predict the presence of such outer membrane proteins; include the presence of A lamellar region of a house that surrenders both sides at its edges, which are on the © shaped © . This region, which has been detected in a large number of outer membrane proteins (Pheor Tyr) in Gram-negative bacteria, is often characterized by residual xerophobic fragments.

V clustered at successive sites of the © terminals (ex: see Fig. 0 yellow 7 Fig. 0 of Cm). Significantly; these sequences were not detected at the dey. (E) block surrounding plasma proteins, allowing for this to happen. Preliminary discrimination between these classes of 0 proteins based on primer sequence data. An additional amino acid sequence motif shown as 0 was found in many of the outer membrane proteins of Bacteria 11.7101, and the alignment of the 0 sequence illustrates

HPylori histidine as 0 fragments of the five-protein sequence of bacteria denoted by a one-letter amino acid symbol. ( , ©) labeled with the retrograde numbers of their amino acid sequences and with the A-terminus of the F-terminus through 5 or until A that five or six blocks (distinctive from uals left to right. As

Phe ( a homologous amino acid residue containing the discriminative phobic residuals

TA

or ¥ according to the one-letter code for the remaining homocysteine fragments) located F or 17 always at sites near the © ends of outer membrane proteins. The presence of multiple common incentives clearly establishes the similarity between the members of this group of: . Proteins There are additional amino acid chaperones for four isolated outer membrane proteins 0 . 1 on bacteria: 11,510, shown as HPylori repeats, sharing outer membrane proteins isolated from SAD bacteria, which also share V segments, additional motifs as shown for two proteins in form, not sharing A. The rest of the rheophobic side of 0 - 0 and as shown for two proteins in the form of . In the motif of the phobic part (of the -© terminal) they share a terminal motif of the -© of another 0 A person skilled in the art will realize that the common sequence motifs are very important and evaluate the similarity between the group of these proteins. It is not possible to distinguish between nucleotides possible multiple GL and infrequently at a specific location in the DNA sequence.In these cases, these are referred to: Confusions by a long alphabetic letter as follows: 0: TUPAC - TUB Below you will find basic symbols for the letter - Official singular: Symbol Basic Description Guanine 0 Arienine A Chimine T X Cytosine 0

Sad] Basic Description: R Purine (GorA) Y K Pyrimidine (UorT or C) (Cor A) (al M K ° Ketone (TorG) Je lis 5 Strong (Gor CQ) Ww Weak interaction (TorA) H : Not © (TorCorA) B Not (TorGorA) A 7 Not T (Not No) ( (GorCorA) D is not (TorGorA) C N (TorCorA) The amino acid shifts of this invention cause confusion in the acid sequence by shifting the ambiguous codon as the letter (XD) 1. In all cases, the remaining fragments of the allowed amino acid are clear from the test of the thorny acid sequence based on the standard genetic code. Gene products of Bacterium: 11.5210, ay of the invention and provided in the list of sequences, those skilled in the art can alter the revealed structure of any (amongst bacteria: 11.5210), for example, by producing parts or homologues; and test the structures produced by Boas for their effectiveness. There are examples on styles

L. Known technicians for those with skill in the intended field listen to the production and testing of parts and analogues that can be used to make and examine polypeptide chains such as random peptide chains or chains of parts or similar parts of cellular proteins to see their ability to bind polypeptides of bacteria 11.7101 and such group tests are useful © for the definition of bacterial defenders HPylori. Fragment generation: Multiple Gobo protein fragments can be produced, such as the recombination method; By digestion that hydrolyzes the protein, or by chemical synthesis, inner or terminal portions of polypeptides can be generated by stripping one or more polypeptides from 0 end (for a terminal portion) or both ways (for an inner portion) from a nucleic acid encoding the polypeptide peptide The embodiment of DNA, the generator of congenital transformation, produces polypeptide fragments. Thus, digestion with endometrial Loe enzymes can generate 8 that encode protein fragments by random shearing, restriction digestion or collection from the previously investigated methods. Protein parts can also be chemically synthesized using known technical methods in the field, such as traditional chemistry for: Merrifield solid Phase -] - Moc or t 06 "For example, JUL divides the peptides of the present invention randomly into parts of a desired length without entanglement of the parts, Or it can be divided into interlocking segments of desired XY length.

Is it a protein, a special domain, or a protein region? The useful methods for this include the method that generates congenital transformation or mutation (PCR) and satisfies this congenital generation. A series of types of random amino acid sequences can also be generated by

Synthesis of a set of sequences pad of fractalized nucleotides.

0 Note that methods for examining proteins in a series of species are found here elsewhere (1) PCR: In transgenic PCR, Gag uses reduced performance Taq polymerase to present random mutations in cloned fragments From DNA, as stated in:

(Leung et al., 1989 Technique 1: 11 - 15)

0 The area of DNA required to generate congenital transformation is enlarged using the polymerase chain reaction (PCR) under conditions that reduce the accuracy of DNA synthesis by means of Taq DNA polymerase, such as: by using the dGTPLDATP ratio of five and adding 107 to the PCR reaction. The amplified DNA fragments are then inserted into an appropriate cloning sequence to provide randomly mutated sequences.

(b) Satisfying Congenital Metagenesis: Satisfying congenital transgenesis allows for the rapid introduction of a large number of Lata substitutions on an individual basis in Helana domestica fragments (according to Mayers: et al., 1985 Science 229: 242 This artistic method includes the generation of transformations, such as by means of chemical treatment or exposure

,. Complementary DNA Glua Monoscale in a Glass Tube for Radiation. and Y cue synthesis.

The transformation frequency can be included by including the processing intensity, and essentially, all inferences can be obtained. basal. Since this procedure does not involve genetic selection of parts of transformation, it is possible to obtain both equivalent variants, as well as all those that change function. Note that the distribution of significant transformations is not biased towards 0 conserved sequence elements. (c) or desiccated oligonucleotides: a sequence of homologues can also be generated from the set of paul gf nucleotides destined sequences. The chemical synthesis of the degenerate sequences can be performed in an automated gel synthesizer where the synthetic genes are then ligated into a suitable transfection vector. Synthesis of oligo-0 methylated nucleotides is known in the art (eg Narange, SA 1983 Tctrabdron 39 : 3 Itakurq et al., (1989) Recombinant DNA, Proc 3rd Clcave land sympos.

Macromolecules, ed.

AG Welton, Amsterdam: Elsevier P P 273 - 289; Itakura et al. (1984) Annu.

Rev.

Biochem. 55 : 323; Itakura et al. Science 198: 1056; IKe et al. (1983) Nucleic Acid Res. 11:477. (1984) Vo and similar techniques have been used in the directed evolution of other proteins. 1 See, for example: Scott et al. (1990) Science 249 : 386 - 390 Robats et al. (1992) ) PNAS 89: 2429 - Devlin et al. (1990) Science 249 : 404 - 406; Cwirla et al. (1990) PNAS 87: 2433: 6382-6378; 2433; I digit 9 0 o,YYY,¢ s ER free rook 0 IB and others). Altering tonic acids and polypeptides: methods for their generation For a moral transformation a laa gl ! Non-random or directed transgenesis techniques can be used to detect specific sequences or alterations in specific regions. These techniques can be used

(Artistic methods) to create different types, including: delete; Insertion, substitutions of remaining parts of a known amino acid sequence of a protein. The sites of transduction can be modified either individually or with © sequences such as by: (1) substitution first with conserved amino acids and then with more transparent options based on the esl nl 0 achieved, (7) deletion of the target residue; or (©) inserting the offal (residual parts) of the same class or of a different class next to the specified location, or a combination of options 1 - ?. (7) ASL: The use of ASL is a useful method To identify specific residuals or regions of a desired protein that are considered as preferred sites or as domains 0 to be transgenic, according to Cunningham and Wells (science 244 : 1081 - 1085, 1989): In the alanine assay, a residual is identified Or with a group of remaining target parts (such as charged residues such as: (Glu, Lys, His, AsP, Arg) and replacing them with a neutrally or negatively charged amino acid (preferably over 1, alanine or polyalanine). Substitution of an amino acid depends on the interaction of the amino acid with the surrounding aqueous environment inside or outside the cell. Functional substitutions Shute is refined by submitting other or different types on or at substitution sites. Thus, while a site to present a different type of amino acid sequence is predetermined, the nature of the transformation need not be predetermined. For example, to optimize shift performance in a specific location; It is possible to connect the alanine or connect a generator of random congenital transformation at the target codon (the basic unit of the genetic code) or in its region, and a group examination is conducted for the different types of

Desirable protein subunits embodied for optimal combination of desired activity. Genetic transformation mediated by oligo (few) nucleotides: The meiotic mutation mediated by (XK) I oligo teclonide is a useful method 3 for the preparation of Bada J I Karem I ¢ insertion of different types of DNA see for example:

(Adelmanetal., (DNA : 183 , 1983) ° In short, the desired DNA is changed by hybridizing an oligo nucleotide that encodes the transformation of a DNA standard, where the standard is a single stranded form of a plasmid or of a bacterium containing a DNA sequence The original or unaltered form of the desired protein and after hybridization, DNA polymerase is used to synthesize a second complementary strand entirely from the calibre that will fuse with the primer of the oligo.

,. a cleonide, and it will encode the selected change in 1118 of the desired protein. Generally 0 . A nucleotide in length at least Yo An oligome uses nucleotides with a nucleotide that is complementary 09 = VY and therefore will include a completely perfect oligonucleotide for titration on each side of the nucleotide (or nucleotides) encoding the change or transformation . This ensures that the oligonucleotide is precisely hybridized with a molecule

10 standard single-stranded DNA. The synthesis of oligonucleotides is easy using techniques known in the field such as those described by:

(Crea et al. (Proc.

Natl.

Academic Science.

USA, 75: 5765 [1978]). of the artistic style I | As described by (Wells et al. (Gene, 34 : 315 [1985]) the starting material is a plasmid (or other vector) containing the DNA subunit

Yo The protein DNA unit to be converted. Note that the symbols or symbols in . The subunit of the protein to be converted is identified. There must be a unique internal glycose-restriction enzyme site on each side of the defined translational site(s). If there are no such restrictive sites, they can be produced using the aforementioned transgene-mediated transgene-mediated DNA oligonucleotides to present them on or at suitable sites in the protein of interest. After introducing the restriction sites into the plasmid, the plasmid is clipped at this point to make it linear. A double-stranded nucleotide oligo encoding between restriction sites but containing the desired DNA mutation(s) is synthesized using standard procedures. The two strands are generated separately and then hybridized together using standard technical methods. This double-stranded oligonucleotide is referred to as a "cassette" (the envelope or carrier) and this carrier or cassette is designed to include the ends of the ? and * are comparable to the ends of the plasmid so that it can bind directly to the plasmid. Thus, this plasmid 0 has been linearized. The desired mutant protein subunit DNA is now biosynthesized at sequence 10: congenic transgenesis (4). 117 of the inventor Lander and others) and in this way. The amino acid sequences line up to a group, homologues, or other proteins of interest; Preferably to raise the analogue to the maximum possible. And Y. can select all the amino acids that appear at a specific site from the lined sequences vi

Creates a date set from aggregate sequences. Either colored or assorted series of

The heterozygotes are generated by congenital or combinatorial transformation, and are coded

By Jane Color Series.

For example. A mixture of oligonucleotides can be enzymatically linked into 0-gene sequences such that the degenerate set of silencer sequences is able to be transcribed into peptides.

individually, or alternatively, as a larger fusion protein group containing a group

degenerate sequences.

Other modifications of nucleic acids and polypeptides of HPylori bacteria:

The structure of polypeptide 11.7107 can be modified for Jie purposes to increase solubility.; 0 Enhancing stability (such as the validity of use outside the living body, i.e. in the warehouse.

And resistance to the degradation of proteolytic (all) protein or peptide can be produced

Bacteria: 117710 rate in which the amino acid sequence has changed, as by

Amino acid substitution 0, 0, omission, or addition as described.

The bacteriophage 1139103 peptide can also be modified by replacing the remaining parts of NO with cysteine, preferably with alanine, pserine, or threonine; or Pliocene, or with residual parts of

Glutamic acid for the purpose of reducing dimerization (the process of combining two similar molecules to form a molecule

a large one by adding one to the other) by means of disulfide bonds. add to that

The amino acid side chains of protein fragments of the present invention can be modified

Lalas. Another modification is peptide synthesis. To enhance stability and/or reactivity, the bacteriophage 11.7101 polypeptide can be modified to incorporate one or more polymorphisms.

in the amino acid sequence of a protein resulting from any normal allelic variation. add to that

D-amino acids can be substituted for abnormal amino acids; or similar ones

no amino acid; Or add them to produce a modified protein that falls within the scope of the present invention. Furthermore, the polypeptide of bacteria 11.710 can be modified using polyethylene glycol (PEG) according to the method of: A.

Sehon and coworkers (Wie et al., supra) 0 PROTEIN PROTEIN CONjugated to polyethylene glycol. In addition, polyethylene glycol can be added during the chemical synthesis of the protein. Other modifications of Ho Pylori proteins include reduction / alkaline / as reported in: Tarrm Methods of protein Microchar a cterization, J.E.

Silver ed., Humana Press, clifton N J 155-194 (1986). and Shiigi, eds, Selected Methods in Cellular Immunology, WH Freeman, San Francisco, Cn 1980, and as stated in US Patent No. 2,374,179; ) Int.

Arch. of Allergy and Applied. 1 mmunol., 41 : 199-215) and in order to facilitate the purification and increase the solubility of the bacterium 11.7101 protein or peptide, it is possible to add a soluble moiety of an amino acid to the parent peptide. For example, hexa-histidine can be added to the protein to purify it by a chromatographically stable alpha-filamentous ion, Y, as stated in: 'Hochuli E, et al., (1988) Bio / Technology, b: 1321 - 1325).

VA

In addition, to facilitate the isolation of free peptides from unrelated sequences, qualitatively cleaved sequences | For smelting la carte ads f sites can be provided. And the peptide, in order to adequately assist in antigen synthesis of antigen determinants within the polypeptide of bacterium 1171017, it is possible to engineer sensitive sites for proteases recognized between at least one by means of an anti-alge epitope where Each of them includes a GLU determinant by recombinant methods or by synthetic methods. For example, acid pairs can be presented to form | Ey] e | 3a A regional yin in a recombinant amino charged RR or KK Sia protein thereof. The resulting peptide can be made sensitive to cleavage by cathepsins and/or other trypsin-like enzymes that can generate protein fragments.

L Ls, Jha containing one or more antigenic determinants. In addition to that you can. These charged amino acids lead to an increase in peptide cyclization: “Primary methods for screening polypeptides and similar ones There are various techniques known in the field for mass or scintigraphic screening of generated mutant gene products. Techniques for the VO scintigraphy assay of large gene sequences often include cloning the gene sequence into a reproducible rendering vector and transforming appropriate cells with the resulting sequence of helices. And the embodiment of genes under conditions in which it is easy to discover a desired activity, such as: as in this case, the binding to a polypeptide of bacteria 11.7101 or a reactive protein is relatively easy to isolate the transporter encoding the gene whose product was discovered. Each of the young methods described later is subject to high XY interfacial analysis. To examine large numbers of sequences that have been synthesized, such as: by means of special technical methods, va

Random congenital mutation. 1) Bi-hybrid systems: SUS hybrid tests such as the system described above (as well as the mass screening or scintigraphy methods described herein) can be used to identify poly

0 peptides: such as: parts or analogues of HPylori polypeptides. (Glas uses the bacterium HPylor as the ards protein, and the chain heterozygotes are embodied as fish fusion proteins.) In a similar vein, a two-hybrid assay (as with the other mass or scintigraphy methods described herein) can be used to find polypeptides that bind a bacterial polypeptide:10(11.

: (b) display series 0 single input for group or scintigraphy calibrations or tests; Peptides are displayed on the surface of a bacterial cell or particle; And the ability of special cells or tail viral particles to bind a suitable receptor protein is discovered by the presented product.

Vo is a surface membrane of a bacterial cell, and the resulting fusion protein detected in vasculature as reported in Patent W. No. 44/. 637 to the inventor, Lander, and others; As stated in: and Goward et al. (1992) TiBs, 1371 - 1370: P Fuchs et al (1991) Bio / Technology

18: 136-140).

In a similar fashion, a distinct ligand can be used in a heuristic way to win symmetries

0 is a potentially functional peptide. Descriptively distinct ligands such as receptors can be used to discover homologues that retain the binding activity of the ligands. The use of distinct adhesive ligands allows cells to be visually examined and separated

A.: Ls cell rice under an X-ray microscope, or where it is separated by

Garrard et al, PCT Publication W092/09690, Marks et al. (1992) J. Biol. chen. 267 : 16007-16010; Griffiths et al. (1993) EmBoJ 12: 725-734, Clackson et al. (1991)

Naturs 352: 624-628, and Barbaset al. (1992) PNAS 89: 445-7-4461). (external membrane protein; E. Coli). There is a general entry that uses a matose metabolite of 0 (Charbitet al. 1986 EMBO 5302p - as a peptide fusing partner. As mentioned in (LamB. 3037) to produce LamB peptides Also, inserting ligand peptides into a plasmid that encodes its binding with antibodies ¢ and can extract 8 responses: Jha is available for binding with ligands: immunoglobulins when the cells are given to animals, and surface proteins of other cells such as 0 (Schorret al. (1991) ) Vaccines 9/, PP387-392) OmpA" (Agterberg et al. 1990, gene 8837-45) (as cited in PhoE and Fuchset al. 1991, Bio/Tech 9 1369-1372) (as cited in PAL and chelated with large bacterial surface structures acted as radiation-induced transduction, wherever cell morphology allows.A gene sequence can be embodied as a fusion protein on the VO.surface of a viral particle For example, in the filamentous phage system, sequences Foreign peptides on the surface of the infected phage, which leads to sharing two important benefits over affinity matrices: First, since such phages can be used for it is possible to screen a large number of Gl per millimeter. TY Good concentrations of more than 0 phagocytes at one time. Second: Since every infected devourer displays a gene product at low ¢, O Led 1 can be enlarged and wrapped in i. = Oo | Waq dale.

A

The phage by another round of infection or infection, and a group is often used for phages and can be 1 in display chains [1, 1113, fd, E Coli] to be a filamentous phage to generate melting proteins without tearing gVIII Use of 11 phosphorylated coated proteins or . The total encapsulation of the viral particle ° and the determinants of foreign antigens can be embodied at the end of the NHy- end of PII and from the phage carrying Shs this determinant recovered from a large excess of agile lacking these determinants according to what was stated in:

Lander et al. PCT PuhLi Cation Wo0/90/02909 for peptide presentation. Peptides can be fused with bilin, a “protein copolymer” to form: an internal bacterial exchange of genetic information as stated in (Pilus - a conduit).

Thiry et al. (1989) APPI. En viron. Microbiol. 55, 984 - 993) and because of its role in interacting with other cells 0 Availability | An excitatory capillary is useful for displaying SAT peptides to the external cellular environment. A large peptide surface structure is the vibrating cilia bacterial stimulus organelle. Fusing peptides with a protein subunit of a vibrating cilia presents a dense array of polypeptide copies on incubating VO cells (Kuwajima et al., (1988) Bio/Tech 6, 1080-1083). Surface proteins of other bacterial genera have served as fusion partners of the peptide of γ such as Neisserig of IgA and an exogenous protease Staphylococcus A. Examples include a protein: reported in Y. (Hansson et al. (1992) J. Bacteriol 174 4239-4245 and Klauser et al. (1990)

EMBO J.9, 1991- 1999).

AY

Described above, LamB binding occurs both in phagocytic and phagocytic systems and within the DNA body that it encodes by physical contamination of the DNA between a peptide and a (cell or phage) bearing the peptide on its surface. And seizing the peptide seizes the particle with it. DNA to form a link between two peptides and the Lack linker DNA and an alternative plan using the L0 protein: as stated in DNA

Cull et al (1992) PNAS USA 89: 1865-1869). With the Lac oligo cloning site, and this system uses a plasmid that contains a nucleotide gene at its tip? . Under controlled induction by Arabetose, the fusion protein Lacl. produces a short "DNA peptide" to bind to the Lack sequence. This fusion retains the natural ability of LacO (LacO). LacO is known as generic.

Lacl and superimposing two copies of 00ma on the rendering plasmid; A peptide fuse tightly binds to a plasmid that it encodes. Given that the plasmids in each cell contain a sequence, the cals peptides are a single oligonucleotide, and each cell embodies a peptide sequence that directs its synthesis, and DNA cells become bound qualitatively and stably with a sequence of a stable metabolite to restore the Wand peptide The DNA chain is gently exposed to the plasmid DNA compounds containing active peptides, and then the compounds are re-entered. To determine the conformity of DNA peptide bonds bound to cells for enlargement and chain

AY

And as proof of the practical usefulness of the method, a large random series of: duodenal peptides was prepared and selected on a monoclonal antibody that is notable for (opioid peptide dynorphin B). Also, classes of peptides were retrieved, related to an agreed sequence corresponding to a part with a six-part 0. Residual 0 dynorphin B as reported in: ( Cull et al. (1992) Proc. Natl Acad. sci. U.S.A 89 - 1869). This method, which is sometimes referred to as peptides-on-plasmids; Two important methods differ from the methods of phage presentation. First: the peptides are bound to the C end of the fusion protein, which leads to the presentation of the chain members as peptides 0 containing a free carboxy terminus. Both proteins are wrapped in a filamentous phage, PII 10111, anchored to the phagosome through its terminal ends, and the catalyst peptides are placed in the terminal domains -[1] extending outwards. In some designs, the phage-displayed peptides appear directly on the amino terminus of the fusion protein. As stated in: (wirla, et al. (1990) proc. Natl Acad. sei U.S.A 87, 6378-6382) Vo There is a second difference, which is the set of biological biases that affect a population confined with Lal peptides that are already present. in chains. The melting particles are the cytoplasm of the incubating cells. The fusions of the phage layer are exposed to the cytoplasm. during transformation but are hidden across the inner membrane in the periplasmic compartment: they are kept anchored in a membrane by their © terminal phobic domains with Y. containing peptides protruding into the periplasm while waiting for N terminals

A$

Aggregate into phagosomes. The peptides in Lael and in the conjugate chains can vary greatly as a result of their exposure to different proteolytic activities. Phage-encapsulated proteins require translocation across the inner membrane, and signaling peptides act as a precursor for integration with the phage. Certain peptides exert a detrimental effect on these

0 operations and are under representation in strings as mentioned in:

( Gallop et al. (1994) J. chem. 37 (9): 1233-1251)

These particular biases are not a factor in the Ladd supply system. The sue of small peptides available in random recombinant sequences is a huge number. Series of independent clones 01-101 are prepared in a routine manner. And the big chains are 101 repeaters

0 unions have been created, but this size exceeds the practical limit of clonal chains. This limit in the size of the chain occurs at the step of gad all the DNA containing parts made randomly into incubating bacterial cells. To overcome this limitation, an all-in-body system has recently been developed based on displaying newly generated peptides in polysaccharide compounds.

Vo and this display chain method have the capacity to produce WY sequences that are many times greater than currently available phage/phagemid sequences or plasmid sequences. Moreover, 0 sequences are synthesized to embody peptides and mass or fluorescence screening in a completely Lyall-free form. And in one use of this method as stated in: /

Gallop et al. (1994) J.

Med.

Chem. 37 (9) : 1233 - 1251) Y. The embodied chain was linked, "01 molecules encoding ten DNA peptides. A chain was created.

millimeter

in Coli S34.13 in vivo with transcription/transformation system. The appropriate conditions were chosen to stop or delay the ribosomes on the mRNA, which caused the accumulation of an essential percentage of RNA in the multiple ribosomal tissues and caused the production of compounds containing newly generated peptides that were still bound to their coding RNA. These multiple repast are strong on

0 purification on immobilized receptors and the same method as screening of conventional recombinant peptide chain widths. Each of the compounds is also retrieved and converted into DNA, and amplified by a total PCR that produces a model for the next round of synthesis and for mass or fluorescence examination. The multiple riboswitch display method can be linked to the phage display system. After following multiple rounds of mass screening or

B" fluorescence I 0 cDAN was cloned from the pool rich in multiple riboswitches into vector 40. This vector performs its function as a peptide-expression transferase and presents fused peptides to enclosed proteins. As a transferase of the DNA sequence for peptide recognition. By expressing derived peptides of polyribosomals on the phage 0. One can complete the affinity selection procedure in this figure or one can test the peptides on clones

1 individual to investigate the binding activity of the phagocytic ELISA; Or to find out the binding specification in completing their 51158 as mentioned:

(Barrett et al., (1992) An al, Biochem, 204, 257-364).

To identify or to determine the sequences of active peptides, one has to sequence the resulting DNA.

About the devouring host (Phagemid).

A

“Collective examination or secondary scintigraphy for polypeptides and homologues”: The choices set out above can be followed by secondary filtering tests in order to identify other biological activities such as those that will allow, for example, a person skilled in the field to distinguish between contractility and anticontractors. The type of secondary 0 will depend on Desired potency that needs to be tested. For example, a test can be conducted in which the ability to prevent an interaction between a concerned protein and its ligand Un Spl is used to identify and identify antibodies from a group of isolated peptide fragments through one of the main tests described above. Therefore, the methods of generating fragments and homologues and testing them to find out their activities are known methods in the field. Once the central sequence is identified, A obtaining homologues for it and the is parts becomes a routine matter for the person skilled in this field “peptide mimetics of HPylor polypeptides” Mimics such as peptide or non-peptide-like factors. And peptide mimetics have the ability to rupture the binding of polypeptides to their antibody, such as: in the case of poly con. Bacteria peptide: 11910 to generate mimics such as a peptide or such as non-peptide factors 0 and peptide mimics have the ability to rupture the binding of polypeptides with their anti-ligand bound by a ligand that occurs in the form of HPylo, such as: in the case of the polypeptide being bacteria

HPylori is normal. The remaining critical fractions of a bacterial polypeptide can be identified from those fractions included in the polypeptide molecular marker. and use it to generate XY.peptide mimetics derived from HPYlo bacteria that inhibit polypeptide binding.

AY

Bacteria:11.5910 which inhibit polypeptide binding Bacteria:1110 competitively or non-EP competitively with a cross-reactive polypeptide (see eg European patent applications (YN, A. -B-EP 1.7) i.e. use of sweeping transgenics To scan (know) remaining parts of oar, for example, an amino acid of polypeptide 11.7105 is involved in the binding of reactive polypeptide 0 and peptide imitators (such as diazepine derivatives or isoquinoline derivatives) can be generated that can mimic these remaining parts in Linking it to a cross-reactive polypeptide, which can prevent the occurrence of bacterial cross-reactive polypeptide 11.7101 11.1017 interfering with the function of a bacterial polypeptide, for example non-hydrolysable peptide analogues can be generated from such 0: remaining fractions using benzodiazees (eg see Freidinger et al., Pe Ptides: chemistry and Biology, G>R> Marshalled., ESCoM).

Publisher: Leiden Netherlands 1988);

Publisher: Leiden Netherlands, 1988), or using alternating gamma-lactam rings as reported in

Garvey et al. in Peptides: chemistry and Biology, G.R. Marshall ed., ESCom

Publisher: Leidan, Netherlands, 1988). : Or by using unreal methylene-keto polypeptides as stated in

Ewenson et al., (1986) J. Med. chem 29:295 and Ewenson et al., in Peptides: structure and function (proceedings of the 9th American Peptide symposium) Pierce chemical Co. Rockland IL, 1985))

They or use central parts of a di-dorbita peptide as reported in: (Nagai et al (1985) Tectrahedron Lett 26:647 and Sato et al. (1986) J. chem soc Perkin Trans 1: 1231), or Use of amino alcohols from beta LS male: 0 ml Gordon et al. (1985) Biochem Blophys Res Commun 126:419; and Dann et Biochem Biophys Res Commun 134: 71) (1986 VI) Vaccine formulations of amino acids and polypeptides of H Pylori This invention further describes formulations or formulations (used herein interchangeably) for the prevention of infection with bacteria: 11.710 and for the treatment of infection with LS, HPylori 0 is used here. The term “prophylaxis against infection with Streptococcus :115710” or the term “aller prophylactic” refers to the use of a vaccine formulation of Streptococcus :11.710 to reduce the risk of infection or to prevent infection in a body at risk of infection with Streptococcus 11.5710177. one incarnation; Vaccine formulations contain one or more Lelia antigen components such as a surface protein, from 1177105 bacteria or a protein thereof and a pharmaceutically acceptable vector. For example, and in one embodiment, the vaccine formulations according to the invention contain at least one polypeptide or a collection of polypeptides from the bacterium :1110 or parts thereof from the same H.Pylori antigens that will be used in XY. The vaccine formulations according to the invention Nucleic acids and polypeptides shown in

father-in-law

List of sequences, preferably those of bacterium nucleic acids: 11.5710 that encode surface proteins or parts thereof. For example, a bacteriophage 3 nucleic acid and polypeptide preferred for use as a vaccine formulation is selected according to the present regulation from the pool of nucleic acids encoding cell envelope proteins; Bacteria cell envelope proteins

HPylor 0 as shown in Table 1. However, in the financial invention, it is possible to use any nucleic acid that encodes the celine-producing protein of 11.101 bacteria and use any H.Pylori bacteria or part thereof. These vaccines have both therapeutic and/or preventive benefits. One manifestation of the invention provides a vaccine formulation for the prevention of infection with 11.7101 bacteria where

H.pylori is a proteolytic protein da. This culture contains part A1 and a pharmaceutically acceptable vector. As for the preferred parts, they contain peptides with a length of ten remaining parts of an amino acid, preferably a remaining part of an amount of coal. In length 11-0

VO and for example JUL, the immunogenic components according to the present invention can be obtained by the screening detection of recombinant polypeptides resulting from the corresponding segments of DNA encoding the total length of the protein of bacteria 11.5710. In addition, the parts can be chemically synthesized using known techniques in the field, such as:

(Conventional Merrifield solid Phase f - Moc or t - Boc chemistry.) Y.

q. In one embodiment, the components of immunogens are determined by the ability of peptides to stimulate T cells and peptides to stimulate T cells as determined by T cell epitope or secretion of cytokinesis, defined here. It contains at least one t-terminator. It is believed that T-cell antigen determinants are involved in the initiation and immortalization of the immune response to the protein arginine responsible for noninfectious clinical symptoms. These T-cell antigen determinants are believed to trigger appropriate early HLA events at the T-cell helper level by binding to the cell surface molecule that represents the antigen; This results in stimulation of the T cell subpopulation of the target T cell receptor for the antigen determinant. These facts lead to the proliferation of T cells, the secretion of lymphokine, objective inflammatory reactions, the recruitment of additional immune cells to the site 00 of the antigen reaction. T cell, stimulating a B cell cascade leading to the production of antibodies. The OR is the smallest unit of lid recognition. The antigen determinant of the T cell is actuated by the T cell receptor; The antigen determinant includes essential amino acids. Residual fractions of an amino acid (Ve 1 to characterize the receptor) as approximately Vo noting that the amino acid sequences are those that mimic the amino acid sequences of determinants. Cell antigens that fall within the scope of the present invention by another embodiment; Identification of antigen components according to the invention through genome vaccination or grafting.The basic protocol is based on the idea of Jie genome chains, embodiments consisting of all or some parts of a pathogen's genome. Genetically incubated pie bacterium: 11.5910 a3 homozygous for clonal reproduction and includes (BLD) and this clonal serial immunization to HPylor plasmids can reduce the genomic embodiment series of a pathogen = such as a bacterium that can perform the task of genetic vaccines. Plasmids can also be designed to encode genetic aids that can surprisingly stimulate the humoral response, and these genetic aids can be delivered at distant sites and made to perform their task in a manner 0. Cellular outer and inner cell attachment and without danger [Tia and this is an entry A recent production of a vaccine that has many benefits for nurses to vaccinate an incubator, which leads to DNA Infectious. It uses an embodiment series to produce the effects of showing a live vaccine antigen without the risk. For example, in the present invention; or from a cosmid or HPylon, random parts of the genome of bacteria 0 from genes distinguished by PCR can be used as plasmid offspring, in addition to using compounds from a genomic sequence for the purpose of vaccinating an incubator. And the possibility of this entrance has been proven by: According to what was stated in . Mycoplasam pulmonis (Barry et al., Nature 377 : 632 - 635, 1995) is a natural pathogen in My coplasma pulmonis that even provided partial expression sequences from Vo . The challenge coming from the pathogen, Fas Rodent Protection, is a technical method that allows the production of a non-infectious multicompartment vaccine. Even though the ELD immune system was used to screen for BLL, little was known about the biology of the pathogen, “because candidate genes. Once isolated, these genes can be used as genetic vaccines or they can be used to develop recombinant protein vaccines.” 0 ay

. BLT 13a allows the production of vaccines with highly condensed systemic immunization. Testing of immunogenic components can be accomplished using one or more titration tests, all of which are tested by several different titration tests. For example, outside the body, the stimulatory activity of a T-cell peptide by contact with a peptide known to be an immunogen.

© or suspected with an antigen-presenting cell that presents appropriate MHC molecules in a T-cell seed. Introducing an immunogenic peptide from bacterium 117108 in association with appropriate MAC molecules stimulates T cells to produce increased levels of cytokinesis; Especially from Interleukin Ym and Interleukin -; . Is it possible to obtain generic fry and test it for interleukin - ? or any cellular movements

0 other known. For example, can any of the multiple traditional tests be used for interleukin - ? , such as the test described in:

(Proc.

Natl.

Acad.

Sci USA 86: 1333 - (1989).

Its parts are incorporated here for reference and reference. The Bue kit for any calibration or any test for interferon production is also available from:

(Genzyme Corporation Cambridge, M A) \o Indicatively; A general test for T-cell proliferation involves measuring tritium-containing thymidine incorporation. T-cell proliferation can be measured in vivo by quantifying cultures. Therefore LOA can repeat from the DNA incorporated in the 3H-tagged thymidine B. In contrast, a measure of cell division, DNA is a measure of average synthesis

Y. It is preferred for vaccine formulations or formulations according to the invention containing one or more components of the (Jie) Lelie antigens HPylor polypeptide or part thereof or nucleic acid ay acceptable J3U containing of a polypeptide encoding bacteria 1159107 or part thereof) a pharmacist. The term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersing agents; Casings, antibacterial agents and antifouling agents. What is added to it is palatial fungi, isotonic agents and delaying agents. Compliant with pharmaceutical use 0 ls For example, pharmaceutically acceptable carriers include one or more types of water. solution, saline solution separated by phosphate, dextrose; Glycerol, ethanol and the like, in addition to a group of them. Pharmaceutically acceptable vectors may also contain small amounts of adjuvants such as wetting or emulsifying agents, preservatives or barrier agents, that enhance shelf life or activity of bacterial DNA or a polypeptide. As for the vaccine formulations of the invention containing poly H.Pylori peptides 1109108, it is preferable to administer the polypeptides in combination with a suitable adjuvant. With the delivery system described here 41/5 or DNA, it will become clear to those skilled in this field that the therapeutically effective amount of the protein of the invention will depend on; Among other things that depend on it, on 0 z 11.5710: the program of administration and the dose of nucleic acid or polypeptide of bacteria given, and depends on the extent to which protein or nucleic acid is given combined with factors of therapeutic efficacy Le yo other treatment or not; And the immune status and health of the patient. For specific protein or nucleic acid.?* Either vaccine formulations are traditionally given by injection, such as subcutaneous injection or: intravenous injection. Methods of immunization by intravenous route are described in

At

Wolff et al. (1990) Science 247 1465 - 1468

Sedegah et al. (1994) Immunology 91 9866 - 9870. Described in D. Other routes of administration include oral and lung formulations; suppositories; and transdermal applications. However, oral immunization is preferred over parenteral administration methods in order to induce protection against infection. By HPylor bacteria as mentioned in: . (642 : 637 11 al. (1993) Vaccine A. (Czinn) Oral formulations include naturally occurring excipients such as, for example, pharmaceutical grades, manitol; lactose; LAS; magnesium citrate; sodium saccharin; cellulose.; carbonate. Magnesium and the like.0 By embodying daly the vaccine formulation includes, on an adjuvant, as a pharmaceutically acceptable carrier.Examples of adjuvants suitable for use in vaccine formulations according to the invention include, without limitation: Aluminum hydroxide, A1-acetyl-muramyl = . 1-threonyl-17-isoglutamine (thr- MDP): 17-acetyl-:10-muramyl-1.-anyl-7-io1-glutamine (CGP 11637, re ferred to as nor - MDP) : 11-acetylmurami-ba Jus - (1-isoglutaminyl-a-alanine - ?-Y=) dipalmitoyl-88-glycero-?-hydroxyphos-furyloxy)- ethylamine (19835/8 (CGP referred to as (a MTP - PE), 18131 « which contains three components of bacteria, a, Apa monophosphorylated; pure almond dimycolate, cell wall structure:

E09 (MPL + TDM + CWS) in VY of squalene/emulsion Tween 8.; and cholera toxin. Other adjuvants that could be used are non-toxic derivatives of the cholera toxin Loy including its subunit B » and/or . genetically engineered conjugates or fusions of Bacterium 71° polypeptide with cholera toxin and its subunit B0 Procholeragenoid fungal polysaccharides, including schizophrenia; Muramyl dipeptide, muramyl dipeptide derivatives, furopol esters, label toxin from 15,001 non-bacterial lysates, 117,108 block polymers or saponins (a group of polysaccharides found in the plant world). 0 by another embodiment; include vaccine formulation; On the JUS delivery system. Pharmaceutical acceptable. Delivery systems suitable for use in vaccine formulations according to the invention include biosoluble microcapsules or immunostimulating compounds (ISCOMs). cochineals, or liposomes “genetically engineered active attached vectors such as viruses or bacteria and virus-like (chimeric) recombinant particles such as” les In another embodiment of the invention, the vaccine formulation comprises both a delivery system Adjunct delivery systems in humans may include enteric-coated capsules.

H.pylori antagonist from the acidic environment of the stomach and containing bacterial polypeptides in an insoluble form as refractory proteins. Among the suitable vectors for vaccines, Y. of the invention, are enteric-coated capsules, polylactide-glycolide microspheres, and diluents.

Suitable is 10811003 0.2N 41/5 Saline Solution. Vaccines of the present invention can be administered as a primary protective agent (Ao) in adults or children, as a secondary prevention; After eradication of gals L: 11.5710 in an incubator of lias or as a therapeutic agent with the aim of inducing an immune response in a suspected incubator to prevent infection by 0 HPylori bacteria, the invention vaccines are given in quantities easily determined by those with ordinary skill in the field. Thus, the appropriate dose for adults is within a range between 01 microgram to 01 pla, preferably between 100 micrograms - 100 milligrams, for example between .5 micrograms - .5 milligrams. An appropriate dose for adults will also be within the range between 0 micrograms - 5 milligrams and similar dose rates will be applicable for children. As for the amount of adjuvant used, it will depend on the type of adjuvant used. For example, when the adjuvant is Cholerae toxin, it is appropriately used in an amount ranging between 5 micrograms and .9 micrograms, such as Yo-01 micrograms, for example. When used in the form of microcapsules, the amount used will depend on 0 the amount used in the Laie microcapsules to achieve the desired dose. Determining this quantity is within the skill of a person of ordinary skill in the field. Those skilled in this field will realize that the optimal dose may increase or decrease based on the patient's weight, on Aloa Al, on the way the vaccine is administered, and on the basis of other factors. Those skilled in this field will also realize that it is possible to obtain appropriate dose levels based on results from known oral vaccines such as, for example, a vaccine based on AV cell lysis yield and with a proteogenic antigen at 0 mg daily dose. and up to: 9 milligrams (1) E. Coli: milligram) as reported in 1 £ doses of enterotoxin-producing E. Coli (Schulman et al., J Urol. 150: 917-921). (1993); Boedecker et al., american

Gastroen-terological Assoc, 999 A-222 (1993)) For formulation and on efficacy data I The number of doses will depend on the disease and on 0 and note that you mean any determination of the group 0 elicited from | For clinical trials [J] and how effective is it possible to take the treatment? - 8 doses of Gla doses given to treat a patient: one month; As mentioned in 1 initial immunization for a period of (Boedeker, American Gastroenterological Assoc, 888 : A-222 (1993) (l). In a preferred embodiment 'a vaccine batch can be established on a killed total preparation of 2 of the selection Ea, H.Pylori bacteria Asm with immunogenic part of E.Coli bacteria with part E. Coli lysing I cells and can be based on the outcome of |e embodied on its surface killed. It will be clear to those skilled in this field that “some of the vaccine formulations according to the invention are useful in preventing infection with No. 11.5710 and some are only useful in treating infection No. 11.10: Some of them are useful for both preventing and treating infection with HPylon bacteria, and in a preferred embodiment, the vaccine composition according to the present invention provides prevention of infection by stimulating medium-cell or humoral immunity against HPylon bacteria. It must be understood that the improvement in Any symptom of H. 3 infection is a desirable clinical objective, including reducing the dose of the drug used to treat 11.7100 Y.

AA

Or an increase in the production of antibodies in HPylor serum or diseases caused by bacteria. In the membranes addressed to patients: 11.10: Antibodies reacting with bacterial polypeptides. 1 The invention also includes special antibodies, antibodies reactive with a polypeptide, bacteria: 11710, and an antiserum, antiprotein / antipeptide, or ©: monoclonal antibodies can be prepared by standard methods (see for example: Antibodies: A Laboratory man ual ed. by Harlow and Lane (Cold Spring Harbor

Press: 1988)) Mammals such as rats and hamsters can be vaccinated. Or rabbit in the form of an immunogenic peptide. Techniques for granting immunogenicity on a protein or on a peptide include 0. Coupling with transitions or other artistic methods known in the field. From u-peptide bacteria 11.7101 in the presence of an assistant, Lelia, and an antigen protein can be given, and the progress of immunization can be monitored by tracking antibody standards in plasma or in standard, assays or other immunological tests, serum ELISA. Al can be used. With an immunogen as an antigen for the evaluation of VO antibody levels for poly olin antigen determinants in a preferred embodiment the antibodies are a treatment peptide of the invention contained in the list of sequences or closely related human equivalent or 780 more preferably at least 0, is .79 structurally similar (synthetically similar non-human mammalian 01S) and in another preferred embodiment of the invention; Antibodies do not react against

TA. Bacteria: 11,210 essentially cross-reacting (i.e. interacting specifically) with a lower protein Y. Similar to the sequence of the invention included in the list of sequences we mean by the term “does not interact”

Essentially mutually exclusive, that the antibodies have a binding affinity for a non-homologous protein of less than 7/10 preferably LAST with less than 70 and preferably LAST and more with less than 1/1 of the binding affinity for the protein of the invention included in the list of sequences. And in a more favorable embodiment. There is no cross-reactivity between Lous antigens

° and bacterial. As used here, the term “O” antibody is intended to indicate that it includes Cia moieties that are also qualitatively reactive with the polypeptides of bacteria 1157101. Antibodies can also be fractionated using conventional techniques, and these fractions are examined in the same way as described for all antibodies. For example, these parts can be generated by scanning with the same

The method described for all antibodies. For example, parts of F (ab) can be generated by treating the antibodies with pepsin. The resulting Al (Ata) parts can be treated to reduce disulfide bonds to produce Fab! parts. The antibody of the invention is intended to include specific binary and mock molecules containing anti-bacterial H.Pylon protein.

SS, Vo Monoclonal and polyclonal antibodies (Ab) directed against Polydala from Bacterium (i sl.

H.Pylori has different H.Pylori polypeptides and antibody fragments (Fabl) Jie and such as Fab'), which can be used to inhibit the action of H.Pylori polypeptides 11.7101. It allows to study the role of H.Pylori polypeptides. pylori of the invention in an abnormal or undesirable signal inside the cell, in addition to

0 Normal cellular function of bacteria: 11.5710, by a simple injection of antibodies. According to the invention HPylori of a bacterial polypeptide, it is also possible to use antibodies that bind sensitizing bacterial determinants in immunohistochemical staining of tissue samples to assess their abundance and to assess . 1 Pattern of expression of antibacterial genes 11.9108 « It can also be used diagnostically © antibodies in immunoprecipitation and in HPylor, anti-bacterial polypeptides, immunostain to track and evaluate the levels of bacteria 11391010, in copies or in bodily fluid as part of Carrying out a clinical examination or examination. Likewise, the ability to monitor a person allows determining the efficacy of a diet, HPylon levels, and polypeptide levels of certain treatment bacteria for a person afflicted with such a disorder. The level of poly-0 peptide 117101 bacteria can be measured in cells present in bodily fluid; such as in urine samples, or can be measured in tissues; Like what results from a gastric biopsy. You can

Wis. HPylor Diagnostic Tests That Use Antibodies Against Bacteria The use of immunological tests designed to assist in the early diagnosis of infections The present invention can also be used as a method for detecting HPylor Bacteria 1 antibodies contained in samples taken from infected individuals | bacteria, and so on. 11.5101 using specific antibacterial genes, and there is another use of polypeptide antibodies 1137108, antibody according to

Jota described in the DNA embodiment vectors of the invention and is in the immunoassay of DNA sequences

A. Azap, 281018-23 01, and AORF8. Hourly sequences of this variety, containing coding sequences included in the correct reading frame and in the correct orientation, can produce fusion proteins. For example. Ag will produce fusion proteins whose amino terminus consists of an amino acid sequence beta-c galactosidases,

0 and its carboxy terminus consists of a foreign polypeptide. The antigenic determinants of the bacterium polypeptide 1137103 could then be tracked, for example, with Jha antibodies; Reactive nitrocellulose filters removed from loli infected with Hod antibodies, anti-bacterial peptides 11091011, and then the phage can be isolated from the infected plate. Thus, it is possible to discover the presence of genetic similarities of the 11.7101 bacteria, and their clones from

0 Other genera 0 Also, reciprocal isoforms (including irregularities connected by argument or superposition) can be detected and reproduced.

VIII “Kits Containing Nucleic Acids, Polypeptides or Antibodies of the Invention” : The Nucleic Acid, Polypeptides and Antibodies of the Invention may be combined with Vo other reagents and with tools to form “Kits” for personal use and these kits are for Diagnostic kits typically include nucleic acid; polypeptides or antibodies in vials or other suitable containers; and kits typically include other reagents, Lala hybridization reactions, polymerase chain reactions (PCR), or for reconstitution of lyophilized components, such as aqueous-salt media, Separators, etc. The tool kits may also contain reagents for treating samples such as antiseptics, salts

Chaotropic" or similar. These kits may also contain classification media such as dyes, radioisotope endorsement reagents, fluorescence agents, luminescent agents or chemiluminescent agents, enzymes intercalating agents, and so on. With the amino acid and nucleic acid sequence information provided in this paper, people with skills in this field can assemble kits to serve their own purposes. In addition, the mentioned kits can include instructions for their uses. IX Drug Screening Tests Using Bacteria Polypeptides :11.5910 Makes Bacteria Polypeptides :11.7710 “purified and recombinant The invention provides all assays that can be used to screen drugs that are either agonists or antagonists of normal cellular function in This case of polypeptides: 11710 1 or its role in signaling inside the cell. And such additives or activities can be useful as therapeutic agents Lua to combat infections with bacteria: 11.5910 Violently, a variety of tests will be sufficient, and in light of the current inventions,. It will be understood by those skilled in this field. NO In the many drug screening programs that screen compound sequences and natural extracts, interstitial tests are highly desirable in order to maximize the number of compounds screened in a given time period and assays performed in cell-free systems0 such as those that can be derived with selective or quasi-protein Pesticides are always preferred because they are “primary” qualifiers in that they can be generated to allow rapid manifestation and/or relatively easy detection of a change in partial target mediated by a test compound. Furthermore, the effects of cytotoxicity and/or bioavailability can be ignored. biology of a compound

Testing is generally done in a 'glass tube' system and rather than focusing the test mainly on the effect of the drug on the molecular target as may be demonstrated by altering its binding affinity with other proteins; Or with a change in the enzymatic properties of the molecular target. Accordingly, in a typical sifting or filtering test according to the present invention, 0 is in contact with the compound | For the meaning of any compound! For testing with Uli dala bacteria H.Pylori ¢ isolated and purified. Filtering tests can be carried out in the “glass tube” with a purified HPylon ¢ polypeptide or a part of it such as HPylon bacterial polypeptide, containing enzymatic activity, as it produces the activity of | Polydata has a trackable, interoperable component [N] for detection. The KFA 3c0 compound can be tested by generating dose-response reserves from the 5xX paraha pu toli 2 data in response to a dose of BBD obtained using various concentrations of the test compound. Furthermore, ||can be performed | A test is required to provide a main line for the J comparison. Suitable compounds include those with discriminant fluorescence absorption or chemiluminescent properties, for example, because the detection can be made mechanistic. A wide variety of synthetic or naturally occurring compounds can be tested in the test to determine those compounds that enjoy or enhance the activity of HPylor polypeptides, and some of these active compounds can be directly or by chemical changes that enhance membrane permeability or solubility that prevent Also, or potentiate the same activity (such as enzymatic activity) as a whole, in the cells of H. pylori bacteria  and some of these 1    4 compounds can directly or  Y, by chemical changes that enhance membrane permeability or solubility can also prevent or potentiation of the same activity (as enzymatic activity) as a whole in Bacterial cells: 11.5710; live.

This invention is further illustrated by the following examples, which should not be taken to limit the invention. The contents of all references and uses of published patents cited throughout this application are incorporated herein by reference. I" to clarify with examples " 0 1 Cloning and sequencing of DNA HPylori bacteria: The chromosomal DNA was separated from bacteria: 11710 according to a basic procedure for DNA stated in: Schleif R.

F. and Wensink P.

C., Practical Methods in Molecular Biology, p.98, (springer-Verlag Ny., 1981) 0, with minor modifications. Briefly, the cells were pelleted, and resuspended in TE (10 mmol 5.01 mmol EDTA, pH (Vv), followed by the addition of Jala regulator 8 (thiospanate guanidium, gram molecular concentration, 5018 with a concentration of R. grammolecular, pH 4, N - lauryl - sarcosin 50/), and cooling the suspension, then adding tetraammonium skewers (NH4Ac) to the concentration of AS ous Lg grammolecular + and DNA extraction Vo with [isoeroyanol ale ge urethane < /V. of EtOH », dried and re-suspended in TE After separation or isolation, all genomic DNA (related to the group of germinating factors) was converted from Bacteria: 11.2010 to spray according to: Bodenteich ct al., automated DNA Sequencing and Analysis (J.C.

Venter, ed.), Academic Press 1994).

M Li has an average size of ‎bp Yoo.‎ .is | to convert | I sprayed the DNA was concentrated and separated on a standard VA agarose gel 'and if it has multiple fragments that correspond to approximate sizes bp \WW..— VY... bp VW..-14.. no - bp YV.. = XY... bp YY... from the gel and purified by (Biblol Inc.) Gene Clean method. At that point, the selected DNA 0 fragments were gelatinized using T4DNA polymerase. DNA has been linked Which has been processed with unique BSIXI-Linker adapters in about 0...- 001 on it from Sasa overflow. These linkages are complementary to the pMPX transporters truncated by BstX1, while the cantilevers are not self-complementary of clay. The truncated transporters re-attach themselves easily. The ligand-adopting fillers were separated from the unfused ligands on ZY 0 gla Garose and cemented using Gene Clean. The adopting ligands were then conjugated to each of the 20 pMPX translocations to create a 'knockout' sequence of subclonal strands. Vectors containing the lacZ gene out-of-frame at the site of cloning become in-frame in an adaptive dimeric cloning state, allowing 1 to avoid translocation by means of its blue flag. All of the following steps were minimal on the multiple DNA sequencing methods presented in: (Church G.

M. and Kieffer - Higgins S. science 240: 185-188, 1988) and the focus was on basic modifications of methods only. In brief, the transfected Yo was then transferred to (DHg-alpha)-competent cells (according to the method of transforming s —=5(Gibco/BRL DHSa).

Assessment of chains by laying them on ampicillin-containing counter plates; methicillin and 1IPTG/Xgal. The plates were incubated overnight on Lysis grade TY, then successful transformations were used to unroll the clones and aggregate them into multiple complexes. The progenitors were captured and collected in .4 ml culture media; and growing 0 seedlings overnight at VV Laie temperature and purifying all the DNA using Qiagen-Midi-Prep inserts and Tip-100 columns (© 10 018860) and in this way 0 μg/g of The DNA of each pool was generated, and Vo-numbered arrays of 451 cavities were generated to obtain an abundance of 0-Ve-fold sequences with average base lengths of 78-Yee. Multiple DNA based 0 on chemical degradation methods : Church G.M. and Kieffer - Higgins S., Science 240 : 185 - 188, 1988) or by dioxyribose chain (Epicenter-Technologies) Sequitherm ¢ and electrophoresis of the chain reactions and their transfer to nylon membranes by direct electrophoresis of .5 cm gels: (Richterich P. and church G.M, Methods in Enzymology 218 : 187 - 222, 1993) \o or by electrophoresis staining as reported in (church, supra) YE sample per gel was used.£0 successful membrane was produced By chemical chain, and the production of A membranes by a deoxy chain.The DNA was covalently bound to the membranes by exposure to Gob violet light, and hybridized with pad yl complementary labeled nucleotides. And the membranes were washed to clean them from

no non-specific restricted probes; And exposing them to an X-ray film to see the individual sequence ladders. Then the hybridized probe was removed by incubating at 659 °C and the hybridization cycle was repeated with i | PVR PPP out go then probe for Sd trance YA time for 8 5 quantitative series trance 1 0 | “ih passed | BL A: di-roxy chain trance. Thus, each generation produced a huge number of films, each of which contains 0 information of the Basa series. Whenever a new blot was processed, an internal standard sequence added to each of the pools was initially probed. It also then generates digital images from | for pens EN | ¢ Caviar ue {a L-scanning laser meter (Moleculr Dynamics, Sunnyvale, CA). The digital images were processed on a computer (40008) (VaxStation) using the program (REPLICA™) as mentioned in: (Church et al., Automated DNA sequencing and Analysis (J.

C. venter, ed. (Academic Press, 1994) Jaa image processing included straight paths, modifications to mitigate differences in density, and enhanced decay by de-wrap of the inductor on a recursive V0 shift. Then the sequences were captured automatically in (REPLICA™). Interactive tests are offered to correct before they are stored in a database. Correction of the experiments was carried out by means of a quick visual inspection (scanning) of the I images of the ged patter film. 3 sa on the displayed images to modify and correct the signals because multiple sequence reads covering the same portion of genomic DNA provide sufficient sequence abundance for publication. Each .?* will then receive an identifier or reference number sequence. This number acts as a permanent sequence identifier so that it is always possible to identify the origin of any particular sequence without the use of a database

FALCON, as cited in: Church, Church et al., automated DNA Sepuencing and Analysis (J.C.

Venter (ed.), Academic press 1994). GCG) (Devereux et al., Nucleic Acid Res. 12: 387 - 95, 1984) that interact with REPLICA™. This opened the way for integrated publication allowing Ve images of multiple sequences to be ordered simultaneously from The REPLICA™ Database presents a US Rapid Inspection Procedure of Contacts and Reads of an Experimental By-Gel Where Discrepancies Occurred between Reads of Different Sequences in the Set 11. Identification, Cloning, and Embodiment of Sequences Bacterial DNA: 11,010 recombinants: to facilitate cloning or cloning; the transcription and purification of membranes and secreted proteins from H.Pylori, which is a powerful gene expression system; and the (Novagen) p ET system, were selected to clone and purify recombinant proteins in BECO bacteria Also, a DNA sequence encoding a peptide code, the His-Tag, was melted at the end of DNA sequences of interest to facilitate the purification of recombinant protein complexes. Do not change any terminal signal sequence 0 and the exception to the above is XY. Ka ppiB O 0 gene clone to use | 9 as a duck in Ld od Tat | to embody ' in this 3 [

In this study, the ppiB sequence of HPylori bacteria contains a DNA sequence encoding 1118-48 fused to the tip* of the total length of the gene; Because the protein complex of this gene does not contain a signal sequence it is embodied as a cytosolic protein. PCR amplification and cloning of DNA sequences containing ORFs of membranes and of secreted 0 proteins from strain 199 of “Helicobacter Pylori”: The selected sequences (from the list of DNA sequences according to the invention) were prepared for cloning from strain 199 of Bacteria:11.5910 “for amplification of cloning by polymerase chain reaction (PCR) as primers or synthetic oligonucleotides (Table 3) specific for the 0' and oY ends of (ORFS) were designed and purchased from: GibcoBRL Life Technologies, Gaitherburg, MD, U.S.A). \.All primers (particularly for pin 0 of the sequence) were designed to contain cloning location 1001/ at the 0 end cc except for .110960 071.87 where Ndel was used. These primers were designed to prevent the transformation of serotonin at a remaining residue of methionine with the residue of valine and the coding sequence Vo for the rest of the DNA sequences of the original HPylori bacteria. The exception was sequence LAY 2471 of Bacterium:1152710, where the starting methionine was immediately followed by the rest of the DNA sequences of Bacterium:11.5710, the original and contained all the spare primers (particularly for the 7th end; of any HPylori ORF) site

to

01 at end 0 to allow all RF JI sequences to be cloned.

HPylori from pET-28b. Transporter PET-28b provides a sequence encoding an amino acid with a carboxy terminus (V1) amino acid only in Hp Seq no. 11740 714 and in Hp Seq no. 15.177 (0).

0 contains six remaining histidine fragments (at the -0-terminus) that contain the His-Tag. The exception to the above, as already noted, is the vector construct of the ppib gene. There is a specific synthetic primer oligonucleotide for the 0' end. Gene PPIB encodes the BamHI site on its extremity 0 and the prologue of the terminal ? From gene 0013 encodes the site 30:01 on its extremity 0# .

ARN

Table? © HPylori « Bacterial DNA PCR sequences primers or oligo-technology primers used to amplify Z Protein 16225006 5'” TATACCATGGTGGG 5-ATGAATTCGAGTAAG

CGCTAA-3' (SEQ ID. GATTTTTG-3' (SEQ ID

TE Sahat Protein 26054702 S-TTAACCATGGTGAAA 5” TAGAATTCGCATAAC

AGCGATA-3' (SEQID GATCAATC-3' (SEQ ID

I'lls Se

Protein 7116626 5'-ATATCCATGGTGAGT 5'-ATGAATTCAATTTIT

TTGATGA-3' (SEQ ID. TATTTTGCCA-3' (SEQ ID

ETE

Protein 29479681 5“AATTCCATGGTGGGG 5'-ATGAATTCTCGATAG

GCTATG-3' (SEQ ID CCAAAATC-3' (SEQ ID [eee

Protein 14640637 S-AATTCCATGGTGCAT 5'“AAGAATTCTCTAGCA

AACTTCCATT-3' (SEQID | TCCAAATGGA-3' (SEQ

Ee

Periplasmic/ Secreted mt I due to Protein 30100332 5'-ATTTCCATGGTCATG 5-ATGAATTCCATCTTT

TCTCATATT-3'(SEQID | TATTCCAC-3' (SEQID [eRe

Protein 4721061 5'-AACCATGGTGATTT S'-AAGAATTCCACTCA

TAAGCATTTGAAAG-3' AAATTTTTTTAACAG-3' (SEQ ID NO:159) (SEQ ID NO:160)

Other Surface Proteins

Protein 4821082 5'“GATCATCCATATGTT | 5-TGAATTCAACCATTT

ATCTTCTAAT-3' (SEQ ID | TAACCCTG-3' (SEQ ID

TTT malian No: 162)

Protein 978477 5'” TATACCATGGTGAA | 5-AGAATTCAATTGCG

ATTTITITCTTTTA-3' TCTTGTAAAAG-3' (SEQ)

Protein 26380318 S-TATACCATGGTGAT | 5-ATGAATTCCCACTT

GGACAAACTC-3' (SEQ GGGGCGATA-3' (SEQ ID — 11 WA 5-1121 1 UMMATOVEL | 5-TATCTCGAGTTATA

CAATTAAAACT-3' (SEQ | GAGAAGGGC-3' (SEQ ID

RO

A genomic DNA prepared from the Jqq strain of bacterium 11.5101 ATCC#9 was used, from:

Genome Therapeutics Corporation, 100 Beavor Street, Waltham, MA 02154) (Current Protocols in Molecular Biology John Wiley and sons 1ns. F. Ausubel et al. 0 eds 1994).

DNA J and then insert. H. pylori bacteria ORF containing DNA to prime the sequence of 3' mmol Y Mgcl2 to act | to contain | 3 EXD) Ls No Gra M in Loo. ) Magiti and primers of oligonucleotides with Fada 1 microgram (forward and reverse primers) A. Complementary L and 3,5-L ORF bacteria Y H.Pylori t. millimoles of each deoxychlorotide triphosphate and dTTP, dCTP, dGTP, dATP and dr? A unit of adiabatic DNA polymerase: Amplitaq, Roche Molecular Systems, Inc. Branchbury, NJ, USA) for a thermal cycler I μl. The following conditions of \.. 8.43 sl in volume of Vo were used to obtain amplified DNA products for each ORF using a thermal cycler of: Perkin Elmer Cetus/ Gene Amp PcR System 9600)

YL NLL 1 OAS 9 Ya AN OAs 9 PAAR Th A As 9 1. VY {AS 9 » Lcd AYN LAY and protein Y. The change of the natural substance or the deformation of the natural properties at 54 degrees Celsius for a period of ? minute .

all ? Cycle at 44 °C for 19 seconds, JOR °C for 18 seconds, and VY °C for 1.9 minutes. XY cycled at 44°C for 10 seconds, 00°C for Vo seconds, and VY at 44°C for 1 minute. ° The reactions were carried out at VY Lita temperature for 6 minutes. Protein 7.. 11775: Deformation of the natural properties or change of the natural substance at 44 degrees Celsius for a period of time? minute . YO cycle at 509 °C for Vo sec, 59 °C for Vo 0 sec; VY is a temperature in Celsius for 1.0 minutes. The reaction was carried out at VY, temperature in Celsius, for minutes. Protein 771.41: change of normal properties at 44 degrees Celsius for a period of ? Yo cycle at a temperature of 44 degrees Celsius for 1 Bul sec, TT at a temperature of C for 10 seconds, No and VY at a temperature of C for 1.9 minutes. ?? A cycle at 94 degrees Celsius for a period of 1 second, 1 leg, a temperature of Celsius for a period of 1 second, and a temperature of VY, a temperature of 1,9 minutes. The reactions were carried out at VY temperature C for 1 min. ,

AR}

YUVA. 718 protein Af changes the natural properties at 94 degrees Celsius for a period of ? minute . ? cycle on

VY Aes sec 09 °C for a period YA leg Lali Vo °C for a duration . for 1.9 minutes Lge temperature

Vo Bul lingering temperature VY eg 19 cycles at 44 °C for 0 YY sec. Celsius temperature for 1.09 minutes VY leg seconds . Minutes 1 ° C for a period of VY The reactions took place on: 1152777 protein. for how long? Minute Liste changing the natural properties at 54 degrees 00 for a period of shad, lym?? dey degree seconds 09 ? Cycle at 954 degrees Celsius for 0. For 1.9 minutes Lista temperature VY leg 09 seconds 09 seconds 909 degrees Celsius for Vo cycle at 92 degrees Celsius for . jo minutes Celsius temperature for VY seconds and . Minutes Il temperature VY Celsius The reactions took place on + 11.7101 ppiB bacteria “Vo . Change of physical properties at 44 °C for a period of ? min sec 11 °C for YY , sec 19 ? Cycle at 44°C for 1°C for 1.9 minutes. Z | VY and 00 sec 01 sec 01 °C for Vo cycle at 954 °C for 0 Y0 . for 1.9 minutes Lhe and ?no temperature | 0

The reactions took place at VY temperature in Celsius for minutes. Upon completion of the thermal cycling reactions, each amplified DNA sample was washed and purified using a purification kit of the type: “Qiaquick Spin PCR” available at: (Qiagen, Gaithersburg, MD, USA) 0 and JS samples were exposed The Digestive Amplified DNA with Endoenzyme Restrictions Neol and EcoRI are available from: (NEW England BioLabs, Beverly, MA, USA) or at AYN LAY HPSeq Ula€ (sequence with reference number (). WA, B, Ndel, and EcoRI. \ As stated in: Current Protocols in Molecular Blology, John wiley and Sons Inc.

F.

Ausubel et al. (al. eds 1994) followed by clive DNA extraction on (FMC Bioproducts, Rockland/1 ME USA) Nu Seive gelatin agarose. The DNA slug was visually exposed by exposing V0 to ethidium bromide and long wave UV radiation. The DNA contained in slices separated on an agarose gel was purified using the Biolol Gene Clean kit method from (Bio lol Vista CA U.S.A) “cloning of HPylori DNA sequences into a prokaryotic embodiment vector pET-28b:

Prepare a pET-28b vector for cloning by digestion with Nol and EcoRI, or in Ula protein AYY LAY £ H.Pylori bacteria with Ncol and EcoRI: According to: Current protocols in Molecular Biology, John wiley and sons Inc., F.C.

Ausubel et al., eds., 1994).0 and in Ula clone ppiB; The PET-28q vector, which encodes a His-Tag that fuses at the 0' end of a gene within, was used, and the cloning site was prepared for cloning with the 0018 gene by digestion with BamHI and Xhol, which are endonuclease restriction enzymes. after digestion; DNA accessions were cloned according to: Current Protocols in Molecular Biology John Wiley and Sons Inc.

F.

Ausbel et al., eds. 1994). ). who will be digested; With the exception of Ie, the macrocephalus ppiB J was cloned into a PET-28q rendering vector. The ligation reaction compounds were then used to transform E.coli strain 3121 according to Current Protocols in Molecular Biology, John Wiley and Sons, Inc.

F.

Ausbel et al. eds 1994) Vo “Transformation of Competent Bacteria with Recombinant Plasmids » The Competent Bacteria were Transformed from Strain 13121 of E.Coli” or from Strain 1 (DE3) of Coli What are the recombinant PET engraftment plasmids with XY execution? The sequences cloned from HPylor according to the standard methods given in:

(Current protocols in Molecular, doh Wiley and Sons Inc., F.

Ausubel et al., eds 1994. Briefly, 1 μL of BIS bonding reaction was conducted with 0.9 μL of electrically qualified LIA and subjected to high voltage pulses, after which; Samples were incubated in SOC 0 (480). milliliter) (Yeast extract 7.9 7 Trypton 1 01 mmol Nacl, Dr. mmol Ve KCL mmol 0 MgCl, mmol 0.ys Mg Sod mmol glucose) on YY at °C with stirring for 1 hour, after which the samples were spread on 1 laurel LB plates containing YO μg/mL of kanamycin sulfate for overnight growth. The transformed colonies of 0,3121 were then captured and analyzed for the evaluation of clonogenic fillers as described below. Identification of recombinant PET expression plasmids carrying the sequences of 11.3102 bacteria: 3121 individual clones mutant with ORFs of bacteria: 10 and 11 (pET-28b) were analyzed by PCR amplification of cloned fillers or accessions using the same forward and reverse primers for each Bacterial sequence: 11,210; Which were used in 1 original PCR amplification cloning reactions. Successful amplification demonstrated the integration of bacteria sequences: 11.7710, into the embodiment vector according to: Current Protocols in Molecular Biology, John Wiley and Sons Inc., F.

Aususbel et al. (al., eds 1994) “Isolation and preparation of plasmid DNA from BL21 transformants” Y. Single clones of 021-286 recombinant vectors carrying ORFS bacteria were considered.

WA

Yo plus LB broth 0 ml properly reproduced and incubated at* 0. 1.0

Jie μg/mL of kanamycin sulfate overnight and the next day: the plasmid was cultured and cultured using the plasmid authentication method according to DNA (Qiagen Inc. chatsworth CA, U.S.A) “Qiagen” “E.Coli recombinant in bacteria” HPylon "represents the sequences of 0

Ji. E.Coli K-12 in any strain of PET bacteria can the vector be bred. For the purpose of cloning or to prepare a plasmid 0 lakh 01 DHS, 11109, HB 101 HMS174 containing a chromosomal copy of the E.Coli gene. Embodiment incubators are Jods “DE3” strains. These incubators are dissolution fairies from a bacterial phagocytosis. T7RNA polymerase derivative hyoid (junction of the sagittal suture and the hypohyoid suture) harbors the L180 gene. and Al 0 inductor

T7RNA and the gene for HAL17 polymerase. The “Lac 5” polymerase is induced by the addition of isopropyl-1-13-thiogalactoside (© 1:4), the L polymerase carrying an inducer 17 and the PET-28b crescent 17 gene that transcribes any target plasmid “such as: meaning and the strains used (include) 3121 (DE3) (Studier, 1.137 ROSENDBERG, A.H., Dunn, J. J. and Dubendorff Vo).

J.W. (1990) Meth. Enzymol. 185, 60-89). nanograms of 09. Recombinant HPylon was used to render bacterium sequences an isolated plasmid as previously described for transforming virulence-competent bacteria DNA as part of the Novagen Expression System Kit as previously described (provided by BL21 (DE3) as is PET- (beta-galactosides) has been described in the LacZ system and the PET gene has been expressed.

Hot for recombinant bacteria: 11710, and the transformed cells were cultured in SOC media for 1 hour, and then the fry were spread on IB plates containing Yo μg/mL kanamycin sulfate. On the day JU, bacterial colonies were collected and grown in LB medium containing kanamycin sulfate YO (0 μg/mL) to an optical density of units of 100 nm in Dr. 1- An outer diameter (OD) where at this point 1 mmol of IPTG is added to the fry for ? Hours to induce gene expression from recombinant DNA structures of H.Pylori bacteria. After induction of gene expression with TPTG, the bacteria were pelleted by centrifugation 0 in a Sorvall 60-33 centrifuge at 0.70.2 p for 9 minutes and on; Celsius temperature. The pellets were then resuspended in 0.5 ml of 01 mmol of Tris-HCI + pH 4 and NACL of R. Gram molecular concentration and 1 R. mmol (STEbuffer) EDTA, then the cells were centrifuged on ... 8 * 7 for 1 minute at 4 degrees Celsius. The wet pellets were weighed and frozen at -4 °C until they were ready for protein purification. 1- “Purification of recombinant proteins from bacteria “E. Coli” Analytical methods: The quantities of concentrations of documented protein preparations were measured by a spectrophotometer: (a measure of the relative intensity of the parts of the spectrum) using a number of absorbance coefficients of

AR

Amino acid contents according to (Perkins S.J. 1986 Eur. J.Biochcm. 157 169-180): Protein concentrations by JE method as (Bradford, M.M. (1976) Anal. Biochem. 72, 248-254 and Lowry, O.H.

Rosebrough N., Farr, A. Ma and Randall, R.J. (1951) J. Biol. chem. 193 Pares 0 265-275 (Glats descended from acrylamide) /Y0-4 polyacrylamide (17//or - SDS). Gelt was purchased from: (BioRad, Hercules, CA USA) Ye and contained Molecular weight indicators of myosin Coomassie and their formulas in blue 0

E.Coli from the bacterium (kDa WN) - Gel Cactosides (.7 kDa). Skeletal muscle of a rabbit.

JY) (KDa LY) or bovine serum albumin cl . (KDa Rnb 3 Rlac | Jae B Willis Phosphorus Soybean Trypsin (KDa YY) eggs (£0 10138), bovine carbonic anhydrase 1,0); and bovine aprotinin (KDA 14) ferment case of egg whites (0.4 (KDa? 1.0) (0) kDa: purification of soluble proteins. 1 All steps were carried out at 4 degrees Celsius, and the frozen cells were thawed and returned

Nacl. pH Khachla ' Tris MilliMol Y. ) Suspension in 0 sizes of regulator | dissolve who? - Mercapto Ze R01 Gluciferol VV Millimol with 50, the? Gray molecular concentration 0 mmol vinyl methyl fluoride 01 ethanol, .. µg/mL yeast state

, 01 µg/mL each leupeptin; Aprotinin 01, and (PMSF) a chloro-sulfonyl-? - [4 - Tussel Amidu] - 7 - Amino - ? -heptanone-1- 1., peptatin chloro-41-7-tosilamido]-4-phenyl-? = iotanone-1-1 + (TLCK) soybean trypsin inhibitor; It was broken up by several passages through a small aan micro-0 flume (TPCK) (Model - M - llos, Microfluidics International Corporation, Newton, MA) 1 hour for 8 * 001 ... and expelled. Centrally on Brijgg 7/1 and the result of homogeneity has been made. To obtain a pure floating substance (crude extract) and after filtration through a filter of the type "50007" with / r. Micrometer available from “Direct Loading of Toxic Extract__Ali (Gelman Sciences, FRG) 0 liter according to aeo with a basic volume of (NTA) Ni 2+ - nitrilotriacetate- agarose : cited in (Hochuli, E., Dbeli, H, and Schacheer, A. (1987) J.

Chromatography 411, 177- 184). 1 and Bij35 7.01R glycerol 701 pre-equilibrated in a buffer containing 05 µL (.5 dish volume) of You buffer were washed on the column B. PMSF mmol of Brij35 and rinsed with successive steps from Brij35 7.01 glycerol 701 solute containing f. 7; PMSF mmol 01 Brij35 7.5000 glycerol (01) buffer A state containing millimol imidazole sequentially, and the fractions were monitored by 9.2.2.2.

Absorption on ODpgonm, and the upper parts were analyzed by PAGE-5138, and the parts containing the recombinant protein were washed in 100 mmol 1 midazole. "Protein 14.177 1 recombinant and proteases, beta-galactosidases (LacZ) and penetidial-prolyl cis-trans isomers" 0 The fragments containing the recombinant proteins were assembled from Al-NiZ¥-NTA columns agarose was concentrated into 10 µl by centrifugal filtration (Centtriprep Amicon, MA) and loaded onto a VAL column (57 ANY cm) by gel filtration media (SePhacryl-S-100). HR). Then equilibrate it in L 01 mmol (Buffer mmol da yu Hepes pH 09011 V0 mmol/h 184 on BUffuA R mmol 5018) and run it in 1 Nacl mol 0

Ya. The fragments containing a recombinant protein were also determined by absorption on the surface, and the fragments were collected and concentrated using . SDS-PAGE tanometer and analysis by . Centrifugal filtration: “protein 1161771 7 recombinant” 0 The fractions containing the recombinant protein were collected from the L-NTA - *2Z 0 6 column and dialyzed (membrane separation) overnight at 1 L of dialysis buffer (10 mmol MORs, pH 1.9 ; .9 mmol of NaCl , 10 mmol of EGTA “ ¥ .7.5 of Brij35 and 1 mm mol of PMSF) and in the morning - a fine white precipitate was removed by centrifugation and the resulting floating material was loaded onto a plate

Type 110008 Type 110008 High Performance Liquid Motografia Cryo Column (mL VoxA) Available from: Pharmacia Biotechnology Inc.

Piscataway, NJ, USA).

and equilibrium in buffer 8 (.1 mmol of MOPS, pH LoR 0.0 mmol of MEGA) (containing .59 mmol of 14861), followed by a column wash of 10

Thin layer volumes of regulator B containing 0.5 mmol NaCl and endorsed with

Hallas 0. from Nacl ).0 -..9 mmol). Protein 1 1161776 recombinant was eluted

as an acute peak of about Veo millimoles Nacl .

0 “Purification of insoluble proteins from inclusion bodies » The following steps were carried out at 0 °C temperatures. Cell pellets or granules were resuspended in a lysate with

0 glycerol, ..? µg lysing yeast, 5 mmol of 015018 mM

1 mole of PMSF SR ./ Mercapto ethanol.

After passing it through a cell disintegrator, the resulting homogenate was made ?R./ Deoxycholate -

and stir for 10 minutes; Then centrifuge at 0..r.7*s for .? minute . and washing of 0 pellets with a lysate containing 7101 glycerol 100 mmol of JN EDTA

01 Triton X-100 mmol of PMSF 7 QR 10 - Mercapto ethanol, followed by several washes

With a urea-containing lysate with a molecular concentration of 1 and 1 mmol of PMSF 30

R Ze who? = mercapti ethanol. The resulting leukocytes were composed of

implicit objects; Free of undisintegrated cells and membrane materials “Proteins 7.7 OE LLY Mantel 1771 LUV YL NLL 11 Recombinant”: The following steps were carried out at room temperature. The purified tacit bodies were dissolved in ? mL of urea with a molecular concentration of 4; In a dissociation regulator with 1 mmol 0 of PMSF and R.7 of ? = mercapty ethanol, and incubated at room temperature for 1 hour. Undissolved materials were removed by centrifugation. This was followed by filtration of the pure floating material and loading it onto a column of NiZ* NTA agafose pre-equilibrated in urea with a molecular concentration of / in lysate, and washing the column with approximately VO mL (of 0.5 plate volume) of the containing lysing buffer contains urea of 0 gram molecular concentration 4 ; and on 1 mmol of PMSF, and on 1 R./ of VY-mercaptyethanol; and denaturing them with sequential steps of a urea lysis regulator with a molar concentration of 4; and on 1 millimole of PMSF, and on (705) of ? = myrbet ethanol and .010007 You ...9 mmol of 1-midazole, sequentially. Parts were monitored by absorbance on 01280708; The upper portions were analyzed by SDS-Jui gy PAGE 1. The portions contained a recombinant protein with about no mmol of 1-midazole. TIAL 14274141 lis yun 47. 1 Recombinant » The pellets containing vibrio bodies were dissolved in buffer solution B containing urea at a gram molecular concentration of 4 and 1 mmol of 11457 and 1 R / of mercaptoethanol, and incubated for 1 An hour at room temperature, followed by removal of insoluble materials by centrifugation

\Yo

Sp- On ... R.?* p for a period of .? minutes, and the pure floating material was loaded onto a milliliter column (1.1**rl/cm) pre-equilibrated in buffer 3; Vo Sepharose; and 1R.77 - mercapto PMSF, a mole of urea load, with a gram molecular concentration, ethanol. And after washing the column with ten companion stratified sizes, it was backed by a descendant. Nacl straight from 0 to .9 mmol ° dialysis and concentration of the protein samples “Urea was slowly removed from the protein samples by dialysis over a buffer solution (Nacl +09 mmol; pH Tris mol 001 TBS) Tris-buffered with sequential reduction in urea concentration as (DOC) containing 50./ deoxycholate of the following: 1 gram molecular concentrations, ? gram molecular concentrations; ? particle concentrations 0

TBs Concentration; 9 t. Gram molecular concentration Finally, 01 gram molecular concentration, Ve Gram, does not contain any urea. And each step of dialysis (membranous separation) took place for a period of time; At least hours at room temperature, and after dialysis, the samples were concentrated by pressure filtration: using amicon-stirred cells, protein concentrations were measured using Bradford methods (Perkins (1986 ur. J. biochem. 157, 169-180). (1976) Anal. Biochem. \o 72 248 - 254) and Lowry ((1951) J. Biol. Chem. 193 Paycs 265-275) and recombinant proteins purified by the methods described above are summarized in FURR yy Lodge.

TT] se [Fe]

Homolog Gene fraction used to Relative MW concentration symbol

J99 Sequence | identified of purify recombinant Method of on SDS-PAGE of Composition : purified protein | ofbuffer

Outer Membrane Proteins | I I EE RR 16225006 | P28635 Inclusion bodies 18kDa | 5 mg/ml | B 26054702 P15929 figH Inclusion bodies His-Tag 37 kDa 1.18 mg/ml

TT | 68 7116626 P26093 e(P4) Soluble fraction His-Tag 29 kDa 0.8 A mg/ml 1.85 0 mg/ml 29479681 P13036 fecA Inclusions bodies SP-Sepharose 23 kDa 2.36 B mg/ml 0.5 mg B ml

TT ean pele 14640637 P16663 TPF1 Soluble fraction His-Tag 17 kDa 2.4 A mg/ml

TT eeimwanonsw00RR | [

Periplasmic/Secreted Protein | 1 3010032 P23847 dppA Inclusion bodies His-Tag 11 kDa 2.88 B mg/ml /

\YY Table child; 0 4721061 P36175 GCp Inclusion bodies His-Tag 38 kDa 2.8 mg/ml

Other Surface Proteins Eye | Rather, 4821082 P08089 M protein | Inclusion bodies His-Tag 20 kDa 1.16 B mg/ml 978477 L28919 FBP34 Inclusion bodies SP-Sepharose 44 kDa 2.56 B mg/ml 0.3 mg/ml

Inner Membrane Proteins I A EE MSc 26380318 P5933 Inclusion bodies | SP-Sepharose | _1TkDa 22 p'8

Control Proteins with His Tag I FE BA 1 poor lacZ Soluble fraction |__HisTag | 11603 | 10 mg/ml] A l 1 0 ys n x a e this h a a ppiB Soluble fraction His-Tag 21 kDa 4.4 A mg/ml y | the

Buffer compositions:

Som Hepes pH OmM NaCOI mM EGTA | | ——————

B=10 mM Tris pH 8.0, 150 mM NaCI 0.3 % DOC I FY ES I

C= 10 mM MOPS pH 6.5, 300 mM NaCl 0.] EGTA AA EE

A 17 Analysis of Candidate HPylori oY Vaccine Proteins to Investigate the Effect of Immune Modulation of H.Pylori 0 Proteins A mouse/model of H.pylori was used in many manifestations. The focus was focused on the effect of oral vaccination in animals infected with H.Pylori bacteria, in order to test the idea of immunotherapy for treatment by 0 by the vaccine. Animals: Two female SPF BALABIC chicks were purchased from the Brombholt Breeding Center in Denmark, and placed in Makrolon regular cages, giving them the opportunity to eat and water as they wish. These animals were about six weeks old when they arrived. 0 Trace: After at least a week had passed since her adaptation, 0 was infected with a strain of type (VacA negative) Y of HPylor bacteria (strain “YEE” originally isolated from a patient with ulcers. Under our hands, this strain has previously been proven The bacteria were cultured overnight in a broth of Brucella supplemented with 1/7 Jae fetal serum VV ley at room temperature (1/0) carbon dioxide, 7/5 oxygen) the animals were given an oral dose of omeprazole (£00 µg/kg) and given after? - 5 hours of eld inoculation or oral inoculation of :11.5910 bacteria in soup (about fefu 901 animal), and after this inoculation with about? -? Weeks, the extent of positive infection was examined for some animals.

“Antigens” Antigens against recombinant H. Pylori bacteria have been criticized on the basis of their binding to cell membranes of exogenously exposed H. Pylori bacteria. These antigens were selected from the following groups: (1) ©: outer membrane proteins () secreted/cytoplasmic proteins (7) outer surface proteins; (8) inner membrane proteins. All the crosslinked proteases were generated with tag 168. -1115 For reasons related to purification, proteases were generated for ligand (b) H.Pylori - galactosides from the bacterium (LacZ ¢ E.Coli) in the same way. That is, they were dissolved either in a buffer adapter from 1-75 or in a buffer adapter containing s/o oxycolate 0000. The antigens are listed in Table 0. “Table 0” Proteins of HElicobacter Pylori: Ve proteins External membranes: ARRAS protein EVYNLY protein 16775.2.7 protein YALVATAN XY protein 0216.177

0: secreted proteins/plasma cytote

YALL YYY PROTEIN : Other cell envelope proteins 071.7 PROTEIN : Flagella bound proteins 17/827148 ° PROTEIN : LACT (LACT) I - glucosides : fortifiers Ye YO 216501 day (day TE) Animals in each group were vaccinated; times over 0

Ves purified antigens were given either in solution or in suspension at a dose of 10 micrograms/vare of poison. As an adjuvant, the animals were also given with each immunization. Animals were also given omeprazole (£02 mmol/CT cholera hrs) as a means of protection F = 0 kg) orally before immunization with about 0 antigens from acidolysis. Specifically infected animals received a buffer solution of CT + HEPES or a buffer solution of CT + DOC and the animals were sacrificed within ? 4 weeks after vaccination. Table 6 shows the results of this study:

As a schedule + result of Law! 5) afl « therapeutic immunization: Ka - | LY and -” s . - . All mice were infected with 23 strains of Ah244 on the 33rd day: Substance Mouse strain Dose/mouse Dates for n=10 dosing Controls, PBS Balb/c 0.3 ml 0, 14, 24, 34 1. Cholera toxin, 10 pg Balb/c 0.3 ml 0, 14, 24,34 2. Protein 16225006, 100 pg + CT 10 pg Balb/c 0.3 ml 0, 14, 24, 34 3. Protein 26054702, 100 pug + CT 10 pug Balb/c 0.3 ml 0, 14,24, 34 .4 Protein 26380318, 100 pug + CT 10 pug Balb/c 0.3 ml 0, 14,24, 34 .5 Protein 29479681, 100 pg + CT 10 pg Balb/c 0.3 ml 0,14,24,34 6. Protein 30100332, 100 pg + CT 10 pg Balb/c 0.3 ml 0, 14, 24, 34 7. Protein 4721061, 100 ng + CT 10 ug Balb/c 0.3 ml 0,14,24 34 8 . Protein 4821082, 100 ug + CT 10 ug Balb/c 0.3 ml 0, 14, 24, 34 9 . Protein 7116626, 100 pg + CT 10 pg Balb/c 0.3ml 0, 14, 24, 34 .10 11.Protein 14640637, 100 ng + CT 10 ug Balb/c 0.3 ml 0, 14, 24, 34

Ym: Infection analysis (infection): Infection or mucosal infection: Mice were sacrificed using carbon dioxide, sad stripping of the neck, opening of the abdomen, and the stomach was removed. After cutting the stomach along its curves, it was rinsed with saline solution. The mucous membrane was scraped from the cavity and then a YO 2 square millimeter part of Leiden was scraped off with a surgical scalpel; The blll was suspended in Brucella solution and spread on row = | Selection of Blood Skirrow . lial I was incubated under Lins air conditions for ? = 0 days, and then the colonies were counted. Tosh 11.59108 was confirmed by urease and catalase (an oxidizing enzyme) assay and by direct 0 microscopy or by staining or gram staining. And the urease binding test was performed according to the following transformation: the reagent was purchased with a concentration of 0 ' and the concentration was diluted | basophils of Agariurea (PX). UL \ . 1 Mixing 1 µL of the diluted concentrate with Yo = 100 µL of actively growing cells of H.Pylori Vo. change | to color to | Please indicate that the cells were 50 lin urea enzyme. As for Staal the enzyme catalase = Pugh, its procedure is basically as follows. 134 13. A preparation was made from reagent 7N (weight in volume in UI) and H.Pylori bacteria cells were dredged on a What man Yl filter paper and covered with 73 solution. The color changed to dark blue indicating that the cells were positive

PURE] catalase. Serological antibodies (from serum): 1 was for serum from yal I | Then prepare it from 1 blood drawn by means of a hole [for the heart. The identification of antigens from SP serum was carried out using systemic technical methods of PA LINEN ELISA 0. The specific antigens of Helicobactor Pylori were published. Antibodies from mucous membranes: Light scrapings were performed for a specific part of the body and four centimeters from the duodenum in .70 mice in order to detect the presence of antibodies in the mucous membrane. The antibody standards were determined by ELISN immunoassay techniques, as was the percentage of antibodies from the sera. Statistical analysis: The “Wilcoxon - Mann - Whitney” sign system test was used to determine the significant effects of antigens on the colonization of B. ey is important. Because the cavity is the primary site of Helicobacter colonization 1 most emphasis is placed on changes in the sinus colony (related to the paranasal sinuses). RESULTS: Antibodies in Serum: All tested antigens treated with CT gave an increase in a specific measurable standard in serum. The highest responses were seen with CV 111 176 protein

Yerwin 11771 LW ; Protein 718 .71740 Protein 1216.177 Protein Am EAYY (see Figure 1). Mucosal antibodies: in mucosal scrapings. Tae ga antibodies were seen against all 0 antigens that were selected. and to the extent replays 3 seen | For the strongest response with 9,17 AS .. 7 protein dependent on it and protein YA mint Aas 1 (Fig. ¥). Effects of therapeutic immunization: All control animals (53) (BALB/C Oo I) colonized well with bacteria (H). pylori (strain AH244) in both stomach lumens. Among the two tested antigens, it gave three proteins (Nata protein, Veg.

YY AS 9 «£ AYN LAY (good and significant reduction, and/or gave annihilation of bacterial infection: 11.710). They were compared with control proteins. The effect of J lyroproteins A "...0 A IATA TAN '/1 YY and 0.2777 0.2777 did not differ from the control proteins. The control protein, lacZ, that is, the protein other than the :11.0710 All data are presented as ?and for soluble proteins in HEPES and in DOC respectively.The data are shown as geometric mean values.01 — A=n test sign system P=wilcoxon - Mann - Whitney or greater than 540+¢ cr 01/- the number of mice that showed bactericidal 11.1011 out of the total number of mice tested.

\Yo

HPylori proteins associated with JS bacteria The data presented indicate that the study leads to the stimulation of an immune response when used as sigs listed as measured by CT in combination with an oral adjuvant pill given by Lelia by specific serum and mucosal membrane antibodies. And the majority of the proteins led to, and in some cases led to the complete annihilation of the colonization of bacteria: 11.5710 in this pada 0 animal model. It should be noted that the reduction or elimination of this was a result of poly1 protection of different origin or different composition rather than similar protection (the HPylori peptides used were based on the sequence of strain 149 of clarified bacteria (AH244). ) in statistical therapeutic studies against a different challenging strain H. pylori. With antigens “Helicobacter Ji other than LacZ cae sy 11.1011 antibacterials, and looking at these data together, the use of 1157103 bacteria proteins was highly pharmacologically supported for use in humans to treat and/or prevent infection with Lilia bacteria in 0 7: H.Pylori “H.Pylori” Gene Sequence Variation Analysis in Bacterial Strains

H.pylori Four genes and their sequence were cloned from various strains of the bacterium

To compare DNA sequences and amino acid sequences that have been inferred. This information was used to determine the sequence difference between 149 strains of HPylori bacteria and 11,0710 other strains of bacteria that were isolated from human patients. Preparation of chromosomal DNA:

0 Cultivars were grown from the following bacteria strains: 11.0710 (as listed in (Assn in BLBB) 7 tryptone/01) peptamine ZV glucose ; R VL yeast extract 50 7 sodium chloride « 70 fetal bovine serum] for Ogg Thee? Then, the cells were centrifuged in a Sorvall RC-3B centrifuge at ..0*p at) °C temperatures for 1V min; the pellets were resuspended at 580 °C. ml of 01 mmol of Tris-Hel; It is OV Millie

0 mol of EDTA (TE) and addition of yeast Ula to an Ales concentration of 1 mg/ml together with RNAse 1, /1l SDS for oo mg/ml and e units/ milliliter, respectively, and incubation at 1 temperature for a final concentration of R. mg / milliliter, incubating the sample at 00 degrees Liston temperature for more than 1 hour and adding Nacl to the sample to a concentration of #1 R. two-gram concentration; with

1 Mix thoroughly, add karr. mL of 10/10 of CTAB in Nacl with a molecular weight of LAR . Is) for the final V. /CTAB 7A millimoles of (Nacl) followed by incubation at 19 °C for 0.7 minutes. At this point, the samples were extracted with chlorine and form: isol amyl alcohol, extracted with phenol, and then extracted again.

no

Bichloroform: Iso-amyl alcohol ¢ and DNA precipitation either by EtoH (1 2°) “volumes” or by Iso Jabs gm (R Xe. volumes) at - A. larval temperature for a period 01 minutes. Lay and wash at .70/7 BIOH and re-suspend for 15 minutes. “PCR amplification and cloning”

fo} ran | you will take! ¢ Genomic DNA prepared from a strain of H.pylori as a template D-DNA for amplification reactions 50 according to: Current Protocols in Molecular Biology, John Wiley and sons, Inc.

F. ausubel et al.

al., editors 1994).

In order to modify the DNA sequence containing the ORF of HPylori bacteria, DNA was inserted

./ Magini) yas Ly.m in a reaction flask containing Y mmol of Mgcl2 and 1 microgram synthetic oligonucleotide primers (forward and reverse primers (see supplementary Vd gon) and surrounding B ORF bacteria: 11710, 1 R. mmol of each of deoxynucleotide phosphate dTTP, dCTP, dGTP, dATP. ¢ and R. 9 units of thermostable DNA polymerase available at:

( Amplitag, Roche Molecular Systems Inc.

Branchburg, NJ, USA). \o . microliters of Ye double reactions in a final volume of

aya

Table V. Ls amplification of DNA PCR sequences and oligonucleotides used to amplify 1 primers. H. Pylori

Outer membrane Forward primer 5' to 3' Reverse primer 5° to 3°

Proteins

Protein 26054702 (for |5'-TTAACCATGGTGAAAAGCG S-TAGAATTCGCCTCTAAAACTT strains AH4, AH13, ATA-3' (SEQ ID NO:169) TAG-3' (SEQ ID NO:170)

AHS61, 5294, 5640, AHI18, and AH244)

Protein 26054702 (for |5-TTAACCATGGTGAAAAGCG 5-TAGAATTCGCATAACGATCA strains AH5, 5155, ATA-3' (SEQ ID NO:171) ATC-3" (SEQ ID NO:172) 7958, AH24.and J99)

Protein 7116626 5-ATATCCATGGTGAGTTTTGA S-ATGAATTCAATTITTTITATTIT

TGA-3' (SEQ ID NO:173) GCCA-3' (SEQID NO:174)

Protein 29479681 5-AATTCCATGGCTATCCAAAT |53-ATGAATTCGCCAAAATCGTA

CCG-3' (SEQ ID NO:175) GTATT-3' (SEQ ID NO:176)

Protein 346 5'-GATACCATGGAATTTATGAA |5-TGAATTCGAAAAAGTGTAGT

AAAG-3' (SEQ ID NO:177) TATAC-3' (SEQ ID NO:178) Amplified all this DNA to obtain free T products I using recycling conditions a as 0

I: Using a thermal cycler from ORF (Perkin Elmer Cetus/gene Amp PCR System 9600). 71 and protein yiyvianm AS 9

As the change of physical properties at AE °C for a period of ? minute ? Cycle at AE at °C for Vo sec, and at Y at °C for 1.8 minutes. YY Cycle at 42°C for Vo sec ; And at 96 degrees Latin for 10 seconds VY Ley temperature Lupin for 1.1 minutes The reactions took place at VY temperature °C for a minutes. VY 06 protein? For strains, oVYo, AHS, for manure, JAA 5 AH24: changing the natural properties at 44 degrees Lia, for a period of ? minute ? Cycle at 4 °C for 119 seconds, Ye eg at °C for Vo seconds, and at VY at °C for 1.09 minutes. 01 CST for 96 doy sec 11 ©? Cycle at 44 degrees Celsius for 1 00 sperm for a period of VY temperature Celsius for 1.1 minutes. The reaction was carried out on La ju VY ley for a second. Minutes right now; that6, AHI5, protein 1967.7? And protein 14417493117 for strains 114 L. HP244, AH16;

A cycle on Ye rendering the physical properties at 54 °C for a period of ? 0 minutes

VY les seconds; 7 °C for 7 seconds. Vo °C for . Celsius temperature for? 0 minutes enthalpy for 0*9 ley sec 11 ºC for duration At©? Cycle on: . Celsius temperature for? minutes VY seconds and at . The reactions took place at VY degrees Celsius for / minutes. Once the thermal cycling reactions were complete, JS standardized a pair of samples and used directly for cloning

Ve. As described later, PCR is used to reduce cloning. PCRTA to PCRTA Cloning HPylon Bacterial DNA Cloning of Sequences: By the method described in PCR?R1 all amplified entries were cloned into a PCRTA Cloning Kit (Original TA Cloning Kit (Invitrogan, San Diego, CA).

INVaF') TOPIOF' The use of ligation reaction compounds to transform the date strain ° as described by EColi of HPylor bacteria in the case of a sequence of .79 of bacteria. Transformation of recombinant bacteria with recombinant plasmids 1117 2 or strain E.Coli from TOPIOF bacteria Recombinant strain carrying pCR sequences was transformed with plasmids of incarnation E.Coli from bacteria 0 . : cloned from Y.:11,710 according to standard methods (Current protocols in Molecular Biology, John Wily and Sons Inc., F. Ausubel et al. editors, 1994) 50. Micromolecular to each BME In short, achiev? 1 microliter from a .5 µl flask of qualified cells. And then, was it mixed up? µl of Vo binding reaction with qualified cells and incubate on ice for .? minute . This was followed by exposing the bY cells and the binding mixture to “heat shock” on SOC for 0.3 seconds, and placed on ice for ? Another minute after which the samples were incubated in the medium; turn? Mili Nacl Mili Mall 001 Dr. (50 µL/ yeast extract, 77 tryptone mmol glucose) 01 and Mgso4 a. mmol Megcl2 mmol 011 mmol KCI mol Y.

VEN

hour. Then, the samples were spread on 1 plates, with stirring for a period of time, at a temperature of VY at 100 µg/mL catamycin sulfate or Yo containing LB sled µg/mL ampicilan for smothering overnight, and collecting colonies. And analyze it to design the inserts or inputs copied INVaF or from TOPIOF 'converted from . As described hereinafter 0: HPylon recombinant bearing PCR bacterial sequences “Identification or identification of plasmids”

PCR, ORFs transformed with INVaF' or from TOPIOF Individual clones were analyzed in 11.7101 recombinant bacteria by magnification +701 of cloned or cloned accessions using the same forward and reverse scores for each sequence from

PCR, which was used in H.Pylon cloning reactions of 0 bacteria sequences in the original H.Pylori transmission. Successful amplification demonstrated the integrity of B.:Transcriptase sequences according to Current Protocols in Molecular Biology, John Wiley and Sons Inc. F. Ausubel et al editors 1994.

The recombinant ORFs carrying PCR were also extracted from individual clones of Vo vectors for the purpose of analyzing their sequences. HPylon cloned from bacteria (Perkin Elmer) was analyzed using standard ABI methods. Sequencing on serials: or in PCRII using vector quality primers (as found in

PCR 2.1, Introgen, San Diego CA). . As listed in Table 8 following ORF and special series graders for VY.

VEY

“A” Table: H. pylori multiplying O DNA of La sequences is smoothed | prove | to a ligo nucleotide used.

Outer membrane | Forward primers 5' to 3' Reverse primers 3° to 3'

Proteins

Protein 26054702 | 5-CCCTTCATTITAGAAATCG-3' 5'-CTTTGGGTAAAAACGCATC-3' (SEQ ID NO:179) (SEQ ID NO:186) 5'-ATTTCAACCAATTCAATGCG-3' S-CGATCTTTGATCCTAATTCA-3' (SEQ ID NO:180) (SEQ ID NO:187) 53'-GCCCCTTTTGATTTGAAGCT-3' 5-ATCAAGTTGCCTATGCTGA-3' (SEQ ID NO:181) (SEQ ID NO:188)

S'-TCGCTCCAAGATACCAAGAAGT- 3' (SEQIDNO:182) 53'-CTTGAATTAGGGGCAAAGATCG- 3' (SEQ ID NO:183) 5'-ATGCGTTTTTACCCAAAGAAGT-3' (SEQ ID NO:184) 5'-ATAACGCCACTTCCTTATTGGT-3' (SEQ ID NO:183) 0]

Protein 7116626 | 5-TTGAACACTIITGATTATGCGG-3' 5-GTCTTTAGCAAAAATGGCGTC-3' (SEQ ID NO:189) (SEQ ID NO:19D) 5'-GGATTATGCGATTGTTTTACAAG- | 5-AATGAGCGTAAGAGAG CCTTC-3' 3 (SEQ ID NO:190) (SEQ ID NO:192)

Protein 5-CTTATGGGGGTATTGTCA-3' (SEQ 5'-AGGTTGTTGCCTAAAGACT-3' 29479681 ID NO:193) (SEQ ID NO:195) 5'-AGCATGTGGGTATCCAGC-3' (SEQ | 5-CTGCCTCCACCTTTTGATC-3 (SEQ i ID NO: 194) ID No: 196).| Protein 346 5-ACCAATATCAATTGGCACT-3' 5-CTTGCTTGTCATATCTAGCS i (SEQID NO:197) (SEQ ID N0O:199) 5-ACTTGGAAAAGCTGCA-3' (SEQ 5-GTTGAAGTGTTGGTGCTA-3" (SEQ

ID NO:198) ID NO:200) : 5-CAAGCAAGTGGTTIGGTTTITAG-3' 5-00 CCATAATCAAAAAGCCCATS (SEQ ID NO:201) (SEQ ID NO:203) 5-TGGAAAGAGCAAATCATTGAAG- | 5 ~CTAAAACCAAACCACTTGCT 3 (SEQ ID NO:202) TGTC-3' (SEQ ID NO:204) ______ 1

Vector Primers 5-GTAAAACGACGGCCAG-3' (SEQ) 5'-CAGGAAACAGCTATGAC-3' (SEQ

Vey: Results In these experiments, five single clones of the PCR tad protein were sequenced to generate a separate JAA modifier from a PCR strain from five daa oc 7-nucleotide reaction mixtures; About 2588 basis AY bacteria: 11.0710 over a total length of clonal DNA, then the sequences were compared. cumulative total DNA from the 000 sequences previously obtained by a different method; That is, the five DNA sequences. A random random reproduction method and a random random series also for the experiments described here as? A fundamental change out of the PCR tha rate has been determined

Fest is less than or equal to the tas basis; Which is equivalent to a rate of 0 ORF knowledge on four different open reading frames DNA. Sequence analysis was performed 0 from a dozen different sequences of PCR bacteria as free and amplified by methods that showed the amino acid sequences resulting from Three open reading frames. 0 3 Among the (8) open frames that were selected for such a study; are statistically significant for proteins identified in other bacterial genera. The BLAST contained homology: the following ORFs for the Vo In the ABC that encodes a ValAand B transporter homologous to the 0EV.Y genes, YU 0EV.Y protein; protein 1711171, homologous to lipoprotein 604 located at 08 membrane receptor fecA protein 9879741 « homologous to Hinfuenzee the outer membrane of

exogenous in JES distyran(111) iron in bacterium 15.0011, the VEN protein was identified as the unrecognized frame from the open read; It showed low homology with sequences in public databases. and to assess the extent of conservation or variation in ORF'S across diverse strains of HPylori 0; Alterations in the resulting DNA sequences and protein sequences were compared with the resulting DNA sequences and protein sequences found in the TAA strain of HPylori bacteria (see Table 4 below). The results are presented as the Losin Ratio of 194 strains of 11.7103 bacteria sequenced by random cloning. To adjust for differences in the 144 sequences, each of the four ORFs 1 was cloned and sequenced again from the bacterium strain 144 and the information of these sequences was compared with the sequence information gathered from the accessions cloned by random random sequencing of strain 144. The data proves that there is a variation in the DNA sequence ranging from a VY// variation (YEN protein strain 144) to about a // variation of (Bredithin YL 0EV.LY - strain (AHS) as shown Sequences, + protein 0 resulting in La) no difference (YET protein, strains 1118 and (AH24) or a ratio of 7.1 amino acids (AHS dbase protein YA 0EVLY)

Table m + falas » 1 DNA sequence of a double strain of Lai ye inoculated with Pylori 1 » J99 Protien #: 26054702 26054702 7116626 7116626 29479681 29479681 346 346 -Length of Region 248 a.a. 746081 232 a.a. 696 nt. 182aa. 548nt. 273 a.a. 8196 Sequenced: Strain Tested AA Nuc.

AA Nuc.

AA Nuc.

AA identity Nuc. n.d. 99.09% 96.71% 98.90% 96.45% 95.04% 95.16% 4M AH4 95.97% 95.98% 97.84% 95.83% n.d. n.d. 97.80% 95.73% AHS 92.34% 93.03% 98280 96.12% 98.91% 96.90% 98.53% 95.73% 96.09% 99.63% 97.99% 99.82% 95.98% 97.41% 94.916% n.d.16m 95.91% AH n.d. 97.84% 95.98% 99.27% 97.44% n.d. n.d. n.d. n.d. n.d. n.d. 99.45% 97.08% 98.53% 95.60% 5155 95.48% 97.07% 97.26% 99.64% 95.40% 98.28% 94.37% 94.35% 5294 nd. n.d. 99.63% 96.46% 95.40% 97.84% 94.10% 94.35% 7958 95.48% 98.53% 97.63% 99.09% 95.69% 97.41% 94.37% 95.16% 5640 n.d. n.d. 98.71% 95.69% 99.64% 97.44% 100.00% 95.97% 8M AH24 94.75% 95.04% 97.84% 95.40% 99.27% 96.71% 100.00% 96.46% n.d. = not done 1 . A sudden experimental method to identify the essential genes of H.Pylori bacteria 0 as effective therapeutic targets. TST selects therapeutic targets from genes whose protein complexes appear to play a role

VET

The therapeutic targets are selected from the genes whose protein compounds appear to play a role. conversion of DNA intrinsic to basic cell pathways such as cell envelope synthesis, germ structure (Ban) or transcription; Transfer ; Organization, colonization/induction (quantity and mutagenicity of ORFs / H.pylori z) and method of deletion of visceral git proteins from the kanamycin resistance envelope in order to identify essential genes of the cell Modified © : From previously published methods

Labigne-Roussel et al., 1988, J. Bacteriology 170, PP 1704 - 1708, Cover et al., 1994 J. Biological Chemistry 269 PP. 10566-10573, Reyrat et al., 1994, Proc.

Nall. Acad. 501.92 PP 8768 - 8772). . A “sudden” or unstudied “knockout” and the result is a gene 0 “H.Pylori” definition and cloning of bacteria gene sequences The selected OL 01878 gene sequences are identified as sudden targets from the sequences / and used to design primers by imposing amplification of jets HPylor is a genome of bacteria, and all synthetic oligonucleotide primers are designed with the help of the program. 95 : from OLIGO yo (National Biosciences Inc., Plymouth mN 55447 USA). : It can be purchased from gibco/BrL Life Technologies Gaithersburg MD, USA Base pair Primers are selected outside the framework of Av a 0001 smaller than the ORF albeit from a 4 genome HPJ strain of bacteria DNA and open reading (ORF) 0

Genome Therapeutic Corporation 100 Beaver street, Waltham MA 02154 as a model DNA source for amplification of ORFs by (polymerase chain reaction) PCR according to (Current protocols in Molecular Biology, John Wiley and Sons) Inc.

F.

Ausubelet al., editois 1994). 0 For the preparation of the genome DNA from 11.9101 bacteria, see Example 1. PCR amplification is carried out by inserting 01 nanograms of HPI DNA from two genomes into a reaction vial containing Vo: 148 012 mmol, ? µm and 2mM of synthetic oligonucleotide primers (forward = Fl and reverse < ) RI 0.1 mmol of each deoxynucleotide triphosphate (dTTP, dCTP, dGTP, dATP 0.4 1.70 units of DNA polymerase Adiabatic Available from: Amplitaq, Roche Molecular Systems, Inc.

Branchburg, NJ, USA). \o (Once the thermal cycling reactions are completed, each amplified DNA sample appears on an agarose gel stain of ?/from TAE with ichydium bromide as stated in: Current Protocols in Molecular Biology John Wiley and sons Inc.

F. Ausubel et al., editors, 1994).

A to specify ob is the product of a signal of magnitude of an expected result from I of a reaction. The SU DNA is then washed and purified using a Qiaquick Spin PCR purification kit. Available at: QIAGEN GAITHERS BURG, MD, USA). , USN) using the TA cloning strategy according to CURRENT PROTOCOLS IN Molecular Biology, John Wiley and sons Inc.

F. Ausubel et al., editors 1994).0 The ligation of the vector PCR product is accomplished by mixing a + ply Grammolecular flood of 0.1 ng PCR product of vector 01 (Novagen) PT7Blue -T microliters of a buffer solution of TADNA 118886 available at: New England Blolabs, Beverly, MA, USA) (5 ..¥ units of (New England Biolabs) TADNA Ligase in the final reaction amount consisting of 10 microliters Ll is allowed for elu vaud to occur at a temperature of 3 C. The binding products are induced electrolytically as stated in: Current Protocols in Molecular Biology, John wiley and Sons Inc.

F. , Ausubel et (al editors, 1994) 0 in the induction rehabilitation of XL-L BLue or in 131158 bacteria aged cells (Clontech Lab, Inc.

Palo Alto, CA, USA) E.Coli .

VEA

. (Clontech Lab, Inc. Palo Alto, CA, USA) E.Coli 1 μL of ligation reaction with .6 μL of competent cells 1 in brief; (25 Micro Farads, 2.5 kv. yeast Lada 7. 50) SOC z Thereafter incubate the samples in 580 + mL of 0.1 218012 mmol 0 KCl t? mMol + Nacl mMol 001?/7Treton oo C temperature with stirring TV mmol glucose (at 70.1 and Mg 504 mmol notPRTDTCP1/g 01) After that, the samples are spread on plates (1 for 100 sodium chloride) containing 1 gram / 101% of Vala yeast extract 0 µg / ml 01 001 µg / ml of ampicillin + R// from 801-36 »and Celsius temperature. Then, 1 and these plates are incubated overnight on IPTG of 0 0. Ampicillin-resistant colonies of white color are selected; It is developed in 0 . μg/mL of ampicillin 001 containing LB/mL of plasmid liquid using the DNA splice method and isolates . (Qiagen, Gaithersburg MO, USA) The correct Qiagen HPylori bacteria DNA has been done to prove that fillers or inserts 1

These PCR models serve to enlarge PTTBLUE plasmid DNAs to be cloned; Entries cloned using the same forward and reverse primers used for amplification from the initial PCR sequence of 144 bacteria [:11.0710] are used. The realization of the preparatory and output

\o. Confirming that the correct entries have been reproduced. and is obtained? - 1 of these is Ve - and frozen on Alas Gua. Questions (clones) for each plasmid of this DNA are collected by PCR for storage. In order to reduce the errors resulting from the questioning, it is used in the following cloning steps. Uses /:015 gene sequences

0 again to design other pairs of primers flanking an H.pylori DNA region to be interrupted or deleted (up to a YO.base pair) within the ORFs but oriented away from each other. The DNAs pools use viral plasmids from previously isolated offspring as models for this cycle of PCR.

0 Since the direction of magnification of this pair of primers is reversed [aad], the part of the ORF located between the primers is not present in the PCR product. Note, the ols, the result of the PCR is a straight piece of DNA with 11.7101 bacteria DNA on each end and with the original vector PT7BLue between them which, in essence, leads to the deletion of part of the ORFs. The PCR product was seen on an agarose gel stained with 1571 ethidium bromide to confirm

Vo indicates that an argument output of the correct size is just capitalized. The LIS resistance carrier binds mycin (according to:

Labigne-Roussel et al., 1988, J.

Bacteriology 170 1704 - 1708). As a result of this PCR using the previously used cloning method 18 and mentioned in:

Ada Current Protocols in Mol Cular Biology, John wiley and Sons Ins.

F.

Ausubel et al., editors 1994. A kanamycin load containing the kanamycin resistance gene Compyloba was obtained by executing an EcoRI digestion of PCTB8 with the hand of the recombinant: Kan as ° in: and part Correct (kb VE) isolated on Gel 71115 and isolated using Lada Gel Kit QIAquick, Qiggen Gaithersburg, MD, USA). 0 Mix 4 μg of the 1′ μl DNA fragment of dTTP, dCTP, dGTP, dTATP in .mmol Yo μl of Klenow buffer (available from New England Bio) labs .4 0 units of Klenow DNA polymerase in 1 large part of (Klenow) available from (New England biolabs) in a Y. microliter reaction, with incubation at .?C for . VO min, and with the enzyme inactivated by No heating to VO 0 °C for 10 minutes.Then this kanamycin carrier was then purified at the gelatinized end through a column (Qiagen Gaithersburg, Qiaquick MD, USA). To get rid of the nucleotides, suspension “1” is then generated by mixing ©mi Crograms of dull-end BIS Meissen carrier; 01 mmol Tris, pH, ALY, 9 mmol KCI. ? MilliMol 118012, 5 DNA polymerase units

Voy (Ampiltaq, Roche Molecular Systems, Inc. Branchburg, NJ, USA). of 1 μl of reaction with 001 incubated in dTTP and . 7 μl of 0 mmol “Kan-T” at 0°C, then the reaction was incubated in TV carrier for ¥ h at . (Qiqgen Gqithersburg MD, USA): (su) QiAquick meter using a “Kan-T” column with Gi all (F2and R2) of PCR primers and the yield of 0 nanograms of Vo-9. Deletion primer, and ng PCR of Yo-01 product by mixing 14301. DNA Ligase and μl of reaction mixture for “Kan-T” carrier DNA (sb J) 553. T4DNALigase washer. microliters of 01 microliter of terminomycin in a reaction (New England Blolabs Beverely MA, USA. temperature 11 hr 11 hr incubation 0 OR to Na1118-215.00 cells by induction XL-1BLue The binding products are converted to

LB cells are spread on SOC-electrophoresis plates as previously described. After recovery, 132 µg/mL ampicillin was grown overnight on 001°C containing. These replica plates are then spread on plates containing µg/mL kanamycin and allowed to grow overnight. The genes Yo on 0 « pT7Blue A produced include the ampicillin resistance genes present in vector 13 and the newly generated kanamycin resistance genes. The colonies are taken up in a plasmid of DNA microg/mL of kanamycin cells, and YO-containing cultured cells are isolated using the method

YoY (Qiagen Gaithersburg, MD, USA) "Qiagen Miniprep" on these plasmids to prove that PCR was multiplexed by amplification and to determine the orientation of the HPylori insertion on the bacteria ORF in kanamycin genes/gods. . HPylori bacteria ORF / kanamycin resistance genes relative to genes

0 In order to prove the kanamycin carrier within the 1157103 bacterium sequence, DNAS plasmids are used as amplification PCR models with primers set mainly used to clone H.Pylori genes/ORFs. The valid PCR result is the size of the deleted gene/ORFs; But it increases in size by adding 1 kilobase of

1 Embodiment of H.pylori 0+ genes Identification of 8-gigatase resistant kanamycin L-associated gene/surprise ORF and both approaches are used effectively in transformations of H. pylori 11.13 (see later). To determine the direction of entry of the kanamycin-resistant lina, primers are designed from the ends of the kanamycin-resistant goethats.

("Kan-1"5'- ATCTTACCTATCACCTCAAAT-3") ae (YoV (sequence with reference number No "Kan-1" 5'- AGACAGCAACATCTTTGTGAA-3' and using all cloning primers in association with each YoA). (sequence with reference number Kanamycin Jala consortia of primers);

Vos

“A” (same direction of transcription is present for HPylor clages and for kanamycin resistance genes); Or in the direction of "8" (the direction of transcription of the genes of bacterium 1157101 is opposite to the direction of kanamycin resistance genes). Clones that share the same orientation (A) or 8) are collected in preparation for subsequent trades and are transformed independently into HPylori bacteria.

“HPylori Lasmid to DNA Cells” Transformation 0: Two strains of 11.5101 are used to copy the Coa from which DNA is obtained; The clinical isolate that provided the ATCC 55679, which is a passable isolate with the ability AH244 Sequence database: 117710 and strain WY temperature The cells to be transformed were completed, and on . all to colonize the stomach

Sheep-Blood either on agar plates Ligh, 700011 CO2 ARE 0 Celsius, and the cells multiply to an exponential phase; And examined microscopically to identify Brucella Broth or in fluid that is actively moving and not contaminated. If grown on LIA the extent to which the cells are “intact” (i.e. 1 platelets are harvested by abrasive cells from the plates with a sterilized loop suspended at maximum speed in an extruder or discarded 1 tabular Brucella Broth) milliliter of liquid

Vo flour) and resuspended in 0.0 microliter of Brucella Broth liquid. And if it takes place in a liquid, BrucellaBroth; Cells are centrifuged (101 min at ...? rpm) in a 6 centrifuge (Beckman TJ) and Galas cell globules are counted in 0.0.0 mL of Brucella fluid 3250 complete section (without residue) of cells to determine the optical density at 01 nm;

\oo

in order to calculate the cell concentration. An aliquot (0-3 nM unit/550 L) of the resuspended cells was placed on a preheated Sheep-Blood agar plate; The plates are also incubated at 1 degree Celsius, 711 carbon dioxide, 7101 bricks for a period of ; hours . After this incubation, a trap of 10 microliters of DNA is placed

0 plasmid Vo (mg per microliter) on these cells. Positive control (plasmid DNA with H genes from RNase denatured by kanamycin straightener genes) and negative control (without DNA plasmid) are performed in parallel and the plates are returned to VV RT; 71 CO for two; Another hour of incubation. The cells are then spread onto the plates using a trowel soaked in liquid

. Carbon dioxide SAB temperature TY 1 hour on 0. And grow for a period of 0 Brucella 0 μg / YO containing Sheep - Blood, and then the cells are transferred to anmar plates at 71 degrees Celsius, second TV, milliliters of kanamycin, and allowed to grow for a period of ? - 0 days on humidity. If colonies appear, they are taken up and re-grown with 700010 μg/yo carbon dioxide containing Sheep - Blood as batches on fresh immunization sheets of

0 mL kanamycin. Three sets of PCR tests are carried out to prove that the transformant colonies arose from similar recombination at the correct chromosomal site. A sample of 018140 colonies) is obtained by a fast-boiling DNA preparation method as follows. A complete aliquot of colonies is introduced into 100 μl of Triton 26-100 1/7, a.

0 mmol Tris, pH Apo, and boiled for 2 minutes. An equal amount of phenol: chloroform (VY) is added and stirred in a vortex manner. The mixture is then centrifuged for 0 minutes and the floating material is used as a template or as a DNA standard for PCR with the following primer combinations to establish a similar combination at the correct chromosomal 0 site. Test 1: PCR uses cloning primers originally used to amplify genes/ORFs. A positive result of a similar recombination at the correct chromosomal location should result in a single predicted PCR product of size oY the size of the deleted genes/ORFs but increased in size by the addition of 1kb of the kanamycin vector. A PCR result of 0 of the same gene size/ORF is proof that the gene was not knocked out and that the transducers are not the result of a similar recombination at the correct chromosomal location. a test? PCR: and F3 (primer designed from higher sequences of the gene/ORF not present on the plasmid) and primer 1580-1 or 1580-2 (primers designed from kanamycin-resistant elisa tips) depending on the extent of the The DNA of the plasmid used is "A" or "8". VO in terms of direction. A similar recombination at the correct chromosomal site will result in a single PCR output of the expected size (ie, from site 13 to the insertion site of the kanamycin resistance gene insertion). of PCR output of incorrect size or sizes proves that the plasmid was not integrated at the correct site and that the genes were not suddenly extruded or extruded.

Lama PCR:Y J Las | with R3 (primer designed from lower sequences of ORF/xa and not present on plasmid) and Kan-1 or Kan-2 primer depending on how DNA is ] of the user plasmid with orientation “A” or “3”. A similar recombination at the correct chromosomal site A will result in a single PCR result of the expected size (i.e., from the knamycin resistance gene entry © site to the downstream site of ) RB and again 'CI' will not indicate that the PCR product or PCR products of the correct size or | of non-invalid sizes indicate that the plasmid was not integrated at the correct site and that the genes were not knocked out (or inactivated). Transformants that show positive results for all three signify Previous tests indicate that the gene is not 0 essential for life in a glass tube.A negative result in any of the above three tests conducted for each transformer indicates that the gene did not break down, and that the gene is essential for life in the glass tube (in the laboratory). Colonies from two independent loadings While the positive control with DNA lyase MED produces H-reonuclease cleaved adapters, DNA from the oY gall Vo population is analyzed before colony information is mediated or released. It certifies that the plasmid can enter the LOAN and tolerate a similar recombination at the correct site. Briefly ; Plasmid DNA is incubated according to the previously described transformation method. DNA is extracted from the cells of bacteria: 11.5710 immediately after incubation with DNAsgs plasmids and with all the DNA used as a model for testing? And to test V will prove

VoA plasmid can enter cells DNA test results? and test? The positive is that it carries a similar recombination at the correct chromosomal site. And if the tests? Failure to obtain viable mutations indicates that the gene Bates and? Positive that the cells that suffer fragmentation in that gene are unable to provide ley, essential. Colony information 0 "Comprehensive sifting or screening test" 1 "" Cloning, expression and purification of a protein The cloning, transformation, expression and purification of the target gene from bacteria and protein producers such as a bacterial enzyme is being performed: 11.5710 for use In test 3 above on [11] I highly comprehensive drug clearance as described in the two examples 0 is substantial. and the development and use of a filtering assay for a specific bacterium 11.7101 gene product; Described later as a specific example, Cis trans or a peptide-biolyl isomerase: an enzyme test: the test is essentially as described by Fischer in

Fisher (Fisher, 6. et al., (1984) Bioned. Biochim. Maat 43: 1101-1111). \o : in a peptide for the Ala-Pro test for a cis-trans bond This test measures the isomer (N - succinyl - Ala - Ala - Pro - Phe - p - nitroaorilide (Sigma # 5-7388, lot # 84HS5805) The test is bound to alpha-chymotrypsin; Where the protease's ability to "trans" occurs 18m "in - 3:0" deal, penetration of the peptide of choice when it is YL

Vod test peptide to isomer "0308" occurs on .4? nanometers: a spectophotometer of the type (Beckman Model D u - 650). The data is collected every second with a temporal scan rate of w. second . and a teflon pH 4, in a final amount of Hepes tests in ¥ 0 mmol of pancreas, 1-9 chymotrypsin (type LT) 0 1 μmol μl, with £ to start. PPlase nanomolene 1 lot 23117020) and bovine C-7762 Plot No.: microliter of yeast (? 01 millimoles of reaction, added

N-Succinyl-Ala-Ala-Pro-Phe-P-nitroanilide in DMSO). . to .4? A microliter of the reaction mixture at room temperature 0 "Enzymatic test in crude bacterial extract"

Brucella .9 ml fry of 11.7101 bacteria (Salama 109) are harvested in liquid and resuspended in a lysosomal buffer with mid-log Phase (OD600Nm ~L) inhibited to: the following proteases: μg / milliliter of each: aprotinin leupeptin; PMSF 001 mmol of 1 Vo and trypsin inhibitor soybean followed by exposing the suspension TPCK, TLCK, pepstatin to temperature C, then 3 minutes to Ve- minutes at V0) for three freeze-thaw cycles (room temperature), sonograms (three .? seconds each), and product expulsion *.? minutes) and test the floating material for effectiveness gx VY.) dissolution centrally. enzyme as previously described by YL

0

Many HPYION enzymes can be expressed at high levels in an active form in E. Coli bacteria, and such a high availability of cross-proteins lends itself to highly comprehensive, diverse drug screening tests. Paradoxes:

0 Those skilled in this field will realize Gl They can use routine experiments to get Laas | ya the special incarnations and methods | to described here. But Mkhthal of these synonyms fall within the Glad invention specified jualin the following protection.

SEQUENCE LISTING GENERAL INFORMATION: (1 (i) APPLICANT: 5 (A) NAME: Astra Aktiebolag (B) STREET: S-151 85 (C) CITY: Sodertalje ( D) STATE: (E) COUNTRY: Sweden 10 (F) POSTAL CODE (ZIP) (ii) TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER PYLORI AND ) VACCINE COMPOSITIONS THEREOF 15 (iii) NUMBER OF SEQUENCES: 208 , (iv) COMPUTER READABLE FORM: 20 (A) MEDIUM TYPE: ({B) COMPUTER: (C) OPERATING SYSTEM: ( D) SOFTWARE: 1

(v) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER (B) FILING DATE: (vi) PRIOR APPLICATION DATA: 30 (A) APPLICATION NUMBER: US 08/739,150 (B) FILING DATE: 28-OCT-1996 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/759,739 35 (B) FILING DATE: 06-DEC-1996 (viii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/891, 928 (B) FILING DATE: 14-JULY-1997 40 (ix) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: LAHIVE & COCKFIELD (BY) STREET: 28 State Street (C) CITY: Boston 45 (D) STATE: Massachusetts (E} COUNTRY: USA (F) ZIP: 02109-1875 : (x) ATTORNEY /AGENT INFORMATION: : 50 (A) NAME: Mandragouras, Amy E. (B) REGISTRATION NUMBER: 36,207 (C) REFERENCE/DOCKET NUMBER: GTN-001CP10SA (xi) TELECOMMUNICATION INFORMATION: 55 (A) TELEPHONE: (617)227-7400 (B) TELEFAX: (617)227-5941

(2) INFORMATION FOR SEQ ID 7 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 561 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double 1 (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA ( genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1... 561 {x1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGATTAAAA GAATTGCTTG TATTTTAAGC TTGAGCGCGA GTTTAGCGTT AGCTGGCGAA 60

GTGRATGGGT TTTTCATGGG TGCGGGTTAT CAACAAGGTC GTTATGGCCC TTATAACAGC 120

AATTACTCTG ATTGGCGTCA TGGCAATGAC CTTTATGGTT TGAATTTCAA ATTAGETTTT 180

GTAGGCTTTG CCAATAAATG GTTTGGGGCT AGGGTGTATG GCTTTTTAGA TTGGTTTAAC 240

ACTTCAGGGA CTGAACACAC CAAAACCAAT TTGCTCACCT ATGGCGGCGGE TGGCGATTTG 300

ATTGTCAATC TCATTCCTTT GGATAAATTC GCTCTAGGTC TCATTGGTGG CGTTCAATTA 360

GCCGGAAACA CTTGGATGTT CCCTTATGAT GTCAATCAAA CCAGATTCCA GTTCTTATGS 420

AATTTAGGCG GAAGAATGCG TGTTGGGGAT CGCAGTGCGT TTGAAGCGGG CGTGAAATTC 480

CCTATGGTTA ATCAGGGTAG CAAAGATGTA GGGCTTATCC GCTACTATTC TTGGTATGTGE 540

GATTATGTCT TCACTTTCTA G 561 (2) INFORMATION FOR SEQ ID NO:2: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 351 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) {iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...351 (x21) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TTGATGCGCA TTATCATAAG GTTACTTTCA TTTAAAATGA ACGCTTTTTT AAAACTCGCG 60

CTCGCTTCTT TGATGGGGGGCTTTGGTATGCTTTTCAATGGCGAAGGCTCTGAGATTGTC120

GCTATAGGGA TTTTTGTGTT GATCTTGTTTT GTTTTTTTTA TCCGCCCTGT GAGTTTTCCAR 180

GACCCAGAARA AACGAGAAGA ATACATAGAA CGGCTTAAAA AAAACCATGA GAGGAAAATG 240

ATCTTACAAG ACAAGCAAAA AGAAGAGCAA ATGCGCCTCT ATCAAGCCAA AARAGAGCGA 300

GAGAGCAGGC AAAAACAAGA CCTTAAAGAA CAAATGAAAA AATACTCATA A 351 {2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1038 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: (ii) circular MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO {vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature {B) LOCATION 1...1038 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGGTTARAC ACTATCTTTT CATGGCGGTT TCGCAGGTCT TTTTCTCCTT CTTTTTAGTG 60

CTGITTTTTA TCTCTTCCAT TGTGTTATTA ATCAGTATTG CAAGCGTAAC GCTCGTGATT 120

AAAGTGAGCT TTTTGGATCT GGTGCARACTC TTTTTGTATT CCTTGCCAGG AACCATTTTT 180

TTTATTTTGC CGATCACTTT TTTTGCGGCT TGCGCTTTGG GGCTTTCAAG GCTTAGCTAT 240

GACCATGAAT TGTTAGTGTT TTTCTCTTTA GGGGTTTCGC CTAAAAAAAT GACTAAAGCG 300

TTTGTGCCTT TAAGTTTGTT AGTGAGCGCG ATTTTATTAG CGTTTTCGCT CATCTTAATC 260

CCCACTTCTA AGAGCGCTTA TTACGGGTTT TTGCGTCAAA AAAAAGACAA GATTGACATT 420

ARCATCAGAG CGGGTGAATT CGGGCAAAAA TTAGGCGATT GGCTCGTGTA TGTGGATAAG 480

ACTGAAAACA ATTCCTATGA TAATTTGGTG CTTTTTTCTA ATAAAAGTCT CTCTCAAGAA 540

AGCTTTATTT TGGCTCARAA AGGCAATATC AACAATCAARA ACGGCGTGTT TGAATTGAAT 600

TTGTATAACG GGCATGCGTA TTTCACTCAA GGCGATAAAA TGCGTAAGGT TGATTTTGAA 660

GAATTGCATT TGCGCAACAA GCTCAAGTCT TTCAATTCTA ATGATGCGGC TTATTTGCAA 720

GGCACGGATT ATTTGGGTTA TTGGAAAAAAA GCCTTTGGTA AAAACGCTAA TAAAMATCAA 780

ARACGCCGTT TTTCTCAAGC GATCTTAGTT TCCTTGTTCC CTTTAGCGAG CGTGTTTTTA 840

ATCCCCTTAT TTGGCATCGC CAACCCGCGA TTCAAAACGA ATTGGAGTTA TTTCTATGTC 900

CTTGGAGCGG TTGGGGTTTA TTTTTTAATG GTGCATGTGA TTTCTACGGA TTTGTTTTTG 960

ATGACCTTTIT TCTTCCCCTT TATTTGGGCG TTTATTTCTT ATTTATTGTT TAGAARATTC 1020

ATTTTAAAGC GTTATTAA 1038 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 831 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO {vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...831 (xi) SEQUENCE DESCRIPTION: SEQID NO:4:

ATGAAGAAAA AAGCAAAAGT CTTTTGGTGT TGTTTTAAAA TGATTCGTTG GTTGTATTTG 60

GCGGTCTTTT TTTTGTTGAG CGTATCAGAC GCTAAAGAAA TCGCTATGCA ACGATTTCAC 120

AAACAAANCC ATAAGATTTTT TGAAATCCTT GCGGATAAAG TGAGCGCCAA AGACAATGTG 180

ATAACCGCCT CAGGGAATGC GATCCTATTG AATTATGACG TGTATATTCT AGCGGATALG 240

GTGCGTTATG ACACCAAGAC TAAAGAAGCG TTATTAGAAG GCAATATTAA GGTTTATAGG 300

GGCGAGGGCT TGCTCGTTAA AACCGATTAT GTGAAATTGA GTTTGAACGA AAAATATGAG 360

ATCATTTTTCC CCTTTTATGT CCAAGACAGC GTGAGCGGGA TTTGGGTGAG CGCGGATATT 420

GCTAGCGGGA AGGATCAAAA ATATAAGATT AAAAACATGA GCGCTTCAGE GTGCAGCATT 480

GACAACCCCA TTTGGCATGT CAATGCGACT TCAGGCTCAT TTAACATGCA AAAATCGCAT 540

TTGTCAATGT GGAATCCTAA GATTTATGTC GGCGATATTC CTGTATTGTA TTTGCCCTAT 600

ATTTTTCATGT CCACGAGCARA TAAAAGAACT ACCGGGTTTT TATACCCTGA GTTTGGCACT 660

TCCAACTTAG ACGGCTTTAT TTATTTGCAA CCCTTTTATT TAGCCCCCAA AAACTCATGGE 720

GATATGACCT TTACCCCACA AATCCGTTAC AAAAGGGGTT TTGGCTTGAA TTTTGAAGCG 780

CGCTACATCA ACTCTAAGAC GCAGGTTTTT ATTCAATGCG CGCTATTTTA G 831 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CEARACTERISTICS: (A) LENGTH: 675 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: (ii) circular MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature , (B) LOCATION 1...675 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: !

ATGATTAGAT TAAAAGGTTT GAATAAAACT TTAAAAACAA GCTTATTAGC TGGGGTTTTTA 60

CTAGGTGCTA CTGCTCCCTT AATGGCAAAG CCTTTATTAA GCGATGAAGA CTTATTGARA 120

CGAGTAAARC TACACAATAT CAAAGAAGAT ACGCTGACTA GCTGTAATGC TAAGGTGGAC 180

GGCTCTCAAT ACTTGAATAG TGGTTGGAAT TTATCTAAAG AATTTCCGCA AGAATATAGA 240

GAAAAGATTT TTGAATCGGT AGAAGAAGAA AAACATAAAC AAGCCCTTAA TTTAATCAAT 300

AAAGRAGACA CTAAAGATAA AGAAGAACTT GCAAAAAAAA TCAAAGAAAT TAAAGAAARA 360

GCTARAGTTT TAAGGCAARA ATTTATGGCT TTTGAAATGA AAGAACACTC TARAGAATTC 420

CCAAATAAAR AGCAACTTCA AACCATGCTT GAGAACGCTT TTGATAATGG AGCTGAAAGT 480

TTTATTGATG ATTGGCACGA ACGCTTTGGG GGTATAAGTA GAGAGAATAC TTATAAAGCA 540

CTTGGCATTA AAGAARTATAG TGATGAAGGA AAGATATTGC CTTTGGCGAA AGAAGTTATA 600

P TTAGACRATA TARAAAAGAT TTTGAAGAAA GCACTTATGA TACTAGACAA CCCTTATCTG 660 CTATGGCTAG TATGA 675 INFORMATION FOR SEQ ID NO:6: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1290 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 10 (ii) MOLECULE TYPE : DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...1290 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: 25 ATGCCATACG CCTTAAGRAA AAGATTTTTC AAACGCCTTT TATTGTTTTTTTTTAATTGTT 60‏ ‎TGTATGATAA ATTTGCATGC CAAAAGCTAT CTGTTTTCTC CTTTGCCCCC AGCGCACCAG 120‏ ‎CARATCATTA AGACAGAGCC TTGCTCTTTG GAGTGCTTGA AAGACTTGAT GCTGCAAAAT 180‏ ‎ CAAATCTTTT CTTTTGTATC CCAATACGAT GATAACAACC AAGATGAGAG CCTTAAAACT 240‏ 30 ‎TATTACAAGG ACATCTTAAA CAAACTCAAC CCCGTATTCA TCGCTTCTCA AACTCCAGCT 300‏ ‎ARAGARAAGCT ATGAGCCTAA GATTGAATTA GCGATTTTAC TGCCTAAARA GGTGGTGGGC 360‏ ‎CGTTATGCGA TTTTAGTGAT GAACACCCTT TTAGCGTATT TGAACACCAG AAACAACGAT 420‏ ‎TTCAATATCC AAGTCTTTGA CAGCGATGAA GAAAGCCCTG AAAAATTAGA AGAAACCTAT 480‏ ‎AARGAAATTG AAAAAGAAAA ATTCCCTTTT ATCATCGCTT TATTGACTAA AGAGGGCGTE 540‏ 35 ‎GAARATTTGC TCCAAAATAC GACTATCAAT ACCCCTACTT ATGTGCCTAC GGTGAATAAA 600‏ ‎ACGCAATTAG AAAATCATAC CGAGCTTTCT TTAAGCGAGC GCTTGTATTT TGGGGGGATT 660‏ ‎GATTATAAAG AGCAATTAGG CATGCTCGCA ACTTTCATTA GCCCTAATTC GCCCGTGATT 720 GRATACGATG ATG ATGGCCT GATAGGTGAA CGCTTGAGGC AAATCACGGA GTCTTTARAC 780‏ ‎ GTTGAAGTCA AACACCAAGA ARACATTTCT TACAAACAAG CGACCAGTTT TTCTAAAAAT 840‏ 40 ‎TTTAGAARAC ATGATGCGTT TTTTARAAAT TCTACCTTAA TTTTGAACAC CCCTACCACT 200‏ ‎TGATCCTTTC TCAAATAGGG CTTTTAGAGT ATAAGCCTCT TAARAATCCTT 960‏ 222260606170 ‎TCCACACAAA TCAATTTCAA CCCCTCTTTA CTCTTGCTCA CCCAGCCTAA AGACAGGAAA 1020‏ ‎AATTTATTCA TTGTCAATGC CTTGCAAAAC AGCGATGAAA CGCTGATAGA ATACGCTTCC 1080‏ ‎ TTATTAGAGA GCGATTTAAG GCATGATTGG GTGAATTATT CCAGCGCGAT AGGGCTAGAG 1140‏ 45 ‎ATGTTTTTAA ACACGCTAGA TCCGCATTTT AAAAAGTCTT TTCAAGAGAG TTTGGAAGAC 1200‏ ‎AATCAAGTCC GTTACCACAA TCAAATTTAT CAGGCTTTAG GGTATTCTTT TGAGCCGATA 1260‏ ‎ARADACGAAA GCGAAACAAA AARAGAATAR 1290‏ ‎INFORMATION FOR SEQ ID NO:7:‏ )2( 50 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1368 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double 55 (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic).

(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: 5 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/ KEY: misc_feature (B) LOCATION 1...1368 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GTGTTAAAAT TTCAAARATT ACCCTTATTG TTTGTTTCCA TTCTTITATAA TCAAAGCCCT 60 TTATTGGCTT TTGATTATAA GTTTAGTGGG GTAGCGGAAT CTGTTTCTAA TAG 1TGG0GTT AACCATTCCA AACTCAATTC CAAAGAAGGG ATTTTCCCTA CAGCCACCTT TGTAACCGCC 180‏ ‎ACGATCAAGC TTCAAGTGGA TTCCAATCTG CTCCCTAAAA ACATTGAAAA ACACAGCTTA 240‏ ‎TTGGGGGGAT TTTAGGAGCG CTCGCTTACG ATTCCACCAA AACGCTCATA 300‏ 2202126006 ‎GACCAAGCCA CGCATCAAAT CTATGGCTCA GAACTTTTTT ACCTCATAGG GCOGTTGGTGS 360‏ ‎ GGGTTTTTAG GCAACGCTCC TTGGAAAGAC TCCCTCATAG AATCTGACGC TCACACCCGT 420‏ 20 ‎AATTATGTGC TGTATAATTC CTATCTGTTT TATTCTTATG GCGATAAATT CCACCTAARA 480 TTAGGGCGTT ATCCTCTAA CATGGATTTT ATGAGTTCCT ACACACAGGE TTTTGAACTG 540 GATTATAAAA TCAATTCTAA AATAGCGTTA AAATGGTTTA GCTCTTTTG GAGGGCGTTG 600 GCTTTTGGGC AATGGATACG GGATTGGTAT GCCCCTATTG TAACTGAAGA TGGCAGARAR 660‏ ‎ GAAGTTTATG ATGGCATCCA TGCCGCGCAA CTCTATTTTT CTAGCAAGCA TGTTCAAGTC 720‏ 25 ‎ATGCCTTTTG CTTATTTTTC GCCTAAGATT TACGGAGCGC CCGGTGTTAA AATCCATATT 780‏ ‎GATAGCAACC CGAAATTCAA AGGCTTAGGG TTAAGGGCTC AAACCACTAT TAATGTGATT 840‏ ‎ATGCTAAAGA TTTATACGAT GTGTATTGGC GTAACTCTAA GATTGGCGAG 900‏ 11000161117 ‎TGGGGCGCAT CGCTTTTGAT CCACCAACGC TTTGACTACA ACGAATTTAA CTTTGGCTTT 960‏ ‎GGTTATTACC AAAATTTTGG CAACGCTAAC GCAAGGATTG GCTGGTATGG TAACCCCATC 1020‏ 30 ‎CCTTTTAATT ATAGAAATAA CAGCGTTTAT GGTGGGGTCT TCAGTAACGC TATTACCGCA 1080‏ ‎GACGCCGTTT CTGGGTATGT CTTTGGTGGG GGGGTGTATA GAGGGTTTTT ATGGGGTATT 1140‏ ‎TTAGGCAGAT ACACTTATGC CACTAGAGCG AGCGAAAGAT CCATCAACTT GAACTTGGGC 1200‏ ‎TATAAATGGG GTTCTTTTGC TAGAGTTGAT GTGAATTTAG AATACTATGT GGTCAGCATS 1260‏ ‎ CACAACGGCT ATAGATTAGA CTATCTCACC GGCCCTTTCA ACAAAGCCTT TAAGGCTGAC 1320 35 GCACAAGATA GGAGTAACCT TATGGTTAGC ATGAAATTCT TTTTTTARA 1368 INFORMATION FOR SEQ ID NO:8: (2) (i) SEQUENCE CHARACTERISTICS: 40 (A) LENGTH: 849 base pairs ( B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 45 (ii) MOLECULE TYPE: DNA (genomic) , (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO 50 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 55 (A) NAME/KEY: misc feature (B) LOCATION 1.. .849 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

N and > ATGGGGTGTT CGTTTATCTT TAARAAAGTT AGGGTTTATT CTAAAATGTT 1160-17 60 GGGCTTTCAA GCGTGTTGAT CGGTTGCGCG ATGAATCCAA GCGCTGAGAC AAAAAAACCA 120 AATGACGCCA AMAACCAACA ACCAGTTCAA ACTCATGAAA GAATGACAAC AAGTTCTGAA . 180‏ ‎ CATGTTACGC CACTAGATTT TAATTACCCG GTGCATATTG TTCAAGCCCC ACAAAACCAT 240‏ 5 ‎CATGTTGTAG GTATTTTAAT GCCACGCATT CAAGTGAGCG ATAATCTAAA ACCCTATATT 300‏ ‎GATAAGTTTC AAGACGCTTT AATTAATCAA ATCCAAACTA TTTTTGAAAA AAGAGGCTAT 360‏ ‎CAAGTGTTGC GTTTTCAAGA TGAAARAGCT TTGAATGTGC AAGATAAGAA AAAGATTTTT 420‏ ‎TCCGTTTTGG ATTTGAAAGG GTGGGTAGGA ATCTTAGAAG ATTTGAAAAT GAATTTAAAR 480‏ ‎ GATCCCAATA GTCCCAATTT AGACACGCTA GTGGATCAAA GCTCAGGCTC TGTATGGTTT 540‏ 10 ‎AATTTTTATG AACCAGAAAG CAATCGTGTC GTCCATGATT TTGCTGTAGA AGTAGGAACT 600‏ ‎TTTCAGGCAA TAACATACAC ATACACCTCT ACTAATAACG CTTCAGGAGG GTTTAATTCT 660‏ ‎TCAARAAGCG TTATCCATGA AAATTTGGAT AAGAATAGAG AAGACGCGAT ACACAAGATT 720‏ ‎TTAAACAGAA TGTATGCGGT TGTCATGAAA AAAGCTGTAA CAGAACTTAC AAAAGAAAAT 780‏ ‎ ATCGCCAAAT ACAGAGACGC TATTGATAGA ATGAAAGGCT TTAAAAGTTC TATGCCTCAA 840 15 AARARGTAG 849 INFORMATION FOR SEQ ID NO:9: (2) (i) SEQUENCE CHARACTERISTICS: 20 (A) LENGTH: 843 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO 30 {vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori ( ix) FEATURE: 35 (A) NAME/KEY: misc_feature (B) LOCATION 1...843 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

‎ATGAAACTGA GAGCAAGTGT TTTAATCGGT GTGGCAATTC TGTGCTTAAT TTTAAGTGCG 60‏ ‎TGCAGTAACT ATGCGAAAAA AGTGGTGAAA CAAAAGAACC ATGTTTATAC GCCTGTGTAT 120‏ ‎AATGAACTGA TAGAGAAGTA TAGTGAGATC CCCTTAAATG ACAAACTCAA AGACACACCA 180‏ ‎TTCATGGTGC AAGTGAAGTT GCCAAATTAC AAGGACTATT TGTTGGATAA TAAACAAGTT 240‏ ‎ GTACTAACTT TCAAACTTGT TCACCATTCT AAAAAGATTA CGCTCATAGG CGATGCCAAT 300‏ 45 ‎AAGATCCTCC AATACAAGAA TTACTTCCAA GCTAACGGGG CAAGATCTGA CATTGATTTT 360‏ ‎TACTTGCAAC CCACTTTGAA TCAAAAGGGT GTGGTGATGA TAGCGAGTAA CTACAATGAT 420‏ ‎AATCCCAACA ACAAAGAARA ACCACAGACC TTTGATGTGT TGCAAGGAAG TCAGCCAATG 480‏ ‎CTAGGAGCTA ACACAARAAA CTTGCATGGC TATGATGTGA GTGGAGCAAA CAACAAGCAA 540‏ ‎GTGATCAATG AAGTGGCAAG AGAAABAGCT CAGCTAGAAA AAATCAATCA GTATTACAAG 600‏ 50 ‎ACTCTCTTGC AAGACAAGGA ACAAGAATAT ACCACTAGGA AAAATAACCA ACGAGAAATT 660 TTAGAAACAT TGAGTAATCG TGCAGGTTAT CAAATGAGGC AGAATGTGAT TAGTTCTGAG 720 ATTTTTAAGA ATGGCAACTT GRACATGCAA GCCAAAGAAG AAGAAGTTAG GGAGARAGCTA 780 CAAGAAGAAA GAGAGAATGA ATACTTGCGC AATCAAATCA GAAGTTTGCT C AGTGGTAAG 840 Tea 843 55 INFORMATION FOR SEQ ID NO:10: (2) (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1179 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO 10 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori ( ix) FEATURE: 15 (A) NAME/KEY: misc_feature (B) LOCATION 1...1179 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

‎ATGAGAAAAC TATTCATCCC ACTTTTATTA TTCAGCGCTT TAGAAGCGAA CGAGAAAAAC 60‏ ‎GGCTTTTTCA TAGAAGCCGG CTTTGAAACT GGGCTATTAG AAGGCACACA AACGCAAGAA 120‏ ‎ARRAGACACA CCACCACAAA AAACACTTAC GCAACTTACA ATTATTTACC CACAGACACG 180‏ ‎ATTTTAAARA GAGCGGCTAA TTTATTCACC AATGCCGAAG CGATTTCAAA ATTAAAATTC 240‏ ‎ TCATCTTTAT CCCCTGTTAG AGTGTTGTAT ATGTATAATG GTCAATTAAC TATAGAAAAC 300‏ 25 ‎TTCTTGCCTT ATAATTTARA TAATGTTAAG CTTAGTTTTA CAGACGCTCA AGCCAATGTG 360‏ ‎ATCGATCTAG GCGTGATAGA GACTATCCCC AAACACTCTA AGATTGTTTT GCCCGGAGAG 420‏ ‎GCATTTGATA GTCTAAAAAT TGACCCCTAT ACTTTATTTC TTCCAAAAAT TGAAGCCACT 480‏ ‎AGCACTTCTA TTTCTGACGC TAACACGCAG AGGGTGTTTG AAACGCTCAA TAAGATTAAG 540‏ ‎ACARATTTGG TCGTAAATTA TAGGAATGAA AACAAATTTA AAGATCACGA AAATCATTGG 600‏ 30 ‎GAAGCCTTTA CCCCACAAAC CGCAGAAGAA TTCACTAATT TAATGTTGAA CATGATCGCT 660 GTTTTAGACT CCCAATCTTG GGGCGATGCG ATCTTAAACG CTCCTTTTGA GTTCACTAAC 720 AGCCCAACAG ATTGCGATAA TGATCCTTCA AAATGCGTAA ATCCTGGGAC AAACGGGCTT 780 GTCAATTCTA AAGTCGATCA AAAATATGTG TTAAACAAAC AAGACATTGT CA ATAAATTT 840‏ ‎AAAAACAAAG CGGATCTTGA TGTAATTGTT TTAAAGGATT CAGGGGTTGT AGGGCTTGGG 900‏ 35 ‎AGTGATATTA CCCCTAGCAA CAATGATGAT GGCAAGCATT ATGGCCAGTT AGGGGTAGTA 960‏ ‎GCTTCTGCTT TAGATCCTAA AAAACTCTTT GGCGATAACC TTAAGACTAT CAATTTAGAG 1020‏ ‎GATTTAAGAA CCATCTTGCA TGAATTCAGC CACACTAAAG GCTATGGGCA TAACGGGAAT 1080‏ ‎ATGACCTATC AAAGAGTGCC GGTAACGARA GATGGTCAAG TGGAAAAGGA TAGTAATGGC 1140‏ ‎ AAGCCAARAG ATTCTGATGG CCTCCCCTAT AATGTGTGT 1179 40 INFORMATION FOR SEQ ID NO:11: (2) (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 813 base pairs 45 (B) TYPE: nucleic acid : (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 50 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE: (AR) ORGANISM: Helicobacter pylori (ix) FEATURE:

(A) NAME/KEY: misc_feature (B) LOCATION 1...813 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

‎ATGAARAAGT TTGTAGCTTT AGGGCTTCTA TCCGCEGTTT TAAGCTCTTC GTTGTTAGCC 60‏ ‎GAAGGTGATG GTGTTTATAT AGGGACTAAT TATCAGCTTG GACAAGCCCG TTTGAATAGC 120‏ ‎AATATTTATA ATACAGGGGA TTGCACAGGG AGTGTTGTAG GTTGCCCCCC AGGTCTTACC 180‏ ‎GCTAATAAGC ATAATCCAGG AGGCACCAAT ATCAATTGGC ACTCCAAATA CGCTAATGGGE 240‏ ‎GCTTTGAATG GTTTTGGGTT GAATGTGGGT TATAAGAAAT TCTTCCAATT CAAGTCGCTA 300‏ 10 ‎GATATGACAA GCAAGTGGTT TGGTTTTAGA GTGTATGGGC TTTTTGATTA CGGGCATGCC 360‏ ‎GATTTAGGTA AACAAGTTTA TGCACCTAAT AAAATCCAGT TGGATATGGT CTCTTGGGGT 420‏ ‎GTGGGGAGCG ATTTGTTAGC TGATATTATT GATAAAGACA ACGCTTCTTT TGGTATTTTT 480‏ ‎GGTGGGGTCG CTATCGGCGG TAACACTTCG AAAAGCTCTG CAGCAAACTA TTGGAAAGAG 540‏ ‎CARATCATTG AAGCCAAAGG TCCTGATGTT TGTACCCCTA CTTATTGTAA CCCTAATGCC 600‏ 15 ‎CCTTATAGCA CCAACACTTC AACCGTCGCT TTTCAAGTGT GGTTGAATTT TGGGGTGAGA 660 GCCAATATCT ACAAGCATAA TGGCGTGGAA TTTGGCGTGA GAGTGCCGCT ACTCATCAAT 720 ARATTTTTGA GCGCGGGTCC TAACGCTACT AACCTTTATT ACCATTTGAA ACGGGATTAT 780 TCGCTTTATT TGGGGTATAA CTACACTTTT TAA 813

INFORMATION FOR SEQ ID NO:12: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 423 base pairs {B) TYPE: nucleic acid 25 (C) STRANDEDNESS: double (D} TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: 35 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY : misc_feature (B) LOCATION 1...423 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: A ATGCATCCTA TAATGTTTTGC CTATATCGCT AACGCGCTCG CTCAAGCTAG AAAGATCAAC 60 GGAACACTTT GCATGGCGTT TCAAAAAATA TCTCAAGTCA AAGAATTAGG CATTGATAR 4 120 GCAAAGAGTT TGATAGGCAA CCTTTCTCAA GTGATTATCT ACCCCACAAA AGATACTGAT 180‏ ‎GAATTAATAG AATGTGGCGT CCCATTAAGC GATAGTGAAA TCAATTTCTT ACACAACACG 240‏ ‎GACATGAGAG CCAGACAAGT GCTAGTAARA AATATCGTTA CAAACGCTTC AGCTTTTATT 300‏ ‎GAAATTGATT TAAAAAAGAT TTGCAAGAAC TACTTTATAT TCTTGATAGC ARTGCTGGTA 360‏ ‎ATAGAAAAAT CCTCAATGAT CTTAAAAAAG CAAACCAAGA AACTTATAAG GAAGAGTATT 420‏ 50 ‎TAA 423‏ ‎ INFORMATION FOR SEQ ID NO:13: (2) (i) SEQUENCE CHARACTERISTICS: 55 (A) LENGTH: 771 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double ( D) TOPOLOGY: circular

\WV. (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...771 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATGTTGGGGA GCGTCAAAAAA AGCGGTTTTIT 26600771707 GTTTGGGGGC GTTGTGTTTA 60

TGCGGGGGGT TAATGGCAGA GCAAGATCCT AAAGAGCTTA TATTTTCAGGE TATAACTATT 120

TACACGGATA AAAATTTCAC TAGAGCTAAG AAATATTTTG AARAAAGCTTG CAAATCAARC 180

GATGCTGATG GCTGTGCAAT CTTAAGAGAG GTTTATTCTA GTGGTAAAGC CATAGCGAGA 240

GARARCGCAA GAGAGAGCAT TGAAAAAGCT CTTGAACACA CCGCTACTGC TAAAGTTTGT 300

AAATTAAACG ATGCTGAAAR ATGCAAGGAC TTAGCAGAGT TTTATTTTAA TGTAAACGAT 360

CTTAAAAATG CTTTAGAATA TTACTCTAAA TCTTGTAAGT TAAATAATGT TGAAGGGTGT 420

ATGCTGTCAG CAACTTTTTA TAACGATATG ATAAAGGGTT TGAAAAAAGA TAAAAAAGAT 480

CTAGAATATT ATTCTAAAGC TTGCGAGTTA AATAACGGTG GAGGGTGTTC TAAATTAGGA 540

GGGGATTATT TTTTTGGTGA AGGCGTAACA AAAGATTTCA AAAAAGCTTT TGAATATTCT 600

GCCAAAGCTT GTGAGTTGAA CGATGCTAAA GGGTGTTACG CTCTAGCAGC GTTTTATAAT 660

GAGGGTAAAG GCGTGGCAAA GGATGAAAAG CAAACGACAG AAAACCTTGA AAAGAGTTGC 720

AAGCTAGGAT TAAAAGAAGC ATGCGATATT CTCAAAGAAC AAAAACAATA A 771 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 729 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: , (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY : misc_feature {B) LOCATION 1...729 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ATGAAARAAT TTTTTTCTCA ATCTTTGTTA GCTCTTATTA TCCTATGAA TGCGGTATCT 60

GGCATGGATG GTAATGGCGT TTTTTTAGGS GCGGGTTATT TGCAAGGACA GGCGCAAATG 120

CATGCGGATA TTAATTCTCA AAAACAAGCC ACCAACGCTA CGATCAAAGG CTTTGACGCG 180

CTCTTGGGGT ATCAATTTTT CTTTGAAAAA CACTTTGGCT TACGCCTTTA TGGGTTTTTT 240

GACTACGCTC ATGCCAATTC TATTAAGCTT AAAAACCCTA ACTATAATAG CGABGCGGCG 300

CAAGTGGCTA GTCAAATTCT TGGGAAACAA GAAATCAATC GTTTAACARA CATTGCCGAT 360

AWA

CCCAGAACTT TTGAGCCGAA CATGCTCACT TATGGGGGGGE CTATGGACGT GATGGTTAAT 420

GTCATCAATA ACGGCATCAT GAGTTTGGGG GCTTTTGGCG GGATACAATT GGCCGGCAAT 480

TCATGGCTTA TGGCGACACC GAGCTTTGAG GGCATTTTAG TGGAACAAGC CCTTGTGAGC 540

AAGAAAGCCA CTTCTTTCCA ATTTTTATTC AATGTGGGGG CTCGCTTAAG GATCTTAAAA 600

CATTCTAGCA TTGAAGCGGG CGTGAAATTC CCCATGCTAA AGAAAAACCC CTACATCACT 660

GCAAAARATT TGGATATAGG GTTTAGGCGC GTGTATTCGT GGTATGTGAA TTACGTGTTC 720

ACTTTCTAG 729 (2) INFORMATION FOR SEQ ID NC:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 804 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...804 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATGAACTACC CTAATCTACC TAACAGCGCT TTAGAGATAR GCGAACAGCC AGAAGTGARA 60

GAAATCACTA ACGAGCTTTT AAAGCAATTA CAAAACGCTT TAAGGAGCAA CGCGCATTTIT 120

AGCGAGCAAG TGGAATTAAG CCTTAAATGC ATCGTTAGGA TTTTAGAAGT GCTTTTGAGT 180

TTGGATTTTT TTAAGAATGC GAATGAGATT GATAGCAGTT TAAGAAATTC CATTGAGTGG 240

CTGACTAACG CCGGCGAGAG CTTGAAATTA AARAATGAAAG AATACGAGCG CTTTTTTAGC 300

GAGTTTAATA CGAGCATGCA TGCCAACGAG CAGGAAGTAA CCAATACCTT AAACGCTAAC 360

GCCGAGAACA TTAAAAGCGA AATTAAAAAAG CTAGAAATC AATTGATAGA AACCACGACA 420

AGACTTTTAA CGAGCTATCA AATCTTTTTTA AACCAAGCCA GAGATAACGC TAACAACCAA 480

ATCACAAAAR ACAAAACCCA AAGCCTTGAR GCGATTACAC AAGCTAAAAA CAACGCTAAT 540

AATGAAATAA GCAACAATCA AACGCAAGCG ATAACTAATA TCACCGAAGC GAAAACGAAC 600

GCTAATAATG AAATAAGCAA CAATCAAACG CAAGCGATAA CTAACATTAA CGAAGCCAAA 660

GAAAGCGCTA CAACGCAAAT AAACGCCAAT AAGCAAGAAG CAATAAATAA CATCACGCAA 720

GAAAAAACCC AAGCCACAAG CGAGATCACC GAAGCGAAAA AGACCGATCA TTATCAAAAC 780

ATTGATTTTT TTGAGTTTGA ATAA 804 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1632 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular {ii ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

\VY (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...1632 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GTGATAGAGA CCATCCCCAA ACACTCTAAG ATTGTTTTAC CCGGGGAGGC GTTTGATAGT 60

TTAAAAGAGG CGTTTGATAA AATTGACCCC TATACTTTCT TTTTTCCARA ATTTGAAGCC 120

ACTAGCACTT CTATTTCTGA TACTAACACG CAGAGGGTGT TTGAAACGCT CAATAACATT 180

AAAACAAATC TTATAATGAA ATATAGTAAT GAAAATCCAA ACAATTTCAA CACTTGTCCT 240

TACAATAATA ATGGTAATAC AARAAATGAT TGTTGGCARA ATTTCACCCC ACAAACCGCA 300

GAAGAATTCA CCAATTTAAT GTTGAACATG ATCGCTGTCT TAGACTCCCA ATCTTGGGGC 360

GATGCGATCT TAAACGCTCC TTTTGAATTC ACTAACAGCT CAACAGATTG CGATAGCGAT 420

CCTTCAAAAT GCGTABRATCC CGGAGTAMDAT GGGCGTGTTG ATACTAAAGT CGATCAACARA 480

TATATACTCA ACAAACAAGG TATTATTAAT AATTTTAGAA AAAAAATAGA AATTGATGCG 540

GTTGTTTTAA AAAATTCAGG GGTTGTAGGG TTAGCCAATG GATATGGCAA TGATGGTGAR 600

TATGGCACAT TAGGGGTAGA AGCCTATGCT TTAGATCCTA AAAAACTCTT TGGCAACGAC 660

CTTAAGACTA TCAATTTAGA AGATTTAAGA ACCATCTTGC ATGAATTCAG CCACACTARZR 720

GGCTATGGGC ATAACGGGAA TATGACCTAT CAAAGAGTGC CGGTAACGAA AGATGGTCARA 780

GTGGAAAAGG ATAGTAATGG CAAGCCAARA GATTCTGATG GCCTCCCCTA TAATGTGTGT 840

TCGCTTTATG GGGGATCCAA TCAGCCCGCT TTCCCTAGCA ACTACCCTAA TTCCATCTAT 900

CACAATTGTG CGGATGTCCC GGCTGGCTTT TTAGGGGTAA CAGCAGCGGT TTGGCAGCAG 960

CTCATCAATC AAAACGCCTT GCCGATCAAC TACGCTAACT TGGGGAGTCA AACARAACTAC 1020

AACCTAAACG CTAGTTTAAA CACGCAAGAT TTAGCCAATT CCATGCTCAG CACCATCCAA 1080 Missing 01110 TAACTTCTAG CGTTACCAAC CACCATTTTT CAAACGCATC GCAAAGTTTT 1140

AGAAGCCCTA TTTTAGGGGT TAACGCTAAA ATAGGCTATC AAAACTACTT TAATGATTTC 1200

ATAGGGTTGG CTTATTATGG CATCATCAAA TACAATTACG CTABRAGCTGT TAATCAAARAA 1260

GTCCAGCAAT TGAGCTAGG TGGGGGGATA GATTTGTTAT TGGATTTCAT CACCACTTAC 1320

TCCAATAARA ATAGCCCTAC AGGCATTCRAA ACCAAAAGGA ATTTTTCTTC ATCTTTGGT 1380

ATCTTTGGGG GGTTAAGGGG CTTGTATAAC AGCTATTATG TGTTGAACAA AGTCAAAGGA 1440

AGCGGCAATT TAGATGTGGC TACCGGGTTG AACTACCGCT ATAAGCATTC TAAATATTCT 1500

GTAGGGATTA GCATCCCTTT AATCCAAAGA 2226012606 TCGTTTCTAG CGGTGGCGAT 1560

TATACGAACT CTTTTGTTTT CAATGAAGGGE GCTAGCCACT TTAAGGTGTT TTTCAATTAC 1620 616561611 TT 1632 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1071 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double . (D) TOPOLOGY: circular :(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: ( A) NAME/KEY: misc_feature (B) LOCATION 1...1071

> يؤل »> ‎(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:‏ ‎TTGATGARAA GCATTTTGCT CTTTATGATT TTTGTAGTTT GTCAGTTAGA AGGCAAAARA 60‏ ‎TTTTCACAAG ATAATTTTAA GGTGGATTAT AACTACTATT TGCGCAAACA GGATTTGCAC 120‏ 5 ‎ATCATTAAAA CGCAAAACGA TTTGTCCAAT GCCTGGTATC TCCCTCCACA AAANGCCCCC 180‏ ‎AAAGAACATT CTTGGGTGGA TTTTGCTAAA AAATATTTAA ACATGATGGA TTATCTAGGC 240‏ ‎ACTTATTTTT TGCCTTTTTA TCATAGTTTC ACCCCCATTT TTCAATGGTA CCACCCTAAT 300‏ ‎ATCAACCCCT ACCAACGCAA TGAGTTTAAG TTCCAAATCA GTTTTAGAGT GCCTGTATTT 360‏ ‎AGGCATATTC TTTGGACTAA AGGCACGCTT TATCTGGCTT ATACCCAAAC TAACTGGTTT 420‏ 10 ‎CAAATTTATA ATGACCCTCA ATCCGCCCCC ATGCGAATGA TCAATTTCAT GCCTGAACTC 480‏ ‎TTTTTCTGAA 540‏ قدو ةو دح أمظ ‎ATCTATGTTT ATCCTATTAA TTTTAAACCT TTTGGEGGTA‏ ‎GTGCGCAATG TTACCAGCCT 600‏ 2 ا ‎ATTTGGATAG GTTGGCAGCA CATTTCTAAT‏ ‎TTTAATAAAG AAGGTAATCC TGAAAACCAG TTTCCAGGAC AACCTGTAAT CGTTAAAGAT 660‏ ‎TATAACGGGC AAAAAGATGT GCGCTGGGGG GGGTGTCKTT CGGTGARCSC GGGCAACSCC 720‏ 15 ‎CTGTGTTTCG TTTTGGTGTG GGAAAAGGGA GGCCTAAAAA TCATGGTCGC TTATTGGCCC 780‏ ‎TATG TCCCTT ATGATCAATC CAACCCTCAA TTGATTGATT ACATGGGGTA TGGTAACGCT 840‏ ‎AARATTGATT ACAGGAGAGG GCGCCACCAT TTTGAATTGC AACTTTATGA TATTTTCACG 900‏ ‎CAATACTGGC GTTATGATCG CTGGCATGGA GCTTTCCGCT TAGGCTATAC CTACCGCATT 360‏ ‎AACCCTTTTG TGGGGATTTA TGCGCAGTGGE TTTAACGGCT ATGGCGATGG CTTGTATGAA 1020‏ 20 ‎TACGATGTTT TTTCCAATCG TATAGGGGTA GGAATACGCT TGAACCCTTA A 1071‏ ‎INFORMATION FOR SEQ ID NO:18: (2) SEQUENCE CHARACTERISTICS: (1) 25 (A) LENGTH: 2028 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO 35 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori ( ix) FEATURE: 40 (A) NAME/KEY: misc feature (B) LOCATION 1...2028 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: 1

‎TTGTCTAARG GTTTGAGTAT CGGTAATARA ATCATATTGT 0010080677 GATTGTGATC 60‏ ‎GTGTGCGTGA GCATTTTAGG GGTGTCCTTA AACAGCAGGG TGAAAGAGAT TTTAARAGAA 120‏ ‎AGCGCTCTGC ATTCAATGCA AGATAGTTTG CATTTCAAGG TTAAGGAAGT GCAAAGTGTT 180‏ ‎TTGGAAAACA CTTATACGAG CATGGGCATT GTCAAAGAAA TGCTCCCTGA AGACACCAAA 240‏ ‎AGAGAAATCA AAATCCAGTT GTTAAAAAAC TTCATTTTAG CCAATTCGCA TGTCGCTGGG 300‏ 50 ‎GTGAGCATGT TTTTTARAAGA CAGAGAGGAT TTGAGATTGA CGCTTTTACG AGATAACGAT 360‏ ‎ACGATCAAGT TGATGGAAAA CCCGTCATTA GGGAGTAACC CTTTAGCGCA AAAAGCGATG 420‏ ‎AAADATARAAG AAATTTCTAA AAGCTTGCCT TATTACAGGA AAATGCCTAA CGGGGCGGAA 480‏ ‎GTTTATGGCG TGGATATTCT TTTACCACTA TTCAAGGAAA ACACGCAAGA AGTGGTGGGG 540‏ ‎GTTCTGATGA TTTTCTTTTC CATTGACAGC TTCAGTAATG AAATCACTAA AAACAGGAGC 600‏ 55 ‎GATTTATTTT TAATTGGCGT TAAAGGTAAA GTGCTTTTGA GCGCGAATAA AAGCTTGCAA 660 GACAAATCCA TCACCGAAAT TTATAARAAGC GTGCCTAAAG CCACTAATGA AGTGATGGCT 720 ATTTTAGARA ATGGCTCTRA AGCGACTTTA GAATACTTGG ATCCCTTTAG CCATAAGGAG 780 AATTTTTTAG CCGTTGAAAC CTTTAAAATG CTAGGCAAAA CAGAAAGTAA AGACAATCTT 840

د ‎AATTGGATGA TCGCTTTGAT CATTGAAAAA GACAAGGTCT ATGAGCAAGT GGGATCGGTG 900‏ ‎CGTTTTGTGG TGGTTGCAGC GAGTGCTATC ATGGTGTTAG CCTTAATCAT AGCGATCACT 960‏ ‎CTTTTAATGC GAGCGATCGT GAGCAATCGT TTGGAAGTCG TTTCTAGCAC CTTGTCTCAT 1020‏ ‎TTCTTTAAAT TATTGAACAA TCAAGCCCAT TCTAGCGACA TTAAATTGGT TGAAGCGCGA 1080‏ ‎ TCTAATGACG AATTAGGGCG CATGCAAACA GCGATCAATA AAAATATCTT GCARACCCAA 1140‏ 5 ‎AAGAAGACAG GCAAGCCGTC CAAGACACCA TTAAAGTGGT TTCAGACGTG 1200‏ 22422002760 ‎ATTTTGCGGT GCGCATCACG GCTGAACCCG CAAGCCCTGA TTTGAARGARA 1260‏ 22200060062 ‎CGCTAAATGG GATCATGGAT TATTTGCAAG AAAGCGTAGG GACTCACATG 1320‏ 1162626206 ‎CCRAGCATTT TCAARATCTT TGAAAGCTAT TCTGGCTTGG ATTTTAGAGG GCGGATCCARA 1380‏ ‎AACGCTTCGG GTAGGGTGGA ATTGGTTACT AACGCTTTAG GGCAAGARAT CCAAAAMATG 1440‏ 10 ‎CGTCTAATTT TGCCAAAGAT CTAGCGAACG ATAGCGCGAA TTTAAAAGAA 1500 1202220117 TGCGTGCARA ATTTAGAAAA GGCTTCAAAC TCCCAACACA AAAGCCTGAT GGAAACTTCC 1560 ARARCGATAG AAAATATCAC CACTTCCATT CAAGGCGTGA GCTCTCAAAG TGAAGCCATG 1620 ATTGARCAAG GGAAAGACAT TAAAAGCATT GTAGAAA TCA TTAGAGATAT TGCCGATCAA 1680‏ ‎ ACGAATCTAT TAGCCCTARA CGCTGCTATT GAAGCCGCAC GAGCCGGCGA GCATGGCAGA 1740‏ 15 ‎GGCTTTGCGG TGGTGGCTGA TGAGGTGAGG AAGCTCGCTG AAAGGACGCA AAAATCCCTC 1800‏ ‎AGTGAGATTG AAGCCAATAT TAATATTCTC GTTCAAAGCA TTTCAGACAC GAGCGAAAGC 1860‏ ‎ATTAAAAACC AGGTTAAAGA AGTAGAAGAG ATCAACGCTT CTATTGAAGC CTTAAGATCG 1920‏ ‎GTTACTGAGG GCAATCTAAA AATCGCTAGC GATTCTTTAG AAATCAGTCA AGAAATTGAC 1980 ARAGTCTCTA ACGATATTTT AGAAGATGTG AATAARAAGC AGTTTTAA 2028 20 INFORMATION FOR SEQ ID NO:19: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 816 base pairs 25 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular {ii) MOLECULE TYPE: DNA (genomic) 30 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO ( vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 40 (B) LOCATION 1...816 (xi) SEQUENCE DESCRIPTION : SEQ ID NO:19:

ATGAACATAT TCAAGCGTAT TATTTGCGTA ACCGCTATTG TTTTAGGTTT TTTTAACCTT 60

TTAGACGCCA ARCACCACAA AGAAAAAAAA GAAGACCACA AAATCACTCG TGAGCTTAAR 120

GTGGGCGCTA ACCCTGTGCC GCATGCGCAA ATCTGCAAT CAGTTGTGGA TGATTTGAAA 180

GAGAAAGGGA TCARATTAGT GATCGTGTCT TTTACGGATT ATGTGTTGCC TAATTTAGCG 240

CTCAATGACG GCTCTTTAGA CGCGAATTAC TTCCAGCACC GCCOTTATTT GGATCGGTTT 300

AATTTGGACA GARAAAATGCA CCTTGTTGGT TTGGCCAATA TCCATGTGGA GCCTTTAAGA 360

TTTTATTCTC AAAAAATCAC AGACATTARA AACCTTAAAA AAGGCTCAGT GATTGCTGTG 420

CCAAATGATC CGGCCAATCA AGGCAGGGCG TTGATTTTAC TCCATAAACA AGGCCTTATC 480

GCTCTCAAAG ACCCAAGCAA TCTATACGCT ACGGAGTTTG ATATTGTCAA AAATCCTTAC 540

ARCATCAAAA TCAAACCCCT AGAAGCTGCG TTATTGCCTA AGGTTTTAGG GGATGTGGAT 600

GGGGCTATCA TAACAGGGAA TTATGCCTTG CAAGCAAAAC TCACCGGAGC CTTATTTTCA 660

GAAGATAAGG ACTCGCCTTA TGCTAATCTT GTAGCCTCTC GTGAGGATAA TGCGCAAGAT 720

GAAGCGATAA AAGCGTTGAT TGAAGCCTTA CAGAGCGAAA AGACCAGGAA ATTCATTTTG 780

GATACCTATA AGGGGGCGAT TATCCCGGCT TTTTRAA 816

\Ve {2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 486 base pairs (5) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...486 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ATGTTTTTTTA AAACTTTATCA AARATTACTG GGCGCGAGCT GTTTGGCGCT GTATTTAGTG 60

GGCTGTGGGA ATGGTGGTGG CGGTGRATCG CCGGTTGAGA TGATTGCAAA TAGCGAGGGT 120

ACGTTTCAAA TCGACTCCAA AGCAGATAGC ATTACTATTC AAGGCGTGAA GCTTAATAGA 180

GGTAATTGTG CTGTCAATTT TGTTCCAGTA AGTGAGACGT TTCAAAATGGG TGTTTTTAAGT 240

CAAGTTACTC CAATCTCTAT ACAGGATTTT AAAGATATGG CAAGCACTTA TAAGATATTT 300

GATCARAAGA AAGGGTTGGC AAACATAGCA AATAAAATTT CTCAATTAGA GCAAAAGGGT 360

GTGATGATGG AACCTCRAAC CCTTAATTTT GGAGAAAGTT TAAAAGGCAT mm 420

TGCAATATTA TAGAGGCAGA AATACAAACC GACAAAGGCG CTTGGACTTT TAACTTTGAT 480

AAATAA 486 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1014 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO , (iv) ANTI-SENSE: NO {vi) ORIGINAL SOURCE: 7 0 a (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...1014 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATGATTAGAT TAAAAGGTTT GAATAAAACT TTAAAAACAA GCTTATTAGC TGGGGTTTTTA 60

CTAGGTGCTA CTGCTCCCTT AATGGCAAAG CCTTTATTAA GCGATTGAAGA CTTATTGAAA 120

CGAGTAARAC TACACAATAT CAAAGAAGAT ACGCTGACTA GCTGTAATGC TAAGGTGGAC 180

حأ ‎GGCTCTCAAT ACTTGAATAG TGGTTGGAAT TTATCTAAAG AATTTCCGCA AGAATATAGA 240‏ ‎GAAAAGATTT TTGAATGCGT AGAAGAAGAA AAACATAARAC AAGCCCTTAA TTTARATCAAT 300‏ ‎AAAGAAGACA CTGAAGATAA AGAAGAACTT GCAAAAAAAA TCAAAGAAAT TAAAGAARRA 360‏ ‎GCTAAAGTTT TAAGGCAAAA ATTTATGGCT TTTGAAATGA AAGAACACTC TAAAGAATTC 420‏ ‎ CCAAATAAAA AGCAACTTCA AACCATGCTT GAGAACGCTT TTGATAATGG AGCTGAAAGT 480‏ 5 ‎TTTATTGATG ATTGGCACGA ACGCTTTGGG GGTATAAGTA GAGAGAATAC TTATAAAGCA 540‏ ‎CTTGGCATTA ARGAATATAG TGATGAAGGA AAGATATTAG CCTTTGGCGA AAGAAGTTAT 600‏ ‎ATTAGACAAT ATAAAAAAGA TTTTGAAGAA AGCACTTATG ATACTAGACA AACCTTATCT 660‏ ‎GCTATGGCTA ATATGAGTGG CGAAAACGAT TATAAAATTA CTTGGTTAAA ACCCARATAT 720‏ ‎CAGCTCCATA GTTCAAATAA TATTAAACCC TTAATGTCAA ACACAGAGTT GTTAAATATG 780‏ 10 ‎ATAGAGCTAA CCAATATCAA AAAAGAATAT GTTATGGGCT GTAATATGGA AATAGATGGT 840 TCTARATATC CCATTCATAA AGATTGGGGA TTTTTTGGTA AGGCAAAAGT CCCAGAAACT 900 TGGAGAAATA AGATTTGGGA ATGTATTAAG AATAAAGTAA AGTCCTATGA CAACACTACC 960 1014 GCTGAARATAG GAATAGTTTG GAAAAAAAAT ACTTATTCT A TCTCTCATCA

INFORMATION FOR SEQ ID NO:22: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1251 base pairs {B) TYPE: nucleic acid 20 (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: 30 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY : misc_feature {B) LOCATION 1...1251 35 {xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: ATGAMAAAAT TAGTTTTTAG CATGCTTTTA TGTTGTAAAA GCGTGTTTTGC AGAGGGGGAA 60 ACCTCTTTGA TTGTCAATGA CCCAGAAAACC CATGTAAGTC AAGGCCACTAT CATAGTAGTAGCAAR 120 GTATCAAAAG ATACGAAGAG ATTATTTCTA AGGCTCAAGC TCAAGTCAAT 180‏ ‎CAGTTACAAA AAGTCAATAA CATGATAAAT ACGACTAATT CTTTGATTAG TAGTAGTGCT 240‏ ‎ATCACTTTAG CCAATCCTAT GCAAGTTTTA CARAACGCTC AGTATCAAAT AGAGAGCATT 300‏ ‎AGATACAACT ATGAGAATTT AAAGCAAAGC ATAGAAAATT GGAACGCACA AAATTTGTTA 360‏ ‎ AGAAACAAAT ACTTACAGCA ACAATGCCCT TGGCTTAATG TCAATGCTCT TACTAACAAT 420‏ 45 ‎AAGATTGTCA ATCTTAAAGA TCTCAATAAC CTAATCACCA AAAATGGCGA ACAAACCCAA 480 ACCGCAAGAG ATGTGCAAAA TCTCATTCAG TCCATTAGTG GCAGTGGCTA TGGAAACATG 540 CAATCACTTG CTGGGGAATT GAGTGGTAGA GCGTGGGGGG AAATGTTGTG TAARATGGTA 600 AACGATAGTA ATTATGAAAG CGAGCAAGCT CTTTTAGCAA CAGG CAATAA CCCAGAAGAG 660‏ ‎CARARACGAA GATTTTTGCT TAGAGTAAAG AAAAAGGTTA ATGATAATAA GCAGTTAARA 720‏ 50 ‎GATARACTTG ACCCATTTCT AAAAAGACTT GATGTCCTAC AAACTGAGTT TGGTGTAACT 780‏ ‎GACCCTACAG CTAACCATAA TAAGCAAGGG ATACATTATT GCACAGAAAA TAAAGAGACA 840‏ ‎GGTAAATGCG ACCCTATTAA AAATGTATTT AGGACAACTC GCTTAGATAA CGAATTAGAA 900‏ ‎CAAGARATCC AAACGCTCAC ACTTGATTTA ATCAAAGCCT CCAATARAAGA CGCTCAAAGC 960‏ ‎CAAGCCTACG CAAATTTCAA TCAAAGGATT AAATTACTTA CTCTAAAATA TTTAAAAGAA 1020‏ 55 ‎ATTACCAATC AAATGCTCTT TTTAAATCAA ACAATGGCAA TGCAAAGCGA GATTATGACA 1080‏ ‎GATGATTATT TTAGGCARAA TAATGATGGC TTTGGGGAAA AAGAAAACCA TATAGACARA 1140‏ ‎CAATTAACGC AAAAAAGAAT RAACGAAAGA GAAAGAGCTA GAATATACTT TCAAAACCCT 1200‏ ‎AATGTTAAAT TTGACCAATT TGGCTTTCCC ATTTTTAGTA TATGGGATTA A 1251‏

INFORMATION FOR SEQ ID NO:23: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1131 base pairs 5 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 10 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

{vi} ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 20 (B) LOCATION 1...1131 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:‏ ‎ GTGAATAAGT GGATTAAAGG GGCGGTTGTT TTTGTAGGGG GTTTTGCAAC GATTACAACC 60‏ 25 ‎TTTTCTTTAA TCTACCACCA AAAGCCAAAA GCCCCCCTAA ATAACCAGCC TAGCCTTTTG 120‏ ‎AATGACGATG AGGTGAAATA CCCCTTACAA GACTACACTT TCACTCAAAA CCCACAGCCA 180‏ 0 ‎ACTAACACGG AAAGCTCCAA AGACGCTACC ATCAAAGCCT TACAAGAACA GCTCAAAGCC 240‏ ‎GCTTTAAAAG CCCTAAACTC CARAGARATG AATTATTCCA AAGAAGAGAC TTTTACTAGC 300‏ ‎ CCTCCCATGG ATCCARAAAC AACCCCCCCT AAAAAAGACT TTTCTCCAAA ACAATTAGAT 360‏ 30 ‎TTACTGGCCT CTCGCATCAC CCCTTTCAAG CARAGCCCTA AAAATTACGA AGARAACCTG 420‏ ‎ATTTTCCCTG TGGATAACCC TAATGGCATT GATAGTTTCA CTAACCTTAA AGAAAAAGAC 480‏ ‎ATCGCCACTA ATGAAAACAA GCTTTTACGC ACCATTACAG CTGACAARAT GATACCCGCT 540‏ ‎TTTTTGATTA CGCCCATTTC TAGCCAGATC GCTGGTAAAG TGATTGCGCA AGTGGAGAGC 600 GATATTTTTG CAAGCATGGG CAARAGCCGTC TTAATCCCCA AAGGCTCTAA AGTCATAGGC 660 35 TATTACAGCA ACAATAAC AA AATGGGCGAA TACCGCTTGG ATATTGTATG GAGTCGAATC 720‏ ‎ATCACTCCCC ATGGCATTAA TATCATGCTC ACTAACGCTA AAGGGGCGGA CATTARAGGE 780‏ ‎TATAACGGCT TAGTGGGGGA ATTGATTGARA AGGAATTTCC AACGCTATGG CGTGCCGTTA 840‏ ‎CTGCTTTCTA CGCTCACTAA CGGCCTATTG ATTGGGATCA CTTCGGCTTT AAACAACAGA 300‏ ‎ GGCAATAAAG AAGAGGTGAC TAATTTCTTT GGGGATTATC TTTTATTGCA ATTGATGAGG 960‏ 40 ‎CARAAGCGGCA TGGGGATCAA TCAAGTGGTC AATCAAATTT TAAGAGACAA GAGCAAGATC 1020 GCCCCCATTG TGGTGATTAG AGAGGGGAGT AGGGTCTTCA TTTCGCCCAA TACTGACATC 1080 TTCTTCCCTA TACCCAGAGA GAATGAAGTC ATCGCTGAGT TTTTGAAGTG A 1131 INFORMATION FOR SEQ ID NO:24: (2) 45 (i) SEQUENICS: 2 LISTACCE: 2 LISTACCE CENGHAR1: 2 LISTACCE: 5 CENGHAR1 base pairs 0 (B) TYPE: nucleic acid (C) STRANDEDNESS: double 50 (D) TOPOLOGY: circular {ii) MOLECULE TYPE: DNA (genomic) . (iii) HYPOTHETICAL: NO 55 (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE:

\VA (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (2) NAME/KEY: misc feature (B) LOCATION 1...2751 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GTGGATTTGA GGATCCAATC TAAAGAAGTC AGTCATAATT TAAAGGAATT 21 Corrected 60

CTAATCAGCT ATCCTTTTGA AAAACATGTA GAAGCTTTAG GGGAACAATG CAGTAACTTC 120

GTTTCTATTC CCATTAACAA TGACGACTAT TCAAATATTT GCACTTTTGT GAGTGATTTT 180

ATAAATCTTA TAGCTTCTTA CAATTTATTA GAATCATTTT TAGATTTTTA TAAAGATARA 240

TTAARATTGA GCGAGCTTGT AACTGAATAT GCCAACGTAA CCAATAATCT GCTTTTCAAA 300

AAATTAATCA AACATTTAAG CGGCAACAAT CAATTGGTTA AAAATTTTTTA TCAGTGTATA 360

AGAGARATTA TAAAATACAA CGCCCCTAAT AAAGAATACA AACCCAATCA ATTTTTTATA 420

ATAGGGAAAG GCAAACAAAA ACAATTAGCA AAAATTTATT CTCATTTAARA AGAACTTAGT 480

GCAAGTGARA TTAAACCACA AGATATGGAA GACATCTTAA AAAAGCTAGA GGAATTAGAT 540

AAAATTTTTTA AAACTACCGA CTTTACAAAA TTCACACCAA AAACTGAAAT TAAGGATATT 600

ATTARAGAAA TAGACGAAAA ATACCCTATC AATGAAAATT TTARACGGCA ATTTAATGAG 660

TTTGAATCAA ATATTGAAAA ACATGATGAA ATAAAAAAGG ATTTTGAGCG AAACAAAGAG 720

TCGCTGATCC GAGAAATTGA AAATCACTGC AAAAATGAAT GCAATAGCGA AGARGAGCCG 780

GAGTATAAGA TTAATGATCT GCTCAAAAAT ATCCAACAAA TATGCAAAAA TTATATAGAA 840

AGTCATGCCG TTAATGATGT GTCTAAAGAT ATTARAATCCA TGATGTGTCA GTTTTATTTG 500

AAACAGATAG ATTTATTAGT CAATTCAGAA ATTGTGCGAT ACAGATACAG CAATCTTTTT 960

GAACCAATAC AAAGATCTTT ATGGGAGAGT ATAAAAATTT TAGATAATGA AAGTGGCATT 1020

TATTTGTTCC CTAARAATAT TGGTGAAATC AAGGATAAAT TTGAAGCAAA CAAGGADAAR 1080

TTCAAACARA GCAAAAATGT TTCTGAGTTC GCAGAATATT GCCGAGAGTG TAACCCCTAT 1140

ACAGCGTTTA ACTTTCATCT AAATATAAAT AATGGTTTTAT CTCATCAATT TGAAAAATTC 1200

GTGCCAATCA TGAAAGAATA CAAAGAGCCA AAAATCACAG ATAATGACCT TGAAGCCATA 1260

TCAACCAAAG AGACTGGTCT TGCTAGCCAA TTATCTGGGC ACTGGTTTTTT TCAGCTTTCG 1320

TTATTTAATA AAACAAACTT TAATCCTAAT AAAATTTGGA TTCCTTTAGA GTTCAATAARZ 1380

AGATCAAAAA TAAAGTTTGA TAAAGATTTA GAAATCTATT TTGATAGTCA TGAATCGTTC 1440

ARTATCTCTA AAAAATACTT GCAAGAAATA GATCAAGAAT CACTAAARAD GATCAAACARA 1500

TCAAAAGATT TTTTTTCAAT TCAAAAAATA GAGAGTAAGC ATGATAATARA CGATATACTG 1560

CAACTTGAAT TTTTTGAGAA TGATACAAGT TTTCTTTTTG CTAAAGGAAG TTTTGCAGRAA 1620

ATTTTAGAAT ACAACATGCA ATTAAAAATA GATTCTTTAA TTACAAAAGA ATTTAATAAG 1680

CTTTTAGCGA TCGTTCAAGA TAGTCCCCAA GATAGTTACC AATTAAAAAT TCGTGTCCGA 1740

CATAACAATA AGCTTCCTAG AGAGAAATAT ACGGAACATG AAATAAAACT TGAAGTTTTAT 1800

GATTGCAGAA AATCCCACGA TCACAATGAG CCAATCATCT TAAGCCAGCA AAGCACCGGC 1860

TTCCAAATGGG CGTTTAATTT CATGTTTGGC TTTCTTTATA ATGTGGGATC ACATTTTAGT 1920

TTTAACCATA ATATTATCTA TGTCATGGAC GAGCCAGCCA CTCATTTGAG CGTGCCAGCC 1980

AGAAAGGAGT TTAGGAAATT TTTAAAAGAA TACGCTCATA AAAATCATGT TACTTTTGTT 2040

TTAGCCACCC ATGACCCCTT TTTAGTGGAT ACGGATCATT TAGATGAAAT AAGGATTGTG 2100

GAARAGGAAA CAGAAGGCTC TGTAATTAAG AATCACTTTA ACTATCCCCT AAATAATGCA 2160

AGCAAAGACT CCGACGCTTT GGACAAAATC AAACGCTCTT TAGGAGTGGG CCAGCATGTT 2220

TTTCATAACC CCCAAAAACA CCGAATCATT TTTGTAGAAG GCATCACGGA TTATTGTTAT 2280

TTGAGCGCTT TTAAATTGTA TTTGCGTTAC AAAGAATACA AGGACAACCC CATTCCTTTC 2340

ACTTTCTTAC CCATTTCAGG GCTTAAAAAC GATTCAAAACG ATATGAAAGA AACCATTGAA 2400

AAACTTTGCG AGTTAGACAA TCACCCTATT GTTTTGACAG ACGATGACAG ARAATGCGTT 2460

TTTAARCCAAC AAGCAACGAG CGAACGATTT AAAAGAGGCTA ATGAAGAAAT GCATGATCCC 2520

ATCACCATCC TACAACTCTC AGACTGCGAT AGGCATTTCA AACAAATTGA AGATTGTTTC 2580

AGCGCAARCG ATAGAAACAA ATACGCTAAA AATAAGCAARA TGGAATTGAG CATGGCTTTT 2640

AARACAAGGC TTTTGTATGG CGGAGAAGAT GCGATAGAAA AACAAAACAAA AAGAAATTTT 2700

TTAARATTAT TCARATGGAT TGCATGGGCT ACAAACTTGA TCAAAAACTA A 2751 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 531 base pairs

. (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 5 (iii) HYPOTHETICAL: NO ( iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 15 (B) LOCATION 1. ..531 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

ATGACTGCAA TGATGCGTTA TTTTCACATC TATGGCACCA CTTTTTTCTT CCCTTTGGCG 60

CTTCTTTTTG CGGTTAGTGG GCTTTCATTG CTCTTTAAAG CGCGCCAAGA CACTGGCGCT 120

AAGATCARAG AATGGGTTTT AGAAAAATCC TTAAAAAAAG AAGAACGATT GGACTTTTTTA 180

AAAGGCTTTA TAAAAGAAAAR CCATATCGCT ATGCCTAAAA AGATAGAGCC TAGAGAGTAT 240

AGGGGAGCGT TAGTCATTGG CACGCCTTTG TATGAAATCA ACCTTGAAAC TAAAGGCACT 300

CADACGAAAA TCAAGACCAT TGAAAGGGGC TTTITAGGCG CGCTCATCAT GCTGCATAAG 360

GCTAAGGTGG GCATCGTGTT TCAGGCGCTT TTAGGGATTT TTTGCGTGTT TTTATTGTTG 420

TTTTACTTGA GCGCGTTTTTT AATGGTGGCT TTTAAAGACA CTAAACGCAT GTTTATAAGC 480

GTTTTAATAG GGAGCGTGGT GTTCTTTGGA GCGATCTATT GGTCTTTGTA G 531 (2) INFORMATION FOR SEQ ID NO:26: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 669 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: : (A) NAME/KEY : misc_feature (B) LOCATION 1...669 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ATGTTTAAAAA ACGCTTTAAA TATACAAGAT TTTTCATTTA AAAATCATAC TAGTACAGCC 60

ATTATTGGCA CAAATGGTGC TGGAAAATCA ACGCTTATCA ACACTATTCT AGGCATTAGA 120

TCAGACTATA ATTTTAAAGC ACAABACAAT AATATTCCAT ACCACGACAA TGTTATACCA 180

CAACGCAAGC AATTGGGAGT TGTCTCTAAC CTATTCAACT ACCCACCTGG ATTAAACGCA 240

AACGACCTTT TTAAATTCTA TCAATTTTTT CACAAAAACT GCACTCTAGA TTTGTTTGAA 300

AAAAATCTTT TAAATAARAC CTACGAACAC CTAAGCGACG GACAAARACA GCGCTTAAAA 360

ATTGACTTAG CTCTTAGCCA TCACCCACAA TTAGTTATTA TGGATGAACC AGAAACCAGT 420

بلا ‎TTAGAGCARA ACGCTCTTAT AAGACTATCA AATCTCATAA GCTTGCGCAA CACCCAACAA 480‏ ‎CTTACAAGTA TCATCGCCAC TCATGATCCT ATTGTCTTAG ATAGTTGCGA ATGGGTATTG 540‏ ‎CTCCTTAAGA ATGGCAACAT TGCTCAATAC AAACCTTTAA ATTCTATATT AAAATCTGTA 600‏ ‎GCTAARACTT TTAACTTTAA AGAAAAACCA ACCACAAAAG ACTTATTAGC GTTACTAAAG 660‏ ‎GaraTTTAA 669‏ 5 ‎INFORMATION FOR SEQ ID NO:27 : ; (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1221 base pairs 10 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 15 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori ( ix) FEATURE: (A) NAME/KEY: misc_feature 25 (B) LOCATION 1...1221 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

ATGTATGCGG CTCATCCTAT TAAACCCATA AAAGCCCCOTA AACTCAAATC TCAATTTTTA 60

AGGCGTGTGT TTGTGGGCGC GTCCATTAGG CGCTGGAATG ACCAAGCATG CCCTTTGGAA 120

TTTGTGGAAT TAGACAAGCA AGCCCATARA GCGATGATTG CGTATCTGCT CGCTARAGAT 180

TTAARAGATA GGGGTAAAGA TTTAGATTTA GATCTTTTAA TCAAATATTT TTGCTTTGAG 240

TTTTTGGAGC GCTTGGTTTT AACCGATATT AAACCCCCTA TTTTTTACGC CCTCCAACAA 300

ACGCATAGTA AAGAGTTAGC TTCCTATGTT GCGCAAAGTT TGCAAGATGA AATCAGTGCG 360

TATTTTTCTT TAGAGGAACT CAAAGAGTAT TTAAGCCACA GGCCTCAAAT TTTAGAAACT 420

CAAATTTTAG AGAGGCCGCA TTTTTATGCG TCTAAGTGGG AGTTTGATAT TATCTATCAT 480

TTTAACCCCA ACATGTATGG CGTGAAAGAG ATTAAAGATA AARATTGACAA GCAACTCCAC 540

AATAACGATC ATTTGTTTGA AGGGCTTTTT GGGGAAAAAAG AAGATTTGAA AAAATTGGTG 600

AGCATGTTTG GGCAGTTGCG TTTCCAAAAG CGCTGGAGEE ARACCCCAAG AGTGCCACAR 660

ACCAGTGTTC TAGGGCATAC TTTATGCGTG GCGATTATGG GGTATTTATT GAGTTTTGAC 720

TTGAAAGCTT GTAAAAGCAT GCGGATCAAT CATTTTTTGG GCGGGCTTTT CCATGATTTA 780

CCCGAAATTT TAACCCGAGA CATTATCACG CCCATCAAAC AAAGCGTTGC AGGGCTTGAT 840

CATTGCATTA AAGAGATTGA AAAAAAGGAA ATGCAAAACA AAGTCTATTC CTTTGTGTCT 900

TTGGGCGTTC AAGAAGATTT GAAATATTTC ACCGAAMACG AGTTTARAAAAA CCGCTACAZA 960

GACARGTCTC ATCAAATCGT TTTCACTAAA GACGCTGAAG AATTATTCAC GCTTTATAAT 1020

AGCGATGAAT ATCTTGGGGT TTGCGGGGAG CTTTTGAAGG TGTGCGATCA TTTGAGCGCE 1080

TTTTTAGAAG CCCAAATCTC TCTTTCTCAT GGCATTTCTA GCTACGATTT AATCCAAGGA 1140

GCTAARARCC TTTTAGAATT GCGATCCCAA ACGGAACTGC TTGATTTGGA TTTAGGGAAA 1200

TTGTTTAGAG ATTTTAAGTA A 1221 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1008 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO 5 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 10 (A) NAME/KEY: misc_feature (B) LOCATION 1...1008 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

‎GTGTTGTGGG TGCTATATTIT TTTAACCAGT TTATTTATTT GCTCTTTGAT TGTTTTCTGG 60‏ ‎TCTAAAAAAT CCATGCTCTT TGTGGATAAC GCTAATAAAA TCCAAGGCTT CCATCATGCA 120‏ ‎AGAACCCCAC GAGCCGGGGG GCTTGGGATC TTTCTTTCTT TTGCGTTGGC TTGTTATCTT 180‏ ‎GAACCTTTTG AGATGCCTTT TAAGGGGCCT TTTGTTTTCT TAGGGCTATC GCTAGTGTTT 240‏ ‎ TTGAGCGGTT TTTTAGAAGA CATTAACCTT TCATTAAGCC CCAARATACG CCTTATTITG 300‏ 20 ‎CAAGCTGTAG GGGTCGTTIG CATCATTTCA TCAACGCCTT TAGTGGTGAG CGATTTTTCG 360‏ ‎CCCCTTTTTA GCTTGCCTTA TTTCATCGCT TTTTTATTCG CTATTTTTAT GCTGGTGRGT 420‏ ‎ATCAGTAACG CTATTAATAT CATTGACGGG TTTAACGGGC TTGCATCTGG GATTTGCGCG 480‏ ‎ATCGCGCTTT TAGTCATTCA TTATATAGAC CCTAGCAGTT TGTCTTGTTT GCTCGCTTAC 540‏ ‎ATGGTGCTTG GGTTTATGGT GTTAAATTTC CCTTCAGGAA AGATTTTTTT AGGCGATGGE 600‏ 25 ‎GGGGCGTATT TTTTGGGTTT GGTGTGCGGG ATTTCTCTCT TGCATTTGAG TTTGGAGCAA 660 ARRATCAGCG TGTTTTTTGG GCTCAATTTA ATGCTTTATC CGGTCATAGA GGTGCTTTTT 720 AGTATCCTTA GGCGCAAAAT AAAACGCCAG AAAGCCACCA TGCCGGATAA TTTGCATTTG 780 CACACCCTTT TATTTAAATT CTTGCAACAA CGCTCTTTCA ATTACCCTAA C CCTTTATGC 840 GGCTTTTATCC TTATTCTATG CAACCTGCCT TTTATTTTAA TAAGCGTTTT GTTTCGCTIG 900 30 GACGCTTATG CGCTCATTGT GATTAGCCTA GTCTTTATCG CATGCTATTT AATAGGCTAT 960 GCTTATTTGA ATAGGCAAGT TTGCGCTTTA GAAAAGCGGG CGTTTAIN ID9: NOATION2 FOR SEQQGG CGTTTAIN ID: 10M:2 FOR SEQ TTTAIN ID: 9

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 291 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 40 (ii) MOLECULE TYPE : DNA (genomic). (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori : 50 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...291‏ ‎(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:‏ 55 ‎ATGAARAAGG TTATTGTGGC TTTAGGCGTT TTGGCGTTCG CAAATGTTTT AATGGCALCC 60‏ ‎GATGTTAAGG CTCTTGTAAA AGGTTGTGCC GCTTGCCATG GGGTTARGTT TGAAARAGRAR 120‏ ‎GCTTTAGGTA AAAGCAAAAT CGTTAACATG ATGAGCGAAA AAGAGATTGA AGAGGATCTT 180‏

AAGGCTTTTA ARAGCGGTGC CAACAAGAAT CCTGTCATGA CCGCGCAAGC TAAAAAATTA 240 AGCGATGAAG ACATCAAAGC TTTAGCCAAA TACATCCCCA CTCTCAAATA A 291 INFORMATION FOR SEQ ID NO:30: (2) 3 SEQUENCE CHARACTERISTICS base: ; (1) (A) LENGTH: 471 pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 10 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...471 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: 25 ATGCGAGATT TCAATAACAT TCAAATCACA CGCTTAAAAG TGCGTCAAAA TGCCGTTTTTT 60‏ ‎GAAAAACTGG ATCTGGAGTT TAAAGATGGC TTGAGCGCGA TTAGTGGGGC TAGTGGGGTG 120‏ ‎GGGAAARGCG TCCTTATTGC GAGCCTTTTA GGGGCGTTTG GGCTTARAGA GAGCAACGCT 180‏ ‎TCAAACATTG AAGTGGAATT GATCGCGCCT TTTTTAGACA CGGAAGARATA CGGCATTTTT 240‏ 30 ‎AGAGAAGATG AGCATGAACC CTTAGTTATT AGCGTGATTA AAAAAGAAAA AACACGCTAT 300‏ ‎TTTTTARACC AAACAAGCCT ATCTAAARAC ACGCTCAAAG CGTTATTAAA GGGGCTTATT 360‏ ‎AAACGCTTAT CTAACGACAG ATTCAGCCAG AATGAACTCA ACGATATTTT AATGCTCTCC 420 TTATTAGATG GCTATATCCA AAATAAAAAT AGGCGTTTAG CCCCCTTTTA G 471

INFORMATION FOR SEQ ID NO:31: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 357 base pairs (B) TYPE: nucleic acid 40 (C) STRANDEDNESS: double (D) TOPOLOGY: circular - (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO , (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: 50 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/ KEY: misc_feature (B) LOCATION 1...357 55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: GTGAGCTAA TGGCAATTTT TACCCCTTAT ATTCTTATTT TGAARATGAT GAAAAAGTCT 60

VAY

ATGAGTTTTAT TCGCCAATAT GGGGTTGGAG CAAATTTTTT GCAACAGAGA CATTAAAGAT 120

TTAAATGATT TTGTTTTTGG TATAGAAGTG GGGCTTGATA GCAATGCGAG AAAAAATCGT 180

AGCAGAAAGG CTATGGAAAA TCATCTTATC GGTCTTTTTG TCCAAGCTCA ATTAAATTTT 240

ARAGAACAAG TAGATATTAG AGAATTTGAG GATTTACGCC AGGCTTTTGG AAATGATACT 300 1

AAAAAATTTG ATTTTGTTAT TTTTAGCARA GAGAAAACTT ATTTTCATAG AAGCTAA 357 (2) INFORMATION FOR SEQ ID NO:32: d (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1068 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY : circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY : misc feature (B) LOCATION 1...1068 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

ATGAATATCA AAATTTTAAA AATATTAGTT GGAGGGTTAT TTTTTTTGAG CTTGAACGCC 60

CATTTATGGG GGAAACAAGA CAATAGCTTT TTAGGGATTG GTGAAAGAGC CTATAAAAGC 120

GGGAATTATT CTAAAGCGGC GTCTTATTTT AARAAAGCAT GCAACGATGG GGTGAGTGAA 180

GGCTGCACGC AATTAGGAAT CATTTATGAA AACGGGCAAG GCACTAGAAT AGATTATARA 240

ARAGCCCTAG AATATTATAA AACCGCATGC CAGGCTGATG ATAGGGAAGG GTGTTTTGGC 300 11200606006 1112162162 GGGTTTAGGC ACGGCTCAAA ATTATCAAGA AGCCATTGAC 360

GCTTACGCTA AGGCATGCGT TTTAAAACAC CCTGAGAGTT GCTACAATTT AGGCATCATT 420

TATGATAGAR AAATCARAGG CAATGCCGCT CAAGCGGTTA CTTACTATCA AAAAAGCTGT 480

AATTTTGATA TGGCTAAGGG GTGTTATATT TTAGGCACTG CCTATGAAAA AGGCTTTTTA 540

GARGTCAAAC AGAGCAACCA TAAAGCCGTT ATCTATTATT TGAAAGCGTG CCGATTGAAT 600 caceeecace CTTGCCGAGC GTTAGGGAGT TTGTTTGAAA ATGGCGATGC AGGGCTTGAT 660

GAAGATTTTG AAGTGGCGTT TGATTATTTG CAAAAAGCTT GCGCTTTAAA CAATTCTGGT 720

GGTTGCGCGA GTTTAGGCTC TATGTATATG TTGGGCAGGT ATGTTAAAAA AGACCCCCAR 780

AAGGCTTTTA ACTATTTCAA GCAAGCATGC GATATGGGGA GCGCGGTGAG TTGCTCTAGG 840

ATGGGCTTTA TGTATTCGCA AGGGGACACT GTTTCAAAAG ACTTGAGGAA AGCCCTTGAT 900

AATTATGAAA GAGGTTGCGA TATGGGCGAT GAAGTGGGTT GCTTGCTCT AGCGGGCATG S60

TATTACAACA TGAAAGATAA AGALAACGCC ATAATGATTT ATGACAAGGG CTGTAAAATTG 1020

GGCATGAAAC AGGCATGCGA AAATCTCACC AAACTCAGGG GGTATTAG 1068 (2) INFORMATION FOR SEQ ID NO:33: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 582 base pairs (B) TYPE: nucleic acid {C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

VAS.

ATGCCTCCCT TAAAAGAAAC TTCGCAAACC TTTTTATATT ATTTTAAAAG CACTAATATT 840

TATTATATTA GTTACAACTA TTTATTGTAA 870 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2007 base pairs’ (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 1...2007 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

ATGAGAAAAC TATTCATCCC ACTTTTATTA TTCAGCGCTT TAGAAGCGAA CGAGAARRAC 60

GGCTTTTTCA TAGAAAGCCGG CTTTGAAACT GGGCTATTAG AAGGCACACA AACGCAAGAA 120

AAAAGACACA CCACCACAAA AAACACTTAC GCAACTTACA ATTATTTACC CACAGACACG 180

ATTTTAAAAA GAGCGGCTAA TTTATTCACC AATGCCGAAG CGATTTCAAA ATTAAAATTC 240

TCATCTTTAT CCCCTGTTAG AGTGTTGTAT ATGTATAATG GTCAATTAAC TATAGAAAAC 300

TTCTTGCCTT ATAATTTAAA TAATGTTAAG CTTAGTTTTTA CAGACGCTCA AGGCAACACG 360

ATTGATCTAG GCGTGATAGA GACCATCCCC AAACACTCTA AGATTGTTTT ACCCGGGGAG 420

GCGTTTGATA GTTTAAAAGA GGCGTTTGAT AAAATTGACC CCTATACTTT ATTTCTTCCA 480

AAATTTGAAG CCACTAGCAC TTCTATTTCT GATACTAACA CGCAGAGGGT GTTTGAAACG 540

CTCAATAACA TTAAAACAAA TCTTATAATG AAATATAGTA ATGAAAATCC AAACAATTTC 600

AACACTTGTC CTTACAATAA TAATGGTAAT ACAAAAAATG ATTGTTGGCA AAATTTCACC 660

CCACARACCG CAGAAGAATT CACCAATTTA ATGTTGAACA TGATCGCTGT CTTAGACTCC 720

CAATCTTGGG GCGATGCGAT CTTAAACGCT CCTTTTGAAT TCACTAACAG CTCAACAGAT 780

TGCGATAGCG ATCCTTCAA ATGCGTAAAT CCCGGAGTAA ATGGGCGTGT TGATACTAAA 840

GTCGATCAAC AATATATACT CAACAAACAA GGTATTATTA ATAATTTTAG AAAAAAAATA 900

GAAATTGATG CGGTTGTTTT AAAAAATTCA GGGGTTGTAG GGTTAGCCAA TGGATATGGC 960

AATGATGGTG AATATGGCAC ATTAGGGGTA GAAGCCTATG CTTTAGATCC TAAAAAACTC 1020

TTTGGCAACG ACCTTAAGAC TATCAATTTA GAAGATTTAA GAACCATCTT GCATGAATTC 1080

AGCCACACTA AAGGCTATGG GCATAACGGG AATATGACCT ATCAAAGAGT GCCGGTAACG 1140

AAAGATGGTC AAGTGGAAAA GGATAGTAAT GGCAAGCCAA AAGATTCTGA TGGCCTCCCC 1200

TATAATGTGT GTTCGCTTTA TGGGGGATCC AATCAGCCCG CTTTCCCTAG CAACTACCCT 1260

AATTCCATCT ATCACAATTG TGCGGATGTC CCGGCTGGCT TTTTAGGGGT AACAGCAGCG 1320

GTTTGGCAGC AGCTCATCAA TCAARACGCC TTGCCGATCA ACTACGCTAA CTTGGGGAGT 1380

CAAACAAACT ACAACCTAAA CGCTAGTTTA AACACGCAAG ATTTAGCCAA TTCCATGCTC 1440

AGCACCATCC AAAAAACCTT TGTAACTTCT AGCGTTACCA ACCACCATTT TTCAAACGCA 1500

TCGCARAGTT TTAGARAGCCC TATTTTAGGG GTTAACGCTA AAATAGGCTA TCABAACTAC 1560

TTTAATGATT TCATAGGGTT GGCTTATTAT GGCATCATCA AATACAATTA CGCTAARAGCT 1620

GTTAATCAAA AAGTCCAGCA ATTGAGCTAT GGTGGGGGGA TAGATTTGTT ATTGGATTTC 1680

ATCACCACTT ACTCCAATAA AAATAGCCCT ACAGGCATTC AAACCAAAAAG GAATTTTTCT 1740

TCATCTTTTG GTATCTTTGG GGGGTTAAGG GGCTTGTATA ACAGCTATTA TGTGTTGAAC 1800

ARAGTCAAAG GAAGCGGCAA TTTAGATGTG GCTACCGGGT TGAACTACCG CTATAAGCAT 1860

TCTAAATATT CTGTAGGGAT TAGCATCCCT TTAATCCAAA GAAAAGCTAG CGTCGTTICT 1920

AGCGGTGGCG ATTATACGAA CTCTTTTGTT TTCAATGAAG GGGCTAGCCA CTTTAAGGTG 1980

1 P7 (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: ' (A) NAME/KEY: misc_feature (B) LOCATION 1...582 ( xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

ATGARAGAAA AAAACTTTTG GCCTTTAGGA ATCATGAGCG TGCTTATTTT TGGGCTTGGG 60

ATCGTGGTGT TTTTAGTGGT GTTTGCCCTA AARAATTCGC CTAAAAATGA TTTAGTGTAT 120

TTCAAGGGTC ATAACGAAGT GGATTTARAC TTTAACGCCA TGCTTAAAAC TTATGAAAAC 180

TTTAAATCCA ATTATCGTTT TTCAGTGGGT TTAAAGCCTC TTACCGAAAG CCCTAAAACC 240

CCCATTTTGC CCTATTTTTC TAAAGGCACG CATGGGGATA AAAAAATCCA AGAAAACCTT 300

TTAAACAACG CTTTGATTTT AGAAAAGTCC AACACGCTTT ATGCACAATT GCAACCGCTC 360

AAACCCGCTT TAGATTCGCC AAATATTCAA GTGTATTTAG CGTTCTATCC CAGCCAATCC 420

CAGCCCAGAT TATTAGGAAC GCTTGATTGT AAAAACGCAT GCGAACCTTT AAAATTTGAT 480

TTGTTAGAGG GCGATAAAGT GGGGCGCTAT AAGATCCTTT TTAATTTGT TTTTAAAAAT 540

AAAGAAGAAT TGATTTTGGA GCAACTGGCT TTTTTTAAGT AG 582 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 870 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO 1 (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 1 (A) NAME/KEY : misc feature (B) LOCATION 1...870 ' (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

TTGGGTATCA ATATGTGTTC TAAAAAAATA AGAAATCTCA TTTTATGCTT TGGTTTTATT 60

TTAAGCTTGT GCGCTGAAGA AAATATCACC AAAGAAARCA TGACTGARAC GAACACGACT 120

GAAGAAAACA CCCCTARAGA CGCTCCCATT CTTTTGGAAG AAAMAACGCGC CCAAACTCTA 180

GAGCTTAAAG AAGAARATGA AGTGGCAAAA AAGATTGATG ARARAAGCCT GCTTGAAGAA 240

ATCCATAAGA AARAAACGCCA GCTTTACATG CTCRAAAGGGEG AATTGCATGA AARAGAATGAA 300

TCCATCTTAT TCCAACAAAT GGCTAAAAAT AAGAGCGGCT TTTTTATAGG CGTGATCCTT 360

GGCGATATAG GGATTAACGC TAATCCTTAT GAGRAAGTTTE AACTTTTAAG CAATATTCAA 420

GCTTCTCCCT TGCTGTATGG TTTAAGGAGC GGGTATCAA AGTATTTCGC TAACGGGATT 480

AGCGCCTTAC GCTTTTATGG GGAATATTTA GGGGGGGCGA TGAAAGGGTT TAAAAGCGAT 540

TCTTTAGCTT CTTATCAAAC CGCAAGCTTG AATATTGATC TGTTGATGGA TAAGCCTATT 600

GACAAAGAAA AAAGGTTTTGC GTTAGGGATA TTTGGAGGCG TTGGAGTGGG GTGGAATGGG 660

ATGTATCAAA ATTTAAAAGA GATTAGAGGGE TATTCACAGC CTAACGCCTT TGGGTTGGTG 720

TTAAATTTAG GGGTGAGCAT GACGCTCAAC CTCAAACACC GCTTTGAATT AGCCCTAAAAN 780

VAT

TTTTTCAATT 206067170007 GTTTTAG 2007 (2) INFORMATION FOR SEQ ID NO:36: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 192 base pairs (B) TYPE: nucleic acid 17 (C) STRANDEDNESS: double (D) TOPOLOGY: circular ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 1...192 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

ATGAATACAG AAATTTTAAC CATCATGTTA GTTGTCTCCG TGCTTATGGGE ATTGGTAGGC 60

TTAATAGCGT TTTTATGGGG GGTTAAAAGC GGTCAGTTTG ACGATGAAAA ACGCATGCTT 120 5222606167 TGTATGACAG CGCGAGCGAC TTGAACGAAG CGATTTTACA AGAAAAACGC 180

CAAAAGAATT AA 192 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1221 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D} TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO - (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B ) LOCATION 1...1221 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATGGTATTTT TTCATAAGRA AATTATTTTA AATTTTATCT ATTCTTTAAT GGTTGCTTTT 60

TTATTCCATT TACCTATGG GGTTCTTTTA ARAGCCGATG GAATGGCTAA AAAGCARACT 120

CTTTTAGTGG GTGAAAGGCT TGTGTGGGAT AAGCTCACGC TGTTAGGGTT TTTAGAARDA 180

AACCATATCC CCCAAAAACT CTACTACAAT TTGAGCTCTC ARGATAAAGA ATTGAGTGCT 240

GAAATCCAAA GCAAATGTTAC CTACTACACT TTAAGAGATG CAAATAACAC GCTCATTCAA 300

GCCCTATCC CTATTAGCCA GGATTTGCAA ATCCATATTT ACRAAARAAGG AGAGGATTAT 360

ارا ‎TTTTTAGACT TTATCCCCAT TGTTTTCACT CGTAAAGAAA GAACCCTCCT TCTTTCCTTA 420‏ ‎CAAACTTCGC CCTATCAAGA TATTGTCAAA GCCACCAATG ACCCCCTTTT AGCCAACCARA 480‏ ‎TTGATGAACG CGTATAAAAA AAGCGTGCCT TTTAAACGCC TAGTGAAAAA CGATAAAATC 540‏ ‎GCTATCGTTT ATACAAGGGA TTATCGTGTG GGGCAAGCGT TTGGCCAGCC GACCATCAAA 600‏ ‎ ATGGCGATGG TTAGCTCTCG TTTGCACCAA TACTATCTTT TTTCCCATTC AAACGGGCGT 660‏ 5 ‎TATTACGATT CAAAAGCGCA AGAAGTGGCA GGGTTTTTAC TAGAAACCCC GGTGAAATAC 720‏ ‎ACCCGCATTT CTTCGCCTTT TTCGTATGGG AGGTTCCATC CTGTTTTAAA AGTTAAACGG 780°‏ ‎CCTCATTACG GCGTGGATTA TGCGGCTAAA CATGGCAGTT TGATCCATTC TGCTTCAGAC 840‏ ‎GGCCGTGTGG GTTTTATAGG GGTTAAGGCG GGTTATGGGA AGGTGGTTGA AATCCATTTG 900‏

AATGAATTGC GCTTGGTGTA TGCTCACATG AGCGCGTTCG CTAACGGATT AAAAAAAGGC 960

TCGTTCGTTA AAAAAGGGCA AATCATAGGA AGAGTGGGAA GCACGGGTTT AAGCACCGGGE 1020

CCGCATTTGC ATTTTGGCGT GTATAAAAAC TCCCGCCCCA TTAATCCTTT AGGCTATATC 1080

CGCACCGCTA AAAGCAAGCT GCATGGCAAA CAAAGAGAGG TTTTTTTAGA AAAAGCTCAG 1140

TATTCTAAGC AAAAATTAGA AGAACTTTTT AAAACCCATT CTTTTGAAAA AAATTCATTT 1200

TATCTTTTAG AGGGTTTTTA A 1221 (2) INFORMATION FOR SEQ ID NO:38: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 891 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double { (D) TOPOLOGY: circular { ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 1...891 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TTGTTTTTAG TCAARAAAAAT AGGCGTGGTA ATAATGATTT TAGTCCTGCTT TTTAGCTTGE 60

TCGCAAGAGA GCTTTATCAA AATGCAAAAA AAAGCCCAAG AGCAAGARAA TGACGGCTCT 120

AARCGCCCCCA GCTATGTGGA TTCGGATTAT GAAGTCTTTA GCGAAACGAT TTTTTTACAA 180

AACATGGTGT ATCAGCCTAT AGAGGARAGA AACGCTTTTT TCCAACTGAC TAAAGATGAA 240

GACAATTCTT TTAACCCTGA AAATTCCGTG ATTTTACTGA ATGAGCCAAG CGATAATAGT 300

GAARARAACC TACTCTCATA CCCAAACGAT CCCAATAACA ATGAAGACAA CGCTAATAAT 360

AGTCAAAAAA ATCCGTTCCT TTACAAAGCCC AAAAGAAAAA CAAAAAACCC AAAACTCATT 420

GAATATTCCC AACAAGATTT CTACCCCCTA AAAAATGGGG ATATTATCAT GAGTAAAGAA 480

GGGGATCAAT GGTTGATAGA AATCCAATCC AAAGCCTTGA AGCGTTTTTT AAAAGATCAA 540

AACGATAAAG ATCGCCAGAT CCAAACTTTC ACTTTTAATG ACACTAAAAC GCAAATCGCG 600

CARATTAAGG GCAAAATTTC TTCGTATGTT TATACCACCA ATAACGGTAG CTTGAGTTTA 660

AGGCCTTTTT ATGAATCGTT TTTGTTAGAA ARAAAGAGCG ATAATGTTTA TACGATAGAG 720

AATAAGGCTT TAGATACTAT GGAGATTTCA AAGTGTCAAA TCGGTGTTAAA AAAGCATTCA 780

ACCGATAAAT TAGACAGCCA GCATAAAGCC ATCAGTATTG ATTTGGATTT TAAAAAAGAG 840

CGCTTTAAGA GCGATACGGA ACTCTTTTTA GAATGTCTTA AGGAAAGTTA GC 891 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS : (A) LENGTH: 747 base pairs

GHGA (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 5 (iii) HYPOTHETICAL: NO i ( iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature 15 (B) LOCATION 1 ...747 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

GTGAGCTATG ACAACACCGA TGATTATTAT TTCCCTAGAA ATGGGGTTAT CTTTAGTTCC 60

TATGGCACAA TGTCTGGTTT GCCAAGCTCT GGCACGCTCA ATTCTTGGARA CGGGTTAGGC 120

GGGRATGTCC GTAACACCAA AGTTTATGGT AAATTCGCCG CTTACCACCA TTTGCAAAAA 180

TATTTATTGA TAGATTTGAT CGCTCGTTTT AAAACGCAAG GGGGCTATAT CTTTAGGTAT 240

AACACCGATG ATTACTTGCC CTTAAACTCC ACTTTCTACA TGGGGGGCGT AACCACGGTG 300

AGAGGCTTTA GGAACGGCTC AATCACACCT 2272621706207 TTGGCTTGTG GCTTGGAGGC 360

GATGGGATTT TTACCGCTTC TACTGAATTG AGCTATGGGG TGTTARAAGC GGCTAAAATG 420

CGTTTAGCGT GGTTTTTTGA CTTTGGTTTC TTAACCTTTA AAACCCCAAC TAGGGGGAGT 480

TTCTTCTATA ACGCTCCCAC CACGACGGCG AATTTTARAG ATTATGGCGT TGTAGGGGCT 540

GGGTTTGAAA GGGCGACTTG GAGGGCTTCT ACAGGCTTAC AGATTGAATG GATTTCGCCC 600

ATGGGGCCTT TGGTGTTGAT TTTCCCTATA GCGTTTTTTCA ACCAATGGGG CGATGGCAAT 660

GGCAAAANAT GTAAAGGGCT GTGCTTTAAC CCTAACATGA ACGATTACAC GCAACATTTTT 720

GAATTTITCTA TGGGAACAAG GTTTTAA 747 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1008 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) : (iii) HYPOTHETICAL: NO » (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...1008 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GTGCAACACT TCAATTTCCT CTATAARGAT TCTTTATTTT CTATCGCTTT ATTCACTTTC 60

ATTATCGCTC TTGTGATTTTT ATTAGAACAG GCTAGAGCGT ATTTCACCCG AAAGAGRAAC 120

ARAARATTTT TGCAAAAATT CGCCCAAAAT CAAAACGCCT ATGCGAGCAG CGAGAATTTA 180

VAA

GACGAGCTTT TAAAGCATGC TAARATTTCC AGTTTGATGT TTTTAGCTAG GGCGTATTCT 240

AAAGCGGATG TGGAAATGAG CATTGARATC TTAAAAGGGC TTTTGAATCG CCCCTTAAAA 300

GATGAAGAAA AAATCGCTGT TTTAGATTTA TTGGCTAAAA ATTATTTTAG CGTGGGGTAT 360

TTGCAGAAAA CAAAAGACAC CGTGAAAGAA ATTTTGCGCT TTTCCCCAAG GAATGTGGAA 420

GCGTTGTTGA AGCTTTTGCA TGCGTATGAA TTAGAAAAAG ATTATTCAAA GGCTTTAGAA 480

ACTTTGGAAT GTTTGGAAGA ATTAGAGGTG CCTAAAATTG AAACGATTAA AAATTACCTC 540

TATTTAATGC ATTTAATAGA GAATAAGGAA GATTGCGGCTA AAATCTTGCA TGTTTCAAAA 600 ;

GCGTCGTTAG ATTTGAARAAA AATCGCTCTG AATCACTTAA AATCGCATGA TGAAAATCTT 660

TTTTGGCAAG AAATTGATAC AACCGAACGG CTAGAAAATG TGATCGATCT TTTATGGGAT 720

ATGAATATCC CTGCTTTTAT TTTAGAAAAA CATGCCCTTT TGCAGGACAT CGCGCGATCT 780

CAAGGGTTGC TTTTGGATCA CAAACCTTGC CAAATTTTTG AATTAGAGGT TTTACGCGCT 840

CTATTGCATA GCCCTATAAA AGCGAGTCTG ACTTTTGAAT ACCGCTGCAA GCATTGCAAA 900

CAAATCTTTC CTTTTGAAAG CCATAGGTGT CCTGTGTGTT ACCAGTTAGC GTTTATGGAT 960

ATGGTGCTTA AAATCTCTAA AAAAACGCAT GCTATGGGAG TGGATTAA 1008 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1242 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...1242 (x1) SEQUENCE DESCRIPTION: SEQ ID NO:41:

ATGAGGAAAA TTTTTTCTTA TATTTCTAAG GTTCTATTAT TTATTGGGGT GGTTTATGCA 60

GAGCCTGATT CTAAAGTGGA AGCCTTAGAA GGGAGGAAGC AAGAGTCTTC TTTGGATAAA 120

ARRATCCGCC AAGAATTGAA GAGTAAGGAA TTGAAGAATA AGGAATTAAA GAATAAGGAT 180

TTGAARAATA AAGAAGAAAA GAAAGAAACA AAAGCCAAGA GAAAACCCAG AGCAGAAGTC 240

CATCATGGGG ACGCCAAAAA TCCCACTCCA AAGATCACGC CTCCTAAAAT CAAAGGGAGT 300

AGTAAGGGCG TTCAAAATCA AGGCGTTCAA AACAACGCGC CAAAACCTGA AGAAAAAGAT 360

ACAACCCCTC AAGCTACTGA AAARMATAMG GAAACAAGCC CTAGCTCTCA ATCAATTCC 420

ATTTTTGGTA ATCCTAATAA CGCTACCAAC AACACCCTTG AAGATAAGGT CGTAGGGGGC 480

ATTTCATTGC TTGTTAATGG TTCGCCTATC ACGCTGTATC AAATCCAAGA AGAGCAAGAA 540

AAATCTRAAAG TGAGTAAGGC TCAAGCTAGG GATCGTTTGA TCGCTGAACG CATTAAAAAC 600

CARGAAATTG AGCGCTTAAA AATCCATGTA GATGATGACA AGCTAGACCA AGAAATGGCG 660

ATGATGGCGC AACAACAAGG CATGGATTTA GACCATTTCA AACAGATGCT TATGGCTGAG 720

GGGCATTATA AACTCTATAG AGATCAACTT AAAGAGCATT TAGAAATGCA AGAATTGTTG 780

CGTAATATTT TGCTCACGAA TGTGGATACC AGCTCTGAAA CCAAAATGCG CGAATATTAC 840

ARCAAACACA AGGAGCAATT CAGTATCCCC ACAGAAATAG AAACCGTGCG CTACACTTCC 900

ACCAATCAAG AGGATTTAGA AAGGGCTATG GCAGACCCTA ATTTGGAAGT CCCAGGGGTG 960

AGTAAGGCCA ATGAAAAAAT AGAGATGAAA ACCCTAAACC CTCAAATCGC CCAAGTCTTT 1020

ATTTCGCATG AGCAAGGCTC TTTCACGCCC GTTATGAATG 0000700000 GCAGTTCATC 1080

ACCTTTTATA TCAAGGAAAA AAGGGGTAAA AATGAAGTGA GCTTCAGTCA GGCCAAGCAA 1140

TTCATCGCCC AARAATTAGT GGAAGAATCT AAGGATAAGA TTTTAGAAGA GCATTTTGAA 1200

ARATTGCGCG TTAAGTCTAG GATTGTGATG ATCAGAGAGT GA 1242

BHA INFORMATION FOR SEQ ID NO:42: )2{ (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 561 base pairs 5 (B) TYPE: nucleic acid (C) STRANDEDNESS: double J (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 10 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: ( A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 20 (B) LOCATION 1...561 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

ATGATTAAAR GAATTGCTTG TATTTTAAGC TTGAGCGCGA GTTTAGCGTT AGCTGGCGAA 60 67162276007 TTTTCATGGG TGCGGGTTAT CAACAAGGTC GTTATGGCCC TTATAACAGC 120

AATTACTCTG ATTGGCGTCA TGGCAATGAC CTTTATGGTT TGAATTTCAA ATTAGGTTTT 180

GTAGGCTTTG CCAATAAATG GTTTGGGGCT AGGGTGTATG GCTTTTTAGA TTGGTTTAAC 240

ACTTCAGGGA CTGAACACAC CAARACCAAT TTGCTCACCT ATGGCGGCGGE TCGCGATTTG 300

ATTGTCAATC TCATTCCTTT GGATAAATTC GCTCTAGGTC TCATTGGTGG CGTTCAATTA 360

GCCGGAAACA CTTGGATGTT CCCTTATGAT GTCAATCAAA CCAGATTCCA GTTCTTATGG 420

AATTTAGGCG GAAGAATGCG TGTTGGGGAT CGCAGTGCGT TTGAAGCGGGE CGTGAAATTC 480

CCTATGGTTA ATCAGGGTAG CAAAGATGTA GGGCTTATCC GCTACTATTC TTGGTATGTG 540

GATTATGTCT TCACTTTCTA G 561 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 729 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A} NAME/KEY: misc_feature (B ) LOCATION 1...729 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

ATGARAARAT TTTTTTCTCA ATCTTTGTTA GCTCTTATTA TCCTATGAA TGCGGTATCT 60

. احا ‎~N‏ ‎GGCATGGATG GTAATGGCGT TTTTTTAGGG GCGGGTTATT TGCAAGGACA GGCGCAAATG 120‏ ‎CATGCGGATA TTAATTCTCA AAAACAAGCC ACCAACGCTA CGATCAAAGG CTTTGACGCG 180‏ ‎CTCTTGGGGT ATCAATTTTT CTTTGAAAAA CACTTTGGCT TACGCCTTTA TGGGTTTTTT 240‏ ‎GACTACGCTC ATGCCAATTC TATTAAGCTT AAAAACCCTA ACTATAATAG CGAAGCGGCG 300‏ ‎CAAGTGGCTA GTCAAATTCT TGGGAAACAA GAAATCAATC GTTTAACAAA CATTGCCGAT 360‏ 5 ‎CCCAGAACTT TTGAGCCGAA CATGCTCACT TATGGGGGGE CTATGGACGT GATGGTTAAT 420‏ ‎GTCATCAATA ACGGCATCAT GAGTTTGGGG GCTTTTEGCG GGATACAATT GGCCGGCAAT 480,‏ ‎TCATGGCTTA TGGCGACACC GAGCTTTGAG GGCATTTTAG TGGAACAAGC CCTTGTGAGC 540‏ ‎CTCGCTTAAG GATCTTAARAA 600‏ و22 ‎AAGAAAGCCA CTTCTTTCCA ATTTTTATTC‏ ‎CATTCTAGCA TTGAAGCGGG CGTGAAATTC CCCATGCTARA AGARAAACCC CTACATCACT 660‏ 10 GCAAAAAATT TGGATATAGG GTTTAGGCGC GTGTATTCGT GGTATGTGAA TTACGTGTTC 720 ACTTTCTAG 729 INFORMATION FOR SEQ ID NO:44: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 771 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 20 (ii) MOLECULE TYPE : DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...771 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: 35 ATGGGATACG CAAGCAAATT AGCTTTAAAG ATTTGTTTGG TAGGTTTATG TTTATTTAGC 60‏ ‎ACCCTTGGTG CAGAACACCT TGAGCAAAAR GGGAATTATA TTTATAAGGG AGAGGAGGECT 120‏ ‎TATAATAATA 2062272702 GCGAGCGECT TCTTTTTATA AGAGCGCTAT TABAAATGGT 180‏ ‎GAGTCGCTTG CTTATATTCT TTTAGGGATC ATGTATGAAA ATGGTAGGGG TGTACCTAAA 240‏ 40 300 ود ‎GATTACAAGA AAGCGGTTGA ATATTTCCAA AAAGCTGTTG ATAACGATAT‏ ‎TATAACAATT TGGGCGTGAT GTATAAAGAG GGTAAGGGAG TTCCTAAAGA TGAAAAGAAA 360‏ ‎ GCGGTGGAAT ATTTTAGAAT AGCTACAGAG ADAGGTTATA CTAACGCTTA TATCAACTTA 420‏ ‎GGCATCATGT ATATGGAGGG CAGGGGAGTT CCAAGTAACT ATGCGAAAGC GACAGAATGT 480‏ ‎TTTAGAAAAG CGATGCATAA GGGCAATGTG GAAGCTTATA TTCTCCTAGG GGATATTTAT 540‏ 45 ‎TATAGCGGGA ATGATCAATT GGGTATTGAG CCGGACAAAG ATRAAGGCTGT TGTCTATTAT 600‏ ‎ARAATGGCGG CTGATGTGAG TTCTTCTAGA GCTTATGAAG GGTTGTCAGA GTCTTATCGG 660‏ ‎TATGGGTTAG GCGTGGAAAA AGATAAAADA AAGGCTGAAG AATACATGCA AAAAGCATGC 720 TTGTAAGAAA AAGAACACTT CAAGCCGATA A 771 GATTTTGACA 50 INFORMATION FOR SEQ ID NO:45: (2) / (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1974 base pairs (B) TYPE: nucleic acid 55 (C} STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

Vay (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 4 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1... 1974 (xi) SEQUENCE DESCRIPTION: SEQ ID 110:45:

ATGAGAAAAC TATTCATCCC ACTTTTATTA TTCAGCGCTT 12622000272 CGAGAAARAC 60

GGCTTTTTCA TAGAAAGCCGGE CTTTGAAACT GGGCTATTAG AAGGCACACA AACGCAAGAA 120

AAAAGACACA CCACCACARA AAACACTTAC GCAACTTACA ATTATTTACC CACAGACACG 180

ATTTTAAARAR GAGCGGCTAA TTTATTCACC AATGCCGAAG CGATTTCAAA ATTAAAATTC 240

TCATCTTTAT CCCCTGTTAG AGTGTTGTAT ATGTATAATG GTCAATTAAC TATAGAARAC 300

TTCTTGCCTT ATAATTTAAA TAATGTTAAG CTTAGTTTTTA CAGACGCTCA AGGCAATGTG 360

ATCGATCTAG GCGTGATAGA GACTATCCCC AAACACTCTA AGATTGTTTT GCCCGGAGAG 420

GCATTTGATA GTCTAAAAAT TGACCCCTAT ACTTTATTTC TTCCAAABMAT TGAAGCCACT 480

AGCACTTCTA TTTCTGACGC TAACACGCAG AGGGTGTTTG AAACGCTCAA TAAGATTAAG 540

ACAAATTTGG TCGTAAATTA TAGGAATGAA AACAAATTTA AAGATCACGA AAATCATTGS 600

GAAGCCTTTA CCCCACABAC CGCAGAAGAA TTCACTAATT TAATGTTGAA CATGATCGCT €60

GTTTTAGACT CCCAATCTTG GGGCGATGCG ATCTTAAACG CTCCTTTTGA GTTCACTAAC 720

AGCCCAACAG ATTGCGATAA TGATCCTTCA AAATGCGTAA ATCCTGGGAC AAACGGGCTT 780

GTCAATTCTA AAGTCGATCA AADATATGTG TTAAACAAAC AAGACATTGT CAATAAATTT 840

AAAAACAAAG CGGATCTTGA TGTAATTGTT TTAAAGGATT CAGGGGTTGT AGGGCTTGGS 300

AGTGATATTA CCCCTAGCAA CAATGATGAT GGCAAGCATT ATGGCCAGTT AGGGGTAGTA S60

GCTTCTGCTT TAGATCCTAA ARAAMACTCTTT GGCGATAACC TTAAGACTAT CAATTTAGAG 1020

GATTTAAGAA CCATCTTGCA TGAATTCAGC CACACTAAAG GCTATGGGCA TAACGGGAAT 1080

ATGACCTATC AAAGAGTGCC GGTAACGAAA GATGGTCAAG TGGAAAAGGA TAGTAATGGEC 1140

AAGCCAAAAG ATTCTGATGE CCTCCCCTAT AATGTGTGTT CGCTTTATGG GGGATCCAAT 1200

CAGCCCGCTT TCCCTAGCAA CTACCCTAAT TCCATCTATC ACAATTGTGC GGATGTCCCE 1260

GCTGGCTTTT TAGGGGTAAC AGCAGCGGTT TGGCAGCAGC TCATCAATCA AAACGCCTTG 1320

CCGATCAACT ACGCTAACTT GGGGAGTCAA ACAAACTACA ACCTAAACGC TAGTTTTARAC 1380

ACGCAAGATT TAGCCAATTC CATGCTCAGC ACCATCCAAA AAACCTTTGT AACTTCTAGC 1440

GTTACCAACC ACCATTTTTC AAACGCATCG CAAAGTTTTTA GAAGCCCTAT TTTAGGGGTT 1500

AACGCTAAAA TAGGCTATCA AAACTACTTIT AATGATTTCA TAGGGTTGGC TTATTATGGC 1560

ATCATCAAAT ACAATTACGC TAAAGCTGTT AATCAAAAAAG TCCAGCAATT GAGCTATGGT 1620

GGGGGGATAG ATTTGTTATT GGATTTCATC ACCACTTACT CCAATAAARAA TAGCCCTACA 1680

GGCATTCARAA CCAAAAGGAA TTTTTCTTCA TCTTTTGGTA TCTTTGGGGEG GTTAAGGGGC 1740

TTGTATAACA GCTATTATGT GTTGAACAARA GTCARAGGAA GCGGCAATTT AGATGTGGCT 1800

ACCGGGTTGA ACTACCGCTA TAAGCATTCT AAATATTCTG TAGGGATTAG CATCCCTTTA 1860

ATCCAAAGAA AAGCTAGCGT CGTTTCTAGC GGTGGCGATT ATACGAACTC TTTTGTTTTC 1520

AATGAAGGGG CTAGCCACTT TAAGGTGTTT TTCAATTACG GGTGGCTGTT TTAG 1974 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 504 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D} TOPOLOGY: (ii) MOLECULE TYPE: circular DNA (genomic) (iii) HYPOTHETICAL: NO

VAY

(iv) ANTI-SENSE: NO {vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: , (A) NAME/KEY: misc_feature ' (B) LOCATION 1...504 (xi) SEQUENCE DESCRIPTION : SEQ ID NO:46:

ATGAAATTGG TGAGTCTTAT TGTAGCGTTA GTTTTTTTIGTT GTTTTTTAGG GGCTGTAGAG 60

TTGCCTGGAG TTTATCAAAC TCAAGAATTT TTATACATGA AAAGCTCTTT TGTGGAGTTT 120

TTTGAGCATA ACGGGAAGTT CTATGCCTAT GGTATTTCTG ATGTGGATGGE CTCTAAAGCC 180

AAADAAGACA AACTCAATCC TAACCCAAAG CTAAGGAATC GCAGCGATAA AGGCGTGGTG 240

TTTTTAAGCG ATTTGATTAA GGTTGGGGAA CAATCTTATA AAGGCGGTAA GGCGTATAAT 300

TTTTATGACG GCAAGACCTA CCATGTGAGA GTCACTCARAA ATTCAAACGG GGATTTGGAZ 360

TTCACTTCAA GCTATGACAA ATGGGGGTAT GTGGGCAAAA CCTTCACCTG GAARACGCCTG 420

AGCGATGAAG AAATCAADAA TCTAAAGCTC AAGCGTTTTTA ACTTGGACGA AGTCCTTAAA 480

ACCCTCAAAG ATAGCCCTAT TTAA 504 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 885 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...885 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

ATGAGTAATC AAGCGAGCCA TTTGGATAAT TTTATGAACG CTAAAAATCC GL 60

TTTGATAATA AGGGGAATAC CAAATTCATC GCTATCACAA GCGGTAAGGG 9K 120

AAATCCAAACA TTAGCGCTZA TTTAGCTTAC TCTTTATACA AGAAAGGTTA TAAGGTAGGG 180

GTATTTGATG CGGATATTGG TTTAGCGAAT TTAGATGTCA TTTTTGCGGT GAAARCCCAT 240

AAAAATATCT TGCATGCCTT AAAAGGCGAA GCCAAATTGC AAGAAATCAT TTGCGAGATT 300

GAACCCGGGC TTTGCTTAAT CCCTGGGGAT AGCGGCGAAG ARATTTTAAA ATACATCAGC 360

GGCGCGGAAG CTTTGGATCG ATTCGTAGAT GAAGAGGGGG TTTTAAGCTC TTTAGATTAT 420

ATTGTGATTG ATACGGGTGC TGGGATTGGG GCCACTACGC AAGCGTTTTTT GAATGCGAGC 480

GATTGCGTGG TGATTGTTAC CACACCCGAT CCTTCAGCGA TTACCGATGC GTATGCATGC 540

ATTAAAATCA ACTCCAAGAA TAAAGATGAA TTGTTCCTTA TCGCTAACAT GGTAGCCCAA 600

CCTAAAGAAG GCAGGGCGAC TTATGARAGG CTATTCAAGG TGGCTAAAAA CAATATCGCT 660

TCATTAGAAT TGCACTATTT AGGGGCGATT GAAAACAGCT CCTTATTGAA ACGCTATGTG 720

AGGGAGCGAA AGATTTTGAG GARAAATAGCC CCTAACGATT TGTTTTCGCA ATCCATTGAC 780

CAGATAGCGA GCCTTTTAGT TTCTAAACTA GAAACCGGCA CTTTAGAAAT ACCAAAAGARA 840

GGTTTAAARA GCTTTTTTARA 2266011116 AAGTATTTGG GGTAG 885 INFORMATION FOR SEQ ID NO:48: (2) (i) SEQUENCE CHARACTERISTICS: 5 (A) LENGTH: 1119 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double : (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (iii) BEYPOTHETICAL: NO (iv) ANTI-SENSE: NO 15 (vi) ORIGINAL.

SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 20 (A) NAME/KEY: misc_feature (B) LOCATION 1...1119 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

‎TTGGAACCTT CAAGAAMATCG CCTAAAACAT GCCGCCTTTT TTGTGGGGCT TTTTATCGTT 60‏ ‎TTGTTTTTAA TTATAATGAA GCACCAAACC TCCCCCTATG CTTTCACGCA TAATCAAGCC 120‏ ‎CTTGTCACTC AAACCCCCCC CTATTTCACG CAACTCACTA TCCCTAAACC AAATGACGCT 180‏ ‎TTAAGCGCGC ATGCGAGCTC TTTAATCAGC TTGCCTAACG ACAATCTTTT GAGCGCTTAT 240‏ ‎TTTAGCGGCA CTAAAGAAGG GGCAAGGGAT GTGAAAATCA GCGCGAATCT TTTTGACAGC 300‏ 30 ‎AAGACTAATC GCTGGAGCGA AGCCTTCATT CTTTTAACCA AAGAAGAGCT TTCTCATCAT 360‏ ‎TCGCATGAAT ACATCAARDAA ATTAGGTAAC CCCTTGCTTT TTTTGCATGA TAATAAAATT 420‏ ‎TTGTTGTTTG TCGTAGGGGET GAGCATGGGC GGGTGGGCCA CTTCTAAAAT CTATCAATTT 480‏ ‎GAAAGCGCTT TAGAGCCGAT TCATTTTAAG TTTGCGCGAA AACTCTCTTT AAGCCCTTTT 540‏ ‎TTAAATTTGA GCCATTTAGT AAGGAATAAG CCTTTAAACA CCACTGATGG CGGGTTTATG 600‏ 35 ‎CTACCACTCT ATCACGAATT AGCCACCCAA TACCCCTTGT TGTTGAAATT TGACCAACAA 660 AATAACCCAA GAGAGCTTTT AAGGCCTAAT ACCTTAAACC ACCAGCTCCA ACCAAGCTTA 720 ACCCCTTTA AAGACTGCGC TGTCATGGCG TTTAGAAACC ATTCTTTTAA AGATAGCCTC 780 ATGCTAGAAA CCTGTAAAAC CCCCACTGAT TGGCARAAAC CCATTTCTAC AAATCTTAAA 840‏ ‎AACTTAGATG ATTCTTTARA TTTACTCAAT TTAAATGGAA TATTGTATTT GATCCACAAC S00‏ 40 ‎CCTAGCGATT TATCACTGCG TCGTAAAGAA CTTTGGCTTT CTAAATTAGA AAACTCCAAC S60‏ ‎TCGTTTAAAA CCTTAAAAGT TTTGGATAAA GCGAATGAAG TGAGTTACCC AAGCTATAGC 1020‏ ‎CTTAATCCGC ATTTTATAGA TATTGTCTAT ACTTACAACC GCTCTCATAT CAAACACATC 1080‏ ‎CGTTTCAATA TGGCTTATTT AAATTCCCTT CTCAAGTGA 1119‏

INFORMATION FOR SEQ ID 10:49: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2937 base pairs (B) TYPE: nucleic acid 50 (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 5 (B) LOCATION 1...2937 (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:49: 4‏ ‎ATGAAGAAAR GAAAACATGT ATCCAAGAAA GTGTTTAATG TCATTATCTT GTTTGTGGCA 60‏ 10 ‎GTATTCACTC TTTTAGTCGT CATTCACAAA ACCCTTTCAA ACGGCATTCA CATACAAAAT 120‏ ‎TTAAARATTG GAAAACTTGG CATTTCTGAA TTATACTTAA AACTCAATAA CAAGCTTTCT 180‏ ‎TTGGAAGTTG AGCGGGTTGA TCTCTCTTCT TTCTTCCATC ARAAACCCAC TAAAAAGCGT 240‏ ‎ TTAGAAGTTT CTGATTTGAT TAAAAATATC CGTTATGGCA TTTGGGCGGT GTCTTATTTT 300‏ ‎GAAAAACTTA AAGTCAAAGA AATCATTTTA GACGATAAAA ATAAAGCCAA TATCTTTTTT 360‏ 15 ‎GATGGGAATA AATACGAGTT AGAATTTCCA GGAATCAAAG GGGAATTTTC CCTAGAAGAC 420‏ ‎GATAAARATA TCAAGCTTAA AATCATCAAT TTGCTTTTTA AAGATGTTAA AGTCCAAGTG 480‏ ‎GATGGCAACG CCCACTATTC ACCCAAAGCC AGGAAAATGG CGTTCAATTT GATTGTCAAG 540‏ ‎CCCTTAGTTG AACCCAGCGC TGCAATTTAT TTGCAAGGGC TAACCGATTT AAAAACCATA 600 GAATTARAAA TTAACACTTC TCCAATGAAA AGCCTAGCGT TTTTAAAGCC TCTTTTCCAR 660 20 CGCCAATCGC AAAAAAA TTT AAAAACGTGG ATTTTTGACA AGATCCAATT TGCCAGCTTT 720‏ ‎AAGATTGATA ACGCTTTAAT CAAGGCTAAT TTCACTCCTA GCGAGTTTAT CCCATCGCTT 780‏ ‎TTGGAARATT CTGTAGTTAA AGCCACTTTG ATTAAGCCTT CAGTCGTTTT TAATGATCEC 840‏ ' ‎TTATCGCCCA TTAAAATGGA TAAAACCGAA TTGATTTTCA AAAACAAACA GCTCCTCATA 900‏ ‎CAGCCCCAAA AAATCACTTA TGAAACCATG GAATTAACCG GCTCTTACGC CACTTTTTCC 960‏ 25 ‎AATTTGTTAG AAGCCCCTAA GTTGGAGGTT TTTTTAAAAA CGACCCCTAA TTATTATGGC 1020‏ ‎GATAGCATTA AGGATTTATT GAGCGCTTAT AAAGTCGTTT TACCTTTGGA TAAAATCAGC 1080‏ ‎ATGCCATCTA GCGCGGATTT GAAGCTCACT TTGCAATTCT TAAAAAACAC CGCCCCCTTA 1140‏ ‎TTTAGCGTTC 2260020007 TAATTTGCAA GAAGGCACTT TCTCGCTCTA TAATATCCCC 1200‏ ‎CTTTACACGC AAAGCGCTCA AATCAATTTG GACATCGCCC AAGAATACCA ATACATCTAC 1260‏ 30 ‎ATAGACACGA TCCACACGCG CTATGCAAAC ATGCTGGATT TAGACGCTAA AATCGCTTTA 1320‏ GATTAGGTC AAAARAAACCT TTCTTTGGAT TCTTTAGTCC ATAAAATCCA AGTCAATACC 1380 AATAACAATA TCAACATGCG CTCTTATGAT CCCAATAACA CTCAAGAAGA TCCGCAAACT 1440 AACTTTACTT TGGATCTAAA AAGCTTGCAT TCTATCATTC AAGAGGGTGA AAATTCAGAA 1500‏ ‎GTTTTTAGAA GAARAATCAT AGACACCATT AAAGCCCAAA GCGAAGATAA ATTCACTAAR 1560‏ 35 ‎GATGTTTTTT ACGCCACAGG AGACACTCTC AAAAGCCTGT CGTTGAGTTT TGATTTTTCC 1620‏ ‎ACATACAATG GAGCGTGCCA CAACTCTTAT TAGAAGGCGA ATTTAAAGAT 1680‏ 2200003210 ‎AACGCCTATA CTTTTAAGAT CAAAGATTTG AAAAAGATCA AGCCCTATTC CCCCATTATG 1740‏ ‎GACTATATTG CCCTAAAAGA CGGCTCTTTA GAGGTTTCTA CGAGCGATTT TGTCAATATT 1800‏ ‎GATTTTTTTG CTAAAGATTT GAAAATCAAC CTCCCCATTT ATAGGAGCGA TGGATCGCAT 1860‏ 40 ‎TTTGATTCTT TTTCTTTATT TGGCTCTATC AATAAAGATG AAATTTCTGT CTATACTCCA 1920‏ ‎AGCAAAAGCA TATCCATAAA AGTTAAGGGG GATCAAAAGG ATATTACCCT TAATAACATT 1980‏ ‎GATTTGAGTA TTGATGATTT CTTGGATAGT AAAATGCCAG CTATTGCGGG ATTATTCTCA 2040‏ ‎AARGAACGAA AAGAAAAGCC TAGCTCTAAA GAAATCCAAG ATGAAGATGT TTTCATTAGC 2100‏ ‎GCCAAACAAC GCTATGAARA AGCCCACAAA ATTATCCCCA TCTCTACACG CATCCATGCT 2160 45 TGCTGATCTA TAAAAAAATG CCTTTTCCTT TAGAAAATCT TGATATTGTC 2220 22206216106 GCTCAAGACG ATAGGGTGAA AATTGATGGC AATTATAARA ACGCCATGAT CATGGCGGAT 2280 TTAGTGCATG GGGCTTTGTA TCTTAAGGCT CATAATTTTA GCGGGGATTA TATCAACACC 2340‏ ‎ATTCTTCAAA AAGATTTCGT AGAAGGAGGC TTATTCACGC TTATTGGGGC TCTTGAAGAT 2400‏ ‎CAGGTTTTCA ATGGCGAATT GAAATTCCAA AACACAAGCT TAAAGAATTT CGCCCTCATG 2460‏ 50 ‎CAAAACATGG TCAATCTCAT CAACACCATT CCCTCCCTCA TTGTCTTTAG AAACCCTCAT 2520‏ ‎TTAGGGGCTA ATGGCTATCA AATCAAAACC GGCTCCGTTG TGTTTGGGAT CACTAAAGRA 2580‏ ‎TATTTAGGGT TAGAAAAAAT TGATCTTGTC GGCAAAACGC TTGATATTGC TGGCAATGGA 2640 ‏ ‎ATCATTGAAT TAGACAAAAA CAAATTAGAT TTAAACTTAG AAGTTTCCAC TATCAAGGCT 2700‏ ‎TTGAGTAATG TCTTAAATAA AATCCCTATC GTGGGCTATC TCGTTTTAGG AAAAGGAGGT 2760‏ 55 ‎AAAATCACCA CTAACGTGAA TGTCAAAGGC ACGTTGGATA AGCCTAAAAC CCAAGTAACT 2820‏ ‎TTAGCGTCAG ATATTATCCA AGCGCCTTTT AAAATCTTAC GCCGTATTTT CACGCCTATT 2880‏ ‎GACATCATCG TGGATGAAGT CAAGAAAAAC ATTGATTCAZA AAAGGAAATT AAAATGA 2937‏

(2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1434 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular ' (ii) MOLECULE TYPE : DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (pn) NAME/KEY: misc_feature (B) LOCATION 1 ...1434 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

ATGAATACTA TTATAAGATA TGCGAGTTTA TGGGGCTTGT GTATTACTCT AACTCTAGCG 60

CAAACCCCCT CTAAAACCCC TGATGAAATC AAGCAAATCC TTAACAATTA TAGCCATAAG 120

AATTTAAAGC TCATTGATCC GCCGACRAAGT TCTTTAGAAG CGACACCGGGE TTTTTTACCC 180

TCGCCTAAAG AAACAGCGAC CACGATCAAT CAAGAGATCG CTAAATACCA TGAAAAAAGC 240

GATAAAGCCG CTTTGGGGCT TTATGAATTG CTAAAGGGGG CTACCACCAA TCTCAGTTTG 300

CAAGCGCAAG AACTCAGTGT CAAGCAAGCG ATGAAGAACC ACACCATCGC CAAAGCGATE 360

TTTTTGCCTA CTTTGAACGC GAGTTATAAT TTTAAAAATG AAGCTAGGGA TACTCCAGAA 420

TATAAGCATT ATAACACCCA ACAACTCCAA GCTCAAGTCA CATTGAATGT GTTTAATGGC 480

TTTAGCAATG TGAATAATGT CAAAGAAAAG TCTGCGACTT ACCGATCCAC TGTGGCTAAT 540

TTAGAATATA GCCGCCAAAG CGTGTATTTG CAAGTGGTGC AACAATACTA CGAGTATTTT 600

AAACAATCTCG CTCGCATGAT CGCTTTGCRAA AAGAAATTAG AGCAAATCCA AACGGACATT 660

AAAAGGGTTA CTAAGCTCTA TGACAAAGGG CTGACCACGA TTGATGATTT ACAAAGCTTA 720

AARGCGCAAG GGAATTTGAG CGAATACGAT ATTTTGGACA TGCAATTTGC TTTGGAGCAA 780

AACCGCTTGA CTTTAGAATA CCTCACTAAC CTCAGTGTGA AAAATTTGAA AAAGACCACG 840

ATTGATGCGC CTAATTTGCA ATTAAGAGAA AGGCAGGATT TGGTTTTCTTT AAGGGAGCAG 300

ATTTCTGCAC TCAGATACCA AAACAAGCAA CTCAATTATT ACCCCAAGAT AGATGTGTTT 960

GACTCATGGC TTTTTTGGAT CCAAAAACCC GCTTATGCCA CAGGGCGTTT TGGGAATTTC 1020

TACCCAGGTC AGCAAAATAC GGCTGGGGTT ACTGCGACTT TGAATATTTT TGATGATATA 1080

GGGTTGAGCT TGCAAAAACA ATCCATCATG CTAGGCCAAT TAGCGRAATGA AAAGAATTTA 1140

GCGTATAAAA AATTGGAGCA AGAAAAAAGAC GAACAGCTTT ACAGAAAGTC GCTTGATATT 1200

GCCAGAGGCTA AGATTGAATC TTCAAAGGCT AGTTTGGATG CGGCCAATCT TTCTTTTGCC 1260

AATATTAAAA GGAAATACGA CGCTAATTTA GTGGATTTCA CTACCTATTT AAGGGGCTTA 1320

ACCACGCGCT TTGATGCAGA AGTGGCTTAC AATTTAGCGC TCAACAATTA CGAAGTGCAA 1380

AAAGCCAATT ACATTTTTAA CAGCGGGCAT AAAATAGACG ACTATGTGCA TTAA 1434 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1239 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: (ii) MOLECULE TYPE: circular DNA (genomic) (iii) HYPOTHETICAL: NO

Now » (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 5 (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...1239

‎(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:‏ ‎ATGCTATCTT TTATAAGCGC GTTTGATAAA AGGGGCGTTT CAATACGCCT TCTAACAGCC 60‏ ‎TTGTTACTGC TTTTTAGTTT GGGTTTGGCT AAAGATTTAG AAATCCAAAC TTTTGTGGCT 120‏ ‎ AAATACCTTT CTAAAAATCA AAAAATACAA GCCCTACAGG AGCAAATTGA CGCTTTAGAT 180‏ 15 ‎TCTCAAGAAA AAGTCGTTAG CAAATGGGAT AACCCTATTT TGTATTTAGG CTATAACAAC 240 ‏ ‎GCTAACGTGA GCGATTTTTT CAGGCTGGAT AGCACCTTARA TGCARAACAT GAGCTTGGGT 300‏ ‎TTGTCTCAAA AAGTGGATTT AAATGGTAAA AAACTCACGC AGTCTAAAAT GATCAATTTA 360‏ ‎GARARACAAA AAADRATATT AGAGCTTAAA AAAACCAAGC AGCAATTGGT GATTAATTTA 420‏ ‎ ATGATAAACG GCATTGAAAA CTATARAAAC CAACAAGAAA TAGAGCTTTT AAACACAGCG 480‏ 20 ‎ATTAAAAATT TAGAAAACAC CCTCTATCAA GCCAACCATT CCAGTTCGCC CGATTTAATA 540‏ ‎GCGATCGCCA AGTTAGAAAT TTTAAAATCG CTATTAGAAA TCCAAAAAAA CGATTTAGAA 600‏ ‎GTAGCGCTCT CTAGCAGCCA TTATTCCATG GGCGAATTGA CTTTTAAAGA AAACGAGATT 660‏ ‎TTAAGCATTG CCCCTAAAAA TTTTGAATTC AATAACGAGC AAGAGCTGCA TAACATTAGC 720‏ ‎ GCCACTAATT ACGATATTGC GATCGCCAGGE CTTGATGAAG AAADRAGCACA AAAAGACATC 780‏ 25 ‎ACTCTG GCTA AAARAAGCTT TTTAGAAGAC ATAAACGTTA CCGGGGTGTA TTATTTCCGC 840‏ ‎TCCAAACAAT ACTATAACTA CGACATGTTT AGCGTCGCTT TGTCTATCCC TTTACCTCTT 900‏ ‎TATGGCAAGC AGGCTAAATT AGTGGAGCAA AAGAAAAAAG AAAGCTTGGC GTTTAAAAGE 960‏ ‎GAAGTGGAAA ACGCCAAAAA CAAAACGCGC CACCTGGCCC TAAAACTCCT TAAAAAATTA 1020‏ ‎GAAACCTTGC AAAAAAACCT GGAATCGATC AATAAAATCA TCAARACAGAA TGAAAARATC 1080‏ 30 ‎GCGCARATTT ATGCGCTTGA TTTGAAAACT AATGGCGATT ACAACGCTTA TTACAACGCE 1140 TTGAATGACA AAATCACTAT TCAAATCACC CAGCTTGAAA CCTTAAGCGC TCTAAATAGT 1200 GCTTATTTGT CCTTACAAAA TCTCAAAGGA TTAGAATGA 1239 INFORMATION FOR SEQ ID NO:52: (2) 35 (i) SEQUENCE CHARACTERISTICS: (A)41: (A) L41: ENG: (A) L41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double 40 (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) . (iii) HYPOTHETICAL: NO 45 (iv) ANTI-SENSE: NO © (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 50 (ix) FEATURE: p (A) NAME/KEY: misc_feature ( B) LOCATION 1...414

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: ATGCGTATAG TTAGAAATTT ATTTCTTGTA TCGTTTGTGG CGTATAGTAG TGCGTTCGCA 60 GCGGATTTAG AAACCGGAAC CAAAAACGAC AAAAAGAGCG GTAAAAAATT TTACAAACTC 120

فخا ‎CATAAAAACC ATGGCTCAGA AACCGAGACT AAAAACGATA AAAAGCTTTA TGATTTCACT 180‏ ‎AAAAATAGCG GATTAGAAGG CGTGGATTTA GAAAAAAGCC CTAACCTTAA AAGCCATAAA 240‏ ‎AARAGCGATA AAAAGTTTTA TAAACAACTC GCTAAARAACA ATATCGCTGA AGGGGTGAGC 300‏ ‎ATGCCGATTG TGAATTTCAA TAAAGCCCTA TCTTTTGGGC CTTATTTTGA AAGGACTAAA 360‏ ‎ AGCARRAAAA CCCAATACAT GGACGGCGGG TTGATGATGC ACATCCGTTT TTAA 414‏ 5 ‎INFORMATION FOR SEQ ID NO:53: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 930 base pairs 10 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 15 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 25 (B) LOCATION 1...930 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

TTGATGCCAC ARAACCAGCT TGTGATCACC ATCATTGATG AATCAGGCTC TAAGCAACTC 60

AAATTTTCTA AAAATTTAAA ACGCAACCTC ATCATTTCTG TTGTCATTCT TTTATTGATC 120

GTGGGGCTTG GCGTGGGGTT TTTAAAATTT TTAATCGCTA AAATGGATAC GATGACAAGC 180

GAGAGGARATG CGGITTTAAG GGATTTTAGG GGTTTGTATC AAAAAAATTA CGCCCTAGCG 240 220202772 AAAACAAGCG AGAAGAGCTT TTTATTGTGG GGCAAAAGAT CCGTGGGCTA 300

GRATCCTTGA TTGAAATCAA AAAGGGGGCT AATGGGGGAG GGCATCTCTA TGATGAAGTG 360

GATTTAGAAA ATTTGAGCTT AAATCAAAAAA CATTTAGCAC TCATGCTCAT TCCTAATGGC 420

ATGCCCCTAA AAACTTATAG CGCTATCAAA CCCACTAAAG AAAGGAACCA CCCCATTAAA 480

AAGATTAAGG GCGTTGAATC CGGGATCGAT TTTATCGCGC CATTGAACAC GCCTGTGTAT 540

GCGAGCGCTG ATGGGATTGT GGATTTTGTG AAGACTCGTT CTAATGCGGG GTATGGGAAC 600

TTGGTGCGCA TTGAACATGC GTTTGGTTTC AGCTCCATTT ATACGCACTT AGATCATGTC 660

AATGTGCAGC CTAAAAGCTT CATCCAAAAA GGGCAGTTGA TTGGCTATAG CGGGAAGAGC 720

GGTAATAGCG GCGGCGAAAA ATTGCATTAT GAAGTGCGGT TTTTGGGTAA AATTTTAGAC 780

GCAGAAARAT TCCTAGCATG GGATTTGGAT CATTTTCARRA GCGCTTTAGA AGAAAATAAA 840

TTTATTGAART GGAAGAATCT GTTTTGGGTT TTAGAAGACA TCGTCCAGCT CCAAGAGCAT 900

GTGGATARAG ACACCTTAAA AGGTCAGTAG 930 (2) INFORMATION FOR SEQ ID NO:54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 999 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 5 (A) NAME/KEY: misc_feature (B) LOCATION 1...999 5 ( xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

‎GTGCTATATT TTTTAACCAG TTTATTTATT TGCTCTTTGA TTGTTTTGTG GTCTAAAAAA 60‏ ‎TCCATGCTCT TTGTGGATAA CGCTAATARA ATCCAAGGCT TCCATCATGC AAGAACCCCA 120‏ ‎CGAGCCGGGG GGCTTGGGAT CTTTCTTTCT TTTGCGTTGG CTTGTTATCT TGAACCTTTT 180‏ ‎GAGATGCCTT TTAAGGGGCC TTTTGTTTTC TTAGGGCTAT CGCTAGTGTT TTTGAGCGGT 240‏ ‎ TTTTTAGAAG ACATTAACCT TTCATTAAGC CCCAAAATAC GCCTTATTTT GCAAGCTGTA 300‏ 15 ‎GGGGTCGTTT GCATCATTTC ATCAACGCCT TTAGTGGTGA GCGATTTTTC GCCCCTTTTT 360‏ ‎AGCTTGCCTT ATTTCATCGC TTTTTTATTC GCTATTTTTA TGCTGGTGGG TATCAGTAAC 420‏ ‎GCTATTAATA TCATTGACGG GTTTAACGGG CTTGCATCTG GGATTTGCGC GATCGCGCTT 480‏ ‎TTAGTCATTC ATTATATAGA CCCTAGCAGT TTGTCTTGTT TGCTCGCTTA CATGGTGCTT 540‏ ‎ GGGTTTATGG TGTTAAATTT CCCTTCAGGA AAGATTTTTT TAGGCGATGG GGGGGCGTAT 600‏ 20 ‎TTTTTGGGTT TGGTGTGCGG GATTTCTCTC TTGCATTTGA GTTTGGAGCA AAAAATCAGC 660 GTGTTTTTTG GGCTCAATTT AATGCTTTAT CCGGTCATAG AGGTGCTTTT TAGTATCOTT 720 AGGCGCAAAA TAAAACGCCA GAAAGCCACC ATGCCGGATA ATTTGCATTT GCACACCCTT 780 TTATTTAAAT TCTTGCAACA ACGCTCTTTC AATTACCCTA ACCCTTTATG C GCGTTTATC 840 CTTATTCTAT GCAACCTGCC TTTTATTTTA ATAAGCGTTT TGTTTCGCTT GGACGCTTAT 900 25 GCGCTCATTG TGATTAGCCT AGTCTTTATC GCATGCTATT TAATAGGCTA TGCTTATTTG 960 AATAGGCAAG TTTGCGCTTT AGAAAAGCGG GCGTTTTAA 960 ID: FOR IN2: NO2 SEQUENCE: ID5: NO

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 816 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 35 (ii) MOLECULE TYPE : DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO. (vi) ORIGINAL SOURCE: . (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: , (A) NAME/KEY: misc_feature (B) LOCATION 1...816 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: 50 ATGAACATAT TCAAGCGTAT TATTTGCGTA ACCGCTATTG TTTTAGGTTT TTTTAACCTT 60 :‏ ‎TTAGACGCCA AACACCACAA AGAAAAAAAA GAAGACCACA AAATCACTCG TGAGCTTAAA 120‏ ‎GTGGGCGCTA ACCCTGTGCC GCATGCGCAA ATCTTGCAAT CAGTTGTGGA TGATTTGARA 180‏ ‎ GAGAAAGGGA TCAAATTAGT GATCGTGTCT TTTACGGATT ATGTGTTGCC TAATTTAGCG 240‏ 55 ‎CTCAATGACG GCTCTTTAGA CGCGAATTAC TTCCAGCACC GCCCTTATTT GGATCGGTTT 300‏ ‎AATTTGGACA GAAAAATGCA CCTTGTTGGT TTGGCCAATA TCCATGTGGA GCCTTTAAGA 360‏ TTTTATTCTC AARAAATCAC AGACATTAAA AACCTTAAAA AAGGCTCAGT GATTGOTGTG 420 CCARATGATC CGGCCAATCA AGGCAGGGCG TTGATTTTAC TCCATAAACA AGGCCTTATC 480

Y..

GCTCTCAAAG ACCCAAGCAA TCTATACGCT ACGGAGTTTG ATATTGTCAA AAATCCTTAC 540

AACATCAAAAA TCAAACCCCT AGAAGCTGCG TTATTGCCTA AGGTTTTAGG GGATGTGGAT 600

GGGGCTATCA TAACAGGGAA TTATGCCTTG CAAGCAAAAC TCACCGGAGC CTTATTTTCA £60

GAAGATAAGG ACTCGCCTTA TGCTAATCTT GTAGCCTCTC GTGAGGATAA TGCGCAAGAT 720

GAAGCGATAA AAGCGTTGAT TGAAGCCTTA CAGAGCGAAA AGACCAGGAA ATTCATTTTG 780

GATACCTATA AGGGGGCGAT TATCCCGGCT TTTTAA 816 (2) INFORMATION FOR SEQ ID NO:56: ! (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 951 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO ( iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...951 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

ATGCAAGAAT TCAGTTTGTG GTGCGATTTT ATAGAAAGGG ATTTTTTAGA AAACGATTTTT 60

TTAAAGCTCA TCAATAAGGG GGCTATTTGC GGGGCGACGA GTAACCCTAG TTTGTTTTGC 120

GAAGCGATCA CAAAAAGCGC GTTTTATCAA GATGAAATCG CTAAACTCAA AGGCAALAAA 180

GCTAAAGAAA TTTATGAAAC TCTGGCACTA AAGGATATTT TACAAGCCTC TAGCGCGTTA 240

ATGCCTTTGT ATGAAAAAGA CCCTAACAAC GGCTACATCA GCCTAGAAAT TGACCCCTTT 300

TTAGAAGACG ATGCGATTAA AAAGCATTGAT GAAGCCAAGC GGTTATTCAA AACATTARAC 360

CGCCCCAATG TGATGATTAA AGTCCCGGCG AGTGAAAGCG CTTTTGAAGT CATTAGCGCT 420

CTGGCTCAAG CCTCTATCCC CATTAATGTA ACTTTAGTCT TTTCGCCTAA AATTGCCGET 480

GAAATCGCTC AAATCTTAGC CAAAGAAGCA CGAAAAAGAG CGGTCATTAG CGTGTTTGTC 540

TCACGATTTG ACAARAGAAAT AGACCCACTA GTGCCACAAA ATTTGCAAGC TCAAAGTGGG 600

ATCATGAACG CTACCGAGTG TTATTATCAA ATCAACCAGC ATGCTAATAA GCTAATAAGC 660

ACCCTTTTTG CATCCACCGG CGTTAAATCT AATTCTTTAG CTAAAGATTA CTACATTAAA 720

GCGCTIGTGTT TTAAAAACTC TATCAACACA GCCCCCCTAG ACGCCCTAAR CGCTTATTTG 780

CTTGACCCAA ACACCGAGTG TCAAACCCCT TTAAAAATCA CAGAAATTGA AGCGTTCAAA 840

AAAGAATTAA AAACGCACAA TATTGATTTA GAAAACACCG CCCAAAAACT CCTTAAAGAA 900

GGCTTGATAG CGTTCAARACA ATCCTTTGAA AAGCTTTTAA GCAGTTTTTG A 951 (2) INFORMATION FOR SEQ ID NO:57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 783 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: (ii) MOLECULE TYPE: circular DNA (genomic) (iii) HYPOTHETICAL: NO

Y.\{iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ; (B) LOCATION 1...783 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

ATGAAAACAA ATGGTCATTT TAAGGATTTT GCATGGAAAA AATGCTTTTT AGGCGCGAGC 60

GTGGTGGCTT TATTAGTGGG GTGTAGCCCG CATATTATTG AAACCAATGA AGTTGCTTTG 120

AAATTGAATT ACCATCCAGC TAGCGAGAAA GTTCAAGCGT TAGATGAAAA GATTTTACTT 180

TTAAGGCCAG CTTTCCAATA CAGCGATAAT ATTGCTAAAG AGTATGAAAA CAAATTCAAG 240

AATCAAACCA CGCTTAAAGT TGAAGAGATC TTGCAAAATC AGGGCTATAA GGTTATTAAT 300

GTGGATAGCA GCGATAAAGA CGATTTTTCT TTTGCGCAAA AAAAAGAAGG GTATTTGGCT 360

GTCGCTATGA ATGGCGAAAT TGTTTTACGC CCCGATCCTA AAAGGACCAT ACAGAAARAA 420

TCAGAACCCG GGTTATTATT CTCCACTGGT TTGGATARAA TGGAAAGGGT TTTAATCCCG 480

GCTGGGTTTG TCAAGGTTAC CATACTAGAG CCTATGAGTG GGGAATCTTT GGATTCTTTT 540

ACGATGGATT TGAGGCAGTT GGACATCCAA GAAAAATTCT TAAAAACCAC CCATTCAAGC 600

CATAGCGGAG GGTTAGTTAG CACTATGGTT AAGGGGACGG ATAATTCTAA TGACGCAATT 660

AAGAGCGCTT TGAATAAGAT TTTTGCAAGT ATCATGCAAG AAATGGATAA GAAACTCACT 720

CAAAGGAATT TAGAATCTTA TCAMAAAAGAC GCCAAGGAAT TAAAAAACAA GAGAAACCGA 780

Tan 783 (2) INFORMATION FOR SEQ ID NO:58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4149 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature ; (B) LOCATION 1...4149 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

TTGRAATTTTA ATAACCTTAC GGCTAATGGG GCGTTAAATT TTAATGGTTA TGCGCCCTCT 60

TTAACTAAGG CTTTAATGAA TGTCAGCGGG CAGTTTGTTTT TAGGGAATAA TGGGGATATT 120

AARTTTATCTG ACATCAATAT CTTTGACAAC ATCACAAAAT CTGTAACTTA CAACATCTTA 180

AACGCTCAAA AAGGGATTAC TGGCATTAGT GGGGCTAATG GCTATGAAAA AATCCTTTTTT 240

TATGGCATGA AAATCCAAAAA CGCTACCTAT AGCGATAATA ACACATCCA AACTTGGTCG 300

TTTATARACC CTCTCAATTC TTCTCAARATC ATTCAAGAGA GCATTAAAAA TGGGGATCTA 360

ACCATAGAAG TTTTAAATAA CCCTAACTCG GCTTCCAACA CTATTTTTAA TATCGCTCCT 420

GAGCTTTATA ATTACCAAGA TTCTAAGCAA AATCCTACCG GCTATAGCTA TGATTATAGC 480

GACAATCAAG CAGGCACTTA TTACTTGACA AGCAACATTA AAGGTCTTTT CACCCCTARA 540

GGCTCTCAAA CGCCTCAAAC CCCAGGCACT TATAGCCCAT TTAACCAGCC TTTGAATAGT 600

1

TTGAATATCT ACAATAAGGG TTTTTCTAGC GAGAATTTAA AAACGCTTTTT AGGGATCCTT 660

TCTCAAAATT CCGCCACCTT AAAAGARATG ATTGAATCCA ACCAACTAGA CAATATCACT 720

ARCATTAATG AAGTGTTGCA ACTCTTAGAT AAGATTAAAAA TCACCCAAGC GCAAAAGCAL 780

GCGCTCCTAG AAACGATCAA CCATTTGACT GACAACATCA ATCAAACCTT TAATAACGGG 840

AATCTCGTTA TAGGCGCTAC CCAAGATAAT GTTACAAACT CTACTAGCTC TATATGGTTT 900

GGGGGCAATG GCTATAGCAG CCCTTGCGCG CTAGATAGCG CCACTTGTTC TTCTTTTAGA 960

AACACTTACT TGGGGCAATT ATTAGGCTCA ACTTCCCCTT ATTTAGGCTA CATTAACGCT 1020 ,

GATTTTAAAG CTAAAAGCAT TTATATTACC GGGACAATTG GAAGTAGTAA CGCTTTTGAA 1080

AGCGGAGGGA GCGCGGATGT AACCTTTCAA AGCGCTAATA ACTTAGTGTT GAATAAAGCT 1140

AACATAGAAG CTCAAGCCAC AGACAATATC TTTAATCTTT TGGGTCAAGA AGGGATTGAT 1200

AAAATCTTTA ATCAGGGGAA TTTAGCGAAT GTTCTTAGTC AAATGGCTAT GGAAARAATC 1260 2260226006 GCGGTTTAGG GAACTTTATA GAAAACGCTC TAAGCCCTTT GAGTAAGGAA 1320

TTACCCGCTA GCTTGCAAGA TGAAACCTTA GGCCAACTTA TAGGTCAAAA TAACTTAGAT 1380

GATTTATTGA ATAATAGTGG AGTCATGAAT GAAATCCAAA ACATTATCAG TCAAAAACTA 1440

AGCATTTTTG GCAATTTTGT TACCCCATCC ATCATAGAAA ACTACCTTGC TAAGCAGTCT 1500

TTAAAAAGCA TGCTAGACGA TAAAGGGCTT TTGAATTTTA TCGGTGGGTA TATAGACGCT 1560

TCTGAATTAR GCTCTATTTT AGGCGTGATT TTAAAGGATA TTACTAACCC CCCTACAAGC 1620

CTGCAAAAAG ACATTGGTGT GGTAGCGAAC GACTTGTTGA ACGAGTTTTTT AGGACAAGAT 1680

GTTGTCRAAA AGCTAGAAAG TCAAGGCTTG GTGAGTAATA TCATCAATAA TGTTATTTCT 1740

CAAGGCGGGT TGAGCGGCGT TTATAATCAA GGTTTAGGGA GCGTGTTGCC GCCCTCTTTA 1800

CAAAACGCGC TCAAAGAAAA CGATTTAGGC ACTCTTTTAT CGCCTAGAGG CTTGCATGAT 1860

TTTTGGCAAA AAGGGTATTT TAACTTTTTTA AGCAATGGCT ATGTTTTTGT CAATAACAGC 1820

TCTTTTAGTA ACGCTACTGG 60601201116 AATTTTGTCG CCAACAAGTC TATTATCTTT 1880

AATGGCGATA ATACGATTGA CTTTAGCAAG TATCAAGGCG CATTGATTTT TGCTTCTAAT 2040

GGTGTTTCTA ATATCAATAT CACCACCCTA AACGCCACTA ATGGCTTAAG CCTTAATGCG 2100

GGTTTGAATA ATGTGAGCGT TCAAAAAGGA GAAATTTGTA TCAATTTAGC CAATTGCCCT 2160

ACAACCAAAA ACAGCTCTCC TGCAAACTCT AGCGTAACCC CCACTAATGA GTCTTTAAGC 2220

GTGCACGCTA ATAATTTCAC TTTCTTAGGC ACAATCATCT CTAATGGGGC CO 2280

TCTCAAGTAA CAAATAATAG CGTTATAGGC ACGCTCAATC TCAATGAAAR TGCGACCTTG 2340

CAAGCTAATA ATTTAACGAT CACCARACGCT TTTAACAACG CCTCTAACTC TACGGCTAAT 2400

ATTGATGGTA ATTTCACCTT AAACCAACAA GCGACTTTAA GCACTAACGC TAGTGGTITG 2460 2216102166 GGAATTTTAA TAGCTATGGC GATTTGGTGT TTAACCTCAG TCATTCAGTT 2520

AGTCATGCTA TTATCAATAC TCAAGGCACA GCGACGATCA TGGCCAATAA TAACCCTTTG 2580

ATCCRATTCA ACGCTTCTTC AAAAGAAGTG GGTACTTACA CGCTGATTGA TAGCGCTAAA 2640

GCCATTTATT ACGGGTATAA CAACCAAATC ACAGGAGGCA GTAGCCTGGA TAATTACCTT 2700 2260111216 CGCTCATTGA TATTAATGGC AAGCACATGG TGATGACTGA CAACGGCTTA 2760

ACCTATAACG GGCAAGCCGT GAGCGTTAAA GATGGCGGTT TAGTTGTAGG CTTTAAGGAC 2820

TCTCAAAATC AATACATTTA CACTTCCATT CTTTATAATA AAGTGAAAAT CGCTGTTTTCT 2880

AATGATCCTA TCAATAACCC ACAAGCCCCC ACTTTAAAAC AATATATCGC TCAAATTCAG 2940

GGCGTTCAAA GCGTGGATAG CATCGATCAA GCTGGGGGAA ATCAAGCGAT TAATTGGCTC 3000

AATAAAATCT TTGAAACTAA AGGAAGCCCT TTATTCGCTC CCTATTATCT AGAGAGCCAC 3060

TCCACRAAAAG ATTTAACCAC GATCGCTGGA GATATTGCTA ACACTTTAGA AGTCATCGCT 3120

ARCCCTAATT TTAAAAATGA CGCCACTAAT ATTTTACAGA TCAAGACCTA CACGCAGCAA 3180

ATGAGTCGTT TAGCCAAGCT CTCTGACACT TCAACTTTCG CCCGTTCTGA TTTCTTAGAA 3240

CGCTTAGAAG CCCTTAAARAA CAAGCGATTC GCTGATGCGA TCCCTAACGC TATGGATGTG 3300

ATTTTAAAAT ACTCTCAAAG GAATAGAGTT ARAAATAATG TGTGGGCGAC AGGAGTTGGA 3360

GGGGCTAGTT TCATTAGTGG AGGTACTGGA ACTTTATATG GTATCAATGT AGGGTATGAT 3420

AGGTTTTATTA AGGGCGTGAT TGTGGGAGGT TATGCCGCTT ATGGGTATAG CGGGTTCCAT 3480

GCAAACATCA CTCAATCAGG CTCTAGCAAT GTCAATGTGG GCGTTTTATAG CCGAGCGTTT 3540

ATCAAAAGAA GCGAGCTAAC CATGAGCTTG AATGAGACTT GGGGATACAA TAAAACTTTC 3600

ATCAACTCCT ATGACCCCCT ACTCTCAATC ATCAATCAGT CTTACAGATA CGACACTTGG 3660

ACGACTGACG CTAAARATCAA TTATGGCTAT GATTTCATGT TTAAAGATAA AAGCGTTATT 3720

TTTAAACCCC AAGTAGGCTT AARGCTATTAT TACATTGGTT TGTCTGGTTTT AAGGGGCATT 3780

ATGGATGATC CTATTTACAA CCAATTCAGA GCCAATGCTG ACCCTAATAA AAAATCCGTT 3840

CTAACGATCA ATTTTGCCCT AGAAAGTCGG CATTATTTCA ATAAAAACTC TTATTATTTT 3900

GTGATTGCGG ATGTGGGCAG AGACTTATTC ATTAATTCTA TGGGGGATAA AATGGTGCGT 3960

TTCATCGGTA ATAACACCCT AAGCTATAGA GATGGTGGCA GATACAACAC TTTTGCTAGC 4020

ATTATCACAG GCGGGGAGAT AAGATTGTTC AARAACCTTTT ATGTGAATGC GGGCATAGGG 4080

GCTAGGTTTG GGCTTGATTA TARAGATATT AATATTACCG GARATATTGG TATGCGCTAT 4140

9: AA 501111 PM 1 4149 (2) INFORMATION FOR SEQ ID NO:59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 789 base pairs (B) TYPE: nucleic acid ; (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori ( ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...789 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

ATGAAAAAARN TTGGTTTGAG 0116161116 GTTTTGAGTT TGGGTTTTTT AAAAGCCCAT 60

GAAGTGAGCG CTGAAGAGAT TGCGGATATT TTCTACAAAC TCAACGCCAA AGAGCCTAAA 120

ATGAAAATCA ACCACACGAA GGGGTTTTGC GCTAAAGGCG TGTTCCTCCC TAACCCGCAA 180

GCAAGAGAGG ATTTAGAGGT GCCACTACTC AATGAAAAAAG AAATCCCCTGC GTCTCTAAGG 240

TATTCTTTAG GGGGCGTGGC GATGGACGAT AAAAGCAAGG TTAGGGGAAT GGCGTTAAAA 300

CTAGAAAATC AARAACGCTAG TTGGACAATG GTGATGCTCA ATACAGAAAT CAATTTTGCC 360

AAAAACCCTG AAGAATTCGC CCAATTTTTT GAAATGAGAC TTCCTAAAAA TGGCAAGGTA 420

GATGAAGCAA GAATCAAAAA GCTTTACGAA GAAGTCCCCT CTTATAGGARA TTTTGCCGCC 480

TATATGAAAA CGATAGGGAT TAGCTCAAGC GTGGCTAATA CGCCTTATTA TAGCGTGCAT 540

GCGTTCAAGT TTAAAGATAA GAAAGAAAAA TTATTGCCTG CGAGGTGGAA ATTTGTGCCT 600

AAAGAGGGCG TTAAATACTT AAATCCTCAA GAATTAAAGC AAAAAGATTC AAATTATCTG 660

CTCTCTTCAT TCCAACAACA CCTTAAAAAT AAACCCATAG AATACCAAAT GTATTTGGTG 720

TTTGCGAATC AAAATGATGC CACCAACGAC ACGACCGCGC TTTGGAAAGG CAGCATAAGG 780

AATTATTAG 789 (2) INFORMATION FOR SEQ ID NO:60: (i) SEQUENCE CHARACTERISTICS: E (A) LENGTH: 741 base pairs (B) TYPE: nucleic acid , (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO 7 (iv) ANTI-SENSE: NO / (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature

(B) LOCATION 1...741 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

ATGAAACAAT TTAAAAAGAA ACCAAAAAAG ATAAAACGAT CGCATCAAAR TCAAAAARACA 60

ATCTTAAARGC GTCCTTTATG GCTTATGCCT TTACTGATTG GCGGGTTTTGC TAGTGGGGTG 120

TATGGGATG GAACAGACAT TTTGGGGCTT AGTTGGGGGG AARAAAGCCA AAAGGTATGC 180 ,

GTGCATCGTC CATGGTATGC TATATGGAGT TGCGATRAAT GGGAGGAAAA AAACACAACAA 240

TTTACAGGAA ACCAACTCAT CACAAAAACT TGGGCAGGGG GTAATGCGGC TAACTACTAC 300

CACTCTCAAA ACAACCAAGA CATCACAGCC AATTTAAAAA ATGATAACGG CACTTATTTT 360

TTAAGCGGTC TGTATAACTA CACCGGAGGG GAATATAATG GGGGGAATTT AGACATTGAA 420

TTAGGCAGTA ACGCTACTTT TAATCTAGGT GCGAGTAGTG GGAATAGCTT CACTTCTTGG 480

TATCCTAATG GGCATACTGA TGTTACTTTT AGCGCTGGGA CTATCAATGT GAATAACAGC 540

GTAGAAGTGG GCAATCGTGT GGGATCGGGA GCTGGCACGC ACACCGGCAC AGCCACTTTA 600

AACTTGAACG CTAATAAGGT TACTATCAAT TCCAATATCA GCGCGTATAA AACTTCGCAA 660

GTGAATGTAG GCAATGCTAA CAGCGTTATT ACCATTAATT CGGTTTTCTTT AAATGGGGAA 720

TACTTGCAGT TCTTTAGCTA G 741 (2) INFORMATION FOR SEQ ID NO:61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 738 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...738 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

ATGATAARAA AGACCCTTGC ATCGGTTTTA TTAGGATTGA GTTTGATGAG TGTGTTAAAT 60

GCCAAAGAAT GCGTTTCGCC CATAACAAGA AGCGTTAAGT ATCATCAGCA AAGTGCTGAG 120

ATCAGAGCCT TGCAATTACA AAGTTACAAA ATGGCGAAAA TGGCGCTAGA CAATAACCTT 180

AAGCCGTTA AAGACAAAAR GCCAGCCGTC ATCTTGGATT TAGATGAAAC CGTTTTGAAC 240

ACTTTTGATT ATGCGGGCTA TTTAGTCAARA AACTGCATTA AATACACCCC AGAAACTTGG 300

GATAAATTTG AAAAAGAAGG CTCCTTACG CTCATTCCTG GAGCGCTAGA CTTTTTAGAA 360

TACGCTAATT CTAAGGGCGT TAAGATTTTT TACATTTCTA ACCGCACCCA AAAARAATAAG 420

GCATTCACTT TAAAAACGCT CAAAAGCTTT AAGCTCCCCC AAGTGAGTGA AGAATCCGTT 480

TTGTTAAAGG AAAAAGGCAA GCCTAARAGCC GTAGGCGGG AGTTAGTCGC TAAGGATTAT 540

GCGATTGTTT TACAAGTGGG CGACACTTTG CATGATTTTG ACGCCATTTT TGCTARAGAC 600

GCTAAAAACA GCCAAGAACA ACAAGCCAAA GTCTTGCAAA ACGCTCAAAA ATTCGGCACA 660

GAATGGATCA TTTTACCCAA CTCTCTTTAT GGCACATGGG AAGATGGGCC TATAAAAGCA 720

TGGCAAAATA AAAAATAA 738 {2) INFORMATION FOR SEQ ID NO:62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 867 base pairs

Y.0 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO’ (iv) ANTI-SENSE: NO . (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...867 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

TTGTGGTGTT TAAAAACCCC TATCATAGGG CATGGCATGA AGAAAAAAGC AAAAGTCTTTT 60

TGGTGTTGTT TTAAAATGAT TCGTTGGTTG TATTTGGCGG TCTTTTTTTT GTTGAGCGTA 120

TCAGACGCTA AAGAAATCGC TATGCAACGA TTTGACARAC AAAACCATAA GATTTTTGAA 180

ATCCTTGCGG ATAAAGTGAG CGCCAAAGAC AATGTGATAA CCGCCTCAGGE GAATGCGATC 240

CTATTGAATT ATGACGTGTA TATTCTAGCG GATAAGGTGC GTTATGACAC CAAGACTAAA 300

GAAGCGTTAT TAGAAGGCAA TATTAAGGTT TATAGGGGCG AGGGCTTGCT CGTTAAAACC 360

GAATTATGTGA AATTGAGTTT GAACGAAAAA TATGAGATCA TTTTCCCCTT TTATGTCCARA 420

GACAGCGTGA GCGGGATTTG GGTGAGCGCG GATATTGCTA GCGGGAAGGA TCAAAAATAT 480

AAGATTARAAA ACATGAGCGC TTCAGGGTGC AGCATTGACA ACCCCATTTG GCATGTCAAT 540

GCGACTTCAG GCTCATTTAA CATGCAARAAA TCGCATTTGT CAATGTGGAA TCCTAAGATT 600

TATGTCGGCG ATATTCCTGT ATTGTATTTG CCCTATATTT TCATGTCCAC GAGCAATAAA 660

AGAACTACCG GGTTTTATA CCCTGAGTTTT GGCACTTCCA ACTTAGACGGE CTTTATTTAT 720

TTGCAACCCT TTTATTTAGC CCCCAAARAC TCATGGGATA TGACCTTTAC CCCACAAATC 780

CGTTACAARA GGGGTTTTGG CTTGAATTTTT GAAGCGCGCT ACATCAACTC TAAGACGCAG 840

GTTTTTATTC AATGCGCGCT ATTTTAG 867 (2) INFORMATION FOR SEQ ID NO:63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 387 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) ,{1ii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 1...387 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: 1162161112 AAAAAATGTG TTTGAGCCTG CTAATGATAA GCGRTGTTTG TGTGGGGGCA 60

AAGGATTTGG ATTTCAAGCT GGATTATCGC 300201735936 GGAAATTCAT GGGGARAATG 120

ACGGACTCTA GTCTTTTAAG TATCACTTCT ATGAACGATG AACCGGTGGT GATTAAAAAC 180

CTTATTGTCA ATAGGGGAAA TTCATGCGAA GCGACTAAAA AAGTAGAACC CAAATTTGGC 240

GATAAGTTTA AARAAGAAAA ACTCTTTGAT CATGAATTAA AATACTCGCA ACAGATATTT 300

TACCGCCTGG ATTGCAAGCC TAACCAATTG TTAGAAGTTA AAATCATCAC GGACAAGGGC 360

GAATATTACC ATAAATTTTC CAAATAG $387 (2) INFORMATION FOR SEQ ID NO:64: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 510 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double {D) TOPOLOGY: circular ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 1...510 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

ATGCAAGCGT TAAAATCATT GCTTGAAGTG ATTACAAAAC TCCAGAATCT AGGCGECTAT 60

TTGATGCATA TAGCTATTTT CATCATTTIT ATTTGGATTG GAGGGCTTAA GTTTGTGCCT 120

TACGAAGCTG AAGGGATCGC CCCTTTTGTG GCCAACTCCC CTTTCTTTTC TTTCATGTAT 180

ARATTTGAAA AACCTGCATA CAAACAACAC AAAATGTCTG AATCCCAATC CATGCAAGAA 240

GAAATGCAAG ATAACCCTAA AATCGTTGAA AACAAAGAAT GGCATAAAGA AAACCGCACT 300

TATTTAGTGG CTGAAGGTTTT AGGGATTACG ATCATGATCC TAGGCATTTTT GGTGCTTTTG 360

GGGCTTTGGA TGCCTTTAAT GGGCGTAGTT GGGGGCTTGC TTGTCGCTGG AATGACGATC 420

ACCACCCTAT TCTTTTTTAT TCACARACGCC AGAAGTGTTTT GTCAATCAGC ATTTCCCATG 480

GCTTCTCTGGG GCTGGAAGGC TAGTGGTTAA 510 (2) INFORMATION FOR SEQ ID NO:65: (i) SEQUENCE CHARACTERISTICS: : (A) LENGTH: 1464 base pairs (B) TYPE: nucleic acid 1 ) STRANDEDNESS: double (D) TOPOLOGY: circular . (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A) NAME/KEY: misc_feature

Y.v (B) LOCATION 1...1464 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65: 35 ATGATTGAAT GGATGCAAAA TCATAGAAAAG TATTTAGTGG TTACGATATG GATAAGCACG 60

ATCGCTTTTA TTGCCGCCGG AATGATAGGT TGGGGGCAAT ACAGCTTTTC TTTAGATAGC 120

GATAGCGCTG CCAAAGTGGG ACAGATTAAG ATTTCTCAAG AAGAATTAGC CCAAGAATAC 180

CGCCGCCTTA AAGACGCCTA TGCTGAGTCT ATCCCTGATT TTAAAGAACT CACCGAAGAT 240°

CAAATCAAAG CCATGCATTT AGAAAAAAGC GCGCTAGATT CGCTCATCAA TCAAGCTTTA 300

TTGAGGAATT TCGCTTTAGA TTTAGGGCTT GGTGCTACCA AGCAAGAAGT GGCCAAAGAG 360

ATCAGAAAAA CGAACGTTTT TCAAAAAGAT GGCGTTTTTG ATGAAGAATT GTATAAAAAT 420

ATCTTAAAAC ARAGCCATTA CCGCCCCAAG CATTTTGAAG ARAGCGTTGA AAGGCTTTTA 480

ATCCTTCAA AAATCAGGCGC TCTATTTCCCC AARACCACCA CCCCTTTGGA GCAATCCAGT 540

CTATCGCTTT GGGCAAAATT GCAAGACAAA TTAGACATTC TTATCCTAAA TCCTAATGAT 600

GTTAARATCT CTCTCAATGA AGAAGAGATG AAAAAATATT ATGAAAACCA TAGAAAAGGAT 660

TTTAAARAGC CCACARGCTT TAAAACACGC TCTTTATATT TTGACGCTAG TTTAGAAAARA 720

ACTGATTTGA AAGAGTTGGA GGAATACTAC CATAAARACA AGGTGTCTTA TTTGGACAAA 780

GAGGGGAAAT TACAGGATTT TAAAAGCGTT CAAGAGCAAG TCAAGCATGA TTTAAAACATG 840

CAAMAGGCGA ATGAAAAAGC CTTAAGGAGC TATATCGCTC TAAAAAAGGG GARCGCACAA 900

AACTACACCA CGCAAGATTT TGAAAAAAAC AACTCCCCCT ATACTGCTGA AATCACGCAR 960

AAACTCACCG CTCTCAAGCC CCTTGAAGTC CTAAAACCAG AGCCTTTTAA AGATGGTTTT 1020

ATCGTGGTGC AGCTTGTCTC TCAAATTARA GACGAATTGC AAAATTTTTGA TGAAGCCAAA 1080

AGCGCTCTTA AAACCCGTCT GACTCAAGAA AAAACCCTTA TGGCGTTGCA AACTTTAGCT 1140

AAAGAAAAGC TTAAGGATTT TAAAGGGAAA AGCGTGGGTT ATGTAAGCCC TAATTTTGGA 1200

GGCACTATCA GTGAACTTAA CCAAGAAGAG AGCGCGAAGT TTATCAACAC CCTTTTTRAC 1260

CGCCAGGAAA AAAAAGGGTT TGTAACCATA GGTAATAAAG TGGTGCTTTTA TCAAATCACA 1320

GAGCAARATT TCAATCACCC CTTTAGTGCA GAAGAAAACC AATACATGCA GCGTTTAGTC 1380

AATAACACTA AAACGGATTT TTTTGATAAA GCGTTGATAG AAGAATTGAA AAAACGCTAT 1440

AAGATAGTCA AATACATTCA ATAA 1464 : (2) INFORMATION FOR SEQ ID NO:66: {i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 429 base pairs (B) TYPE: nucleic acid {C) STRANDEDNESS: double (D) TOPOLOGY: circular ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO . {vi) ORIGINAL SOURCE: ; (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...429 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

ATGAAAACGA ACTTTTATAA AATTAAATTA CTATTTGCTT GGTGTCTTAT CATTGGCATG 60

TTTAACGCTC CGCTTAACGC TGACCAAAAC ACGGATATAA AAGATATTAG TCCTGAAGAT 120

ATGGCGCTAA ATAGCGTGGG GCTTGTTTTCT AGAGATCAGC TAAAAATAGA GATCCCTAAA 180

GAAACCCTAG AGCAAAAAGT GGCCATACTC AATGACTATA ATGATAAGAA TGTTAATATC 240

AAGTTTGACG ACATAAGTTT AGGGAGTTTC CAACCTAATG ATAATCTAGG TATCAATGCG 300

ATGTGGGGCA TTCAAAATCT TCTCATGAGC CAAATGATGA GCAATTACGG TCCAAACAAT 360

Y.A

TCTTTTCATGT ATGGCTATGC GCCAACATAC TCAGATTCAT CGTTTTACC ACCGATCTTA 420

GGGTATTAA 429 (2) INFORMATION FOR SEQ ID NO:67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 627 base pairs ; (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: ( A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...627 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

TTGATCAACA ATAATAATAA CAATAAAAAA CTGAGAGGCT TTTTTTTGAA AGTTCTCTTA 60

AGTCTCGTTG TTTTCAGTTC GTATGGGTCA GCAAATGACG ATAAAGAAGC CAAAAAAGRA 120

GCGCTAGAAA AAGAAAAAAA CACTCCCAAT GGGCTTGTTT ATACGAATTT AGATTTTGAT 180

AGTTTTARAG CGACTATCAA ARATTTGAAAR GACAAGAAAG TAACTTTCAA AGAAGTCAAT 240

CCCGATATTA TCAAAGATGA AGTTTTTGAC TTCGTGATTG TCAATAGAGT CCTTAAAARA 300

ATARAGGATT TGAAGCATTA CGATCCAGTT ATTGAAAAAA TCTTTGATGA AAAGGGTAAA 360

GAAATGGGAT TGAATGTAGA ATTACAGATC AATCCTGAAG TGAAAGACTT TTTTACTTTC 420

AARAGCATCA GCACGACCAA CAAACAACGC TGCTTTCTAT CATTGCACGG AGAAACBAAGA 480

GABATTTTAT GCGATGATAA GCTATATAAT GTTTTATTGG CCGTATTCAA TTCTTATGAT 540

CCTAATGATC TTTTGAAACA CATTAGCACC ATAGAGTCTC TCAAARAAAAT CTTTTATACG 600

ATTACATGTG AAGCGGTATA TCTATAA 627 (2) INFORMATION FOR SEQ ID NO:68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 738 base pairs 1 (B) TYPE: nucleic acid - (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...738

Y.A + ~N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

ATGGCAGGCA CACAAGCTAT ATATGAATCA TCTTCTGCAG GATTCTTATC GCAAGTCCTCC 60

TCAATCATCT CAAGCACAAG TGGTGTCGCA GGGCCATTTG CAGGAATAGT AGCGGGCGCT 120

ATGACAGCAG CGATTATTCC TATTGTTGTG GGATTTACTA ATCCGCAAAT GACCGCTATC 180

ATGACCCAAT ACAATCAAAG CATCGCTGAA GCTGTAAGCG TGCCTATGAA AGCCGCTAAC 240

CAACAATACA ACCAATTGTA TCAAGGTTTT AACGATCAAA GCATGGCTGT GGGGAACAAT 300 ,

ATCTTAAATA TCAGCAAATT AACAGGGGAA TTTAACGCGC AAGGCAACAC GCAAAGCGCE 360

CAAATTAGTG CTGTCAATAG TCAGATTGCA AGCATTTTAG CGAGTAACAC TACCCCTAAA 420

AATCCTAGCG CTATTGAAGC TTATGCGACG AATCARATCG CTGTTCCTAG CGTGCCAACA 480

ACGGTTGAAA TGATGAGCGG TATATTAGGC AATATTACAA GCGCAGCACC AAAATACGCC 540

CTAGCTCTAC AAGAGCAACT GCGTTCTCAA GCAAGCAACA GCTCAATGAA TGATACAGCC 600

GATTCCCTTG ATAGCTGTAC CGCTTTAGGC GCACTTGTTG GCTCATCAAA AGTGTTTTTC 660

AGTTGCATGC AAATTTTCTAT GACTCCTATG AGTGTTTCTA TGCCCACTGT TATGCCAAAT 720

ACCAGCGGTT GCCACTAR 738 (2) INFORMATION FOR SEQ ID NO:69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1104 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...1104 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

ATGATTAARA GCGTAGAGAT TGAAAATTAC AAAAATTTTG AGCACCTTAA AATGGAAAAT 60

TTTAAACTCA TCAACTTTTT TACCGGTCAA AACGATGCGG GTAAAACCAA TCTTTTAGAA 120

GCTCTTTATA CCAACACAGG CCTTTGTGAT CCTACTGCCA ATCAAGTCAG TCTTCCTCCT 180

GAACATGCCG TGAATATTAG TGAATTCAGA AAAATCAAAC TCGATGCCGA CAACCTAAAA 240 } ACCTTTTTTT ATCAAGGAAA CACCGCTAAT CCCATTAGTA TCCGCACTGA ATTTGAACAT 300

GCTACTATCC CTCTTACTAT CCAATACCCC ACACAAACCA GTTACAGCAA AGACATCAAT 360

TTGAATAGCG ATGATGCTCA TATGACAAAC CTTATAAACA CAACAATAAC GAAGCCACAG 420

CTCCAATTTT CCTACAATCC ATCCCTTTCC CCCATGACAA TGACTTATGA ATTTGAAAGG 480

CAAAACCTAG GTTTAATCCA TTCTARATTTA GATAAAATCG CTCAAACCTA TAAAGARAAT 540

GCGATGTTTA TTCCTATAGA ATTATCTATT GTTAATTCTC TTAAAGCATT GGAAAATTTA 600

CAATTAGCAA GCAAAGAAAA AGAATTGATT GAAATCCTAC AATGTTTCAA CCCTAATATT 660

TTARATGCTA ATACAATAAG AAAGTCTGTC TATATCCAAA TCAAAGATGA AAACACACCG 720

CTAGAAGAAA GTCCCAAAAG GCTTTTAAAT TTGTTTGGTT GGGGTTTTAT CAAATTCTTT 780

ATTATGGTGA GCATTCTTAT AGACAATCGT GTCAAGTATC TTTTTATTGA TGAAATAGAA 840

AGCGGTTTGC ACCATACAAA AATGCAAGAG TTTTTAAAAG CTCTGTTTAA GTTAGCTCAA 900

AAATTACAGA TTCAAATTTT TGCCACCACG CACAATAAGG AATTTTTATT AAACGCCATC 960

AACACGATAT CCGATAATGA AACGGGAGTT TTTAAAGACA TAGCCTTGTT TGAGCTTGAA 1020

ARAGAAAGCG CTTCTGGCTT TATCAGACAC AGCTATTCTA TGCTAGAAAA AGCGCTTTAT 1080

AGGGGTATGG AGGTTAGAGG CTGA 1104

(2) INFORMATION FOR SEQ ID NO:70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1230 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1. ..1230 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

ATGTCCTTGA TTAGAGTGAA TGGGGAAGCT TTTAAACTCT CTTTGGAAAG TTTAGAAGAA 60

GATCCTTTTG AAACTAAAGA AACGCTAGAA ACGCTAGAAA CGCTTATCAA ACAAACGAGC 120

GTTGTTTTAT TGGCCGCTGG GGAGTCTAAG CGTTTTTCTC GTGCGATTAA AAAGCAGTGG i80

CTACGCTCTC ACCACACCCC CTTATGGCTC AGCGTGTATG AAAGCTTTAA AGAAGCCCCTA 240

GACTTTAAGG AAGTCATTCT AGTTGTAAGC GAATTGGATT ATGTTTTATAT CCAACGCCAT 300

TACCCCAAAA TCAAGCTTGT AAAAGGCGGG GCATCAAGGC AAGAATCCGT GCGTAACGCT 360

TTGAAAGTAA TTGATAGCAC TTACACGATC ACCAGCGATG TGGCTAGGGE TTTAGCGAAT 420

ATGGAAGCGC TTAAAAGCTT GTTTTTAACC CTCCAACAAA CGAGCCATTA TTGCATCGCC 480

CCTTACTTGC CTTGCTATGA CACAGCGATC TATTATAACG AGGCTTTAGA TAGAGAAGCG 540

ATCAAACTCA TTCAAACCCC GCAATTAAGC CACACCAAAA CGCTCCAATC AGCCCTRAAAC 600

CAAGGGGGTT TTAAAGATGA AARGCAGCGCG ATTTTACAAG CTTTCCCTAA CTCTGTGAGC 660

TATATTGAAG GCAGTAAGGA TTTGCACAAA CTCACCACARA 0000022777 AAAGTTTTTT 720

ACGCCTTTTT TTAACCCAGC AAAGGACACT TTTATAGGCA TGGGTTTTGA TACGCATGCG 780

TTCATTAAAG ATAAGCCTAT GGTTTTAGGG GGGGTTGTTT TGGATTGCGA GTTTGGGTTA 840

ARGGCTCATA GCGATGGCGA TGCTTTATTG CATGCGGTTA TTGATGCGAT TTTAGGAGCG 900

ATTARAGGGG GGGATATTGG CGAATGGTTC CCTGATAATG ACCCCAAATA CAAAMACGCC 960

TCTTCTAAAG AGCTTTTAAA AATCGTGTTG GATTTTTCTC AAAGCATTGG GTTTGAATTG 1020

CTTGAAATGG GAGCGACCAT CTTTAGCGAA ATCCCTAAAA TCACTCCTTA CAAACCGGCG 1080

ATTTTAGAGA ATTTGAGCCA ACTTTTGGGT TTAGAAAAAT CTCAAATCAG CTTGAAAGCC 1140

ACTACAATGG AAAAAATGGGTTCATTGGC AAACAAGAAG GGCTGTTAGT CCARAGCGCAT 1200

GTGAGCATGC GTTATAAACA AAAACTTTARZA 1230 (2). INFORMATION FOR SEQ ID NO:71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 813 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (I) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

11 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...813 ‘ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: :

ATGAAAAAGT TTGTAGCTTT AGGGCTTCTA TCCGCGGTTT TAAGCTCTTC GTTGTTAGCC 60

GAAGGTGATG GTGTTTTATAT AGGGACTAAT TATCAGCTTG GACAAGCCCG TTTGAATAGC 120

AATATTTATA ATACAGGGGA TTGCACAGGG AGTGTTGTAG GTTGCCCCCC AGGTCTTACC 180

GCTAATAAGC ATAATCCAGG AGGCACCAAT ATCAATTGGC ACTCCAAATA CGCTAATGGG 240

GCTTTGAATG GTTTTGGGTT GAATGTGGGT TATAAGAAAT TCTTCCAATT CAAGTCGCTA 300

GATATGACAA GCAAGTGGTT TGGTTTTAGA GTGTATGGGC TTTTTGATTA CGGGCATGCC 360

GATTTAGGTA AACAAGTTTA TGCACCTAAT AAAATCCAGT TGGATATGGT CTCTTGGGGT 420

GTGGGGAGCG ATTTGTTAGC TGATATTATT GATAAAGACA ACGCTTCTTT TGGTATTTTT 480

GGTGGEGTCG CTATCGGCGG TAACACTTGG AAMAGCTCTG CAGCAAACTA TTGGAAAGAG 540

CAAATCATTG AAGCCAAAGG TCCTGATGTT TGTACCCCTA CTTATTGTAA CCCTAATGCC 600

CCTTATAGCA CCAACACTTC AACCGTCGCT TTTCAAGTGT GGTTGAATTT TGGGGTGAGA 660

GCCAATATCT ACAAGCATAA TGGCGTGGAA TTTGGCGTGA GAGTGCCGCT ACTCATCAAT 720

AAATTTTTTGA GCGCGGGTCC TAACGCTACT AACCTTTATT ACCATTTGAA ACGGGATTAT 780

TCGCTTTATT TGGGGTATAA CTACACTTTT TAA 813 (2) INFORMATION FOR SEQ ID NO:72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature . (B) LOCATION 1...1317 . (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

ATGGCTTACA AACCTAACAA AAAGAAGTTA AAAGAATTAA GAGAGCAACC GAATTTATTIT 60

AGCATCTTAG ATAAGGGCGA TGTTGCAACA AACAATCCTG TTGAAGAGTC AGACAAGGCC 120

AATAARATAC AAGAGCCACT CCCTTATGTC GTGAAAACGC AAATCAATAA AGCARGCATG 180

ATTTCTAGAG ATCCTATTGA ATGGGCAAAG TATTTAAGCT TTGAAAAACG AGTCTATAAG 240

GATAATAGTA AAGAAGATGT CAATTTCTTT GCCAATGGTG AGATAAAAGA AAGTTCTCGT 300

GTTTATGAAG CGAATAAAGA AGGGTTTGAA AGGCGCATCA CTAAAAGATA CGATCTGATT 360

GATAGAAATA TTGATAGAAA TAGAGAATTT TTTATAARAG AAATTGAAAT TCTAACCCAC 420

ACARACAGCT TAARAGAATT GARAGAGCAA GGGTTAGAAA TCCAATTGAC CCACCATAAT 480

GAAACGCATA AGAAAGCCTT AGAAARATGGC AATGAAATCG TTAAAGAATA CGACCATCTT 540

AAAGATATTT ACCAAGAAGT AGAAAGAAACA AAAGATGGTG GATTGGTAAG AGAAATAATC 600

CCCAGTATTT CTAGCGCTGA GTATTTCAAG CTTTACAACA AACTGCCTTT TGAATCARATA 660

AACAATGAAA ATACCAAACT GAATACTAAC GACAATGAAG AAGTTAAAAA ACTAGAATTT 720

GAATTAGCTA AAGAAGTGCA TATTTTAATC CTAGAGCAAC AATTGCTTTC AGCAACAAAT 780

TATTATTCTT GGATAGATAA AGATGATAAT GCGAATTTTG CTTGGAAAAT GCATAGGCTT 840

ATCAATGAAA ATAAACTCAA AGAAAACCAT CTCAGCGCCA ATAACGCTAA TBAGATTAAG 900

CAATTTTTCT TTAATAATGG TTCTATTTTA GGCTGGACTA AAGAAGAACA AAGCGCTATA 960

CAAGAAAACA GAGATTATTC TTTAAGARGC GCTCTTTTAA GTTTAGAAGA AATCGCTCAA 1020

GCAAAAATTG AATTGCAAAA ATACTATGAA AGCGTTTATG TTAATGGTGA TGGGAATAAA 1080

AGAGAAATCA AGCCTTTTAA AGAAATTTTA AGAGACACCA ACAATTTTGA AAAAGCTTAT 1140+

AAGGAGCGTT ATGACAAATT GGTAAGCTTG AGTGCAGCAA TCATTCAAGC TAAAGAGGGT 1200

GGTAATGAGC GACCAAATTC TAGTGCAAAT AACAATAACC CTATTAAAAA TACAATAGAG 1260

ACTAATACTT CTAACAATAT TATTCAAAAT AATGATAATA TAATCATCCA AATTTAA 1317 (2) INFORMATION FOR SEQ ID NO:73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 648 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: (ii) MOLECULE TYPE: circular (genomic) DNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO 25 . (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...648 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

ATGCAAGCGT TAAAATCATT GCTTGAAGTG ATTACAAAAC TCCAGAATCT AGGCGGCTAT 60

TTGATGCATA TAGCTATTTT CATCATTTTT ATTTGGATTG GAGGGCTTAA GTTTGTGCCT 120

TACGAAGCTG AAGGGATCGC CCCTTTTGTG GCCARCTCCC CTTTCTTTTC TTTCATGTAT 180

ABATTTGARA AACCTGCATA CAAACAACAC AAAATGTCTG AATCCCAATC CATGCAAGAA 240

GRATGCAAG ATAACCCTAA AATCGTTGAA AACAAAGAAT GGCATAAAGA AAACCGCACT 300

TATTTAGTGG CTGAAGGTTTT AGGGATTACG ATCATGATCC TAGGCATTTTT GGTGCTTTTG 360

GGGCTTTGGA TGCCTTTAAT GGGCETAGTT GGGGGCTTGC TTGTCGCTGG AATGACGATC 420

ACCACCCTAT CTTTTTTATT CACAACGCCA GAAGTGTTTG TCAATCAGCA TTCCCATGG 480

CTTTCTGGGG CTGGAAGGCT AGTGGTTARA GACTTGGCGT TATTTGCTGG AGGCTTGTTT 540

GTGGCCGGAT TTGATGCGAA ACGCTATTTG GAGGGTAAAG GGTTTTGCTT GATGGACCGC 600

TCATCGGTAG GGATTAAAAC TAAATGCTCT AGCGGGTGTT GCTCTTAA 648 (2) INFORMATION FOR SEQ ID NO:74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 186 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

YAY

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...186 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: For Met Ile Lys Arg Ile Ala Cys Ile Leu Ser Leu Ser Ala Ser Leu Ala 1 5 10 15

Leu Ala Gly Glu Val Asn Gly Phe Phe Met Gly Ala Gly Tyr Gln Gln 20 25 30

Gly Arg Tyr Gly Pro Tyr Asn Ser Asn Tyr Ser Asp Trp Arg His Gly 35 40 45

Asn Asp Leu Tyr Gly Leu Asn Phe Lys Leu Gly Phe Val Gly Phe Ala 50 55 60

Asn Lys Trp Phe Gly Ala Arg Val Tyr Gly Phe Ley Asp Trp Phe Asn 65 70 75 80

Thr Ser Gly Thr Glu His Thr Lys Thr Asn Leu Leu Thr Tyr Gly Gly 85 90 95

Gly Gly Asp Leu Ile Val Asn Leu Ile Pro Leu Asp Lys Phe Ala Leu 100 105 110

Gly Leu Ile Gly Gly Val Gln Leu Ala Gly Asn Thr Trp Met Phe Pro 115 120 125

Tyr Asp Val Asn Gln Thr Arg Phe Gln Phe Leu Trp Asn Leu Gly Gly 130 135 140

Arg Met Arg Val Gly Asp Arg Ser Ala Phe Glu Ala Gly Val Lys Phe 145 150 155 160

(2) INFORMATION FOR SEQ ID NO:75: (i) SEQUENCE CHARACTERISTICS: (A ) LENGTH: 116 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...116 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Leu Met Arg Ile Ile Ile Arg Leu Leu Ser Phe Lys Met Asn Ala Phe 1 5 10 15

Leu Lys Leu Ala Leu Ala Ser Leu Met Gly Gly Leu Trp Tyr Ala Phe 20 25 30

Asn Gly Glu Gly Ser Glu Ile Val Ala Ile Gly Ile Phe Val Leu Ile 35 40 45

Leu Phe Val Phe Phe Ile Arg Pro Val Ser Phe Gln Asp Pro Glu Lys

50 55 60

Arg Glu Glu Tyr Ile Glu Arg Leu Lys Lys Asn His Glu Arg Lys Met 65 70 75 80

Ile Leu Gln Asp Lys Gln Lys Glu Glu Gln Met Arg Leu Tyr Gln Ala 85 90 95

Lys Lys Glu Arg Glu Ser Arg Gln Lys Gln Asp Leu Lys Glu Gln Met 100 105 110 ;

Lys Lys Tyr Ser 115 (2) INFORMATION FOR SEQ ID NO:76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 345 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...345 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Met Val Lys His Tyr Leu Phe Met Ala Val Ser Gln Val Phe Phe Ser 1 5 10 15

Phe Phe Leu Val Leu Phe Phe Ile Ser Ser Ile Val Leu Leu Ile Ser 20 25 30

Ile Ala Ser Val Thr Leu Val Ile Lys Val Ser Phe Leu Asp Leu Val 35 40 45

Gln Leu Phe Leu Tyr Ser Leu Pro Gly Thr Ile Phe Phe Ile Leu Pro 50 55 60

Ile Thr Phe Phe Ala Ala Cys Ala Leu Gly Leu Ser Arg Leu Ser Tyr ss 70 75 80

Asp His Glu Leu Leu Val Phe Phe Ser Leu Gly Val Ser Pro Lys Lys 85 90 95

Met Thr Lys Ala Phe Val Pro Leu Ser Leu Leu Val Ser Ala Ile Leu 100 105 110

Leu Ala Phe Ser Leu Ile Leu Ile Pro Thr Ser Lys Ser Ala Tyr Tyr 1 115 120 125

Gly Phe Leu Arg Gln Lys Lys Asp Lys Ile Asp Ile Asn Ile Arg Ala 130 135 140

Gly Glu Phe Gly Gln Lys Leu Gly Asp Trp Leu Val Tyr Val Asp Lys 5 150 155 160

Thr Glu Asn Asn Ser Tyr Asp Asn Leu Val Leu Phe Ser Asn Lys Ser 165 170 175

Leu Ser Gln Glu Ser Phe Ile Leu Ala Gln Lys Gly Asn Ile Asn Asn 180 185 130 Duration Asn Gly val Phe Glu Leu Asn Leu Tyr Asn Gly His Ala Tyr Phe 195 200 205

Thr Gln Gly Asp Lys Met Arg Lys Val Asp Phe Glu Glu Leu His Leu 210 215 220

Arg Asn Lys Leu Lys Ser Phe Asn Ser Asn Asp Ala Ala Tyr Leu Gln

Yio. ~225 230 235 240

Gly Thr Asp Tyr Leu Gly Tyr Trp Lys Lys Ala Phe Gly Lys Asn Ala 245 250 255

Asn Lys Asn Gln Lys Arg Arg Phe Ser Gln Ala Ile Leu Val Ser Leu 260 265 270

Phe Pro Leu Ala Ser Val Phe Leu Ile Pro Leu Phe Gly Ile Ala Asn 275 280 285 f

Pro Arg Phe Lys Thr Asn Trp Ser Tyr Phe Tyr Val Leu Gly Ala Val 290 285 300

Gly Val Tyr Phe Leu Met Val His Val Ile Ser Thr Asp Leu Phe Leu 305 310 315 320

Met Thr Phe Phe Phe Pro Phe Ile Trp Ala Phe Ile Ser Tyr Leu Leu 325 330 335

Phe Arg Lys Phe Ile Leu Lys Arg Tyr 340 345 (2) INFORMATION FOR SEQ ID NO:77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 276 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear ( ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...276 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

Met Lys Lys Lys Ala Lys Val Phe Trp Cys Cys Phe Lys Met Ile Arg 1 5 10 15

Trp Leu Tyr Leu Ala Val Phe Phe Leu Leu Ser Val Ser Asp Ala Lys 20 25 30

Glu Ile Ala Met Gln Arg Phe Asp Lys Gln Asn His Lys Ile Phe Glu 35 40 45

Ile Leu Ala Asp Lys Val Ser Ala Lys Asp Asn Val Ile Thr Ala Ser 50 55 60

Gly Asn Ala Ile Leu Leu Asn Tyr Asp Val Tyr Ile Leu Ala Asp Lys 65 70 75 80

Val Arg Tyr Asp Thr Lys Thr Lys Glu Ala Leu Leu Glu Gly Asn Ile 85 90 95

Lys Val Tyr Arg Gly Glu Gly Leu Leu Val Lys Thr Asp Tyr Val Lys 100 105 110

Leu Ser Leu Asn Glu Lys Tyr Glu Ile Ile Phe Pro Phe Tyr Val Gln 115 120 125

Asp Sex Val Ser Gly Ile Trp Val Ser Ala Asp Ile Ala Ser Gly Lys 130 135 140 asp Gln Lys Tyr Lys Ile Lys Asn Met Ser Ala Ser Gly Cys Ser Ile 145 150 155 160

Asp Asn Pro Ile Trp His Val Asn Ala Thr Ser Gly Ser Phe Asn Met 165 170 175

Gln Lys Ser His Leu Ser Met Trp Asn Pro Lys Ile Tyr Val Gly Asp

Tn 190 185 180 Ile Pro Val Leu Tyr Leu Pro Tyr Ile Phe Met Ser Thr Ser Asn Lys 205 200 195 Arg Thr Thr Gly Phe Leu Tyr Pro Glu Phe Gly Thr Ser Asn Leu Asp 21s 220 210 5 Gly Phe Ile Tyr Leu Gln Pro Phe Tyr Leu Ala Pro Lys Asn Ser Trp 4 240 235 230 225 Asp Met Thr Phe Thr Pro Gln Ile Arg Tyr Lys Arg Gly Phe Gly Leu 255 250 245 Gluphe Ala Arg Tyr Ile Asn Ser Lys Thr Gln Val Phe Ile Gln Dmh 10 270 265 260 Cys Ala Leu Phe 275 INFORMATION FOR SEQ ID NO:78: (2) 15 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 224 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 20 (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES 25 (vi) ORIGINAL SOURCE: ( A) ORGANISM: Helicobacter pylori (ix) FEATURE: 1 (AR) NAME/KEY: misc_feature 30 (B) LOCATION 1...224 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: Met Ile Arg Leu Lys Gly Leu Asn Lys Thr Leu Lys Thr Ser Leu Leu 35 10 5 1 Ala Gly Val Leu Leu Gly Ala Thr Ala Pro Leu Met Ala Lys Pro Leu 25 20 Leu Ser Asp Glu Asp Leu L eu Lys Arg Val Lys Leu His Asn Ile Lys 40 35 40 Glu Asp Thr Leu Thr Ser Cys Asn Ala Lys Val Asp Gly Ser Gln Tyr 60 55 50 Leu Asn Ser Gly Trp Asn Leu Ser Lys Glu Phe Pro Gln Glu Tyr Arg 80 75 70 65 Glu Lys Ile Phe Glu Cys Val Glu Glu Glu Lys His Lys Gln Ala Leu 45 95 90 85 , Asn Leu Ile Asn Lys Glu Asp Thr Lys Asp Lys Glu Glu Leu Ala Lys 110 108 100 Lys Ile Lys Glu Ile Lys Glu Lys Ala Lys Val Leu Arg Gln Lys Phe 125 120 115 50 Met Ala Phe Glu Met Lys Glu His Ser Lys Glu Phe Pro Asn Lys Lys 140 135 130 Gln Leu Gln Thr Met Leu Glu Asn Ala Phe Asp Asn Gly Ala Glu Ser 160 155 150 145 Phe Ile Asp Asp Trp His Glu Arg Phe Gly Gly Ile Ser Arg Glu Asn 55 175 170 165 Thr Tyr Lys Ala Leu Gly Ile Lys Glu Tyr Ser Asp Glu Gly Lys Ile 190 185 180 Leu Pro Leu Ala Lys Glu Val Ile Leu Asp Asn Ile Lys Lys Ile Leu

Ba 205 200 195 Lys Lys Ala Leu Met Ile Leu Asp Asn Pro Tyr Leu Leu Trp Leu Val 220 215 210 INFORMATION FOR SEQ ID NO:79: (2) 5 (i) SEQUENCE CHARACTERISTICS: : ( A) LENGTH: 429 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 10 (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 20 (B) LOCATION 1...429 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: 25 20 Ser Pro Leu Pro Pro Ala His Gln Gln Ile Ile Lys Thr Glu Pro Cys 0 35 40 45 30 Ser Leu Glu Cys Leu Lys Asp Leu Met Leu Gln Asn Gln Ile Phe Ser 60 55 50 Phe Val Ser Gln Tyr Asp Asp Asn Asn Gln Asp Glu Ser Leu Lys Thr 80 75 70 65 Tyr Tyr Lys Asp Ile Leu Asn Lys Leu Asn Pro Val Phe Ile Ala Ser 35 95 90 85 Gln Thr Pro Ala Lys Glu Ser Tyr Glu Pro Lys Ile Glu Leu Ala Ile 110 105 100 Leu Leu Pro Lys Lys Val Val Gly Arg Tyr Ala Ile Leu Val Met Asn 11s 120 125 40 Thr Leu Leu Ala Tyr Leu Asn Thr Arg Asn Asn Asp Phe Asn Ile Gln 140 135 130 Val Phe Asp Ser Asp Glu Glu Ser Pro Glu Lys Leu Glu Glu Thr Tyr 160 155 150 145 Lys Glu Ile Glu Lys Glu Lys Phe Pro Phe Ile Ile Ala Leu Leu Thr 45 175 170 165 : Lys Glu Gly Val Glu Asn Leu Leu Gln Asn Thr Thr Ile Asn Thr Pro 130 185 180 Thr Tyr Val Pro Thr Val Asn Lys Thr Gln Leu Glu Asn His Thr Glu 205 200 195 50 Leu Ser Leu Ser Glu Arg Leu Tyr Phe Gly Gly Ile Asp Tyr Lys Glu 220 215 210 Gln Leu Gly Met Leu Ala Thr Phe Ile Ser Pro Asn Ser Pro Val Ile 240 235 230 225 Glu Tyr Asp Asp Asp Gly Leu Ile Gly Glu Arg Leu Arg Gln Ile Thr 55 255 250 245 Glu Ser Leu Asn Val Glu Val Lys His Gln Glu Asn Ile Ser Tyr Lys 270 265 260 Gln Ala Thr Ser Phe Ser Lys Asn Phe Arg Lys His Asp Ala Phe Phe

285 280 275 Lys Asn Ser Thr Leu Ile Leu Asn Thr Pro Thr Thr Lys Ser Gly Leu 300 295 290 Ile Leu Ser Gln Ile Gly Leu Leu Glu Tyr Lys Pro Leu Lys Ile Leu 320 315 310 35 5 Ser Thr Gln Ile Asn Phe Asn Pro Ser Leu Leu Leu Leu Thr Gln Pro ¢ 335 330 325 Lys Asp Arg Lys Asn Leu Phe Ile Val Asn Ala Leu Gln Asn Ser Asp 350 345 340 Glu Thr Leu Ile Glu Tyr Ala Ser Leu Leu Glu Ser Asp Leu Arg His 10 365 360 355 Asp Trp Val Asn Tyr Ser Ser Ala Ile Gly Leu Glu Met Phe Leu Asn 380 375 370 Thr Leu Asp Pro His Phe Lys Lys Ser Phe Gln Glu Ser Leu Glu Asp 400 395 390 5 15 Asn Gln Val Arg Tyr His Asn Gln Ile Tyr Gln Ala Leu Gly Tyr Ser 415 410 405 Phe Glu Pro Ile Lys Asn Glu Ser Glu Thr Lys Lys Glu 425 420 20 INFORMATION FOR SEQ ID NO:80: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 455 amino acids (B) TYPE: amino acid 25 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES 30 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 35 (A) NAME/KEY: misc_feature (B) LOCATION 1...455 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80: 40 Val Leu Lys Phe Gln Lys Leu Pro Leu Leu Phe Val Ser Ile Leu Tyr 10 5 1 Asn Gln Ser Pro Leu Leu Ala Phe Asp Tyr Lys Phe Ser Gly Val Ala 25 20 Glu Ser Val Ser Lys Val Gly Phe Asn His Ser Lys Leu Asn Ser Lys 45 s 35 40 45 Glu Gly Ile Phe Pro Thr Ala Thr Phe val Thr Ala Thr Ile Lys Leu 60 55 50 Gln Val Asp Ser Asn Leu Leu Pro Lys Asn Ile Glu Lys His Ser Leu 80 75 70 5 50 Lys Ile Gly Val Gly Gly Ile Leu Gly Ala Leu Ala Tyr Asp Ser Thr 95 90 85 Lys Thr Leu Ile Asp Gln Ala Thr His Gln Ile Tyr Gly Ser Glu Leu 110 105 100 Phe Tyr Leu Ile Gly Arg Trp Trp Gly Phe Leu Gly Asn Ala Pro Trp 55 125 120 115 Lys Asp Ser Leu Ile Glu Ser Asp Ala His Thr Arg Asn Tyr Val Leu 140 135 130 Tyr Asn Ser Tyr Leu Phe Tyr Ser Tyr Gly Asp Lys Phe His Leu Lys

Yi4 145 150 155 160

Leu Gly Arg Tyr Leu Ser Asn Met Asp Phe Met Ser Ser Tyr Thr Gln 165 170 175

Gly Phe Glu Leu Asp Tyr Lys Ile Asn Ser Lys Ile Ala Leu Lys Trp 180 185 190

Phe Ser Ser Phe Gly Arg Ala Leu Ala Phe Gly Gln Trp Ile Arg Asp 195 200 205 ‘

Trp Tyr Ala Pro Ile Val Thr Glu Asp Gly Arg Lys Glu Val Tyr Asp 210 215 220

Gly Ile His Ala Ala Gln Leu Tyr Phe Ser Ser Lys His val Gln 1 225 230 235 240

Met Pro Phe Ala Tyr Phe Ser Pro Lys Ile Tyr Gly Ala Pro Gly Val 245 250 255

Lys Ile His Ile Asp Ser Asn Pro Lys Phe Lys Gly Leu Gly Leu Arg 260 265 270

Ala Gln Thr Thr Ile Asn Val Ile Phe Pro Val Tyr Ala Lys Asp Leu 275 280 285

Tyr Asp Val Tyr Trp Arg Asn Ser Lys Ile Gly Glu Trp Gly Ala Ser 290 295 300

Leu Leu Ile His Gln Arg Phe Asp Tyr Asn Glu Phe Asn Phe Gly Phe 305 310 315 320

Gly Tyr Tyr Gln Asn Phe Gly Asn Ala Asn Ala Arg Ile Gly Trp Tyr 325 330 335

Gly Asn Pro Ile Pro Phe Asn Tyr Arg Asn Asn Ser Val Tyr Gly Gly 340 345 350

Val Phe Ser Asn Ala Ile Thr Ala Asp Ala Val Ser Gly Tyr Val Phe 355 360 365

Gly Gly Gly Val Tyr Arg Gly Phe Leu Trp Gly Ile Leu Gly Arg Tyr 370 375 380

Thr Tyr Ala Thr Arg Ala Ser Glu Arg Ser Ile Asn Leu Asn Leu Gly 385 390 385 400

Tyr Lys Trp Gly Ser Phe Ala Arg Val Asp Val Asn Leu Glu Tyr Tyr 405 410 415

Val Val Ser Met His Asn Gly Tyr Arg Leu Asp Tyr Leu Thr Gly Pro 420 425 430

Phe Asn Lys Ala Phe Lys Ala Asp Ala Gln Asp Arg Ser Asn Leu Met 435 440 445

Val Ser Met Lys Phe Phe Phe 450 455 (2) INFORMATION FOR SEQ ID NO:81: (i) SEQUENCE CHARACTERISTICS: 1 (A) LENGTH: 282 amino acids (B) TYPE: amino acid : (D) TOPOLOGY: linear ( ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...282 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

YY.

Met Gly Cys Ser Phe Ile Phe Lys Lys Val Arg Val Tyr Ser Lys Met 1 5 A 10 15

Leu Val Ala Leu Gly Leu Ser Ser Val Leu Ile Gly Cys Ala Met Asn 20 25 30

Pro Ser Ala Glu Thr Lys Lys Pro Asn Asp Ala Lys Asn Gln Gln Pro 35 40 45 ‘

Val Gln Thr His Glu Arg Met Thr Thr Ser Ser Glu His Val Thr Pro 50 55 60

Leu Asp Phe Asn Tyr Pro Val His Ile Val Gln Ala Pro Gln Asn His 65 70 75 80

His Val Val Gly Ile Leu Met Pro Arg Ile Gln Val Ser Asp Asn Leu 85 20 95

Lys Pro Tyr Ile Asp Lys Phe Gln Asp Ala Leu Ile Asn Gln Ile Gln 100 105 110

Thr Ile Phe Glu Lys Arg Gly Tyr Gln Val Leu Arg Phe Gln Asp Glu 115 120 125

Lys Ala Leu Asn Val Gln Asp Lys Lys Lys Ile Phe Ser Val Leu Asp 130 135 140

Leu Lys Gly Trp Val Gly Ile Leu Glu Asp Leu Lys Met Asn Leu Lys 145 150 155 160

Asp Pro Asn Ser Pro Asn Leu Asp Thr Leu Val Asp Gln Ser Ser Gly 165 170 : 175

Ser Val Trp Phe Asn Phe Tyr Glu Pro Glu Ser Asn Arg Val Val His 180 185 190

Asp Phe Ala Val Glu Val Gly Thr Phe Gln Ala Ile Thr Tyr Thr Tyr 195 200 205

Thy Ser Thr Asn Asn Ala Ser Gly Gly Phe Asn Ser Ser Lys Ser Val 210 215 220

Ile His Glu Asn Leu Asp Lys Asn Arg Glu Asp Ala Ile His Lys Ile 225 230 235 240

Leu Asn Arg Met Tyr Ala Val Val Met Lys Lys Ala Val Thr Glu Leu 245 250 255

Thr Lys Glu Asn Ile Ala Lys Tyr Arg Asp Ala Ile Asp Arg Met Lys 260 265 270

Gly Phe Lys Ser Ser Met Pro Gln Lys Lys 275 280 (2) INFORMATION FOR SEQ ID NO:82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 280 amino acids (B) TYPE: amino acid 7 (D) TOPOLOGY: linear » (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1... 280(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Met Lys Leu Arg Ala Ser Val Leu Ile Gly Val Ala Ile Leu Cys Leu

: f > 1 5 10 15

Ile Leu Ser Ala Cys Ser Asn Tyr Ala Lys Lys Val Val Lys Gln Lys 20 25 30

Asn His Val Tyr Thr Pro Val Tyr Asn Glu Leu Ile Glu Lys Tyr Ser 35 40 45

Glu Ile Pro Leu Asn Asp Lys Leu Lys Asp Thr Pro Phe Met Val Gln , 50 55 60 1

Val Lys Leu Pro Asn Tyr Lys Asp Tyr Leu Leu Asp Asn Lys Gln Val 65 70 75 80 val Leu Thr Phe Lys Leu Val His His Ser Lys Lys Ile Thr Leu Ile 85 20 95

Gly Asp Ala Asn Lys Ile Leu Gln Tyr Lys Asn Tyr Phe Gln Ala Asn 100 105 110

Gly Ala Arg Ser Asp Ile Asp Phe Tyr Leu Gln Pro Thr Leu Asn Gin 115 120 125

Lys Gly Val val Met Ile Ala Ser Asn Tyr Asn Asp Asn Pro Asn Asn 130 135 140

Lys Glu Lys Pro Gln Thr Phe Asp Val Leu Gln Gly Ser Gln Pro Met 145 150 155 160

Leu Gly Ala Asn Thr Lys Asn Leu His Gly Tyr Asp Val Ser Gly Ala 165 170 175

Asn Asn Lys Gln Val Ile Asn Glu Val Ala Arg Glu Lys Ala Gln Leu 180 185 190

Glu Lys Ile Asn Gln Tyr Tyr Lys Thr Leu Leu Gln Asp Lys Glu Gln 195 200 205

Glu Tyr Thr Thr Arg Lys Asn Asn Gln Arg Glu Ile Leu Glu Thr Leu 210 215 220

Ser Asn Arg Ala Gly Tyr Gln Met Arg Gln Asn Val Ile Ser Ser Glu 225 230 235 240

Ile Phe Lys Asn Gly Asn Leu Asn Met Gln Ala Lys Glu Glu Glu Val 245 250 255

Arg Glu Lys Leu Gln Glu Glu Arg Glu Asn Glu Tyr Leu Arg Asn Gln 260 265 270

Ile Arg Ser Leu Leu Ser Gly Lys 275 280 (2) INFORMATION FOR SEQ ID NO:83: (i) SEQUENCE CHARACTERISTICS: (RB) LENGTH: 393 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear — ( ii) MOLECULE TYPE: protein - (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...393 (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Met Arg Lys Leu Phe Ile Pro Leu Leu Leu Phe Ser Ala Leu Glu Ala 1 5 10 15

Asn Glu Lys Asn Gly Phe Phe Ile Glu Ala Gly Phe Glu Thr Gly Leu

YYY

20 25 30

Leu Glu Gly Thr Gln Thr Gln Glu Lys Arg His Thr Thr Thr Lys Asn 35 40 45

Thr Tyr Ala Thr Tyr Asn Tyr Leu Pro Thr Asp Thr Ile Leu Lys Arg 50 55 60

Ala Ala Asn Leu Phe Thr Asn Ala Glu Ala Ile Ser Lys Leu Lys Phe 0 65 70 75 80

Ser Ser Leu Ser Pro Val Arg Val Leu Tyr Met Tyr Asn Gly Gln Leu 85 90 95

Thr Ile Glu Asn Phe Leu Pro Tyr Asn Leu Asn Asn Val Lys Leu Ser 100 105 110

Phe Thr Asp Ala Gln Gly Asn Val Ile Asp Leu Gly Val Ile Glu Thr 115 120 125

Ile Pro Lys His Ser Lys Ile Val Leu Pro Gly Glu Ala Phe Asp Ser 130 135 140

Leu Lys Ile Asp Pro Tyr Thr Leu Phe Leu Pro Lys Ile Glu Ala Thr 145 150 155 160

Ser Thr Ser Ile Ser Asp Ala Asn Thr Gln Arg Val Phe Glu Thr Leu 165 170 175

Asn Lys Ile Lys Thr Asn Leu Val Val Asn Tyr Arg Asn Glu Asn Lys 180 185 190

Phe Lys Asp His Glu Asn His Trp Glu Ala Phe Thr Pro Gln Thr Ala 195 200 205

Glu Glu Phe Thr Asn Leu Met Leu Asn Met Ile Ala Val Leu Asp Ser 210 215 220

Gln Ser Trp Gly Asp Ala Ile Leu Asn Ala Pro Phe Glu Phe Thr Asn 225 230 235 240

Ser Pro Thr Asp Cys Asp Asn Asp Pro Ser Lys Cys Val Asn Pro Gly 245 250 255

Thr Asn Gly Leu Val Asn Ser Lys Val Asp Gln Lys Tyr Val Leu Asn 260 265 270

Lys Gln Asp Ile Val Asn Lys Phe Lys Asn Lys Ala Asp Leu Asp Val 275 280 285

Ile Val Leu Lys Asp Ser Gly Val Val Gly Leu Gly Ser Asp Ile Thr 290 295 300

Pro Ser Asn Asn Asp Asp Gly Lys His Tyr Gly Gln Leu Gly Val val 305 310 315 320

Ala Ser Ala Leu Asp Pro Lys Lys Leu Phe Gly Asp Asn Leu Lys Thr 325 330 335

Ile Asn Leu Glu Asp Leu Arg Thr Ile Leu His Glu Phe Ser His Thr 340 345 350

Lys Gly Tyr Gly His Asn Gly Asn Met Thr Tyr Gln Arg Val Pro Val 355 360 365

Thr Lys Asp Gly Gln Val Glu Lys Asp Ser Asn Gly Lys Pro Lys Asp 370 375 380

Sex Asp Gly Leu Pro Tyr Asn Val Cys 385 350 (2) INFORMATION FOR SEQ ID NO:84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear ( ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (3) NAME/KEY: misc feature (B) LOCATION 1...270 ) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Met Lys Lys Phe Val Ala Leu Gly Leu Leu Ser Ala Val Leu Ser Ser 1 5 10 15

Ser Leu Leu Ala Glu Gly Asp Gly Val Tyr Ile Gly Thr Asn Tyr Gln 20 25 30

Leu Gly Gln Ala Arg Leu Asn Ser Asn Ile Tyr Asn Thr Gly Asp Cys 35 40 45

Thr Gly Ser Val Val Gly Cys Pro Pro Gly Leu Thr Ala Asn Lys His 50 55 60

Asn Pro Gly Gly Thr Asn Ile Asn Trp His Ser Lys Tyr Ala Asn Gly 65 70 75 80

Ala Leu Asn Gly Phe Gly Leu Asn Val Gly Tyr Lys Lys Phe Phe Gln " 85 90 95

Phe Lys Ser Leu Asp Met Thr Ser Lys Trp Phe Gly Phe Arg Val Tyr 100 105 110

Gly Leu Phe Asp Tyr Gly His Ala Asp Leu Gly Lys Gln Val Tyr Ala 115 120 125

Pro Asn Lys Ile Gln Leu Asp Met Val Ser Trp Gly Val Gly Ser Asp 130 135 140

Leu Leu Ala Asp Ile Ile Asp Lys Asp Asn Ala Ser Phe Gly Ile Phe 145 150 155 160

Gly Gly val Ala Ile Gly Gly Asn Thr Trp Lys Ser Ser Ala Ala Asn 165 170 175

Tyr Trp Lys Glu Gln Ile Ile Glu Ala Lys Gly Pro Asp Val Cys Thr 180 185 150

Pro Thr Tyr Cys Asn Pro Asn Ala Pro Tyr Ser Thr Asn Thr Ser Thr 195 200 205

Val Ala Phe Gln Val Trp Leu Asn Phe Gly Val Arg Ala Asn Ile Tyr 210 215 220

Lys His Asn Gly Val Glu Phe Gly val Arg Val Pro Leu Leu Ile Asn 225 230 235 240

Lys Phe Leu Ser Ala Gly Pro Asn Ala Thr Asn Leu Tyr Tyr His Leu 245 250 255

Lys Arg Asp Tyr Ser Leu Tyr Leu Gly Tyr Asn Tyr Thr Phe 260 265 270 (2) INFORMATION FOR SEQ ID NO:85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 140 amino acids (B) TYPE: amino acid ( D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE:

YY¢ (A) NAME/KEY: misc_feature (B) LOCATION 1...140 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Met His Pro Ile Met Phe Ala Tyr Ile Ala Asn Ala Leu Ala Gln Ala 1 5 10 15!

Arg Lys Ile Asn Gly Thr Leu Cys Met Ala Phe Gln Lys Ile Ser Gln 20 25 30 val Lys Glu Leu Gly Ile Asp Lys Ala Lys Ser Leu Ile Gly Asn Leu 35 40 45

Ser Gln Val Ile Ile Tyr Pro Thr Lys Asp Thr Asp Glu Leu Ile Glu 50 55 60

Cys Gly Val Pro Leu Ser Asp Ser Glu Ile Asn Phe Leu His Asn Thr 65 70 75 80

Asp Met Arg Ala Arg Gln Val Leu Val Lys Asn Ile Val Thr Asn Ala 85 90 95

Ser Ala Phe Ile Glu Ile Asp Leu Lys Lys Ile Cys Lys Asn Tyr Phe 100 105 110

Ile Phe Leu Ile Ala Met Leu Val Ile Glu Lys Ser Ser Met Ile Leu 115 120 125

Lys Lys Gln Thr Lys Lys Leu Ile Arg Lys Ser Ile 130 135 140 (2) INFORMATION FOR SEQ ID NO:86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 256 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1... 256 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86: '

Met Leu Gly Ser Val Lys Lys Ala Val Phe Arg Val Leu Cys Leu Gly 1 5 10 15

Ala Leu Cys Leu Cys Gly Gly Leu Met Ala Glu Gln Asp Pro Lys Glu 20 25 30

Leu Ile Phe Ser Gly Ile Thr Ile Tyr Thr Asp Lys Asn Phe Thr Arg 35 40 45

Ala Lys Lys Tyr Phe Glu Lys Ala Cys Lys Ser Asn Asp Ala Asp Gly 50 55 60

Cys Ala Ile Leu Arg Glu Val Tyr Ser Ser Gly Lys Ala Ile Ala Arg 65 70 75 80

Glu Asn Ala Arg Glu Ser Ile Glu Lys Ala Leu Glu His Thr Ala Thr 85 30 95

Ala Lys Val Cys Lys Leu Asn Asp Ala Glu Lys Cys Lys Asp Leu Ala 100 105 110

Glu Phe Tyr Phe Asn Val Asn Asp Leu Lys Asn Ala Leu Glu Tyr Tyr

115 120 125

Ser Lys Ser Cys Lys Leu Asn Asn Val Glu Gly Cys Met Leu Ser Ala 130 135 140

Thr Phe Tyr Asn Asp Met Ile Lys Gly Leu Lys Lys Asp Lys Lys Asp 5 150 155 160

Leu Glu Tyr Tyr Ser Lys Ala Cys Glu Leu Asn Asn Gly Gly Gly Cys , 165 170 175

Ser Lys Leu Gly Gly Asp Tyr Phe Phe Gly Glu Gly Val Thr Lys Asp 180 185 190 ‘

Phe Lys Lys Ala Phe Glu Tyr Ser Ala Lys Ala Cys Glu Leu Asn Asp 200 205

Ala Lys Gly Cys Tyr Ala Leu Ala Ala Phe Tyr Asn Glu Gly Lys Gly 210 215 220

Val Ala Lys Asp Glu Lys Gln Thr Thr Glu Asn Leu Glu Lys Ser Cys 15 225 230 235 240

Lys Leu Gly Leu Lys Glu Ala Cys Asp Ile Leu Lys Glu Gln Lys Gln 245 250 255 (2) INFORMATION FOR SEQ ID NO:87: : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 242 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...242 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Met Lys Lys Phe Phe Ser Gln Ser Leu Leu Ala Leu Ile Ile Ser Met 1 5 10 15

Asn Ala Val Ser Gly Met Asp Gly Asn Gly Val Phe Leu Gly Ala Gly 20 25 - 30

Tyr Leu Gln Gly Gln Ala Gln Met His Ala Asp Ile Asn Ser Gln Lys 35 40 45

Gln Ala Thr Asn Ala Thr Ile Lys Gly Phe Asp Ala Leu Leu Gly Tyr 60

Gln Phe Phe Phe Glu Lys His Phe Gly Leu Arg Leu Tyr Gly Phe Phe 65 70 75 80

Asp Tyr Ala His Ala Asn Ser Ile Lys Leu Lys Asn Pro Asn Tyr Asn 50 85 90 95

Ser Glu Ala Ala Gln Val Ala Ser Gln Ile Leu Gly Lys Gln Glu Ile 100 105 110

Asn Arg Leu Thr Asn Ile Ala Asp Pro Arg Thr Phe Glu Pro Asn Met 115 120 125 55 Leu Thr Tyr Gly Gly Ala Met Asp Val Met Val Asn Val Ile Asn Asn 130 135 140

Gly Ile Met Ser Leu Gly Ala Phe Gly Gly Ile Gln Leu Ala Gly Asn 145 150 155 160

Ser Trp Leu Met Ala Thr Pro Ser Phe Glu Gly Ile Leu Val Glu Gln

165 170 175

Ala Leu Val Ser Lys Lys Ala Thr Ser Phe Gln Phe Leu Phe Asn Val 180 185 130

Gly Ala Arg Leu Arg Ile Leu Lys His Ser Ser Ile Glu Ala Gly Val 195 200 205

Lys Phe Pro Met Leu Lys Lys Asn Pro Tyr Ile Thr Ala Lys Asn Leu 210 215 220

Asp Ile Gly Phe Arg Arg Val Tyr Ser Trp Tyr Val Asn Tyr Val Phe 225 230 235 240 1

Thr Phe (2) INFORMATION FOR SEQ ID NO:88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 267 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...267 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Met Asn Tyr Pro Asn Leu Pro Asn Ser Ala Leu Glu Ile Ser Glu Gln 1 5 10 15

Pro Glu Val Lys Glu Ile Thr Asn Glu Leu Leu Lys Gln Leu Gln Asn 20 25 30

Ala Leu Arg Ser Asn Ala His Phe Ser Glu Gln Val Glu Leu Ser Leu 35 40 45

Lys Cys Ile Val Arg Ile Leu Glu Val Leu Leu Ser Leu Asp Phe Phe 50 55 60

Lys Asn Ala Asn Glu Ile Asp Ser Ser Leu Arg Asn Ser Ile Glu Trp 65 70 75 80

Leu Thr Asn Ala Gly Glu Ser Leu Lys Leu Lys Met Lys Glu Tyr Glu 85 90 95

Arg Phe Phe Ser Glu Phe Asn Thr Ser Met His Ala Asn Glu Gln Glu 100 105 110

Val Thr Asn Thr Leu Asn Ala Asn Ala Glu Asn Ile Lys Ser Glu Ile 115 120 125

Lys Lys Leu Glu Asn Gln Leu Ile Glu Thr Thr Thr Arg Leu Leu Thr 130 135 140

Ser Tyr Gln Ile Phe Leu Asn Gln Ala Arg Asp Asn Ala Asn Asn Gln 145 150 155 160

Ile Thr Lys Asn Lys Thr Gln Ser Leu Glu Ala Ile Thr Gln Ala Lys 165 170 175

Asn Asn Ala Asn Asn Glu Ile Ser Asn Asn Gln Thr Gln Ala Ile Thr 180 185 190

Asn Ile Thr Glu Ala Lys Thr Asn Ala Asn Asn Glu Ile Ser Asn Asn 195 200 205

Gln Thr Gln Ala Ile Thr Asn Ile Asn Glu Ala Lys Glu Ser Ala Thr

YYV

> 210 215 220

Thr Gln Ile Asn Ala Asn Lys Gln Glu Ala Ile Asn Asn Ile Thr Gln 225 230 235 240

Glu Lys Thr Gln Ala Thr Ser Glu Ile Thr Glu Ala Lys Lys Thr Asp 245 250 255

His Tyr Gln Asn Ile Asp Phe Phe Glu Phe Glu 260 265 d (2) INFORMATION FOR SEQ ID NO:89: ' (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 544 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1... 544 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Val Tle Glu Thr Ile Pro Lys His Ser Lys Ile Val Leu Pro Gly Glu 1 5 10 15

Ala Phe Asp Ser Leu Lys Glu Ala Phe Asp Lys Ile Asp Pro Tyr Thr 20 25 30

Phe Phe Phe Pro Lys Phe Glu Ala Thr Ser Thr Ser Ile Ser Asp Thr 35 Asn Thr Gln Arg Val Phe Glu Thr Leu Asn Asn Ile Lys Thr Asn Leu 60

Ile Met Lys Tyr Ser Asn Glu Asn Pro Asn Asn Phe Asn Thr Cys Pro 65 70 75 80

Tyr Asn Asn Asn Gly Asn Thr Lys Asn Asp Cys Trp Gln Asn Phe Thr 40 85 90 95

Pro Gln Thr Ala Glu Glu Phe Thr Asn Leu Met Leu Asn Met Ile Ala 100 105 110

Val Leu Asp Ser Gln Ser Trp Gly Asp Ala Tle Leu Asn Ala Pro Phe 115 120 125 45 Glu Phe Thr Asn Ser Ser Thr Asp Cys Asp Ser Asp Pro Ser Lys Cys 130 135 140

Val Asn Pro Gly Val Asn Gly Arg Val Asp Thr Lys Val Asp Gln Gln: 145 150 155 160

Tyr Ile Leu Asn Lys Gln Gly Ile Ile Asn Asn Phe Arg Lys Lys Ile 50 165 170 175

Glu Ile Asp Ala Val Val Leu Lys Asn Ser Gly Val val Gly Leu Ala 180 , 185 190

Asn Gly Tyr Gly Asn Asp Gly Glu Tyr Gly Thr Leu Gly Val Glu Ala 15 200 205 55 Tyr Ala Leu Asp Pro Lys Lys Leu Phe Gly Asn Asp Leu Lys Thr Ile 210 215 220

Asn Leu Glu Asp Leu Arg Thr Ile Leu His Glu Phe Ser His Thr Lys 225 230 * 235 240

Gly Tyr Gly His Asn Gly Asn Met Thr Tyr Gln Arg Val Pro Val Thr

YYA

245 250 255

Lys Asp Gly Gln Val Glu Lys Asp Ser Asn Gly Lys Pro Lys Asp Ser 260 265 270

Asp Gly Leu Pro Tyr Asn Val Cys Ser Leu Tyr Gly Gly Ser Asn Gln 275 280 285

Pro Ala Phe Pro Ser Asn Tyr Pro Asn Ser Ile Tyr His Asn Cys Ala 290 295 300¢

Asp Val Pro Ala Gly Phe Leu Gly Val Thr Ala Ala 721 Trp Gln Gln 305 310 315 320 ,

Leu Ile Asn Gln Asn Ala Leu Pro Ile Asn Tyr Ala Asn Leu Gly Ser 325 330 335

Gln Thr Asn Tyr Asn Leu Asn Ala Ser Leu Asn Thr Gln Asp Leu Ala 340 345 350

Asn Ser Met Leu Ser Thr Ile Gln Lys Thr Phe Val Thr Ser Ser Val 355 360 365

Thr Asn His His Phe Ser Asn Ala Ser Gln Ser Phe Arg Ser Pro Ile 370 375 380

Leu Gly Val Asn Ala Lys Ile Gly Tyr Gln Asn Tyr Phe Asn Asp Phe 385 390 395 400

Ile Gly Leu Ala Tyr Gly Ile Ile Lys Tyr Asn Tyr Ala Lys Ala. 405 410 415

Val Asn Gln Lys Val Gln Gln Leu Ser Tyr Gly Gly Gly Ile Asp Leu 420 425 430

Leu Leu Asp Phe Ile Thr Thr Tyr Ser Asn Lys Asn Ser Pro Thr Gly 435 440 445 º Ile Gln Thr Lys Arg Asn Phe Ser Ser Ser Phe Gly Ile Phe Gly Gly 450 455 460

Leu Arg Gly Leu Tyr Asn Ser Tyr Tyr Val Leu Asn Lys Val Lys Gly 465 470 475 480

Ser Gly Asn Leu Asp Val Ala Thr Gly Leu Asn Tyr Arg Tyr Lys His 485 490 495

Ser Lys Tyr Ser Val Gly Ile Ser Ile Pro Leu Ile Gln Arg Lys Ala 500 505 510

Ser Val val Ser Ser Gly Gly Asp Tyr Thr Asn Ser Phe Val Phe Asn 515 520 525

Glu Gly Ala Ser His Phe Lys Val Phe Phe Asn Tyr Gly Gly Cys Phe 530 535 540 (2) INFORMATION FOR SEQ ID NO:90: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 356 amino acids (B) TYPE: amino acid 1 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...356 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Leu Met Lys Ser Ile Leu Leu Phe Met Ile Phe Val Val Cys Gln Leu

YYA

1 5 10 15

Glu Gly Lys Lys Phe Ser Gln Asp Asn Phe Lys Val Asp Tyr Asn Tyr 20 25 30

Tyr Leu Arg Lys Gln Asp Leu His Ile Ile Lys Thr Gln Asn Asp Leu 35 40 45

Ser Asn Ala Trp Tyr Leu Pro Pro Gln Lys Ala Pro Lys Glu His Ser 50 55 60 1

Trp Val Asp Phe Ala Lys Lys Tyr Leu Asn Met Met Asp Tyr Leu Gly 65 70 75 80 ‘

Thr Tyr Phe Leu Pro Phe Tyr His Ser Phe Thr Pro Ile Phe Gln Trp 85 90 95

Tyr His Pro Asn Ile Asn Pro Tyr Gln Arg Asn Glu Phe Lys Phe Gln 100 105 110

Ile Ser Phe Arg Val Pro Val Phe Arg His Ile Leu Trp Thr Lys Gly 115 120 125

Thr Leu Tyr Leu Ala Tyr Thr Gln Thr Asn Trp Phe Gln Ile Tyr Asn 130 135 140

Asp Pro Gln Ser Ala Pro Met Arg Met Ile Asn Phe Met Pro Glu Leu 145 150 155 160

Ile Tyr Val Tyr Pro Ile Asn Phe Lys Pro Phe Gly Gly Lys Ile Gly 165 170 175

Asn Phe Ser Glu Ile Trp Ile Gly Trp Gln His Ile Ser Asn Gly val 180 185 130

Gly Gly Ala Gln Cys Tyr Gln Pro Phe Asn Lys Glu Gly Asn Pro Glu 195 200 205

Asn Gln Phe Pro Gly Gln Pro Val Ile Val Lys Asp Tyr Asn Gly Gln 210 215 220

Lys Asp Val Arg Trp Gly Gly Cys Xaa Ser Val Xaa Xaa Gly Asn Xaa 225 230 235 240

Leu Cys Phe Val Leu Val Trp Glu Lys Gly Gly Leu Lys Ile Met Val 245 250 255

Ala Tyr Trp Pro Tyr Val Pro Tyr Asp Gln Ser Asn Pro Gln Leu Ile 260 265 270

Asp Tyr Met Gly Tyr Gly Asn Ala Lys Ile Asp Tyr Arg Arg Gly Arg 275 280 285

His His Phe Glu Leu Gln Leu Tyr Asp Ile Phe Thr Gln Tyr Trp Arg 290 295 300

Tyr Asp Arg Trp His Gly Ala Phe Arg Leu Gly Tyr Thr Tyr Arg Ile 305 310 315 320

Asn Pro Phe Val Gly Ile Tyr Ala Gln Trp Phe Asn Gly Tyr Gly Asp 325 330 335

Gly Leu Tyr Glu Tyr Asp Val Phe Ser Asn Arg Ile Gly val Gly Ile 340 345 i 350

Arg Leu Asn Pro 355 (2) INFORMATION FOR SEQ ID NO:91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 675 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

YY. (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...675 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: )

Leu Ser Lys Gly Leu Ser Ile Gly Asn Lys Ile Ile Leu Cys Val Ala 1 5 10 15 ‘

Leu Ile Val Ile Val Cys Val Ser Ile Leu Gly Val Ser Leu Asn Ser 20 25 30

Arg Val Lys Glu Ile Leu Lys Glu Ser Ala Leu His Ser Met Gln Asp 35 40 45

Ser Leu His Phe Lys Val Lys Glu Val Gln Ser val Leu Glu Asn Thr 50 55 60

Tyr Thr Ser Met Gly Ile Val Lys Glu Met Leu Pro Glu Asp Thr Lys 65 70 75 80

Arg Glu Ile Lys Ile Gln Leu Leu Lys Asn Phe Ile Leu Ala Asn Ser 85 90 95

His val Ala Gly Val Ser Met Phe Lys Asp Arg Glu Asp Leu Arg 100 105 110

Leu Thr Leu Leu Arg Asp Asn Asp Thr Ile Lys Leu Met Glu Asn Pro 115 120 125

Ser Leu Gly Ser Asn Pro Leu Ala Gln Lys Ala Met Lys Asn Lys Glu 130 135 140

Ile Ser Lys Ser Leu Pro Tyr Tyr Arg Lys Met Pro Asn Gly Ala Glu 145 150 155 160

Val Tyr Gly Val Asp Ile Leu Leu Pro Leu Phe Lys Glu Asn Thr Gln 165 170 175

Glu Val Val Gly Val Leu Met Ile Phe Phe Ser Ile Asp Ser Phe Ser 180 185 1380

Asn Glu Ile Thr Lys Asn Arg Ser Asp Leu Phe Leu Ile Gly Val Lys 15 200 205

Gly Lys Val Leu Leu Ser Ala Asn Lys Ser Leu Gln Asp Lys Sex Ile 210 215 220

Thr Glu Ile Tyr Lys Ser Val Pro Lys Ala Thr Asn Glu Val Met Ala 225 230 235 240

Ile Leu Glu Asn Gly Ser Lys Ala Thr Leu Glu Tyr Leu Asp Pro Phe 245 250 255

Ser His Lys Glu Asn Phe Leu Ala Val Glu Thr Phe Lys Met Leu Gly 260 265 270

Lys Thr Glu Ser Lys Asp Asn Leu Asn Trp Met Ile Ala Leu Ile Ile 275 280 285

Glu Lys Asp Lys Val Tyr Glu Gln Val Gly Ser Val Arg Phe Val val 290 295 300

Val Ala Ala Ser Ala Ile Met Val Leu Ala Leu Ile Ile Ala Ile Thr 305 310 315 320

Leu Leu Met Arg Ala Ile Val Ser Asn Arg Leu Glu Val Val Ser Ser 325 330 335

Thr Leu Ser His Phe Phe Lys Leu Leu Asn Asn Gln Ala His Ser Ser 340 345 350

Asp Ile Lys Leu Val Glu Ala Arg Ser Asn Asp Glu Leu Gly Arg Met 355 360 365

Gln Thr Ala Ile Asn Lys Asn Ile Leu Gln Thr Gln Lys Thr Met Gln 370 375 380

Glu Asp Arg Gln Ala Val Gln Asp Thr Ile Lys Val val Ser Asp Val 385 390 35 400

Lys Ala Gly Asn Phe Ala Val Arg Ile Thr Ala Glu Pro Ala Ser Pro 405 410 415

Asp Leu Lys Glu Leu Arg Asp Ala Leu Asn Gly Ile Met Asp Tyr Leu 420 425 430

Gln Glu Ser Val Gly Thr His Met Pro Ser Ile Phe Lys Ile Phe Glu 435 440 445 ser Tyr Ser Gly Leu Asp Phe Arg Gly Arg Ile Gln Asn Ala Ser Gly 450 455 460

Arg Val Glu Leu Val Thr Asn Ala Leu Gly Gln Glu Ile Gln Lys Met 465 470 475 480

Leu Glu Thr Ser Ser Asn Phe Ala Lys Asp Leu Ala Asn Asp Ser Ala 485 490 495 ‘

Asn Leu Lys Glu Cys Val Gln Asn Leu Glu Lys Ala Ser Asn Ser Gln 500 505 510

His Lys Ser Leu Met Glu Thr Ser Lys Thr Ile Glu Asn Ile Thr Thr 515 520 525 ser Ile Gln Gly Val Ser Ser Gln Ser Glu Ala Met Ile Glu Gln Gly 530 535 540

Lys Asp Ile Lys Ser Ile Val Glu Ile Ile Arg Asp Ile Ala Asp Gln 545 550 555 560

Thr Asn Leu Leu Ala Leu Asn Ala Ala Ile Glu Ala Ala Arg Ala Gly 565 570 575

Glu His Gly Arg Gly Phe Ala Val Val Ala Asp Glu Val Arg Lys Leu 580 585 590

Ala Glu Arg Thr Gln Lys Ser Leu Ser Glu Ile Glu Ala Asn Ile Asn 595 600 605

Ile Leu Val Gln Ser Ile Ser Asp Thr Ser Glu Ser Ile Lys Asn Gln 610 615 620

Val Lys Glu Val Glu Glu Ile Asn Ala Ser Ile Glu Ala Leu Arg Ser 625 630 635 640

Val Thr Glu Gly Asn Leu Lys Ile Ala Ser Asp Ser Leu Glu Ile Ser 645 650 655

Gln Glu Ile Asp Lys Val Ser Asn Asp Ile Leu Glu Asp Val Asn Lys 660 665 670

Lys Gln Phe 675 (2) INFORMATION FOR SEQ ID NO:92: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 271 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein . (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...271 (xi) SEQUENCE DESCRIPTION: SEQ ID NO :92:

Met Asn Ile Phe Lys Arg Ile Ile Cys Val Thr Ala Ile Val Leu Gly 1 5 10 15

Phe Phe Asn Leu Leu Asp Ala Lys His His Lys Glu Lys Lys Glu Asp 20 25 30

His Lys Ile Thr Arg Glu Leu Lys Val Gly Ala Asn Pro Val Pro His 35 40 45

Ala Gln Ile Leu Gln Ser Val Val Asp Asp Leu Lys Glu Lys Gly Ile 50 55 60

Lys Leu Val Ile Val Ser Phe Thr Asp Tyr Val Leu Pro Asn Leu Ala 65 70 75 80 :

Leu Asn Asp Gly Ser Leu Asp Ala Asn Tyr Phe Gln His Arg Pro Tyr 85 90 95

Leu Asp Arg Phe Asn Leu Asp Arg Lys Met His Leu Val Gly Leu Ala 100 105 110

Asn Ile His Val Glu Pro Leu Arg Phe Tyr Ser Gln Lys Ile Thr Asp 115 120 125

Ile Lys Asn Leu Lys Lys Gly Ser Val Ile Ala Val Pro Asn Asp Pro 130 135 140 ala asn Gln Gly Arg Ala Leu Ile Leu Leu His Lys Gln Gly Leu Ile 145 150 155 160

Ala Leu Lys Asp Pro Ser Asm Leu Tyr Ala Thr Glu Phe Asp Ile 1 165 170 175

Lys Asn Pro Tyr Asn Ile Lys Ile Lys Pro Leu Glu Ala Ala Leu Leu 180 185 190

Pro Lys Val Leu Gly Asp Val Asp Gly Ala Ile Ile Thr Gly Asn Tyr 185 200 205

Ala Leu Gln Ala Lys Leu Thr Gly Ala Leu Phe Ser Glu Asp Lys Asp 210 215 220

Ser Pro Tyr Ala Asn Leu Val Ala Ser Arg Glu Asp Asn Ala Gln Asp 225 230 235 240

Glu Ala Ile Lys Ala Leu Ile Glu Ala Leu Gln Ser Glu Lys Thr Arg 245 250 255

Lys Phe Ile Leu Asp Thr Tyr Lys Gly Ala Ile Ile Pro Ala Phe 260 265 270 (2) INFORMATION FOR SEQ ID NO:93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 161 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein : (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...161 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Met Phe Phe Lys Thr Tyr Gln Lys Leu Leu Gly Ala Ser Cys Leu Ala 1 5 10 15

Leu Tyr Leu val Gly Cys Gly Asn Gly Gly Gly Gly Glu Ser Pro Val 20 25 30

Glu Met Ile Ala Asn Ser Glu Gly Thr Phe Gln Ile Asp Ser Lys Ala: 35 40 45

Asp Ser Ile Thr Ile Gln Gly Val Lys Leu Asn Arg Gly Asn Cys Ala 50 55 60

A thousand Val Asn Phe Val Pro Val Ser Glu Thr Phe Gln Met Gly Val Leu Ser 80 75 70 65 Gln Val Thr Pro Ile Ser Ile Gln Asp Phe Lys Asp Met Ala Ser Thr 95 90 85 Tyr Lys Ile Phe Asp Gln Lys Lys Gly Leu Ala Asn Ile Ala Asn Lys 5 110 105 100 Ile Ser Gln Leu Glu Gln Lys Gly Val Met Met Glu Pro Gln Thr Leu 125 120 115 Asn Phe Gly Glu Ser Leu Lys Gly Ile Ser Gln Gly Cys Asn Ile Ile 140 135 130 10 Glu Ala Glu Ile Gln Thr Asp Lys Gly Ala Trp Thr Phe Asn Phe Asp 160 155 150 145 Lys : 15 INFORMATION FOR SEQ ID NO:94: (2) SEQUENCE CHARACTERISTICS: (1) (A) LENGTH: 337 amino acids (B) TYPE: amino acid 20 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL : YES 25 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 30 (A) NAME/KEY: misc_feature (B) LOCATION 1...337 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:35 L ys Pro Leu 25 20 Leu Ser Asp Glu Asp Leu Leu Lys Arg Val Lys Leu His Asn Ile Lys 40 40 35 Glu Asp Thr Leu Thr Ser Cys Asn Ala Lys Val Asp Gly Ser Gln Tyr 60 - 55 50 Leu Asn Ser Gly Trp Asn Leu Ser Lys Glu Phe Pro Gln Glu Tyr Arg 80 75 70 65 45 Glu Lys Ile Phe Glu Cys Val Glu Glu Glu Lys His Lys Gln Ala Leu 95 90 85 Asn Leu Ile Asn Lys Glu Asp Thr Glu Asp Lys Glu Glu Leu Ala Lys 110 105 100 Lys Ile Lys Glu Ile Lys Glu Lys Ala Lys Val Leu Arg Gln Lys Phe 50 125 120 115 Met Ala Phe Glu Met Lys Glu His Ser Lys Glu Phe Pro Asn Lys Lys 140 135 130 Gln Leu Gln Thr Met Leu Glu Asn Ala Phe Asp Asn Gly Ala Glu Ser 160 155 150 5 55 Phe Ile Asp Asp Trp His Glu Arg Phe Gly Gly Ile Ser Arg Glu Asn 175 170 165 Thr Tyr Lys Ala Leu Gly Ile Lys Glu Tyr Ser Asp Glu Gly Lys Ile 190 188 180

Leu Ala Phe Gly Glu Arg Ser Tyr Ile Arg Gln Tyr Lys Lys Asp Phe 195 200 205

Glu Glu Ser Thr Tyr Asp Thr Arg Gln Thr Leu Ser Ala Met Ala Asn 210 215 220 3 Met Ser Gly Glu Asn Asp Tyr Lys Ile Thr Trp Leu Lys Pro Lys Tyr 225 230 235 240

Gln Leu His Ser Ser Asn Asn Ile Lys Pro Leu Met Ser Asn Thr Glu + 245 250 255

Leu Leu Asn Met Ile Glu Leu Thr Asn Ile Lys Lys Glu Tyr Val Met , 260 265 270

GlyCys Asn Met Glu Ile Asp Gly Ser Lys Tyr Pro Ile His Lys Asp 275 280 285

Trp Gly Phe Phe Gly Lys Ala Lys Val Pro Glu Thr Trp Arg Asn Lys 230 295 300

Ile Trp Glu Cys Ile Lys Asn Lys Val Lys Ser Tyr Asp Asn Thr Thr 305 310 315 320

Ala Glu Ile Gly Ile Val Trp Lys Lys Asn Thr Tyr Ser Ile Ser His 325 330 335

His (2) INFORMATION FOR SEQ ID NO:95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 416 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL : YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...416 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Met Lys Lys Leu Val Phe Ser Met Leu Leu Cys Cys Lys Ser Val Phe 1 5 10 - 15

Ala Glu Gly Glu Thr Pro Leu Ile Val Asn Asp Pro Glu Thr His Val 20 25 30

Ser Gln Ala Thr Ile Ile Gly Lys Met Val Asp Ser Ile Lys Arg Tyr 35 40 45

Glu Glu Ile Ile Ser Lys Ala Gln Ala Gln Val Asn Gln Leu Gln Lys 60 50 val asn asn Met Ile Asn Thr Thr Asn Ser Leu Ile Ser Ser Ser Ala 65 70 - 75 80

Ile Thr Leu Ala Asn Pro Met Gln Val Leu Gln Asn Ala Gln Tyr Gln 85 90 95

Ile Glu Ser Ile Arg Tyr Asn Tyr Glu Asn Leu Lys Gln Ser Ile Glu 35 100 105 110

Asn Trp Asn Ala Gln Asn Leu Leu Arg Asn Lys Tyr Leu Gln Gln Gln 115 120 125

Cys Pro Trp Leu Asn Val Asn Ala Leu Thr Asn Asn Lys Ile val Asn 130 135 140

p. Gln Ser Leu Ala Gly Glu Leu Ser Gly Arg Ala Trp 5 190 185 180 Gly Glu Met Leu Cys Lys Met Val Asn Asp Ser Asn Tyr Glu Ser Glu ° 205 200 195 Gln Ala Leu Leu Ala Thr Gly Asn Asn Pro Glu Glu Gln Lys Arg Arg |220 215 210 10 : Phe Leu Leu Arg Val Lys Lys Lys Val Asn Asp Asn Lys Gln Leu Lys 240 235 230 225 Asp Lys Leu Asp Pro Phe Leu Lys Arg Leu Asp Val Leu Gln Thr Glu 255 250 245 phe Gly Val Thr Asp Pro Thr Ala Asn His Asn Lys Gln Gly Ile His 15 270 265 260 Tyr Cys Thr Glu Asn Lys Glu Thr Gly Lys Cys Asp Pro Ile Lys Asn 285 280 275 Val Phe Arg Thr Thr Arg Leu Asp Asn Glu Leu Glu Gln Glu Ile Gln 300 295 290 20 Thr Leu Thr Leu Asp Leu Ile Lys Ala Ser Asn Lys Asp Ala Gln Ser 320 315 310 305 Gln Ala Tyr Ala Asn Phe Asn Gln Arg Ile Lys Leu Leu Thr Leu Lys 335 330 325 Tyr Leu Lys Glu Ile Thr Asn Gl n Met Leu Phe Leu Asn Gln Thr Met 25 350 345 340 Ala Met Gln Ser Glu Ile Met Thr Asp Asp Tyr Phe Arg Gln Asn Asn 365 360 355 Asp Gly Phe Gly Glu Lys Glu Asn His Ile Asp Lys Gln Leu Thr Gln 380 375 370 30 Lys Arg Ile Asn Glu Arg Glu Arg Ala Arg Ile Tyr Phe Gln Asn Pro 400 395 390 385 Asn Val Lys Phe Asp Gln Phe Gly Phe Pro Ile Phe Ser Ile Trp Asp 415 410 405 35 INFORMATION FOR SEQ ID NO:96: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 amino acids (B) TYPE: amino acid 40 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ' (iii) HYPOTHETICAL: YES 45 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 50 (A) NAME/ KEY: misc_feature (B) LOCATION 1...376 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: 55 Val Asn Lys Trp Ile Lys Gly Ala val Val Phe Val Gly Gly Phe Ala 10 5 1 Thr Ile Thr Thr Phe Ser Leu Ile Tyr His Gln Lys Pro Lys Ala Pro 25 20

Leu Asn Asn Gln Pro Ser Leu Leu Asn Asp Asp Glu Val Lys Tyr Pro 35 40 45

Leu Gln Asp Tyr Thr Phe Thr Gln Asn Pro Gln Pro Thr Asn Thr Glu 50 55 60

Ser Ser Lys Asp Ala Thr Ile Lys Ala Leu Gln Glu Gln Leu Lys Ala 65 70 75 go +; 2la Leu Lys Ala Leu Asn Ser Lys Glu Met Asn Tyr Ser Lys Glu Glu 85 90 95

Thr Phe Thr Ser Pro Pro Met Asp Pro Lys Thr Thr Pro Pro Lys Lys ‘ 100 105 110

Asp Phe Ser Pro Lys Gln Leu Asp Leu Leu Ala Ser Arg Ile Thr Pro 115 120 125

Phe Lys Gln Ser Pro Lys Asn Tyr Glu Glu Asn Leu Ile Phe Pro Val 130 135 140

Asp Asn Pro Asn Gly Ile Asp Ser Phe Thr Asn Leu Lys Glu Lys Asp 145 150 155 160

Ile Ala Thr Asn Glu Asn Lys Leu Leu Arg Thr Ile Thr Ala Asp Lys 165 170 175

Met Ile Pro Ala Phe Leu Ile Thr Pro Ile Ser Ser Gln Ile Ala Gly 180 185 190

Lys Val Ile Ala Gln Val Glu Ser Asp Ile Phe Ala Ser Met Gly Lys 195 200 205

Ala Val Leu Ile Pro Lys Gly Ser Lys Val Ile Gly Tyr Tyr Ser Asn 210 215 220

Asn Asn Lys Met Gly Glu Tyr Arg Leu Asp Ile Val Trp Ser Arg Ile 225 230 235 240

Ile Thr Pro His Gly Ile Asn Ile Met Leu Thr Asn Ala Lys Gly Ala 245 250 255

Asp Ile Lys Gly Tyr Asn Gly Leu Val Gly Glu Leu Ile Glu Arg Asn 260 265 270

Phe Gln Arg Tyr Gly Val Pro Leu Leu Leu Ser Thr Leu Thr Asn Gly 275 280 285

Leu Leu Ile Gly Ile Thr Ser Ala Leu Asn Asn Arg Gly Asn Lys Glu 20 255 300

Glu Val Thr Asn Phe Phe Gly Asp Tyr Leu Leu Leu Gln Leu Met Arg 305 310 315 320

Gln Ser Gly Met Gly Ile Asn Gln Val Val Asn Gln Ile Leu Arg Asp 325 330 335

Lys Ser Lys Ile Ala Pro Ile Val val Ile Arg Glu Gly Ser Arg Val 340 345 350

Phe Ile Ser Pro Asn Thr Asp Ile Phe Phe Pro Ile Pro Arg Glu Asn 355 360 : 365

Glu Val Ile Ala Glu Phe Leu Lys 370 375 (2) INFORMATION FOR SEQ ID NO:97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 916 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) ) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

- (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1. . 6. (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

Val Asp Leu Arg Ile Gln Ser Lys Glu Val Ser His Asn Leu Lys Glu 1 5 10 : 15

Leu Ser Lys Thr Leu Ile Ser Tyr Pro Phe Glu Lys His Val Glu Ala ‘ 20 25 30

Leu Gly Glu Gln Cys Ser Asn Phe Val Ser Ile Pro Ile Asn Asn Asp 35 40 45

Asp Tyr Ser Asn Ile Cys Thr Phe Val Ser Asp Phe Ile Asn Leu Ile 50 55 60

Ala Ser Tyr Asn Leu Leu Glu Ser Phe Leu Asp Phe Tyr Lys Asp Lys 65 70 75 80

Leu Lys Leu Ser Glu Leu Val Thr Glu Tyr Ala Asn Val Thr Asn Asn 85 90 95

Leu Leu Phe Lys Lys Leu Ile Lys His Leu Ser Gly Asn Asn Gln Leu 100 105 110

Val Lys Asn Phe Tyr Gln Cys Ile Arg Glu Ile Ile Lys Tyr Asn Ala 115 120 125

Pro Asn Lys Glu Tyr Lys Pro Asn Gln Phe Phe Ile Ile Gly Lys Gly 130 13S 140

Lys Gln Lys Gln Leu Ala Lys Ile Tyr Ser His Leu Lys Glu Leu Ser 145 150 155 160

Ala Ser Glu Ile Lys Pro Gln Asp Met Glu Asp Ile Leu Lys Lys Leu 165 170 175

Glu Glu Leu Asp Lys Ile Phe Lys Thr Thr Asp Phe Thr Lys Phe Thr 180 185 190

Pro Lys Thr Glu Ile Lys Asp Ile Ile Lys Glu Ile Asp Glu Lys Tyr 195 200 205

Pro Ile Asn Glu Asn Phe Lys Arg Gln Phe Asn Glu Phe Glu Ser Asn 210 215 220

Ile Glu Lys His Asp Glu Ile Lys Lys Asp Phe Glu Arg Asn Lys Glu 225 230 235 240 : Ser Leu Ile Arg Glu Ile Glu Asn His Cys Lys Asn Glu Cys Asn Ser 245 250 255

Glu Glu Glu Pro Glu Tyr Lys Ile Asn Asp Leu Leu Lys Asn Ile Gln 260 265 270

Gin Ile Cys Lys Asn Tyr Ile Glu Ser His Ala Val Asn Asp val Ser 275 280 - 285

Lys Asp Ile Lys Ser Met Met Cys Gln Phe Tyr Leu Lys Gln Ile Asp 290 285 300

Leu Leu Val Asn Ser Glu Ile val Arg Tyr Arg Tyr Ser Asn Leu Phe 305 310 315 320

Glu Pro Ile Gln Arg Ser Leu Trp Glu Ser Ile Lys Ile Leu Asp Asn 325 330 335

Glu Ser Gly Ile Tyr Leu Phe Pro Lys Asn Ile Gly Glu Ile Lys Asp 340 345 350

Lys Phe Glu Ala Asn Lys Glu Lys Phe Lys Gln Ser Lys Asn Val Ser 355 360 365

Glu Phe Ala Glu Tyr Cys Arg Glu Cys Asn Pro Tyr Thr Ala Phe Asn 370 375 380

Phe His Leu Asn Ile Asn Asn Gly Leu Ser His Gln Phe Glu Lys Phe 385 390 395 400

Val Pro Ile Met Lys Glu Tyr Lys Glu Pro Lys Ile Thr Asp Asn Asp 405 410 415

Leu Glu Ala Ile Ser Thr Lys Glu Thr Gly Leu Ala Ser Gln Leu Ser

YYA

420 425 430

Gly His Trp Phe Phe Gln Leu Ser Leu Phe Asn Lys Thr Asn Phe Asn 435 440 445

Pro Asn Lys Ile Trp Ile Pro Leu Glu Phe Asn Lys Arg Ser Lys Ile 450 455 460

Lys Phe Asp Lys Asp Leu Glu Ile Tyr Phe Asp Ser His Glu Ser Phe + 465 470 475 480

Asn Ile Ser Lys Lys Tyr Leu Gln Glu Ile Asp Gln Glu Ser Leu Lys 485 4380 495 ,

Lys Ile Lys Gln Ser Lys Asp Phe Phe Ser Ile Gln Lys Ile Glu Ser 500 505 510

Lys His Asp Asn Asn Asp Ile Leu Gln Leu Glu Phe Phe Glu Asn Asp 515 520 525

Thr Ser Phe Leu Phe Ala Lys Gly Ser Phe Ala Glu Ile Leu Glu Tyr 530 535 540

Asn Met Gln Leu Lys Ile Asp Ser Leu Ile Thr Lys Glu Phe Asn Lys 545 550 555 560

Leu Leu Ala Ile Val Gln Asp Ser Pro Gln Asp Ser Tyr Gln Leu Lys 565 570 575

Ile Arg Val Arg His Asn Asn Lys Leu Pro Arg Glu Lys Tyr Thr Glu 580 585 590

His Glu Ile Lys Leu Glu Val Tyr Asp Cys Arg Lys Ser His Asp His 555 600 605

Asn Glu Pro Ile Ile Leu Ser Gln Gln Ser Thr Gly Phe Gln Trp Ala 610 615 620

Phe Asn Phe Met Phe Gly Phe Leu Tyr Asn Val Gly Ser His Phe Ser 625 630 635 60

Phe Asn His Asn Ile Ile Tyr Val Met Asp Glu Pro Ala Thr His Leu 645 650 655

Ser Val Pro Ala Arg Lys Glu Phe Arg Lys Phe Leu Lys Glu Tyr Ala 660 665 670

His Lys Asn His Val Thr Phe Val Leu Ala Thr His Asp Pro Phe Leu 675 680 685

Val Asp Thr Asp His Leu Asp Glu Ile Arg Ile val Glu Lys Glu Thr 690 695 700

Glu Gly Ser val Ile Lys Asn His Phe Asn Tyr Pro Leu Asn Asn Ala 705 710 718 720

Ser Lys Asp Ser Asp Ala Leu Asp Lys Ile Lys Arg Ser Leu Gly Val 725 730 735

Gly Gln His val Phe His Asn Pro Gln Lys His Arg Ile Ile Phe Val 740 745 750

Glu Gly Ile Thr Asp Tyr Cys Tyr Leu Ser Ala Phe Lys Leu Tyr Leu 755 760 765

Arg Tyr Lys Glu Tyr Lys Asp Asn Pro Ile Pro Phe Thr Phe Leu Pro 770 775 780

Ile Ser Gly Leu Lys Asn Asp Ser Asn Asp Met Lys Glu Thr Ile Glu 785 7380 785 800

Lys Leu Cys Glu Leu Asp Asn His Pro Ile Val Leu Thr Asp Asp Asp 805 810 815

Arg Lys Cys Val Phe Asn Gln Gln Ala Thr Ser Glu Arg Phe Lys Arg 820 825 830

Ala Asn Glu Glu Met His Asp Pro Ile Thr Ile Leu Gln Leu Ser Asp 835 840 845

Cys Asp Arg His Phe Lys Gln Ile Glu Asp Cys Phe Ser Ala Asn Asp 850 855 860

Arg Asn Lys Tyr Ala Lys Asn Lys Gln Met Glu Leu Ser Met Ala Phe 865 870 875 880

Lys Thr Arg Leu Leu Tyr Gly Gly Glu Asp Ala Ile Glu Lys Gln Thr 885 890 895

Fa Lys Arg Asn Phe Leu Lys Leu Phe Lys Trp Ile Ala Trp Ala Thr Asn S00 905 910 Leu Ile Lys Asn 915

For INFORMATION FOR SEQ ID NO:98: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 176 amino acids . (B) TYPE: amino acid 10 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES 15 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 20 (A) NAME/ KEY: misc_feature (B) LOCATION 1...176 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98: 25 Met Thr Ala Met Arg Tyr Phe His Ile Tyr Ala Thr Thr Phe Phe 10 5 1 Phe Pro Leu Ala Leu Leu Phe Ala Val Ser Gly Leu Ser Leu Leu Phe 25 20 Lys Ala Arg Gln Asp Thr Gly Ala Lys Ile Lys Glu Trp Val Leu Glu 30 40 35 Lys Ser Leu Lys Lys Glu Arg Leu Asp Phe Leu Lys Gly Phe Ile 60 55 50 Lys Glu Asn His Ile Ala Met Pro Lys Lys Ile Glu Pro Arg Glu Tyr es 70 75 80 35 Arg Gly Ala Leu Val Ile Gly Thr Pro Leu Tyr Glu Ile Asn Leu Glu 95 90 85 Thr Lys Gly Thr Gln Thr Lys Ile Lys Thr Ile Glu Arg Gly Phe Leu 110 105 100 Gly Ala Leu Ile Met Leu His Lys Ala Lys Val Gly Ile Val Phe Gln 40 125 120 115 , Ala Leu Leu Gly Ile Phe Cys Val Phe Leu Leu Leu Leu Phe Tyr Leu Ser 140 135 130 Ala Phe Leu Met Val Ala Phe Lys Asp Thr Lys Arg Met Phe Ile Ser 14s 150 155 160 45 Val Leu Ile Gly Ser Val Val Phe Phe Gly Ala Ile Tyr Trp Ser Leu 175 170 165 NFORMATION FOR SEQ ID NO:99: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 222 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES

9 ~ (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...222 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Met Phe Lys Asn Ala Leu Asn Ile Gln Asp Phe Ser Phe Lys Asn His 1 5 10 15

Thr Ser Thr Ala Ile Ile Gly Thr Asn Gly Ala Gly Lys Ser Thr Leu 20 25 30

Ile Asn Thr Ile Leu Gly Ile Arg Ser Asp Tyr Asn Phe Lys Ala Gln 35 40 45

Asn Asn Asn Ile Pro Tyr His Asp Asn Val Ile Pro Gln Arg Lys Gln 50 55 60

Leu Gly Val Val Ser Asn Leu Phe Asn Tyr Pro Pro Gly Leu Asn Ala 65 70 75 80

Asn Asp Leu Phe Lys Phe Tyr Gln Phe Phe His Lys Asn Cys Thr Leu 85 30 95

Asp Leu Phe Glu Lys Asn Leu Leu Asn Lys Thr Tyr Glu His Leu Ser 100 105 110

Asp Gly Gln Lys Gln Arg Leu Lys Ile Asp Leu Ala Leu Ser His His 115 120 125

Pro Gln Leu Val Ile Met Asp Glu Pro Glu Thr Ser Leu Glu Gln Asn 130 135 140

Ala Leu Ile Arg Leu Ser Asn Leu Ile Ser Leu Arg Asn Thr Gln Gln 145 150 155 160

Leu Thr Ser Ile Ile Ala Thr His Asp Pro Ile Val Leu Asp Ser Cys 165 170 175

Glu Trp Val Leu Leu Leu Lys Asn Gly Asn Ile Ala Gln Tyr Lys Pro 180 185 190

Leu Asn Ser Ile Leu Lys Ser Val Ala Lys Thr Phe Asn Phe Lys Glu 195 200 205

Lys Pro Thr Thr Lys Asp Leu Leu Ala Leu Leu Lys Asp Ile 210 215 220 (2) INFORMATION FOR SEQ ID NO:100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 406 amino acids (B) TYPE: amino acid : (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...406 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

Met Tyr Ala Ala His Pro Ile Lys Pro Ile Lys Ala Pro Lys Leu Lys

YEN

1 5 10 15

Ser Gln Phe Leu Arg Arg Val Phe Val Gly Ala Ser Ile Arg Arg Trp 20 25 30

Asn Asp Gln Ala Cys Pro Leu Glu Phe Val Glu Leu Asp Lys Gln Ala 35 40 45

His Lys Ala Met Ile Ala Tyr Leu Leu Ala Lys Asp Leu Lys Asp Arg 50 55 60 0

Gly Lys Asp Leu Asp Leu Asp Leu Leu Ile Lys Tyr Phe Cys Phe Glu 65 70 75 80

Phe Leu Glu Arg Leu Val Leu Thr Asp Ile Lys Pro Pro Ile Phe Tyr 85 90 95

Ala Leu Gln Gln Thr His Ser Lys Glu Leu Ala Ser Tyr Val Ala Gin 100 105 110

Ser Leu Gln Asp Glu Ile Ser Ala Tyr Phe Ser Leu Glu Glu Leu Lys 115 120 125

Glu Tyr Leu Ser His Arg Pro Gln Ile Leu Glu Thr Gln Ile Leu Glu 130 135 140

Ser Ala His Phe Tyr Ala Ser Lys Trp Glu Phe Asp Ile Ile Tyr His 145 150 155 160

Phe Asn Pro Asn Met Tyr Gly Val Lys Glu Ile Lys Asp Lys Ile Asp 165 170 175

Lys Gln Leu His Asn Asn Asp His Leu Phe Glu Gly Leu Phe Gly Glu 180 185 190

Lys Glu Asp Leu Lys Lys Leu Val Ser Met Phe Gly Gln Leu Arg Phe 195 200 205

Gln Lys Arg Trp Ser Gln Thr Pro Arg Val Pro Gln Thr Ser Val Leu 210 215 220

Gly His Thr Leu Cys Val Ala Ile Met Gly Tyr Leu Leu Ser Phe Asp 225 230 235 240

Leu Lys Ala Cys Lys Ser Met Arg Ile Asn His Phe Leu Gly Gly Leu 245 250 255

Phe His Asp Leu Pro Glu Ile Leu Thr Arg Asp Ile Ile Thr Pro Ile 260 265 270

Lys Gln Ser Val Ala Gly Leu Asp His Cys Ile Lys Glu Ile Glu Lys 275 280 285

Lys Glu Met Gln Asn Lys Val Tyr Ser Phe Val Ser Leu Gly Val Gln 290 295 300

Glu Asp Leu Lys Tyr Phe Thr Glu Asn Glu Phe Lys Asn Arg Tyr Lys 305 310 315 320

Asp Lys Ser His Gln Ile Val Phe Thr Lys Asp Ala Glu Glu Leu Phe 325 330 335

Thr Leu Tyr Asn Ser Asp Glu Tyr Leu Gly Val Cys Gly Glu Leu Leu 340 345 ’ 350

Lys Val Cys Asp His Leu Ser Ala Phe Leu Glu Ala Gln Ile Ser Leu 355 360 365

Ser His Gly Ile Ser Ser Tyr Asp Leu Ile Gln Gly Ala Lys Asn Leu 370 375 380

Leu Glu Leu Arg Ser Gln Thr Glu Leu Leu Asp Leu Asp Leu Gly Lys 385 390 395 400

Leu Phe Arg Asp Phe Lys 405 (2) INFORMATION FOR SEQ ID NO:101: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: 5 (A) ORGANISM: Helicobacter pylori , (ix) FEATURE: (A) NAME/ KEY: misc feature ' (B) LOCATION 1...335 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101: Val Leu Trp Val Leu Tyr Phe Leu Thr Ser Leu Phe Ile Cys Ser Leu 10 5 1 15 Ile Val Leu Trp Ser Lys Lys Ser Met Leu Phe Val Asp Asn Ala Asn 25 20 Lys Ile Gln Gly Phe His Ala Arg Thr Pro Arg Ala Gly Gly Leu 40 35 Gly Ile Phe Leu Ser Phe Ala Leu Ala Cys Tyr Leu Glu Pro Phe Glu 20 60 55 50 Met Pro Phe Lys Gly Pro Phe Val Phe Leu Gly Leu Ser Leu Val Phe 80 75 70 65 Leu Ser Gly Phe Leu Glu Asp Ile Asn Leu Ser Leu Ser Pro Lys Ile 95 90 85 25 Arg Leu Ile Leu Gln Ala Val Gly Val val Cys Ile Ile Ser Ser Thr 110 105 100 Pro Leu Val Val Ser Asp Phe Ser Pro Leu Phe Ser Leu Pro Tyr Phe 125 120 115 Ile Ala Phe Leu Phe Ala Ile Phe Met Leu Val Gly Ile Ser Asn Ala 30 140 135 130 Ile Asn Ile Ile Asp Gly Phe Asn Gly Leu Ala Ser Gly Ile Cys Ala 160 155 150 145 Ile Ala Leu Leu Val Ile His Tyr Ile Asp Pro Ser Ser Leu Ser Cys 175 170 165 35 Leu Leu Ala Tyr Met Val Leu Gly Phe Met Val Leu Asn Phe Pro Ser 190 185 180 Gly Lys Ile Phe Leu Gly Asp Gly Gly Ala Tyr Phe Leu Gly Leu Val 205 200 195 Cys Gly Ile Ser Leu Leu His Leu Ser Leu Glu Gln Lys Ile Ser 1 40 220 215 210 Phe Phe Gly Leu Asn Leu Met Leu Tyr Pro Val Ile Glu Val Leu Phe 240 235 230 225 Ser Ile Leu Arg Arg Lys Ile Lys Arg Gln Lys Ala Thr Met Pro Asp 255 250 245 45 Asn Leu His Leu His Thr Leu Leu Phe Lys Phe Leu Gln Gln Arg Ser 270 265 260 Phe Asn Tyr Pro Asn Pro Leu Cys Ala Phe Ile Leu Ile Leu Cys Asn 285 280 275 Leu Pro Phe Ile Leu Ile Ser Val Leu Phe Arg Leu Asp Ala Tyr Ala 50 300 285 290 Leu Ile Val Ile Ser Leu Val Phe Ile Ala Cys Tyr Leu Ile Gly Tyr 320 315 310 305 Ala Tyr Leu Asn Arg Gln Val Cys Ala Leu Glu Lys Arg Ala Phe 335 330 325 55 INFORMATION FOR SEQ ID NO:102: (2) (i) SEQUENCE CHARACTERISTICS: yey

N

(A) LENGTH: 96 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES i (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 1 ( ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...96 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

Met Lys Lys Val Ile Val Ala Leu Gly Val Leu Ala Phe Ala Asn Val 1 5 10 15

Leu Met Ala Thr Asp Val Lys Ala Leu Val Lys Gly Cys Ala Ala Cys 20 25 30

His Gly Val Lys Phe Glu Lys Lys Ala Leu Gly Lys Ser Lys Ile Val 35 40 45

Asn Met Met Ser Glu Lys Glu Ile Glu Glu Asp Leu Met Ala Phe Lys 50 55 60

Ser Gly Ala Asn Lys Asn Pro Val Met Thr Ala Gln Ala Lys Lys Leu 65 70 75 80

Ser Asp Glu Asp Ile Lys Ala Leu Ala Lys Tyr Ile Pro Thr Leu Lys 85 90 95 (2) INFORMATION FOR SEQ ID NO:103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 156 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...156 (x1) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

Met Arg Asp Phe Asn Asn Ile Gln Ile Thr Arg Leu Lys Val Arg Gln 1 5 10 15

Asn Ala Val Phe Glu Lys Leu Asp Leu Glu Phe Lys Asp Gly Leu Ser: 20 25 30

Ala Ile ser Gly Ala Ser Gly val Gly Lys Ser Val Leu Ile Ala Ser 35 40 45

Leu Leu Gly Ala Phe Gly Leu Lys Glu Ser Asn Ala Ser Asn Ile Glu 50 55 60

Val Glu Leu Ile Ala Pro Phe Leu Asp Thr Glu Glu Tyr Gly Ile Phe

N 80 75 70 65 Arg Glu Asp Glu His Glu Pro Leu Val Ile Ser Val Ile Lys Lys Glu 95 90 85 Lys Thr Arg Tyr Phe Leu Asn Gln Thr Ser Leu Ser Lys Asn Thr Leu 110 105 100 5 Lys Ala Leu Leu Lys Gly Leu Ile Lys Arg Leu Ser Asn Asp Arg Phe 125 120 115 Ser Gln Asn Glu Leu Asn Asp Ile Leu Met Leu Ser Leu Leu Asp Gly ' 140 135 130 Tyr Ile Gln Asn Lys Asn Arg Arg Leu Ala Pro Phe 10 1 150 155 145 INFORMATION FOR SEQ ID NO:104: (2) (i) SEQUENCE CHARACTERISTICS: 15 (A) LENGTH: 118 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein 20 (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 25 (ix ) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...118 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104: Val Met Leu Met Ala Ile Phe Thr Pro Tyr Ile Leu Ile Leu Lys Met 10 5 1 Met Lys Lys Ser Met Ser Leu Phe Ala Asn Met Gly Leu Glu Gln Ile 35 25 20 Phe Cys Asn Arg Asp Ile Lys Asp Leu Asn Asp Phe Val Phe Gly Ile 40 3 5 Glu Val Gly Leu Asp Ser Asn Ala Arg Lys Asn Arg Ser Arg Lys Ala 60 55 50 40 Met Glu Asn His Leu Ile Gly Leu Phe Val Gln Ala Gln Leu Asn Phe 80 75 70 65 Lys Glu Gln Val Asp Ile Arg Glu Phe Glu Asp Leu Arg Gln Ala Phe 95 90 85 Gly Asn Asp Thr Lys Lys Phe Asp Phe Val Ile Phe Ser Lys Glu Lys 45 110 105 100 Thr Tyr Phe His Arg Ser 115 INFORMATION FOR SEQ ID NO:105: (2) 50 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 55 (ii) ) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature : (B) LOCATION 1...355 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105: .

Met Asn Ile Lys Ile Leu Lys Ile Leu Val Gly Gly Leu Phe Phe Leu 1 5 10 15

Ser Leu Asn Ala His Leu Trp Gly Lys Gln Asp Asn Ser Phe Leu Gly 20 25 30

Ile Gly Glu Arg Ala Tyr Lys Ser Gly Asn Tyr Ser Lys Ala Ala Ser 35 40 45

Tyr Phe Lys Lys Ala Cys Asn Asp Gly Val Ser Glu Gly Cys Thr Gln 50 55 60

Leu Gly Ile Ile Tyr Glu Asn Gly Gln Gly Thr Arg Ile Asp Tyr Lys 5 70 75 80

Lys Ala Leu Glu Tyr Tyr Lys Thr Ala Cys Gln Ala Asp Asp Arg Glu 85 90 95

GlyCys Phe Gly Leu Gly Gly Leu Tyr Asp Glu Gly Leu Gly Thr Ala 100 105 110 ©ln Asn Tyr Gln Glu Ala Ile Asp Ala Tyr Ala Lys Ala Cys Val Leu 115 120 125

Lys His Pro Glu Ser Cys Tyr Asn Leu Gly Ile Ile Tyr Asp Arg Lys 130 135 140

Ile Lys Gly Asn Ala Ala Gln Ala val Thr Tyr Tyr Gln Lys Ser Cys 5 150 155 160

Asn Phe Asp Met Ala Lys Gly Cys Tyr Ile Leu Gly Thr Ala Tyr Glu 165 170 175

Lys Gly Phe Leu Glu Val Lys Gln Ser Asn His Lys Ala Val Ile Tyr 180 185 190

Tyr Leu Lys Ala Cys Arg Leu Asn Glu Gly Gln Ala Cys Arg Ala Leu 195 200 205

Gly Ser Leu Phe Glu Asn Gly Asp Ala Gly Leu Asp Glu Asp Phe Glu 210 215 220

Val Ala Phe Asp Tyr Leu Gln Lys Ala Cys Ala Leu Asn Asn Ser Gly 22s 230 235 240

GlyCys Ala Ser Leu Gly Ser Met Tyr Met Leu Gly Arg Tyr Val Lys. 245 250 - 255

Lys Asp Pro Gln Lys Ala Phe Asn Tyr Phe Lys Gln Ala Cys Asp Met 260 265 270

Gly Ser Ala Val Ser Cys Ser Arg Met Gly Phe Met Tyr Ser Gln Gly 275 280 285

Asp Thr Val Ser Lys Asp Leu Arg Lys Ala Leu Asp Asn Tyr Glu Arg 250 295 300

GlyCys Asp Met Gly Asp Glu Val Gly Cys Phe Ala Leu Ala Gly Met 5 310 315 320

Tyr Tyr Asn Met Lys Asp Lys Glu Asn Ala Ile Met Ile Tyr Asp Lys 325 330 335

GlyCys Lys Leu Gly Met Lys Gln Ala Cys Glu Asn Leu Thr Lys Leu 340 345 350 arg Gly Tyr 355 (2) INFORMATION FOR SEQ ID NO:106:

Yen : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 193 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: ' ( A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature {B) LOCATION 1...193 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

Met Lys Glu Lys Asn Phe Trp Pro Leu Gly Ile Met Ser Val Leu Ile 1 5 10 15

Phe Gly Leu Gly Ile Val Val Phe Leu Val Val Phe Ala Leu Lys Asn 20 25 30

Ser Pro Lys Asn Asp Leu Val Tyr Phe Lys Gly His Asn Glu Val Asp 35 40 45

Leu Asn Phe Asn Ala Met Leu Lys Thr Tyr Glu Asn Phe Lys Ser Asn 50 55 60 -

Tyr Arg Phe Ser Val Gly Leu Lys Pro Leu Thr Glu Ser Pro Lys Thr 65 70 75 80

Pro Ile Leu Pro Tyr Phe Ser Lys Gly Thr His Gly Asp Lys Lys Ile 85 90 95

Gln Glu Asn Leu Leu Asn Asn Ala Leu Ile Leu Glu Lys Ser Asn Thr 100 105 110

Leu Tyr Ala Gln Leu Gln Pro Leu Lys Pro Ala Leu Asp Ser Pro Asn 115 120 125

Ile Gln Val Tyr Leu Ala Phe Tyr Pro Ser Gln Ser Gln Pro Arg Leu 130 135 140

Leu Gly Thr Leu Asp Cys Lys Asn Ala Cys Glu Pro Leu Lys Phe Asp 145 150 155 160

Leu Leu Glu Gly Asp Lys Val Gly Arg Tyr Lys Ile Leu Phe Lys Phe 165 170 15

Val Phe Lys Asn Lys Glu Glu Leu Ile Leu Glu Gln Leu Ala Phe Phe 180 185 130

Lys (2) INFORMATION FOR SEQ ID NO:107: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 289 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL : YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

Hand (ix) FEATURE: (A) NAME/KEY: misc_feature (BR) LOCATION 1...289 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107: 5 Leu Gly Ile Asn Met Cys Ser Lys Lys Ile Arg Asn Leu Ile Leu Cys ' 15 10 5 1 Phe Gly Phe Ile Leu Ser Leu Cys Ala Glu Glu Asn Ile Thr Lys Glu ' 30 25 20 10 Asn Met Thr Glu Thr Asn Thr Thr Glu Glu Asn Thr Pro Lys Asp Ala 40 35 pro Ile Leu Leu Glu Glu Lys Arg Ala Gln Thr Leu Glu Leu Lys Glu 60 55 50 Glu Asn Glu val Ala Lys Lys Ile Asp Glu Lys Ser Leu Leu Glu Glu 15 80 175 70 65 Ile His Lys Lys Lys Arg Gln Leu Tyr Met Leu Lys Gly Glu Leu His 95 90 85 Glu Lys Asn Glu Ser Ile Leu Phe Gln Gln Met Ala Lys Asn Lys Ser 110 105 100 20 Gly Phe Phe Ile Gly Val Ile Leu Gly Asp Ile Gly Ile Asn Ala Asn 125 120 115 Pro Tyr Glu Lys Phe Glu Leu Leu Ser Asn Ile Gln Ala Ser Pro Leu 140 135 130 Leu Tyr Gly Leu Arg Ser Gly Tyr Gln Lys Tyr Phe Ala Asn Gly Ile 25 160 155 150 145 Ser Ala Leu Arg Phe Tyr Gly Glu Tyr Leu Gly Gly Ala Met Lys Gly 175 170 165 Phe Lys Ser Asp Ser Leu Ala Ser Tyr Gln Thr Ala Ser Leu Asn Ile 190 185 180 30 Asp Leu Leu Met Asp Lys Pro Ile Asp Lys Glu Lys Arg Phe Ala Leu 205 200 185 Gly Ile Phe Gly Gly Val Gly Val Gly Trp Asn Gly Met Tyr Gln Asn 220 215 210 Leu Lys Glu Ile Arg Gly Tyr Ser Gln Pro Asn Ala Phe Gly Leu Val 35 240 235 230 - 225 Leu Asn Leu Gly Val Ser Met Thr Leu Asn Leu Lys His Arg Phe Glu 255 250 245 Leu Ala Leu Lys Met Pro Pro Leu Lys Glu Thr Ser Gln Thr Phe Leu 270 265 260 40 Tyr Tyr Phe Lys Ser Thr Asn Ile Tyr Tyr Ile Ser Tyr Asn Tyr Leu 285 280 275 Leu - 45 INFORMATION FOR SEQ ID NO:108: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 668 amino acids (B) TYPE: amino acid 50 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES 35 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

YEA

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...668 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

Met Arg Lys Leu Phe Ile Pro Leu Leu Leu Phe Ser Ala Leu Glu Ala 1 5 10 15 L Asn Glu Lys Asn Gly Phe Phe Ile Glu Ala Gly Phe Glu Thr Gly Leu 20 25 30

Leu Glu Gly Thr Gln Thr Gln Glu Lys Arg His Thr Thr Thr Lys Asn 35 40 45

Thr Tyr Ala Thr Tyr Asn Tyr Leu Pro Thr Asp Thr Ile Leu Lys Arg 50 55 60

Ala Ala Asn Leu Phe Thr Asn Ala Glu Ala Tle Ser Lys Leu Lys Phe 65 70 75 80

Ser Ser Leu Ser Pro Val Arg Val Leu Tyr Met Tyr Asn Gly Gln Leu 85 90 95

Thr Ile Glu Asn Phe Leu Pro Tyr Asn Leu Asn Asn Val Lys Leu Ser 100 105 110

Phe Thr Asp Ala Gln Gly Asn Thr Ile Asp Leu Gly Val Ile Glu Thr 115 120 125

Ile Pro Lys His Ser Lys Ile Val Leu Pro Gly Glu Ala Phe Asp Ser 130 135 140

Leu Lys Glu Ala Phe Asp Lys Ile Asp Pro Tyr Thr Leu Phe Leu Pro 145 150 155 160

Lys Phe Glu Ala Thr Ser Thr Ser Ile Ser Asp Thr Asn Thr Gln Arg 165 170 175

Val Phe Glu Thr Leu Asn Asn Ile Lys Thr Asn Leu Ile Met Lys Tyr 180 185 190

Ser Asn Glu Asn Pro Asn Asn Phe Asn Thr Cys Pro Tyr Asn Asn Asn 195 200 205

Gly Asn Thr Lys Asn Asp Cys Trp Gln Asn Phe Thr Pre Gln Thr Ala 210 215 220

Glu Glu Phe Thr Asn Leu Met Leu Asn Met Ile Ala Val Leu Asp Ser 225 230 235 240

Gln Ser Trp Gly Asp Ala Ile Leu Asn Ala Pro Phe Glu Phe Thr Asn 245 250 255

Ser Ser Thr Asp Cys Asp Ser Asp Pro Ser Lys Cys Val Asn Pro Gly 260 265 270

Val Asn Gly Arg Val Asp Thr Lys Val Asp Gln Gln Tyr Ile Leu Asn ) 275 280 285

Lys Gln Gly Ile Ile Asn Asn Phe Arg Lys Lys Ile Glu Ile Asp Ala 290 285 7 300 val 1 Leu Lys Asn Ser Gly Val Val Gly Leu Ala Asn Gly Tyr Gly 305 310 315 320

Asn Asp Gly Glu Tyr Gly Thr Leu Gly Val Glu Ala Tyr Ala Leu Asp 325 330 335

Pro Lys Lys Leu Phe Gly Asn Asp Leu Lys Thr Ile Asn Leu Glu Asp 340 345 350

Leu Arg Thr Ile Leu His Glu Phe Ser His Thr Lys Gly Tyr Gly His 355 360 365

Asn Gly Asn Met Thr Tyr Gln Arg Val Pro Val Thr Lys Asp Gly Gln 370 375 380 val Glu Lys Asp Ser Asn Gly Lys Pro Lys Asp Ser Asp Gly Leu Pro 385 350 3395 400

Tyr Asn Val Cys Ser Leu Tyr Gly Gly Ser Asn Gln Pro Ala Phe Pro 405 410 415

Ser Asn Tyr Pro Asn Ser Ile Tyr His Asn Cys Ala Asp Val Pro Ala

YEA

420 425 430

Gly Phe Leu Gly Val Thr Ala Ala Val Trp Gln Gln Leu Ile Asn Gln 435 440 445

Asn Ala Leu Pro Ile Asn Tyr Ala Asn Leu Gly Ser Gln Thr Asn Tyr 450 455 460

Asn Leu Asn Ala Ser Leu Asn Thr Gln Asp Leu Ala Asn Ser Met Leu 465 470 475 480

Ser Thr Ile Gln Lys Thr Phe Val Thr Ser Ser Val Thr Asn His His 485 4390 495 1

Phe Ser Asn Ala Ser Gln Ser Phe Arg Ser Pro Ile Leu Gly Val Asn 500 505 510

Ala Lys Ile Gly Tyr Gln Asn Tyr Phe Asn Asp Phe Ile Gly Leu Ala 515 520 525

Tyr Tyr Gly Ile Ile Lys Tyr Asn Tyr Ala Lys Ala Val Asn Gln Lys 530 535 540

Val Gln Gln Leu Ser Tyr Gly Gly Gly Ile Asp Leu Leu Leu Asp Phe 545 550 555 560

Ile Thr Thr Tyr Ser Asn Lys Asn Ser Pro Thr Gly Ile Gln Thr Lys 565 570 575

Arg Asn Phe Ser Ser Ser Phe Gly Ile Phe Gly Gly Leu Arg Gly Leu 580 585 590

Tyr Asn Ser Tyr Tyr Val Leu Asn Lys Val Lys Gly Ser Gly Asn Leu 5395 600 605

Asp Val Ala Thr Gly Leu Asn Tyr Arg Tyr Lys His Ser Lys Tyr Ser 610 615 620

Val Gly Ile Ser Ile Pro Leu Ile Gln Arg Lys Ala Ser Val Val Ser 625 630 635 640

Ser Gly Gly Asp Tyr Thr Asn Ser Phe Val Phe Asn Glu Gly Ala Ser 645 650 655

His Phe Lys Val Phe Phe Asn Tyr Gly Trp Val Phe 660 665 . (2) INFORMATION FOR SEQ ID NO:109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 amino acids (B) TYPE: amino acid * (i) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) ) HYPOTHETICAL: YES A (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...63 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

Met Asn Thr Glu Ile Leu Thr Ile Met Leu Val Val Ser Val Leu Met 1 5 10 15

Gly Leu Val Gly Leu Ile Ala Phe Leu Trp Gly Val Lys Ser Gly Gln 20 25 30

Phe Asp Asp Glu Lys Arg Met Leu Glu Ser Val Leu Tyr Asp Ser Ala 35 40 45

Ser Asp Leu Asn Glu Ala Ile Leu Gln Glu Lys Arg Gln Lys Asn

Yo. .

N

50 55 60 (2) INFORMATION FOR SEQ ID NO:110: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 406 amino acids for (B) TYPE: amino acid ¢ (D) TOPOLOGY: linear {ii) MOLECULE TYPE : protein 1 (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...406 (xi) SEQUENCE DESCRIPTION : SEQ ID NO: 110:

Met Val Phe Phe His Lys Lys Ile Ile Leu Asn Phe Ile Tyr Ser Leu 1 5 10 15

Met Val Ala Phe Leu Phe His Leu Ser Tyr Gly val Leu Leu Lys Ala 20 25 30

Asp Gly Met Ala Lys Lys Gln Thr Leu Leu Val Gly Glu Arg Leu Val 35 40 45 1 Trp Asp Lys Leu Thr Leu Leu Gly Phe Leu Glu Lys Asn His Ile Pro 50 55 60

Gln Lys Leu Tyr Tyr Asn Leu Ser Ser Gln Asp Lys Glu Leu Ser Ala 65 70 75 80

Glu Ile Gln Ser Asn Val Thr Tyr Tyr Thr Leu Arg Asp Ala Asn Asn 85 90 95

Thr Leu Ile Gln Ala Leu Ile Pro Ile Ser Gln Asp Leu Gln Ile His 100 105 110

Ile Tyr Lys Lys Gly Glu Asp Tyr Phe Leu Asp Phe Ile Pro Ile Val 115 120 125

Phe Thr Arg Lys Glu Arg Thr Leu Leu Leu Ser Leu Gln Thr Ser Pro 130 135 140

Tyr Gln Asp Ile Val Lys Ala Thr Asn Asp Pro Leu Leu Ala Asn Gln 145 150 155 ’ 160

Leu Met Asn Ala Tyr Lys Lys Ser Val Pro ‘Phe Lys Arg Leu Val Lys 165 170 175 2sn Asp Lys Ile Ala Ile Val Tyr Thr Arg Asp Tyr Arg Val Gly Gln 180 185 190

Ala Phe Gly Gln Pro Thr Ile Lys Met Ala Met Val Ser Ser Arg Leu 195 200 205

His Gln Tyr Tyr Leu Phe Ser His Ser Asn Gly Arg Tyr Tyr Asp Ser 210 215 220

Lys Ala Gln Glu Val Ala Gly Phe Leu Leu Glu Thr Pro Val Lys Tyr 225 230 235 240

Thr Arg Ile Ser Ser Pro Phe Ser Tyr Gly Arg Phe His Pro Val Leu 245 250 255

Lys val Lys Arg Pro His Tyr Gly Val Asp Tyr Ala Ala Lys His Gly 260 265 270

Ser Leu Ile His Ser Ala Ser Asp Gly Arg Val Gly Phe Ile Gly Val 275 280 285

Lys Ala Gly Tyr Gly Lys Val val Glu Ile His Leu Asn Glu Leu Arg

11 290 295 300

Len Val Tyr Ala His Met Ser Ala Phe Ala Asn Gly Leu Lys Lys Gly 305 310 315 320

Ser Phe Val Lys Lys Gly Gln Ile Ile Gly Arg Val Gly Ser Thr Gly 325 330 335

Leu Ser Thr Gly Pro His Leu His Phe Gly Val Tyr Lys Asn Ser Arg 340 345 350

Pro Ile Asn Pro Leu Gly Tyr Ile Arg Thr Ala Lys Ser Lys Leu His 355 360 365

Gly Lys Gln Arg Glu Val Phe Leu Glu Lys Ala Gln Tyr Ser Lys Gln 370 375 380

Lys Leu Glu Glu Leu Phe Lys Thr His Ser Phe Glu Lys Asn Ser Phe 385 390 395 400

Tyr Leu Leu Glu Gly Phe 405 (2) INFORMATION FOR SEQ ID NO:111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE : protein (iii) HYPOTHETICAL: YES {vi} ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...296 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Leu Phe Leu Val Lys Lys Ile Gly Val val Ile Met Ile Leu Val Cys 1 5 10 15

Phe Leu Ala Cys Ser Gln Glu Ser Phe Ile Lys Met Gln Lys Lys Ala 20 25 30

Gln Glu Gln Glu Asn Asp Gly Ser Lys Arg Pro Ser Tyr Val Asp Ser 35 40 45

Asp Tyr Glu Val Phe Ser Glu Thr Ile Phe Leu Gln Asn Met Val Tyr 50 55 60

Gla Pro Ile Glu Glu Arg Asn Ala Phe Phe Gln Leu Thr Lys Asp Glu 65 70 75 80

Asp Asn Ser Phe Asn Pro Glu Asn Ser Val Ile Leu Leu Asn Glu Pro 85 90 95

Ser Asp Asn Ser Glu Lys Asn Leu Leu Ser Tyr Pro Asn Asp Pro Asn 100 105 110

Asn Asn Glu Asp Asn Ala Asn Asn Ser Gln Lys Asn Pro Phe Leu Tyr 115 120 125

Lys Pro Lys Arg Lys Thr Lys Asn Pro Lys Leu Ile Glu Tyr Ser Gln 130 135 140

Gln Asp Phe Tyr Pro Leu Lys Asn Gly Asp Ile Ile Met Ser Lys Glu 145 150 155 160

Gly Asp Gln Trp Leu Ile Glu Ile Gln Ser Lys Ala Leu Lys Arg Phe 165 170 175

Leu Lys Asp Gln Asn Asp Lys Asp Arg Gln Ile Gln Thr Phe Thr Phe

YoY180 185 1380

Asn Asp Thr Lys Thr Gln Ile Ala Gln Ile Lys Gly Lys Ile Ser Ser 195 200 1 205

Tyr Val Tyr Thr Thr Asn Asn Gly Ser Leu Ser Leu Arg Pro Phe Tyr 210 215 220

Glu Ser Phe Leu Leu Glu Lys Lys Ser Asp Asn Val Tyr Thr Ile Glu , 225 230 235 240

Asn Lys Ala Leu Asp Thr Met Glu Ile Ser Lys Cys Gln Met Val Leu 245 250 255 1

Lys Lys His Ser Thr Asp Lys Leu Asp Ser Gln His Lys Ala Ile Ser 260 265 270

Ile Asp Leu Asp Phe Lys Lys Glu Arg Phe Lys Ser Asp Thr Glu Leu 275 280 285

Phe Leu Glu Cys Leu Lys Glu Ser 290 295 (2) INFORMATION FOR SEQ ID NO:112: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 248 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) ) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES {vi) ORIGINAL SOURCE: : (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...248 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

Val Ser Tyr Asp Asn Thr Asp Asp Tyr Tyr Phe Pro Arg Asn Gly Val 1 5 10 15

Ile Phe Ser Ser Tyr Ala Thr Met Ser Gly Leu Pro Ser Ser Gly Thr 20 25 30

Leu Asn Ser Trp Asn Gly Leu Gly Gly Asn Val Arg Asn Thr Lys val 35 40 - 45

Tyr Gly Lys Phe Ala Ala Tyr His His Leu Gln Lys Tyr Leu Leu Ile 50 55 60

Asp Leu Ile Ala Arg Phe Lys Thr Gln Gly Gly Tyr Ile Phe Arg Tyr 65 70 75 80

Asn Thr Asp Asp Tyr Leu Pro Leu Asn Ser Thr Phe Tyr Met Gly Gly 85 90 95

Val Thr Thr Val Arg Gly Phe Arg Asn Gly Ser Ile Thr Pro Lys Asp 100 105 110

Glu Phe Gly Leu Trp Leu Gly Gly Asp Gly Ile Phe Thr Ala Ser Thr 115 120 125

Glu Leu Ser Tyr Gly Val Leu Lys Ala Ala Lys Met Arg Leu Ala Trp 130 135 140

Phe Phe Asp Phe Gly Phe Leu Thr Phe Lys Thr Pro Thr Arg Gly Ser 145 . 150 155 160

Phe Phe Tyr Asn Ala Pro Thr Thr Thr Ala Asn Phe Lys Asp Tyr Gly 165 170 175

Val Val Gly Ala Gly Phe Glu Arg Ala Thr Trp Arg Ala Ser Thr Gly

YoY0: 180 185 190

Leu Gln Ile Glu Trp Ile Ser Pro Met Gly Pro Leu Val Leu Ile Phe 185 200 205

Pro Ile Ala Phe Phe Asn Gln Trp Gly Asp Gly Asn Gly Lys Lys Cys 210 215 220

Lys Gly Leu Cys Phe Asn Pro Asn Met Asn Asp Tyr Thr Gln His Phe 225 230 235 240

Glu Phe Ser Met Gly Thr Arg Phe 245 1 (2) INFORMATION FOR SEQ ID ” 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: i (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...335 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:

Val Gln His Phe Asn Phe Leu Tyr Lys Asp Ser Leu Phe Ser Ile Ala 1 5 10 15

Leu Phe Thr Phe Ile Ile Ala Leu Val Ile Leu Leu Glu Gln Ala Arg 20 25 30

Ala Tyr Phe Thr Arg Lys Arg Asn Lys Lys Phe Leu Gln Lys Phe Ala 35 40 45

Gln Asn Gln Asn Ala Tyr Ala Ser Glu Asn Leu Asp Glu Leu Leu 50 55 60

Lys His Ala Lys Ile Ser Ser Leu Met Phe Leu Ala Arg Ala Tyr Ser 65 70 75 80

Lys Ala Asp Val Glu Met Ser Ile Glu Ile Leu Lys Gly Leu Leu Asn 85 90 - 95 ’

Arg Pro Leu Lys Asp Glu Glu Lys Ile Ala Val Leu Asp Leu Leu Ala 100 105 110

Lys Asn Tyr Phe Ser Val Gly Tyr Leu Gln Lys Thr Lys Asp Thr Val 115 120 125

Lys Glu Ile Leu Arg Phe Ser Pro Arg Asn Val Glu Ala Leu Leu Lys 130 135 140

Leu Leu His Ala Tyr Glu Leu Glu Lys Asp Tyr Ser Lys Ala Leu Glu 5 150 155 160

Thr Leu Glu Cys Leu Glu Glu Leu Glu Val Pro Lys Ile Glu Thr Ile 165 , 170 175

Lys Asn Tyr Leu Tyr Leu Met His Leu Ile Glu Asn Lys Glu Asp Ala 180 185 190

Ala Lys Ile Leu His Val Ser Lys Ala Ser Leu Asp Leu Lys Lys Ile 195 200 205

Ala Leu Asn His Leu Lys Ser His Asp Glu Asn Leu Phe Trp Gln Glu 210 215 220

Ile Asp Thr Thr Glu Arg Leu Glu Asn Val Ile Asp Leu Leu Trp Asp

p. Glu Leu Glu Val Leu Arg Ala Leu Leu His Ser Pro Ile Lys Ala 1 285 280 275 Ser Leu Thr Phe Glu Tyr Arg Cys Lys His Cys Lys Gln Ile Phe Pro , 300 295 290 Phe Glu Ser His Arg Cys Pro Val Cys Tyr Gln Leu Ala Phe Met Asp 10 320 315 310 305 Met Val Leu Lys Ile Ser Lys Lys Thr His Ala Met Gly Val Asp 335 330 325 INFORMATION FOR SEQ ID NO:114: (2) 15 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 413 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 20 (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES 25 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 30 (B) LOCATION 1...413 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114: Met Arg Lys Ile Phe Ser Tyr Ile Ser Lys Val Leu Leu Phe Ile Gly 35 10 5 1 Val Val Tyr Ala Glu Pro Asp Ser Lys Val Glu Ala Leu Glu Gly Arg 25 20 Lys Gln Glu Ser Ser Leu Asp Lys Lys Ile Arg Gln Glu Leu Lys Ser 40 35 40 Lys Glu Leu Lys Asn Lys Glu Leu Lys Asn Lys Asp Leu Lys Asn Lys 60 - 55 50 Glu Glu Lys Lys Glu Thr Lys Ala Lys Arg Lys Pro Arg Ala Glu Val 80 75 70 65 His His Gly Asp Ala Lys Asn Pro Thr Pro Lys Ile Thr Pro Pro Lys 45 95 90 85 Ile Lys Gly Ser Ser Lys Gly 731 Gln Asn Gln Gly Val Gln Asn Asn 110 105 100 Ala Pro Lys Pro Glu Glu Lys Asp Thr Thr Pro Gln Ala Thr Glu Lys 125 120 115 50 Asn Lys Glu Thr Ser Pro Sex Ser Gln Phe Asn Ser Ile Phe Gly Asn 140 135 130 Pro Asn Asn Ala Thr Asn Asn Thr Leu Glu Asp Lys Val val Gly Gly 160 155 150 145 Ile Ser Leu Leu Val Asn Gly Ser Pro Ile Thr Leu Tyr Gln Ile Gln 55 175 170 165 Glu Glu Gln Glu Lys Ser Lys Val Ser Lys Ala Gln Ala Arg Asp Arg 150 185 180 Leu Ile Ala Glu Arg Ile Lys Asn Gln Glu Ile Glu Arg Leu Lys Ile

Yoo195 200 205

His Val Asp Asp Asp Lys Leu Asp Gln Glu Met Ala Met Ala Gln 210 215 220

Gln Gln Gly Met Asp Leu Asp His Phe Lys Gln Met Leu Met Ala Glu 225 230 235 240

Gly His Tyr Lys Leu Tyr Arg Asp Gln Leu Lys Glu His Leu Glu Met 245 250 255

Gln Glu Leu Leu Arg Asn Ile Leu Leu Thr Asn Val Asp Thr Ser Ser 3 260 265 270

Glu Thr Lys Met Arg Glu Tyr Tyr Asn Lys His Lys Glu Gln Phe Ser 275 280 285

Ile Pro Thr Glu Ile Glu Thr Val Arg Tyr Thr Ser Thr Asn Gln Glu 290 295 300

Asp Leu Glu Arg Ala Met Ala Asp Pro Asn Leu Glu Val Pro Gly 1 5 310 315 320

Ser Lys Ala Asn Glu Lys Ile Glu Met Lys Thr Leu Asn Pro Gln Ile 325 330 335

Ala Gln Val Phe Ile Ser His Glu Gln Gly Ser Phe Thr Pro Val Met 340 345 350

Asn Gly Gly Gly Gly Gln Phe Ile Thr Phe Tyr Ile Lys Glu Lys Arg 355 360 365

Gly Lys Asn Glu Val Ser Phe Ser Gln Ala Lys Gln Phe Ile Ala Gln 370 375 380

Lys Leu Val Glu Glu Ser Lys Asp Lys Ile Leu Glu Glu His Phe Glu 5 390 395 400

Lys Leu Arg Val Lys Ser Arg Ile Val Met Ile Arg Glu 405 410 (2) INFORMATION FOR SEQ ID NO:115: (1) SEQUENCE CHARACTERISTICS: . (A) LENGTH: 186 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: i (A) NAME/KEY: misc_feature : (B) LOCATION 1...186 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115:

Met Ile Lys Arg Ile Ala Cys Ile Leu Ser Leu Ser Ala Ser Leu Ala 1 5 10 15

Leu Ala Gly Glu Val Asn Gly Phe Phe Met Gly Ala Gly Tyr Gln Gln 20 25 30

Gly Arg Tyr Gly Pro Tyr Asn Ser Asn Tyr Ser Asp Trp Arg His Gly 35 40 45

Asn Asp Leu Tyr Gly Leu Asn Phe Lys Leu Gly Phe Val Gly Phe Ala 50 55 60

Asn Lys Trp Phe Gly Ala Arg 1 Tyr Gly Phe Leu Asp Trp Phe Asn 65 70 75 80

Thr Ser Gly Thr Glu His Thr Lys Thr Asn Leu Leu Thr Tyr Gly Gly

. You 85 90 95

Gly Gly Asp Leu Ile Val Asn Leu Ile Pro Leu Asp Lys Phe Ala Leu 100 105 110

Gly Leu Ile Gly Gly Val Gln Leu Ala Gly Asn Thr Trp Met Phe Pro 115 120 125

Tyr Asp Val Asn Gln Thr Arg Phe Gln Phe Leu Trp Asn Leu Gly Gly 130 135 140 $

Arg Met Arg Val Gly Asp Arg Ser Ala Phe Glu Ala Gly Val Lys Phe 145 150 155 160 .

Pro Met Val Asn Gln Gly Ser Lys Asp Val Gly Leu Ile Arg Tyr Tyr 165 170 175

Ser Trp Tyr Val Asp Tyr Val Phe Thr Phe 180 185 (2) INFORMATION FOR SEQ ID NO:116: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 242 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...242 (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 116:

Met Lys Lys Phe Phe Ser Gln Ser Leu Leu Ala Leu Ile Ile Ser Met 1 5 10 15

Asn Ala Val Ser Gly Met Asp Gly Asn Gly Val Phe Leu Gly Ala Gly 20 25 30

Tyr Leu Gln Gly Gln Ala Gln Met His Ala Asp Ile Asn Ser Gln Lys 35 40 45

Gln Ala Thr Asn Ala Thr Ile Lys Gly Phe Asp Ala Leu Leu Gly Tyr 50 55 60

Gln Phe Phe Phe Glu Lys His Phe Gly Leu Arg Leu Tyr Gly Phe Phe 65 70 75 80

Asp Tyr Ala His Ala Asn Ser Ile Lys Leu Lys Asn Pro Asn Tyr Asn 85 90 95

Ser Glu Ala Ala Gln Val Ala Ser Gln Ile Leu Gly Lys Gln Glu Ile 100 105 110

Asn Arg Leu Thr Asn Ile Ala Asp Pro Arg Thr Phe Glu Pro Asn Met 11s 120 125

Leu Thr Tyr Gly Gly Ala Met Asp Val Met Val Asn Val Ile Asn Asn 130 135 140

Gly Ile Met Ser Leu Gly Ala Phe Gly Gly Ile Gln Leu Ala Gly Asn 145 150 155 160

Ser Trp Leu Met Ala Thr Pro Ser Phe Glu Gly Ile Leu val Glu Gln 165 170 175

Ala Leu Val Ser Lys Lys Ala Thr Ser Phe Gln Phe Leu Phe Asn Val 180 185 130

Gly Ala Arg Leu Arg Ile Leu Lys His Ser Ser Ile Glu Ala Gly Val

YoVv 195 200 205

Lys Phe Pro Met Leu Lys Lys Asn Pro Tyr Ile Thr Ala Lys Asn Leu 210 215 220

Asp Ile Gly Phe Arg Arg Val Tyr Ser Trp Tyr Val Asn Tyr Val Phe 225 230 235 240

Thr Phe (2) INFORMATION FOR SEQ ID NO:117: . (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 256 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear : (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A) NAME/KEY: misc_feature {B) LOCATION 1...256 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

Met Gly Tyr Ala Ser Lys Leu Ala Leu Lys Ile Cys Leu Val Gly Leu 1 5 10 15

Cys Leu Phe Ser Thr Leu Gly Ala Glu His Leu Glu Gln Lys Gly Asn 20 25 30

Tyr Ile Tyr Lys Gly Glu Glu Ala Tyr Asn Asn Lys Glu Tyr Glu Arg 35 Ala Ala Ser Phe Tyr Lys Ser Ala Ile Lys Asn Gly Glu Ser Leu Ala 60

Tyr Ile Leu Leu Gly Ile Met Tyr Glu Asn Gly Arg Gly Val Pro Lys 65 70 75 80

Asp Tyr Lys Lys Ala Val Glu Tyr Phe Gln Lys Ala Val Asp Asn Asp 40 85 90 95

Ile Pro Arg Gly Tyr Asn Asn Leu Gly Val Met Tyr Lys Glu Gly Lys 100 105 110

Gly Val Pro Lys Asp Glu Lys Lys Ala Val Glu Tyr Phe Arg Ile Ala 115 120 ) 125 45 Thr Glu Lys Gly Tyr Thr Asn Ala Tyr Ile Asn Leu Gly Ile Met Tyr 130 135 140

Met Glu Gly Arg Gly Val Pro Ser Asn Tyr Ala Lys Ala Thr Glu Cys 145 150 155 160

Phe Arg Lys Ala Met His Lys Gly Asn Val Glu Ala Tyr Ile Leu Leu 50 165 170 17s

Gly Asp Ile Tyr Tyr Ser Gly Asn Asp Gln Leu Gly Ile Glu Pro Asp 180 185 190

Lys Asp Lys Ala Val Val Tyr Tyr Lys Met Ala Ala Asp Val Ser Ser 195 200 205 55 Ser Arg Ala Tyr Glu Gly Leu Ser Glu Ser Tyr Arg Tyr Gly Leu Gly 210 215 220

Val Glu Lys Asp Lys Lys Lys Ala Glu Glu Tyr Met Gln Lys Ala Cys 225 230 235 240

Asp Phe Asp Ile Asp Lys Asn Cys Lys Lys Lys Asn Thr Ser Ser Arg

YoA 245 250 255 (2) INFORMATION FOR SEQ ID NO:118: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 657 amino acids (B) TYPE: amino acid ! (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein 1 (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...657 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

Met Arg Lys Leu Phe Ile Pro Leu Leu Leu Phe Ser Ala Leu Glu Ala 1 5 10 15

Asn Glu Lys Asn Gly Phe Phe Ile Glu Ala Gly Phe Glu Thr Gly Leu 20 25 30

Leu Glu Gly Thr Gln Thr Gln Glu Lys Arg His Thr Thr Thr Lys Asn 35 40 45

Thr Tyr Ala Thr Tyr Asn Tyr Leu Pro Thr Asp Thr Ile Leu Lys Arg 50 55 60

Ala Ala Asn Leu Phe Thr Asn Ala Glu Ala Ile Ser Lys Leu Lys Phe 65 70 75 80

Ser Ser Leu Ser Pro Val Arg Val Leu Tyr Met Tyr Asn Gly Gln Leu 85 90 95

Thr Ile Glu Asn Phe Leu Pro Tyr Asn Leu Asn Asn Val Lys Leu Ser 100 105 110

Phe Thr Asp Ala Gln Gly Asn Val Ile Asp Leu Gly Val Ile Glu Thr 115 120 125

Ile Pro Lys His Ser Lys Ile Val Leu Pro Gly Glu Ala Phe Asp Ser 130 135 140

Leu Lys Ile Asp Pro Tyr Thr Leu Phe Leu Pro Lys Ile Glu Ala Thr 145 150 155 160

Ser Thr Ser Ile Ser Asp Ala Asn Thr Gln ‘Arg Val Phe Glu Thr Leu 165 170 175

Asn Lys Ile Lys Thr Asn Leu Val Val Asn Tyr Arg Asn Glu Asn Lys 180 185 190

Phe Lys Asp His Glu Asn His Trp Glu Ala Phe Thr Pro Gln Thr Ala 15 200 205

Glu Glu Phe Thr Asn Leu Met Leu Asn Met Ile Ala Val Leu Asp Ser 210 215 220

Gln Ser Trp Gly Asp Ala Ile Leu Asn Ala Pro Phe Glu Phe Thr Asn 225 230 235 240

Ser Pro Thr Asp Cys Asp Asn Asp Pro Ser Lys Cys Val Asn Pro Gly 245 250 255

Thr Asn Gly Leu Val Asn Ser Lys Val Asp Gln Lys Tyr Val Leu Asn 260 265 270

Lys Gln Asp Ile Val Asn Lys Phe Lys Asn Lys Ala Asp Leu Asp Val 275 280 285

Ile Val Leu Lys Asp Ser Gly val Val Gly Leu Gly Ser Asp Ile Thr

Ake 300 295 290 Pro Ser Asn Asn Asp Asp Gly Lys His Tyr Gly Gln Leu Gly Val val 320 315 310 305 Ala Ser Ala Leu Asp Pro Lys Lys Leu Phe Gly Asp Asn Leu Lys Thr 335 330 325 5 Ile Asn Leu Glu Asp Leu Arg Thr Ile Leu His Glu Phe Ser His Thr : 350 } 345 340 Lys Gly Tyr Gly His Asn Gly Asn Met Thr Tyr Gln Arg Val Pro Val ' 365 360 355 Thr Lys Asp Gly Gln Val Glu Lys Asp Ser Asn Gly Lys Pro Lys Asp 10 380 375 370 Ser Asp Gly Leu Pro Tyr Asn Val Cys Ser Leu Tyr Gly Gly Ser Asn 400 395 390 385 Gln Pro Ala Phe Pro Ser Asn Tyr Pro Asn Ser Ile Tyr His Asn Cys 415 410 405 15 Ala Asp Val Pro Ala Gly Phe Leu Gly Val Thr Ala Ala Val Trp Gln 430 425 420 Gln Leu Ile Asn Gln Asn Ala Leu Pro Ile Asn Tyr Ala Asn Leu Gly 445 440 435 Ser Gln Thr Asn Tyr Asn Leu Asn Ala Ser Leu Asn Thr Gln Asp Leu 20 460 455 450 Ala Asn Ser Met Leu Ser Thr Ile Gln Lys Thr Phe Val Thr Ser Ser 480 475 470 465 Val Thr Asn His His Phe Ser Asn Ala Ser Gln Ser Phe Arg Ser Pro 495 490 485 25 Ile Leu Gly Val Asn Ala Lys Ile Gly Tyr Gln Asn Tyr Phe Asn Asp 510 5085 500 Phe Ile Gly Leu Ala Tyr Tyr Gly Ile Ile Lys Tyr Asn Tyr Ala Lys 525 520 515 Ala Val Asn Gln Lys Val Gln Gln Leu Ser Tyr Gly Gly Gly Ile Asp 30 540 535 530 Leu Leu Leu Asp Phe Ile Thr Thr Tyr Ser Asn Lys Asn Ser Pro Thr 560 555 550 545 Gly Ile Gln Thr Lys Arg Asn Phe Ser Ser Ser Phe Gly Ile Phe Gly 575 570 565 35 Gly Leu Arg Gly Leu Tyr Asn Ser Tyr Tyr Val Leu Asn Lys Val Lys 590 585 580 Gly Ser Gly Asn Leu Asp Val Ala Thr Gly Leu Asn Tyr Arg Tyr Lys 605 600 595 His Ser Lys Tyr Ser Val Gly Ile Ser Ile Pro Leu Ile Gln Arg Lys 40 620 615 610 Ala Ser Val Val Ser Ser Gly Gly Asp Tyr Thr Asn Ser Phe Val Phe 640 635 630 625 Asn Glu Gly Ala Ser His Phe Lys Val Phe Phe Asn Tyr Gly Trp Val 655 650 645 45 Phe INFORMATION FOR SEQ ID NO:119: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 167 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES

Yi. (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...167 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

Met Lys Leu Val Ser Leu Ile Val Ala Leu Val Phe Cys Cys Phe Leu 1 5 10 15

Gly Ala Val Glu Leu Pro Gly Val Tyr Gln Thr Gln Glu Phe Leu Tyr 20 25 30

Met Lys Ser Ser Phe Val Glu Phe Phe Glu His Asn Gly Lys Phe Tyr 35 40 45

Ala Tyr Gly Ile Ser Asp Val Asp Gly Ser Lys Ala Lys Lys Asp Lys 50 55 60

Leu Asn Pro Asn Pro Lys Leu Arg Asn Arg Ser Asp Lys Gly val val 65 70 75 80

Phe Leu Ser Asp Leu Ile Lys Val Gly Glu Gln Ser Tyr Lys Gly Gly 85 90 95 1ys Ala Tyr Asn Phe Tyr Asp Gly Lys Thr Tyr His Val Arg Val Thr 100 105 110

Gln Asn Ser Asn Gly Asp Leu Glu Phe Thr Ser Ser Tyr Asp Lys Trp 115 120 125

Gly Tyr Val Gly Lys Thr Phe Thr Trp Lys Arg Leu Ser Asp Glu Glu 130 135 140

Ile Lys Asn Leu Lys Leu Lys Arg Phe Asn Leu Asp Glu Val Leu Lys 145 150 155 160

Thr Leu Lys Asp Ser Pro Ile 165 (2) INFORMATION FOR SEQ ID NO:120: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 294 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (2) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...294 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

Met Ser Asn Gln Ala Ser His Leu Asp Asn Phe Met Asn Ala Lys Asn 1 5 10 15 33 Pro Lys Ser Phe Phe Asp Asn Lys Gly Asn Thr Lvs Phe Ile Ala Ile 20 25 30

Thr Ser Gly Lys Gly Gly Val Gly Lys Ser Asn Ile Ser Ala Asn Leu 35 40 45

Ala Tyr Ser Leu Tyr Lys Lys Gly Tyr Lys Val Gly Val Phe Asp Ala

50 55 60

Asp Ile Gly Leu Ala Asn Leu Asp Val Ile Phe Gly Val Lys Thr His 65 70 75 80 . Lys Asn Ile Leu His Ala Leu Lys Gly Glu Ala Lys Leu Gln Glu Ile 85 90 95

Ile Cys Glu Ile Glu Pro Gly Leu Cys Leu Ile Pro Gly Asp Ser Gly 100 105 110

Glu Glu Ile Leu Lys Tyr Ile Ser Gly Ala Glu Ala Leu Asp Arg Phe 115 120 125 . val asp Glu Glu Gly Val Leu Ser Ser Leu Asp Tyr Ile Val Ile Asp 130 135 140

Thr Gly Ala Gly Ile Gly Ala Thr Thr Gln Ala Phe Leu Asn Ala Ser 145 150 155 160

Asp Cys Val Val Ile Val Thr Thr Pro Asp Pro Ser Ala Ile Thr Asp 165 170 175

Ala Tyr Ala Cys Ile Lys Ile Asn Ser Lys Asn Lys Asp Glu Leu Phe 180 185 130

Leu Ile Ala Asn Met Val Ala Gln Pro Lys Glu Gly Arg Ala Thr Tyr 15 200 205

Glu Arg Leu Phe Lys Val Ala Lys Asn Asn Ile Ala Ser Leu Glu Leu 210 215 220

His Tyr Leu Gly Ala Ile Glu Asn Ser Ser Leu Leu Lys Arg Tyr Val 225 230 235 240

Arg Glu Arg Lys Ile Leu Arg Lys Ile Ala Pro Asn Asp Leu Phe Ser 245 250 255

Gln Ser Ile Asp Gln Ile Ala Ser Leu Leu Val Ser Lys Leu Glu Thr 260 265 270

Gly Thr Leu Glu Ile Pro Lys Glu Gly Leu Lys Ser Phe Phe Lys Arg 275 280 285

Leu Leu Lys Tyr Leu Gly 290 (2) INFORMATION FOR SEQ ID NO:121: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE : protein (iii) HYPOTHETICAL: YES. (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...372 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

Leu Glu Pro Ser Arg Asn Arg Leu Lys His Ala Ala Phe Phe Val Gly 1 5 10 15

Leu Phe Ile Val Leu Phe Leu Ile Ile Met Lys His Gln Thr Ser Pro 20 25 30

Tyr Ala Phe Thr His Asn Gln Ala Leu Val Thr Gln Thr Pro Pro Tyr 35 40 45

Phe Thr Gln Leu Thr Ile Pro Lys Pro Asn Asp Ala Leu Ser Ala His iy. >» 50 55 60

Ala Ser Ser Leu Ile Ser Leu Pro Asn Asp Asn Leu Leu Ser Ala Tyr 65 70 75 80

Phe Ser Gly Thr Lys Glu Gly Ala Arg Asp Val Lys Ile Ser Ala Asn 85 90 95

Leu Phe Asp Ser Lys Thr Asn Arg Trp Ser Glu Ala Phe Ile Leu Leu 100 105 110 :

Thr Lys Glu Glu Leu Ser His His Ser His Glu Tyr Ile Lys Lys Leu 115 120 125

Gly Asn Pro Leu Leu Phe Leu His Asp Asn Lys Ile Leu Leu Phe Val 130 135 140

Val Gly Val Ser Met Gly Gly Trp Ala Thr Ser Lys Ile Tyr Gln Phe 145 150 155 160

Glu Ser Ala Leu Glu Pro Ile His Phe Lys Phe Ala Arg Lys Leu Ser 165 170 175

Leu Ser Pro Phe Leu Asn Leu Ser His Leu Val Arg Asn Lys Pro Leu 180 185 190

Asn Thr Thr Asp Gly Gly Phe Met Leu Pro Leu Tyr His Glu Leu Ala 15 200 205

Thr Gln Tyr Pro Leu Leu Leu Lys Phe Asp Gln Gln Asn Asn Pro Arg 210 215 220

Glu Leu Leu Arg Pro Asn Thr Leu Asn His Gln Leu Gln Pro Ser Leu 225 230 235 240

Thr Pro Phe Lys Asp Cys Ala Val Met Ala Phe Arg Asn His Ser Phe 245 250 255

Lys Asp Ser Leu Met Leu Glu Thr Cys Lys Thr Pro Thr Asp Trp Gln 260 265 270

Lys Pro Ile Ser Thr Asn Leu Lys Asn Leu Asp Asp Ser Leu Asn Leu 275 280 285

Leu Asn Leu Asn Gly Ile Leu Tyr Leu Ile His Asn Pro Ser Asp Leu 290 2385 300

Ser Leu Arg Arg Lys Glu Leu Trp Leu Ser Lys Leu Glu Asn Ser Asn 305 310 315 320

Ser Phe Lys Thr Leu Lys Val Leu Asp Lys Ala Asn Glu Val Ser Tyr 32s 330 335

Pro Ser Tyr Ser Leu Asn Pro His Phe Ile Asp Ile Val Tyr Thr Tyr 340 345 350

Asn Arg Ser His Ile Lys His Ile Arg Phe Asn Met Ala Tyr Leu Asn 355 360 365 ser Leu Leu Lys 370 (2) INFORMATION FOR SEQ ID NO:122:7 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 978 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear {ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES / (vi) ORIGINAL SOURCE: 53 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME /KEY: misc_feature (B) LOCATION 1...978

Yay (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

Met Lys Lys Arg Lys His Val Ser Lys Lys Val Phe Asn Val Ile Ile 1 5 10 15

Leu Phe Val Ala Val Phe Thr Leu Leu Val Val Ile His Lys Thr Leu 20 25 30 ‘

Ser Asn Gly Ile His Ile Gln Asn Leu Lys Ile Gly Lys Leu Gly Ile 35 40 45

Ser Glu Leu Tyr Leu Lys Leu Asn Asn Lys Leu Ser Leu Glu Val Glu 50 55 60

Arg Val Asp Leu Ser Ser Phe Phe His Gln Lys Pro Thr Lys Lys Arg 65 70 75 80

Leu Glu Val Ser Asp Leu Ile Lys Asn Ile Arg Tyr Gly Ile Trp Ala 85 90 95

Val Ser Tyr Phe Glu Lys Leu Lys Val Lys Glu Ile Ile Leu Asp Asp 100 105 110

Lys Asn Lys Ala Asn Ile Phe Phe Asp Gly Asn Lys Tyr Glu Leu Glu 115 120 125

Phe Pro Gly Ile Lys Gly Glu Phe Ser Leu Glu Asp Asp Lys Asn Ile 130 135 140

Lys Leu Lys Ile Ile Asn Leu Leu Phe Lys Asp Val Lys Val Gln Val 145 150 155 160

Asp Gly Asn Ala His Tyr Ser Pro Lys Ala Arg Lys Met Ala Phe Asn 165 170 175

Leu Ile Val Lys Pro Leu Val Glu Pro Ser Ala Ala Ile Tyr Leu Gln 180 185 190

Gly Leu Thr Asp Leu Lys Thr Ile Glu Leu Lys Ile Asn Thr Ser Pro 195 200 205

Met Lys Ser Leu Ala Phe Leu Lys Pro Leu Phe Gln Arg Gln Ser Gln 210 215 220

Lys Asn Leu Lys Thr Trp Ile Phe Asp Lys Ile Gln Phe Ala Ser Phe 225 230 235 240

Lys Ile Asp Asn Ala Leu Ile Lys Ala Asn Phe Thr Pro Ser Glu Phe 245 250 255

Ile Pro Ser Leu Leu Glu Asn Ser Val Val Lys Ala Thr Leu Ile Lys 260 265 270

Pro Ser Val Val Phe Asn Asp Gly Leu Ser Pro Ile Lys Met Asp Lys } 275 280 285

Thr Glu Leu Ile Phe Lys Asn Lys Gln Leu Leu Ile Gln Pro Gln Lys 290 295 300

Ile Thr Tyr Glu Thr Met Glu Leu Thr Gly Ser Tyr Ala Thr Phe Sex 305 310 315 320

Asn Leu Leu Glu Ala Pro Lys Leu Glu Val Phe Leu Lys Thr Thr Pro 325 330 335

Asn Tyr Tyr Gly Asp Ser Ile Lys Asp Leu Leu Ser Ala Tyr Lys Val 340 345 350

Val Leu Pro Leu Asp Lys Ile Ser Met Pro Ser Ser Ala Asp Leu Lys 355 360 365

Leu Thr Leu Gln Phe Leu Lys Asn Thr Ala Pro Leu Phe Ser Val Gln © 370 375 380

Gly Ser 731 Asn Leu Gln Glu Gly Thr Phe Ser Leu Tyr Asn Ile Pro 385 390 395 400

Leu Tyr Thr Gln Ser Ala Gln Ile Asn Leu Asp Ile Ala Gln Glu Tyr 405 410 415

Gln Tyr Ile Tyr Ile Asp Thr Ile His Thr Arg Tyr Ala Asn Met Leu 420 425 430

Asp Leu Asp Ala Lys Ile Ala Leu Asp Leu Gly Gln Lys Asn Leu Ser 435 440 445

Leu Asp Ser Leu Val His Lys Ile Gln Val Asn Thr Asn Asn Asn Ile 450 455 460

Asn Met Arg Ser Tyr Asp Pro Asn Asn Thr Gln Glu Asp Pro Gln Thr 465 470 475 480

Asn Phe Thr Leu Asp Leu Lys Ser Leu His Ser Ile Ile Gln Glu Gly 485 4350 495

Glu Asn Ser Glu Val Phe Arg Arg Lys Ile Ile Asp Thr Ile Lys Ala + 500 505 S510

Gln Ser Glu Asp Lys Phe Thr Lys Asp Val Phe Tyr Ala Thr Gly Asp , 515 520 525

Thr Leu Lys Ser Leu Ser Leu Ser Phe Asp Phe Ser Asn Pro Asp His 530 535 540

Ile Gln Trp Ser Val Pro Gln Leu Leu Leu Glu Gly Glu Phe Lys Asp 545 550 555 560

Asn Ala Tyr Thr Phe Lys Ile Lys Asp Leu Lys Lys Ile Lys Pro Tyr 565 570 575

Ser Pro Ile Met Asp Tyr Ile Ala Leu Lys Asp Gly Ser Leu Glu Val 580 585 '590

Ser Thr Ser Asp Phe Val Asn Ile Asp Phe Phe Ala Lys Asp Leu Lys 595 600 605

Ile Asn Leu Pro Ile Tyr Arg Ser Asp Gly Ser His Phe Asp Ser Phe 610 615 620

Ser Leu Phe Gly Ser Ile Asn Lys Asp Glu Ile Ser Val Tyr Thr Pro 625 630 635 640

Ser Lys Ser Ile Ser Ile Lys Val Lys Gly Asp Gln Lys Asp Ile Thr 645 650 655

Leu Asn Asn Ile Asp Leu Ser Ile Asp Asp Phe Leu Asp Ser Lys Met 660 665 670

Pro Ala Ile Ala Gly Leu Phe Ser Lys Glu Arg Lys Glu Lys Pro Ser 675 680 685

Ser Lys Glu Ile Gln Asp Glu Asp Val Phe Ile Ser Ala Lys Gln Arg 6590 695 700

Tyr Glu Lys Ala His Lys Ile Ile Pro Ile Ser Thr Arg Ile His Ala 705 710 715 720

Lys Asp Val Val Leu Ile Tyr Lys Lys Met Pro Phe Pro Leu Glu Asn 725 730 735

Leu Asp Ile Val Ala Gln Asp Asp Arg Val Lys Ile Asp Gly Asn Tyr 740 745 750

Lys Asn Ala Met Ile Met Ala Asp Leu Val His Gly Ala Leu Tyr Leu 755 760 765

Lys Ala His Asn Phe Ser Gly Asp Tyr Ile Asn Thr Ile Leu Gln Lys 770 775 780

Asp Phe Val Glu Gly Gly Leu Phe Thr Leu Tle Gly Ala Leu Glu Asp 785 730 795 800

Gln Val Phe Asn Gly Glu Leu Lys Phe Gln Asn Thr Ser Leu Lys Asn 805 810 815

Phe Ala Leu Met Gln Asn Met Val Asn Leu Ile Asn Thr Ile Pro Ser 820 825 830

Leu Ile Val Phe Arg Asn Pro His Leu Gly Ala Asn Gly Tyr Gln Ile 835 840 845

Lys Thr Gly Ser val Val Phe Gly Ile Thr Lys Glu Tyr Leu Gly Leu 850 855 860

Glu Lys Ile Asp Leu Val Gly Lys Thr Leu Asp Ile Ala Gly Asn Gly 85 870 875 880

Ile Ile Glu Leu Asp Lys Asn Lys Leu Asp Leu Asn Leu Glu Val Ser 885 890 895

Thr Ile Lys Ala Leu Ser Asn Val Leu Asn Lys Ile Pro Ile Val Gly

S00 905 910

Tyr Leu Val Leu Gly Lys Gly Gly Lys Ile Thr Thr Asn Val Asn 1

Yo 915 920 925

Lys Gly Thr Leu Asp Lys Pro Lys Thr Gln Val Thr Leu Ala Ser Asp 930 935 940

Ile Ile Gln Ala Pro Phe Lys Ile Leu Arg Arg Ile Phe Thr Pro Ile 5 950 955 960

Asp Ile Ile Val Asp Glu Val Lys Lys Asn Ile Asp Ser Lys Arg Lys 965 970 75 ‘

Leu Lys (2) INFORMATION FOR SEQ ID NO:123: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 477 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...477 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123 :

Met Asn Thr Ile Ile Arg Tyr Ala Ser Leu Trp Gly Leu Cys Ile Thr 1 5 10 15

Leu Thr Leu Ala Gln Thr Pro Ser Lys Thr Pro Asp Glu Ile Lys Gln 20 25 30

Ile Leu Asn Asn Tyr Ser His Lys Asn Leu Lys Leu Ile Asp Pro Pro 35 40 45

Thr Ser Ser Leu Glu Ala Thr Pro Gly Phe Leu Pro Ser Pro Lys Glu 50 55 60

Thr Ala Thr Thr Ile Asn Gln Glu Ile Ala Lys Tyr His Glu Lys Ser 5 70 75 80

Asp Lys Ala Ala Leu Gly Leu Tyr Glu Leu Leu Lys Gly Ala Thr Thr 85 90 95

Asn Leu Ser Leu Gln Ala Gln Glu Leu Ser Val Lys Gln Ala Met Lys 100 105 110

Asn His Thr Ile Ala Lys Ala Met Phe Leu Pro Thr Leu Asn Ala Ser 115 120 125

Tyr Asn Phe Lys Asn Glu Ala Arg Asp Thr Pro Glu Tyr Lys His Tyr 130 135 140

Asn Thr Gln Gln Leu Gln Ala Gln Val Thr Leu Asn Val Phe Asn Gly 5 150 155 160

Phe Ser Asn Val Asn Asn Val Lys Glu Lys Ser Ala Thr Tyr Arg Ser 165 170 175

Thr Val Ala Asn Leu Glu Tyr Ser Arg Gln Ser val Tyr Leu Gln 1 180 185 190 val Gln Gln Tyr Tyr Glu Tyr Phe Asn Asn Leu Ala Arg Met Ile Ala 1385 200 205

Leu Gln Lys Lys Leu Glu Gln Ile Gln Thr Asp Ile Lys Arg Val Thr 210 215 220

Lys Leu Tyr Asp Lys Gly Leu Thr Thr Ile Asp Asp Leu Gln Ser Leu ya 225 230 235 240

Lys Ala Gln Gly Asn Leu Ser Glu Tyr Asp Ile Leu Asp Met Gln Phe 245 250 255

Ala Leu Glu Gln Asn Arg Leu Thr Leu Glu Tyr Leu Thr Asn Leu Ser 260 265 270

Val Lys Asn Leu Lys Lys Thr Thr Ile Asp Ala Pro Asn Leu Gln Leu 275 280 285 ;

Arg Glu Arg Gln Asp Leu Val Ser Leu Arg Glu Gln Ile Ser Ala Leu 290 295 300

Arg Tyr Gln Asn Lys Gln Leu Asn Tyr Tyr Pro Lys Ile Asp Val Phe 1 305 310 315 320

Asp Ser Trp Leu Phe Trp Ile Gln Lys Pro Ala Tyr Ala Thr Gly Arg 325 330 335

Phe Gly Asn Phe Tyr Pro Gly Gln Gln Asn Thr Ala Gly Val Thr Ala 340 345 350

Thr Leu Asn Ile Phe Asp Asp Ile Gly Leu Ser Leu Gln Lys Gln Ser 355 360 365

Ile Met Leu Gly Gln Leu Ala Asn Glu Lys Asn Leu Ala Tyr Lys Lys 370 375 380

Leu Glu Gln Glu Lys Asp Glu Gln Leu Tyr Arg Lys Ser Leu Asp Ile 385 380 395 400

Ala Arg Ala Lys Ile Glu Ser Ser Lys Ala Ser Leu Asp Ala Ala Asn 405 410 415

Leu Ser Phe Ala Asn Ile Lys Arg Lys Tyr Asp Ala Asn Leu Val Asp 420 425 430

Phe Thr Thr Tyr Leu Arg Gly Leu Thr Thr Arg Phe Asp Ala Glu Val 435 440 445

Ala Tyr Asn Leu Ala Leu Asn Asn Tyr Glu Val Gln Lys Ala Asn Tyr 450 455 460

Ile Phe Asn Ser Gly His Lys Ile Asp Asp Tyr Val His 465 470 475 (2) INFORMATION FOR SEQ ID NO:124:1 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 412 amino acids (B) TYPE: amino acid ( D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES {vi) ORIGINAL SOURCE: : (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1 ...412 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124:

Met Leu Ser Phe Ile Ser Ala Phe Asp Lys Arg Gly Val Ser Ile Arg 1 5 10 15

Leu Leu Thr Ala Leu Leu Leu Leu Phe Ser Leu Gly Leu Ala Lys Asp 20 25 30

Leu Glu Ile Gln Thr Phe Val Ala Lys Tyr Leu Ser Lys Asn Gln Lys 35 40 45

Ile Gln Ala Leu Gln Glu Gln Ile Asp Ala Leu Asp Ser Gln Glu Lys yy 50 55 60

Val Val Ser Lys Trp Asp Asn Pro Ile Leu Tyr Leu Gly Tyr Asn Asn 65 70 75 80

Ala Asn Val Ser Asp Phe Phe Arg Leu Asp Ser Thr Leu Met Gln Asn 85 90 95 : Met Ser Leu Gly Leu Ser Gln Lys Val Asp Leu Asn Gly Lys Lys Leu 100 105 110

Thr Gln Ser Lys Met Ile Asn Leu Glu Lys Gln Lys Lys Ile Leu Glu 115 : 120 125

Leu Lys Lys Thr Lys Gln Gln Leu Val Ile Asn Leu Met Ile Asn Gly 000 130 135 140

Ile Glu Asn Tyr Lys Asn Gln Gln Glu Ile Glu Leu Leu Asn Thr Ala 145 150 155 160

Ile Lys Asn Leu Glu Asn Thr Leu Tyr Gln Ala Asn His Ser Ser Ser 165 170 175

Pro Asp Leu Ile Ala Ile Ala Lys Leu Glu Ile Leu Lys Ser Leu Leu 180 185 190

Glu Ile Gln Lys Asn Asp Leu Glu Val Ala Leu Ser Ser Ser His Tyr 195 200 205

Ser Met Gly Glu Leu Thr Phe Lys Glu Asn Glu Ile Leu Ser Ile Ala 210 215 220

Pro Lys Asn Phe Glu Phe Asn Asn Glu Gln Glu Leu His Asn Ile Ser 225 230 235 240

Ala Thr Asn Tyr Asp Ile Ala Ile Ala Arg Leu Asp Glu Glu Lys Ala 245 250 255

Gln Lys Asp Ile Thr Leu Ala Lys Lys Ser Phe Leu Glu Asp Ile Asn 260 265 270

Val Thr Gly val Tyr Tyr Phe Arg Ser Lys Gln Tyr Tyr Asn Tyr Asp 275 280 285

Met Phe Ser Val Ala Leu Ser Ile Pro Leu Pro Leu Tyr Gly Lys Gln 290 285 300

Ala Lys Leu Val Glu Gln Lys Lys Lys Glu Ser Leu Ala Phe Lys Ser 305 310 315 320

Glu Val Glu Asn Ala Lys Asn Lys Thr Arg His Leu Ala Leu Lys Leu 325 330 335

Leu Lys Lys Leu Glu Thr Leu Gln Lys Asn Leu Glu Ser Ile Asn Lys 340 345 350

Ile Ile Lys Gln Asn Glu Lys Ile Ala Gln Ile Tyr Ala Leu Asp Leu 355 360 365

Lys Thr Asn Gly Asp Tyr Asn Ala Tyr Tyr Asn Ala Leu Asn Asp Lys 370 375 380

Ile Thr Ile Gln Ile Thr Gln Leu Glu Thr Leu Ser Ala Leu Asn Ser 385 390 395 400

Ala Tyr Leu Ser Leu Gln Asn Leu Lys Gly Leu Glu 405 410 (2) INFORMATION FOR SEQ ID NO:125: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 137 amino acids (B) TYPE: amino acid (D) TOPOLOGY : linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

Ya

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...137 a (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125: ,

Met Arg Ile Val Arg Asn Leu Phe Leu Val Ser Phe Val Ala Tyr Ser 1 5 10 15 ,

Ser Ala Phe Ala Ala Asp Leu Glu Thr Gly Thr Lys Asn Asp Lys Lys 20 25 30

Ser Gly Lys Lys Phe Tyr Lys Leu His Lys Asn His Gly Ser Glu Thr 35 40 45

Glu Thr Lys Asn Asp Lys Lys Leu Tyr Asp Phe Thr Lys Asn Ser Gly 50 55 60

Leu Glu Gly Val Asp Leu Glu Lys Ser Pro Asn Leu Lys Ser His Lys 65 70 75 80

Lys Ser Asp Lys Lys Phe Tyr Lys Gln Leu Ala Lys Asn Asn Ile Ala 85 90 95

Glu Gly Val Ser Met Pro Ile Val Asn Phe Asn Lys Ala Leu Ser Phe 100 105 110

Gly Pro Tyr Phe Glu Arg Thr Lys Ser Lys Lys Thr Gln Tyr Met Asp 115 120 125

Gly Gly Leu Met Met His Ile Arg Phe 130 135 (2) INFORMATION FOR SEQ ID NO:126: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear ( ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...309 (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Leu Met Pro Gln Asn Gln Leu Val Ile Thr Ile Ile Asp Glu Ser Gly 1 5 10 15

Ser Lys Gln Leu Lys Phe Ser Lys Asn Leu Lys Arg Asn Leu Ile Ile 20 25 30

Ser Val Val Ile Leu Leu Leu Ile Val Gly Leu Gly Val Gly Phe Leu 35 40 45

Lys Phe Leu Ile Ala Lys Met Asp Thr Met Thr Ser Glu Arg Asn Ala 50 55 60 val Leu Arg Asp Phe Arg Gly Leu Tyr Gln Lys Asn Tyr Ala Leu Ala 65 70 75 80

Lys Glu Ile Lys Asn Lys Arg Glu Glu Leu Phe Ile Val Gly Gln Lys 85 90 95

Ile Arg Gly Leu Glu Ser Leu Ile Glu Ile Lys Lys Gly Ala Asn Gly

100 105 110

Gly Gly His Leu Tyr Asp Glu Val Asp Leu Glu Asn Leu Ser Leu Asn 115 120 125

Gln Lys His Leu Ala Leu Met Leu Ile Pro Asn Gly Met Pro Leu Lys 130 135 140

Thr Tyr Ser Ala Ile Lys Pro Thr Lys Glu Arg Asn His Pro Ile Lys 145 150 155 } 160 Lys Ile Lys Gly Val Glu Ser Gly Ile Asp Phe Ile Ala Pro Leu Asn 165 170 175

Thr Pro Val Tyr Ala Ser Ala Asp Gly Ile Val Asp Phe Val Lys Thr 180 185 190

Arg Ser Asn Ala Gly Tyr Gly Asn Leu Val Arg Ile Glu His Ala Phe 195 200 205

Gly Phe Ser Ser Ile Tyr Thr His Leu Asp His Val Asn Val Gln Pro 210 215 220

Lys Ser Phe Ile Gln Lys Gly Gln Leu Ile Gly Tyr Ser Gly Lys Ser 225 230 235 240

Gly Asn Ser Gly Gly Glu Lys Leu His Tyr Glu Val Arg Phe Leu Gly 245 250 255

Lys Ile Leu Asp Ala Glu Lys Phe Leu Ala Trp Asp Leu Asp His Phe 260 265 270

Gln Ser Ala Leu Glu Glu Asn Lys Phe Ile Glu Trp Lys Asn Leu Phe 275 280 285

Trp Val Leu Glu Asp Ile Val Gln Leu Gln Glu His Val Asp Lys Asp 290 295 300

Thr Leu Lys Gly Gln 305 (2) INFORMATION FOR SEQ ID NO:127: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 332 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 7 (A) NAME/KEY: misc_feature (B) LOCATION 1...332 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Val Leu Tyr Phe Leu Thr Ser Leu Phe Ile Cys Ser Leu Ile Val Leu 1 5 10 15

Trp Ser Lys Lys Ser Met Leu Phe Val Asp Asn Ala Asn Lys Ile Gln 20 25 30

Gly Phe His His Ala Arg Thr Pro Arg Ala Gly Gly Leu Gly Ile Phe 35 40 45

Leu Ser Phe Ala Leu Ala Cys Tyr Leu Glu Pro Phe Glu Met Pro Phe 50 55 60

Lys Gly Pro Phe Val Phe Leu Gly Leu Ser Leu Val Phe Leu Ser Gly 65 70 75 80

Phe Leu Glu Asp Ile Asn Leu Ser Leu Ser Pro Lys Ile Arg Leu Ile

YV. 85 90 95

Leu Gln Ala val Gly Val Val Cys Ile Ile Ser Ser Thr Pro Leu Val 100 105 110

Val Ser Asp Phe Ser Pro Leu Phe Ser Leu Pro Tyr Phe Ile Ala Phe 115 120 125

Leu Phe Ala Ile Phe Met Leu Val Gly Ile Ser Asn Ala Ile Asn Ile 130 135 140

Ile Asp Gly Phe Asn Gly Leu Ala Ser Gly Ile Cys Ala Ile Ala Leu i 145 150 155 160

Leu Val Ile His Tyr Ile Asp Pro Ser Ser Leu Ser Cys Leu Leu Ala 165 170 175

Tyr Met Val Leu Gly Phe Met Val Leu Asn Phe Pro Ser Gly Lys Ile 180 185 180

Phe Leu Gly Asp Gly Gly Ala Tyr Phe Leu Gly Leu Val Cys Gly Ile 195 200 205

Ser Leu Leu His Leu Ser Leu Glu Gln Lys Ile Ser Val Phe Phe Gly 210 215 220

Leu Asn Leu Met Leu Tyr Pro Val Ile Glu Val Leu Phe Ser Ile Leu 225 230 235 240

Arg Arg Lys Ile Lys Arg Gln Lys Ala Thr Met Pro Asp Asn Leu His 245 250 255

Leu His Thr Leu Leu Phe Lys Phe Leu Gln Gln Arg Ser Phe Asn Tyr 260 265 270

Pro Asn Pro Leu Cys Ala Phe Ile Leu Ile Leu Cys Asn Leu Pro Phe 275 280 285

Ile Leu Ile Ser Val Leu Phe Arg Leu Asp Ala Tyr Ala Leu Ile 1 290 295 300

Ile Ser Leu Val Phe Ile Ala Cys Tyr Leu Ile Gly Tyr Ala Tyr Leu 305 310 315 320

Asn Arg Gln Val Cys Ala Leu Glu Lys Arg Ala Phe 325 330 (2) INFORMATION FOR SEQ ID NO:128: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 271 amino acids (B) TYPE: amino acid (D) TOPOLOGY : linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: i (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 1 (A) NAME/KEY: misc_feature (B) LOCATION 1.. .271 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128:

Met Asn Ile Phe Lys Arg Ile Ile Cys Val Thr Ala Ile Val Leu Gly 1 5 10 15 phe Phe Asn Leu Leu Asp Ala Lys His His Lys Glu Lys Lys Glu Asp 20 25 30

His Lys Ile Thr Arg Glu Leu Lys Val Gly Ala Asn Pro Val Pro His 35 40 45

Ala Gln Ile Leu Gln Ser val Val Asp Asp Leu Lys Glu Lys Gly Ile

Falah 60 55 50 Lys Leu Val Ile Val Ser Phe Thr Asp Tyr Val Leu Pro Asn Leu Ala 80 75 70 65 Leu Asn Asp Gly Ser Leu Asp Ala Asn Tyr Phe Gln His Arg Pro Tyr 95 90 85 5 Leu Asp Arg Phe Asn Leu Asp Arg Lys Met His Leu Val Gly Leu Ala . 110 105 100 Asn Ile His Val Glu Pro Leu Arg Phe Tyr Ser Gln Lys Ile Thr Asp : 125 120 115 Ile Lys Asn Leu Lys Lys Gly Ser Val Ile Ala Val Pro Asn Asp Pro 10 140 135 130 Ala Asn Gln Gly Arg Ala Leu Ile Leu Leu His Lys Gln Gly Leu Ile 160 155 150 145 Ala Leu Lys Asp Pro Ser Asn Leu Tyr Ala Thr Glu Phe Asp Ile val 175 170 165 15 Lys Asn Pro Tyr Asn Ile Lys Ile Lys Pro Leu Glu Ala Ala Leu Leu 150 185 180 Pro Lys Val Leu Gly Asp Val Asp Gly Ala Ile Ile Thr Gly Asn Tyr 205 200 135 Ala Leu Gln Ala Lys Leu Thr Gly Ala Leu Phe Ser Glu Asp Lys Asp 20 220 215 210 Ser Pro Tyr Ala Asn Leu Val Ala Ser Arg Glu Asp Asn Ala Gln Asp 240 235 230 225 Glu Ala Ile Lys Ala Leu Ile Glu Ala Leu Gln Ser Glu Lys Thr Arg 255 250 245 25 Lys Phe Ile Leu Asp Thr Tyr Lys Gly Ala Ile Ile Pro Ala Phe 270 265 260 INFORMATION FOR SEQ ID NO:129: (2) 30 (i} SEQUENCE CHARACTERISTICS: (A) LENGTH: 316 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 35 (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: 40 (A) ORGANISM: Helicobacter pylori (ix) ) FEATURE: (A) NAME/KEY: misc_feature 1 (B) LOCATION 1...316 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129: Met Gln Glu Phe Ser Leu Trp Cys Asp Phe Ile Glu Arg Asp Phe Leu 10 5 1 50 Glu Asn Asp Phe Leu Lys Leu Ile Asn Lys Gly Ala Ile Cys Gly Ala 25 20 Thr Ser Asn Pro Ser Leu Phe Cys Glu Ala Ile Thr Lys Ser Ala Phe 40 35 Tyr Gln Asp Glu Ile Ala Lys Leu Lys Gly Lys Lys Ala Lys Glu Ile 55 60 55 50 Tyr Glu Thr Leu Ala Leu Lys Asp Ile Leu Gln Ala Ser Ser Ala Leu 80 75 70 65 Met Pro Leu Tyr Glu Lys Asp Pro Asn Asn Gly Tyr Ile Ser Leu Glu

85 90 95

Ile Asp Pro Phe Leu Glu Asp Asp Ala Ile Lys Ser Ile Asp Glu Ala 100 105 110

Lys Arg Leu Phe Lys Thr Leu Asn Arg Pro Asn Val Met Ile Lys Val 115 120 125

Pro Ala Ser Glu Ser Ala Phe Glu Val Ile Ser Ala Leu Ala Gln Ala 130 135 140

Ser Ile Pro Ile Asn Val Thr Leu Val Phe Ser Pro Lys Ile Ala Gly: 145 150 155 160

Glu Ile Ala Gln Ile Leu Ala Lys Glu Ala Arg Lys Arg Ala Val Ile 165 170 175

Ser Val Phe Val Ser Arg Phe Asp Lys Glu Ile Asp Pro Leu Val Pro 180 185 190

Gln Asn Leu Gln Ala Gln Ser Gly Ile Met Asn Ala Thr Glu Cys Tyr 195 200 205

Tyr Gln Ile Asn Gln His Ala Asn Lys Leu Ile Ser Thr Leu Phe Ala 210 215 220

Ser Thr Gly Val Lys Ser Asn Ser Leu Ala Lys Asp Tyr Tyr Ile Lys 225 230 235 240 ala Leu Cys Phe Lys Asn Ser Ile Asn Thr Ala Pro Leu Asp Ala Leu 245 250 255

Asn Ala Tyr Leu Leu Asp Pro Asn Thr Glu Cys Gln Thr Pro Leu Lys 260 265 270

Ile Thr Glu Ile Glu Ala Phe Lys Lys Glu Leu Lys Thr His Asn Ile 275 280 285

Asp Leu Glu Asn Thr Ala Gln Lys Leu Leu Lys Glu Gly Leu Ile Ala 290 295 300

Phe Lys Gln Ser Phe Glu Lys Leu Leu Ser Ser Phe 305 310 315 (2) INFORMATION FOR SEQ ID NO:130: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 1 (ix) FEATURE: (A) NAME/KEY: misc_feature (B} LOCATION 1.. .260 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130:

Met Lys Thr Asn Gly His Phe Lys Asp Phe Ala Trp Lys Lys Cys Phe 1 5 10 15

Leu Gly Ala Ser Val Val Ala Leu Leu Val Gly Cys Ser Pro His Ile 20 25 30

Ile Glu Thr Asn Glu Val Ala Leu Lys Leu Asn Tyr His Pro Ala Ser 35 40 45

Glu Lys Val Gln Ala Leu Asp Glu Lys Ile Leu Leu Leu Arg Pro Ala 50 55 60

Phe Gln Tyr Ser Asp Asn Ile Ala Lys Glu Tyr Glu Asn Lys Phe Lys

YVY

65 70 75 80

Asn Gln Thr Thr Leu Lys Val Glu Glu Ile Leu Gln Asn Gln Gly Tyr 85 90 95

Lys Val Ile Asn Val Asp Ser Ser Asp Lys Asp Asp Phe Ser Phe Ala 100 105 110

Gln Lys Lys Glu Gly Tyr Leu Ala Val Ala Met Asn Gly Glu Ile 1 115 120 125

Leu Arg Pro Asp Pro Lys Arg Thr Ile Gln Lys Lys Ser Glu Pro Gly 130 135 140

Leu Leu Phe Ser Thr Gly Leu Asp Lys Met Glu Arg Val Leu Ile Pro 145 150 155 160

Ala Gly Phe Val Lys Val Thr Ile Leu Glu Pro Met Ser Gly Glu Ser 165 170 175

Leu Asp Ser Phe Thr Met Asp Leu Ser Glu Leu Asp Ile Gln Glu Lys 180 185 150

Phe Leu Lys Thr Thr His Ser Ser His Ser Gly Gly Leu Val Ser Thr 195 200 205

Met Val Lys Gly Thr Asp Asn Ser Asn Asp Ala Ile Lys Ser Ala Leu 210 215 220

Asn Lys Ile Phe Ala Ser Ile Met Gln Glu Met Asp Lys Lys Leu Thr 225 230 235 240

Gln Arg Asn Leu Glu Ser Tyr Gln Lys Asp Ala Lys Glu Leu Lys Asn 245 250 255

Lys Arg Asn Arg 260 (2) INFORMATION FOR SEQ ID NO:131: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1382 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SQURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...1382 Ll (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

Leu Asn Phe Asn Asn Leu Thr Ala Asn Gly Ala Leu Asn Phe Asn Gly 1 5 10 15

Tyr Ala Pro Ser Leu Thr Lys Ala Leu Met Asn Val Ser Gly Gln Phe 20 25 30

Val Leu Gly Asn Asn Gly Asp Ile Asn Leu Ser Asp Ile Asn Ile Phe 35 40 45

Asp Asn Ile Thr Lys Ser Val Thr Tyr Asn Ile Leu Asn Ala Gln Lys 50 55 60

Gly Ile Thr Gly Ile Ser Gly Ala Asn Gly Tyr Glu Lvs Ile Leu Phe 65 70 75 80

Tyr Gly Met Lys Ile Gln Asn Ala Thr Tyr Ser Asp Asn Asn Asn Ile 85 90 95

Gln Thr Trp Ser Phe Ile Asn Pro Leu Asn Ser Ser Gln Ile Ile Gln

17 p. 110 105 100 Glu Ser Ile Lys Asn Gly Asp Leu Thr Ile Glu Val Leu Asn Asn Pro 125 120 115 Asn Ser Ala Ser Asn Thr Ile Phe Asn Ile Ala Pro Glu Leu Tyr Asn 140 135 130 5 Tyr Gln Asp Ser Lys Gln Asn Pro Thr Gly Tyr Ser Tyr Asp Tyr Ser; 160 155 150 145 Asp Asn Gln Ala Gly Thr Tyr Tyr Leu Thr Ser Asn Ile Lys Gly Leu ) 175 170 165 phe Thr Pro Lys Gly Ser Gln Thr Pro Gln Thr Pro Gly Thr Tyr Ser 10 150 185 180 Pro Phe Asn Gln Pro Leu Asn Ser Leu Asn Ile Tyr Asn Lys Gly Phe 205 200 195 Ser Ser Glu Asn Leu Lys Thr Leu Leu Gly Ile Leu Ser Gln Asn Ser 220 215 210 15 Ala Thr Leu Lys Glu Met Ile Glu Ser Asn Gln Leu Asp Asn Ile Thr 240 235 230 225 Asn Ile Asn Glu Val Leu Gln Leu Leu Asp Lys Ile Lys Ile Thr Gln 255 250 245 Ala Gln Lys Gln Ala Leu Leu Glu Thr Ile Asn His Leu Thr Asp Asn 20 270 265 260 Ile Asn Gln Thr Phe Asn Asn Gly Asn Leu Val Ile Gly Ala Thr Gln 285 280 275 Asp Asn Val Thr Asn Ser Thr Ser Ser Ile Trp Phe Gly Gly Asn Gly 300 295 290 25 Tyr Ser Ser Pro Cys Ala Leu Asp Ser Ala Thr Cys Ser Ser Phe Arg 320 315 310 305 Asn Thr Tyr Leu Gly Gln Leu Leu Gly Ser Thr Ser Pro Tyr Leu Gly 335 330 325 Tyr Ile Asn Ala Asp Phe Lys Ala Lys Ser Ile Tyr Ile Thr Gly Thr 30 350 345 340 Ile Gly Ser Ser Asn Al a Phe Glu Ser Gly Gly Ser Ala Asp Val Thr 365 360 355 Phe Gln Ser Ala Asn Asn Leu Val Leu Asn Lys Ala Asn Ile Glu Ala 380 375 370 35 Gln Ala Thr Asp Asn Ile Phe Asn Leu Leu Gly Gln Glu Gly Ile Asp 400 385 390 385 Lys Ile Phe Asn Gln Gly Asn Leu Ala Asn Val Leu Ser Gln Met Ala 415 410 405 Met Glu Lys Ile Lys Gln Ala Gly Gly Leu Gly Asn Phe Ile Glu Asn 40 430 425 420 Ala Leu Ser Pro Leu Ser Lys Glu Leu Pro Ala Ser Leu Gln Asp Glu 445 1 440 435 Thr Leu Gly Gln Leu Ile Gly Gln Asn Asn Leu Asp Asp Leu Leu Asn 460 455 450 45 Asn Ser Gly Val Met Asn Glu Ile Gln Asn Ile Ile Ser Gln Lys Leu 480 475 470 465 Ser Ile Phe Gly Asn Phe Val Thr Pro Ser Ile Ile Glu Asn Tyr Leu 495 490 485 Ala Lys Gln Ser Leu Lys Ser Met Leu Asp Asp Lys Gly Leu Leu Asn 50 510 505 500 Phe Ile Gly Gly Tyr Ile Asp Ala Ser Glu Leu Ser Ser Ile Leu Gly 525 520 515 Val Ile Leu Lys Asp Ile Thr Asn Pro Pro Thr Ser Leu Gln Lys Asp 540 535 530 55 Ile Gly Val Val Ala Asn Asp Leu Leu Asn Glu Phe Leu Gly Gln A sp 560 555 550 545 Val val Lys Lys Leu Glu Ser Gln Gly Leu Val Ser Asn Ile Ile Asn 575 570 565

M7 Asn Val Ile Ser Gln Gly Gly Leu Ser Gly Val Tyr Asn Gln Gly Leu 590 585 580 Gly Ser Val Leu Pro Pro Ser Leu Gln Asn Ala Leu Lys Glu Asn Asp 605 600 595 Leu Gly Thr Leu Leu Ser Pro Arg Gly Leu His Asp Phe Trp Gln Lys 5 620 615 610 Gly Tyr Phe Asn Phe Leu Ser Asn Gly Tyr Val Phe Val Asn Asn Ser + 640 635 630 625 Ser Phe Ser Asn Ala Thr Gly Gly Ser Leu Asn Phe Val Ala Asn Lys 655 650 645 10 Ser Ile Ile Phe Asn Gly Asp Asn Thr Ile Asp Phe Ser Lys Tyr Gln 670 665 660 Gly Ala Leu Ile Phe Ala Ser Asn Gly Val Ser Asn Ile Asn Ile Thr 685 680 675 Thr Leu Asn Ala Thr Asn Gly Leu Ser Leu Asn Ala Gly Leu Asn Asn 15 700 695 690 Val Ser Val Gln Lys Gly Glu Ile Cys Ile Asn Leu Ala Asn Cys Pro 720 715 710 705 Thr Thr Lys Asn Ser Ser Pro Ala Asn Ser Ser Val Thr Pro Thr Asn 735 730 725 20 Glu Ser Leu Ser Val His Ala Asn Asn Phe Thr Phe Leu Gly Thr Ile 750 745 740 Ile Ser Asn Gly Ala Ile Asp Leu Ser Gln Val Thr Asn Asn Ser Val 765 760 755 Ile Gly Thr Leu Asn Leu Asn Glu Asn Ala Thr Leu Gln Ala Asn Asn 25 780 775 770 Leu Thr Ile Thr Asn Ala Phe Asn Asn Ala Ser Asn Ser Thr Ala Asn 800 795 790 785 Ile Asp Gly Asn Phe Thr Leu Asn Gln Gln Ala Thr Leu Ser Thr Asn 815 810 805 30 Ala Ser Gly Leu Asn Val Met Gly Asn Phe Asn Ser Tyr Gly Asp Leu 830 825 820 Val Phe Asn Leu Ser His Ser Val Ser His Ala Ile Ile Asn Thr Gln 845 840 835 Gly Thr Ala Thr Ile Met Ala Asn Asn Asn Pro Leu Ile Gln Phe Asn 35 860 855 850 Ala Ser Ser Lys Glu Val Gly Thr Tyr Thr Leu Ile Asp Ser Ala Lys 880 875 870 865 Ala Ile Tyr Tyr Gly Tyr Asn Asn Gln Ile Thr Gly Gly Ser Ser Leu 895 890 885 40 Asp Asn Tyr Leu Lys Leu Tyr Ala Leu Ile Asp Ile Asn Gly Lys His 910 905 800 Met Val Met Thr Asp Asn Gly Leu Thr Tyr Asn Gly Gln Ala Val Ser 925 920 915 val Lys Asp Gly Gly Leu Val val Gly Phe Lys Asp Ser Gln Asn Gln 45 940 935 930 Tyr Ile Tyr Thr Ser Ile Leu Tyr Asn Lys Val Lys Ile Ala Val Ser 960 855 950 945 Asn Asp Pro Ile Asn Asn Pro Gln Ala Pro Thr Leu Lys Gln Tyr Ile 975 970 965 50 Ala Gln Ile Gln Gly Val Gln Ser Val Asp Ser Ile Asp Gln Ala Gly 990 985 980 Gly Asn Gln Ala Ile Asn Trp Leu Asn Lys Ile Phe Glu Thr Lys Gly 1008 1000 995 Ser Pro Leu Phe Ala Pro Tyr Tyr Leu Glu Ser His Ser Thr Lys Asp 55 1020 1015 1010 Leu Thr Thr Ile Ala Gly Asp Ile Ala Asn Thr Leu Glu val Ile Ala 1040 1035 1030 1025 Asn Pro Asn Phe Lys Asn Asp Ala Thr Asn Ile Leu Gln Ile Asn Thr va 1045 1050 1055

Tyr Thr Gln Gln Met Ser Arg Leu Ala Lys Leu Ser Asp Thr Ser Thr 1060 1065 1070

Phe Ala Arg Ser Asp Phe Leu Glu Arg Leu Glu Ala Leu Lys Asn Lys 1075 1080 1085

Arg Phe Ala Asp Ala Ile Pro Asn Ala Met Asp Val Ile Leu Lys Tyr 10920 1095 1100 !

Ser Gln Arg Asn Arg Val Lys Asn Asn Val Trp Ala Thr Gly Val Gly 1105 1110 1115 1120

Gly Ala Ser Phe Ile Ser Gly Gly Thr Gly Thr Leu Tyr Gly Ile Asn A 1125 1130 1135

Val Gly Tyr Asp Arg Phe Ile Lys Gly Val Ile Val Gly Gly Tyr Ala 1140 1145 1150

Ala Tyr Gly Tyr Ser Gly Phe His Ala Asn Ile Thr Gln Ser Gly Ser 1155 1160 1165

Ser Asn Val Asn Val Gly Val Tyr Ser Arg Ala Phe Ile Lys Arg Ser 1170 1175 1180

Glu Leu Thr Met Ser Leu Asn Glu Thr Trp Gly Tyr Asn Lys Thr Phe 1185 1190 1185 1200

Ile Asn Ser Tyr Asp Pro Leu Leu Ser Ile Ile Asn Gln Ser Tyr Arg 1205 1210 1215

Tyr Asp Thr Trp Thr Thr Asp Ala Lys Ile Asn Tyr Gly Tyr Asp Phe 1220 1225 1230

Met Phe Lys Asp Lys Ser Val Ile Phe Lys Pro Gln Val Gly Leu Ser 1235 1240 1245

Tyr Tyr Tyr Ile Gly Leu Ser Gly Leu Arg Gly Ile Met Asp Asp Pro 1250 1255 1260

Ile Tyr Asn Gln Phe Arg Ala Asn Ala Asp Pro Asn Lys Lys Ser Val 1265 1270 1275 1280

Leu Thr Ile Asn Phe Ala Leu Glu Ser Arg His Tyr Phe Asn Lys Asn 1285 1290 12395

Ser Tyr Tyr Phe Val Ile Ala Asp Val Gly Arg Asp Leu Phe Ile Asn 1300 1305 1310

Ser Met Gly Asp Lys Met Val Arg Phe Ile Gly Asn Asn Thr Leu Ser 1315 1320 1325

Tyr Arg Asp Gly Gly Arg Tyr Asn Thr Phe Ala Ser Ile Ile Thr Gly 1330 1335 1340

Gly Glu Ile Ar Leu Phe Lys Thr Phe Tyr Val Asn Ala Gly Ile Gly 1345 1350 1355 1360 .

Ala Arg Phe Gly Leu Asp Tyr Lys Asp Ile Asn Ile Thr Gly Asn Ile 1365 1370 1375

Gly Met Arg Tyr Ala Phe 1380 1 (2) INFORMATION FOR SEQ ID NO:132: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 262 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE:

(A) NAME/KEY: misc feature (B) LOCATION 1...262 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

Met Lys Lys Ile Gly Leu Ser Leu Cys Leu Val Leu Ser Leu Gly Phe! 15 10 5 1 Leu Lys Ala His Glu Val Ser Ala Glu Glu Ile Ala Asp Ile Phe Tyr 25 20 Lys Leu Asn Ala Lys Glu Pro Lys Met Lys Ile Asn His Thr Lys Gly 10 45 40 35 Phe Cys Ala Lys Gly Val Phe Leu Pro Asn Pro Gln Ala Arg Glu Asp 60 55 50 Leu Glu Val Pro Leu Leu Asn Glu Lys Glu Ile Pro Ala Ser Val Arg 80 75 70 65 15 Tyr Ser Leu Gly Gly Val Ala Met Asp Asp Lys Ser Lys Val Arg Gly 95 90 85 Met Ala Leu Lys Leu Glu Asn Gln Asn Ala Ser Trp Thr Met Val Met 110 105 100 Leu Asn Thr Glu Ile Asn Phe Ala Lys Asn Pro Glu Glu Phe Ala Gln 20 125 120 115 Phe Phe Glu Met Arg Leu Pro Lys Asn Gly Lys Val Asp Glu Ala Arg 140 135 130 Ile Lys Lys Leu Tyr Glu Glu Val Pro Ser Tyr Arg Asn Phe Ala Ala 160 155 150 5 25 Tyr Met Lys Thr Ile Gly Ile Ser Ser Ser Val Ala Asn Thr Pro Tyr 175 170 165 Tyr Ser Val His Ala Phe Lys Phe Lys Asp Lys Lys Glu Lys Leu Leu 130 185 180 Pro Ala Arg Trp Lys Phe Val Pro Lys Glu Gly Val Lys Tyr Leu Asn 30 205 200 195 ‎Pro Gln Glu Leu Lys Gln Lys Asp Ser Asn Tyr Leu Leu Ser Ser Phe 220 215 210 Gln Gln His Leu Lys Asn Lys Pro Ile Glu Tyr Gln Met Tyr Leu Val 22s 230 235 240 35 Phe Ala Asn Gln Asn Asp Ala Thr Asn Asp Thr Thr Ala Leu Trp Lys 255 250 245 Gly Ser Ile Arg Asn Tyr 260

INFORMATION FOR SEQ ID NO:133: (2) (i) SEQUENCE CHARACTERISTICS: ' (A) LENGTH: 246 amino acids (B) TYPE: amino acid 45 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES 50 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 55 (A) NAME/KEY : misc_feature (B) LOCATION 1...246 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

YVA

Met Lys Gln Phe Lys Lys Lys Pro Lys Lys Ile Lys Arg Ser His Gln 1 5 10 15

Asn Gln Lys Thr Ile Leu Lys Arg Pro Leu Trp Leu Met Pro Leu Leu 20 25 30

Ile Gly Gly Phe Ala Ser Gly Val Tyr Ala Asp Gly Thr Asp Ile Leu 35 40 45

Gly Leu Ser Trp Gly Glu Lys Ser Gln Lys Val Cys Val His Arg Pro 50 55 60

Trp Tyr Ala Ile Trp Ser Cys Asp Lys Trp Glu Glu Lys Thr Gln Gln 65 70 75 80

Phe Thr Gly Asn Gln Leu Ile Thr Lys Thr Trp Ala Gly Gly Asn Ala 85 90 95

Ala Asn Tyr Tyr His Ser Gln Asn Asn Gln Asp Ile Thr Ala Asn Leu 100 105 110

Lys Asn Asp Asn Gly Thr Tyr Phe Leu Ser Gly Leu Tyr Asn Tyr Thr 115 120 125

Gly Gly Glu Tyr Asn Gly Gly Asn Leu Asp Ile Glu Leu Gly Ser Asn 130 135 140

Ala Thr Phe Asn Leu Gly Ala Ser Ser Gly Asn Ser Phe Thr Ser Trp 145 150 155 160

Tyr Pro Asn Gly His Thr Asp Val Thr Phe Ser Ala Gly Thr Ile Asn 165 170 175

Val Asn Asn Ser Val Glu Val Gly Asn Arg Val Gly Ser Gly Ala Gly 180 185 190

Thr His Thr Gly Thr Ala Thr Leu Asn Leu Asn Ala Asn Lys Val Thr 195 200 205

Ile Asn Ser Asn Ile Ser Ala Tyr Lys Thr Ser Gln Val Asn Val Gly 210 215 220

Asn Ala Asn Ser Val Ile Thr Ile &Asn Ser Val Ser Leu Asn Gly Glu 225 230 235 240

Tyr Leu Gln Phe Phe Ser 245 (2) INFORMATION FOR SEQ ID NO:134: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 245 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE : protein (iii) HYPOTHETICAL: YES 1 (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...245 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134:

Met Ile Lys Lys Thr Leu Ala Ser Val Leu Leu Gly Leu Ser Leu Met 1 5 10 15

Ser Val Leu Asn Ala Lys Glu Cys Val Ser Pro Ile Thr Arg Ser Val 20 25 30

Lys Tyr His Gln Gln Ser Ala Glu Ile Arg Ala Leu Gln Leu Gln Ser

35 40 45

Tyr Lys Met Ala Lys Met Ala Leu Asp Asn Asn Leu Lys Leu Val Lys 50 55 60

Asp Lys Lys Pro Ala Val Ile Leu Asp Leu Asp Glu Thr Val Leu Asn 65 70 75 80

Thr Phe Asp Tyr Ala Gly Tyr Leu Val Lys Asn Cys Ile Lys Tyr Thr 85 90 95

Pro Glu Thr Trp Asp Lys Phe Glu Lys Glu Gly Ser Leu Thr Leu Ile 100 105 110

Pro Gly Ala Leu Asp Phe Leu Glu Tyr Ala Asn Ser Lys Gly Val Lys 115 120 125

Ile Phe Tyr Ile Ser Asn Arg Thr Gln Lys Asn Lys Ala Phe Thr Leu 130 135 7 140

Lys Thr Leu Lys Ser Phe Lys Leu Pro Gln Val Ser Glu Glu Ser Val 5 150 155 160

Leu Leu Lys Glu Lys Gly Lys Pro Lys Ala val Arg Arg Glu Leu Val 165 170 175 . Ala Lys Asp Tyr Ala Ile Val Leu Gln Val Gly Asp Thr Leu His Asp 180 185 190

Phe Asp Ala Ile Phe Ala Lys Asp Ala Lys Asn Ser Gln Glu Gln Gln 195 200 205

Ala Lys Val Leu Gln Asn Ala Gln Lys Phe Gly Thr Glu Trp Ile Ile 210 215 220

Leu Pro Asn Ser Leu Tyr Gly Thr Trp Glu Asp Gly Pro Ile Lys Ala 5 230 235 240

Trp Gln Asn Lys Lys 245 (2) INFORMATION FOR SEQ ID NO:135: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 288 amino acids (B} TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES {vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...288 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

Leu Trp Cys Leu Lys Thr Pro Ile Ile Gly His Gly Met Lys Lys Lys 1 5 10 15

Ala Lys Val Phe Trp Cys Cys Phe Lys Met Ile Arg Trp Leu Tyr Leu 20 25 30

Ala Val Phe Phe Leu Leu Ser Val Ser Asp Ala Lys Glu Ile Ala Met 35 40 45

Gln Arg Phe Asp Lys Gln Asn His Lys Ile Phe Glu Ile Leu Ala Asp 50 55 60

Lys Val Ser Ala Lys Asp Asn Val Ile Thr Ala Ser Gly Asn Ala Ile 65 70 75 80

Leu Leu Asn Tyr Asp Val Tyr Ile Leu Ala Asp Lys Val Arg Tyr Asp

Ya. 85 90 95

Thr Lys Thr Lys Glu Ala Leu Leu Glu Gly 2sn Ile Lys Val Tyr Arg 100 105 110

Gly Glu Gly Leu Leu Val Lys Thr Asp Tyr Val Lys Leu Ser Leu Asn 115 120 125

Glu Lys Tyr Glu Ile Ile Phe Pro Phe Tyr Val Gln Asp Ser Val Ser 130 135 140

Gly Ile Trp Val Ser Ala Asp Ile Ala Ser Gly Lys Asp Gln Lys Tyr 145 150 155 160

Lys Ile Lys Asn Met Ser Ala Ser Gly Cys Ser Ile Asp Asn Pro Ile 165 170 175

Trp His Val Asn Ala Thr Ser Gly Ser Phe Asn Met Gln Lys Ser His 180 - 185 190

Leu Ser Met Trp Asn Pro Lys Ile Tyr Val Gly Asp Ile Pro Val Leu 195 200 205

Tyr Leu Pro Tyr Ile Phe Met Ser Thr Ser Asn Lys Arg Thr Thr Gly 210 215 220

Phe Leu Tyr Pro Glu Phe Gly Thr Ser Asn Leu Asp Gly Phe Ile Tyr 225 230 235 240

Leu Gln Pro Phe Tyr Leu Ala Pro Lys Asn Ser Trp Asp Met Thr Phe 245 250 255

Thr Pro Gln Ile Arg Tyr Lys Arg Gly Phe Gly Leu Asn Phe Glu Ala 260 265 270

Arg Tyr Ile Asn Ser Lys Thr Gln Val Phe Ile Gln Cys Ala Leu Phe 275 280 285 (2) INFORMATION FOR SEQ ID NO:136: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 128 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE 1722: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...128 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136:

Leu 'Met Phe Lys Lys Met Cys Leu Ser Leu Leu Met Ile Ser Gly 1 1 5 10 15

Cys Val Gly Lys Zsp Leu Asp Phe Lys Leu Asp Tyr Arg Ala Thr 20 25 30

Gly Gly Lys Phe Met Gly Lys Met Thr Asp Ser Ser Leu Leu Ser Ile 35 40 45

Thr Ser Met Asn Asp Glu Pro Val Val Ile Lys Asn Leu Ile Val Asn 50 55 60 53 Arg Gly Asn Ser Cys Glu Zla Thr Lys Val Glu Pro Lys Phe Gly 65 70 75 80

Asp Lys Phe Lys Lys Glu Lys Leu Phe Asp His Glu Leu Lys Tyr Ser 85 20 95

Gln Gln Ile Phe Tyr Erg Leu Asp Cys Lys Pro Asn Gln Leu Leu Glu

YAN

100 10s 110

Val Lys Ile Ile Thr Asp Lys Gly Glu Tyr Tyr His Lys Phe Ser Lys 115 120 125 (2) INFORMATION FOR SEQ ID NO:137: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 169 amino acids (B) TYPE: amino acid ) (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: 0 (A) NAME/KEY: misc_feature (B) ) LOCATION 1...169 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137:

Met Gln Ala Leu Lys Ser Leu Leu Glu Val Ile Thr Lys Leu Gln Asn 1 5 10 15

Leu Gly Gly Tyr Leu Met His Ile Ala Ile Phe Ile Ile Phe Ile Trp

R 20 25 30

Ile Gly Gly Leu Lys Phe Val Pro Tyr Glu Ala Glu Gly Ile Ala Pro

Phe Val Ala Asn Ser Pro Phe Phe Ser Phe Met Tyr Lys Phe Glu Lys 60

Pro Ala Tyr Lys Gln His Lys Met Ser Glu Ser Gln Ser Met Gln Glu 65 70 75 80 35 Glu Met Gln Asp Asn Pro Lys Ile Val Glu Asn Lys Glu Trp His Lys 85 90 95

Glu Asn Arg Thr Tyr Leu Val Ala Glu Gly Leu Gly Ile Thr Ile Met 100 105 110

Ile Leu Gly Ile Leu Val Leu Leu Gly Leu Trp Met Pro Leu Met Gly 40 115 120 125

Val Val Gly Gly Leu Leu Val Ala Gly Met Thr Ile Thr Thr Leu Phe 130 135 140

Phe Phe Ile His Asn Ala Arg Ser Val Cys Gln Ser Ala Phe Pro Met 145 150 155 160 45 Ala Phe Trp Gly Trp Lys Ala Ser Gly 165 (2) INFORMATION FOR SEQ ID NO:138:50 {i) SEQUENCE CHARACTERISTICS: ( A) LENGTH: 487 amino acids (B) TYPE: amino acid (0) TOPOLOGY: linear 55 (ii) MOLECULE TYPE: protein

B (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE:

YAY

(A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...487 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

Met Ile Glu Trp Met Gln Asn His Arg Lys Tyr Leu Val Val Thr Ile 31 5 10 15 1

Trp Ile Ser Thr Ile Ala Phe Ile Ala Ala Gly Met Ile Gly Trp Gly 20 25 30

Gln Tyr Ser Phe Ser Leu Asp Ser Asp Ser Ala Ala Lys Val Gly Gln 35 40 45 1le Lys Ile Ser Gln Glu Glu Leu Ala Gln Glu Tyr Arg Arg Leu Lys 50 55 60

Asp Ala Tyr Ala Glu Ser Ile Pro Asp Phe Lys Glu Leu Thr Glu Asp 65 70 75 80

Gln Ile Lys Ala Met His Leu Glu Lys Ser Ala Leu Asp Ser Leu Ile 85 90 95

Asn Gln Ala Leu Leu Arg Asn Phe Ala Leu Asp Leu Gly Leu Gly Ala 100 105 110

Thr Lys Gln Glu Val Ala Lys Glu Ile Arg Lys Thr Asn Val Phe Gln 115 120 125

Lys Asp Gly Val Phe Asp Glu Glu Leu Tyr Lys Asn Ile Leu Lys Gln 130 135 140

Ser His Tyr Arg Pro Lys His Phe Glu Glu Ser Val Glu Arg Leu Leu 145 150 155 160

Ile Leu Gln Lys Ile Ser Ala Leu Phe Pro Lys Thr Thr Thr Pro Leu 165 170 175

Glu Gln Ser Ser Leu Ser Leu Trp Ala Lys Leu Gln Asp Lys Leu Asp 180 185 190

Ile Leu Ile Leu Asn Pro Asn Asp Val Lys Ile Ser Leu Asn Glu Glu 195 200 205

Glu Met Lys Lys Tyr Tyr Glu Asn His Arg Lys Asp Phe Lys Lys Pro 210 215 220

Thr Ser Phe Lys Thr Arg Ser Leu Tyr Phe Asp Ala Ser Leu Glu Lys 225 230 235 240

Thr Asp Leu Lys Glu Leu Glu Glu Tyr Tyr His Lys Asn Lys Val Ser 245 250 255

Tyr Leu Asp Lys Glu Gly Lys Leu Gln Asp Phe Lys Ser Val Gln Glu 260 265 270

Gln Val Lys His Asp Leu Asn Met Gln Lys Ala Asn Glu Lys Ala Leu 275 280 285

Arg Ser Tyr Ile Ala Leu Lys Lys Gly Asn Ala Gln Asn Tyr Thr Thr 250 295 300

Gln Asp Phe Glu Lys Asn Asn Ser Pro Tyr Thr Ala Glu Ile Thr Gln 305 310 315 320 : Lys Leu Thr Ala Leu Lys Pro Leu Glu Val Leu Lys Pro Glu Pro Phe 325 330 335

Lys Asp Gly Phe Ile Val Val Gln Leu Val Ser Gln Ile Lys Asp Glu 340 345 350

Leu Gln Asn Phe Asp Glu Ala Lys Ser Ala Leu Lys Thr Arg Leu Thr 355 360 365

Gln Glu Lys Thr Leu Met Ala Leu Gln Thr Leu Ala Lys Glu Lys Leu 370 375 380

Lys Asp Phe Lys Gly Lys Ser Val Gly Tyr Val Ser Pro Asn Phe Gly 385 390 385 400

Gly Thr Ile Ser Glu Leu Asn Gln Glu Glu Ser Ala Lys Phe Ile Asn

YAY

405 410 415

Thr Leu Phe Asn Arg Gln Glu Lys Lys Gly Phe Val Thr Tle Gly Asn 420 425 430

Lys Val val Leu Tyr Gln Ile Thr Glu Gln Asn Phe Asn His Pro Phe 435 440 445

Ser Ala Glu Glu Asn Gln Tyr Met Gln Arg Leu Val Asn Asn Thr Lys 450 455 460

Thr Asp Phe Phe Asp Lys Ala Leu Ile Glu Glu Leu Lys Lys Arg Tyr 465 470 475 480 ,

Lys Ile val Lys Tyr Ile Gln 485 (2) INFORMATION FOR SEQ ID NO:139: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 142 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...142 (xi) SEQUENCE DESCRIPTION : SEQ ID NO: 139:

Met Lys Thr Asn Phe Tyr Lys Ile Lys Leu Leu Phe Ala Trp Cys Leu 1 5 10 15

Ile Ile Gly Met Phe Asn Ala Pro Leu Asn Ala Asp Gln Asn Thr Asp 20 25 30

Ile Lys Asp Ile Ser Pro Glu Asp Met Ala Leu Asn Ser Val Gly Leu 35 40 45

Val Ser Arg Asp Gln Leu Lys Ile Glu Ile Pro Lys Glu Thr Leu Glu 50 55 60

Gln Lys Val Ala Ile Leu Asn Asp Tyr Asn Asp Lys Asn Val Asn Ile 65 70 75 80

Lys Phe Asp Asp Ile Ser Leu Gly Ser Phe Gln Pro Asn Asp Asn Leu 85 90 95

Gly Ile Asn Ala Met Trp Gly Ile Gln Asn Leu Leu Met Ser Gln Met 100 105 110

(2) INFORMATION FOR SEQ ID NO:140: (i) ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 208 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 5 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1 ...208,

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:140: Leu Ile Asn Asn Asn Asn Asn Asn Lys Lys Leu Arg Gly Phe Phe Leu 10 5 1 Lys Val Leu Leu Ser Leu Val Val Phe Ser Ser Tyr Gly Ser Ala Asn 15 25 20 Asp Asp Lys Glu Ala Lys Lys Glu Ala Leu Glu Lys Glu Lys Asn Thr 40 35 Pro Asn Gly Leu Val Tyr Thr Asn Leu Asp Phe Asp Ser Phe Lys Ala 60 55 50 20 Thr Ile Lys Asn Leu Lys Asp Lys Lys Val Thr Phe Lys Glu Val Asn 80 75 70 65 Pro Asp Ile Ile Lys Asp Glu Val Phe Asp Phe Val Ile Val Asn Arg 95 90 85 val Leu Lys Lys Ile Lys Asp Leu Lys His Tyr Asp Pro Val Ile Glu 25 110 105 100 Lys Ile Phe Asp Glu Lys Gly Lys Glu Met Gly Leu Asn Val Glu Leu 125 120 115 Gln Ile Asn Pro Glu Val Lys Asp Phe Phe Thr Phe Lys Ser Ile Ser 140 135 130 30 Thr Thr Asn Lys Gln Arg Cys Phe Leu Ser Leu His Gly Glu Thr Arg 160 . 155 150 145 Glu Ile Leu Cys Asp Asp Lys Leu Tyr Asn Val Leu Leu Ala Val Phe 175 170 165 Asn Ser Tyr Asp Pro Asn Asp Leu Leu Lys His Ile Ser Thr Ile Glu 35 190 185 180 Ser Leu Lys Lys Ile Phe Tyr Thr Ile Thr Cys Glu Ala Val Tyr Leu 205 200 1395 INFORMATION FOR SEQ ID NO:141: (2) 40 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 245 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 45 (ii) MOLECULE TYPE: protein 1 (iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 55 (B) LOCATION 1...245 (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO:141:

Yao

Met Ala Gly Thr Gln Ala Ile Tyr Glu Ser Ser Ser Ala Gly Phe Leu 1 5 10 15

Ser Gln Val Ser Ser Ile Ile Ser Ser Thr Ser Gly Val Ala Gly Pro 20 25 30

Phe Ala Gly Ile Val Ala Gly Ala Met Thr Ala Ala Ile Ile Pro Ile 35 40 45

Val val Gly Phe Thr Asn Pro Gln Met Thr Ala Ile Met Thr Gln Tyr 50 55 60

Asn Gln Ser Ile Ala Glu Ala Val Ser Val Pro Met Lys Ala Ala Asn 65 70 75 80 ‘

Gln Gln Tyr Asn Gln Leu Tyr Gln Gly Phe Asn Asp Gln Ser Met Ala 85 . 90 95

Val Gly Asn Asn Ile Leu Asn Ile Ser Lys Leu Thr Gly Glu Phe Asn 100 105 110 12la Gln Gly Asn Thr Gln Ser Ala Gln Ile Ser Ala Val Asn Ser Gln 115 120 125

Ile Ala Ser Ile Leu Ala Ser Asn Thr Thr Pro Lys Asn Pro Ser Ala 130 135 140

Ile Glu Ala Tyr Ala Thr Asn Gln Ile Ala Val Pro Ser Val Pro Thr 5 150 155 160

Thr Val Glu Met Met Ser Gly Ile Leu Gly Asn Ile Thr Ser Ala Ala 165 170 175

Pro Lys Tyr Ala Leu Ala Leu Gln Glu Gln Leu Arg Ser Gln Ala Ser 180 185 190

Asn Ser Ser Met Asn Asp Thr Ala Asp Ser Leu Asp Ser Cys Thr Ala 15 200 205

Leu Gly Ala Leu Val Gly Ser Lys Val Phe Phe Ser Cys Met Gln 210 215 220

Ile Ser Met Thr Pro Met Ser Val Ser Met Pro Thr Val Met Pro Asn 5 230 235 240

Thr Ser Gly Cys His 245 (2) INFORMATION FOR SEQ ID NO:142: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 367 amino acids (BY TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: : (A) NAME/KEY: misc_feature (B) LOCATION 1...367 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

Met Ile Lys Ser Val Glu Ile Glu Asn Tyr Lys Asn Phe Glu His Leu 1 5 10 15

Lys Met Glu Asn Phe Lys Leu Ile Asn Phe Phe Thr Gly Gln Asn Asp 20 25 30

Ala Gly Lys Thr Asn Leu Leu Glu Ala Leu Tyr Thr Asn Thr Gly Leu 35 40 45

Ya

>

Cys Asp Pro Thr Ala Asn Gln Val Ser Leu Pro Pro Glu His Ala Val 50 55 60

Asn Ile Ser Glu Phe Arg Lys Ile Lys Leu Asp Ala Asp Asn Leu Lys 65 70 75 80

Thr Phe Phe Tyr Gln Gly Asn Thr Ala Asn Pro Ile Ser Ile Arg Thr 85 90 95

Glu Phe Glu His Ala Thr Ile Pro Leu Thr Ile Gln Tyr Pro Thr Gln 100 105 110 A Thr Ser Tyr Ser Lys Asp Ile Asn Leu Asn Ser Asp Asp Ala His Met 11s 120 125 '

Thr Asn Leu Ile Asn Thr Thr Ile Thr Lys Pro Gln Leu Gln Phe Ser 130 135 140

Tyr Asn Pro Ser Leu Ser Pro Met Thr Met Thr Tyr Glu Phe Glu Arg : 145 150 155 160

Gln Asn Leu Gly Leu Ile His Ser Asn Leu Asp Lys Ile Ala Gln Thr 165 170 175

Tyr Lys Glu Asn Ala Met Phe Ile Pro Ile Glu Leu Ser Ile Val Asn 180 185 130

Ser Leu Lys Ala Leu Glu Asn Leu Gln Leu Ala Ser Lys Glu Lys Glu 195 200 205

Leu Ile Glu Ile Leu Gln Cys Phe Asn Pro Asn Ile Leu Asn Ala Asn 210 215 220

Thr Ile Arg Lys Ser Val Tyr Ile Gln Ile Lys Asp Glu Asn Thr Pro 225 230 235 240

Leu Glu Glu Ser Pro Lys Ar Leu Leu Asn Leu Phe Gly Trp Gly Phe 245 250 255

Ile Lys Phe Phe Ile Met Val Ser Ile Leu Ile Asp Asn Arg Val Lys 260 265 270

Tyr Leu Phe Ile Asp Glu Ile Glu Ser Gly Leu His His Thr Lys Met 275 280 285

Gln Glu Phe Leu Lys Ala Leu Phe Lys Leu Ala Gln Lys Leu Gln Ile 290 295 300

Gln Ile Phe Ala Thr Thr His Asn Lys Glu Phe Leu Leu Asn Ala Ile 305 310 315 320

Asn Thr Ile Ser Asp Asn Glu Thr Gly Val Phe Lys Asp Ile Ala Leu 325 330 335

Phe Glu Leu Glu Lys Glu Ser Ala Ser Gly Phe Ile Arg His Ser Tyr 340 345 350

Ser Met Leu Glu Lys Ala Leu Tyr Arg Gly Met Glu Val Arg Gly 355 360 365 (2) INFORMATION FOR SEQ ID NO:143: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 409 amino acids (B} TYPE: amino acid (D) TOPOLOGY: linear ; (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: / (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...409 A,

YAV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

Met Ser Leu Ile Arg Val Asn Gly Glu Ala Phe Lys Leu Ser Leu Glu 1 5 10 15 ser Leu Glu Glu Asp Pro Phe Glu Thr Lys Glu Thr Leu Glu Thr Leu 20 25 30

Glu Thr Leu Ile Lys Gln Thr Ser val Val Leu Leu Ala Ala Gly Glu 35 40 45

Ser Lys Arg Phe Ser Arg Ala Ile Lys Lys Gln Trp Leu Arg Ser His , 50 55 60

His Thr Pro Leu Trp Leu Ser Val Tyr Glu Ser Phe Lys Glu Ala Leu 65 70 75 80

Asp Phe Lys Glu Val Ile Leu Val Val Ser Glu Leu Asp Tyr Val Tyr 85 90 95

Ile Gln Arg His Tyr Pro Lys Ile Lys Leu Val Lys Gly Gly Ala Ser 100 105 110

Arg Gln Glu Ser Val Arg Asn Ala Leu Lys Val Ile Asp Ser Thr Tyr 115 120 125

Thr Ile Thr Ser Asp Val Ala Arg Gly Leu Ala Asn Met Glu Ala Leu 130 135 140

Lys Ser Leu Phe Leu Thr Leu Gln Gln Thr Ser His Tyr Cys Ile Ala 145 150 155 160

Pro Tyr Leu Pro Cys Tyr Asp Thr Ala Ile Tyr Tyr Asn Glu Ala Leu 165 170 175

Asp Arg Glu Ala Ile Lys Leu Ile Gln Thr Pro Gln Leu Ser His Thr 180 185 190

Lys Thr Leu Gln Ser Ala Leu Asn Gln Gly Gly Phe Lys Asp Glu Ser 195 200 205

Ser Ala Ile Leu Gln Ala Phe Pro Asn Ser Val Ser Tyr Ile Glu Gly 210 215 220

Ser Lys Asp Leu His Lys Leu Thr Thr Ser Gly Asp Leu Lys Phe Phe 225 230 235 240

Thr Pro Phe Phe Asn Pro Ala Lys Asp Thr Phe Ile Gly Met Gly Phe 245 250 255

Asp Thr His Ala Phe Ile Lys Asp Lys Pro Met Val Leu Gly Gly val 260 265 270

Val Leu Asp Cys Glu Phe Gly Leu Lys Ala His Ser Asp Gly Asp Ala 275 280 285

Leu Leu His Ala Val Ile Asp Ala Ile Leu Gly Ala Ile Lys Gly Gly 290 295 300

Asp Ile Gly Glu Trp Phe Pro Asp Asn Asp Pro Lys Tyr Lys Asn Ala 305 310 315 320

Ser Ser Lys Glu Leu Leu Lys Ile Val Leu Asp Phe Ser Gln Ser Ile 325 330 335

Gly Phe Glu Leu Leu Glu Met Gly Ala Thr Ile Phe Ser Glu Ile Pro 340 345 350

Lys Ile Thr Pro Tyr Lys Pro Ala Ile Leu Glu Asn Leu Ser Gln Leu : 355 360 365

Leu Gly Leu Glu Lys Ser Gln Ile Ser Leu Lys Ala Thr Thr Met Glu 370 375 380

Lys Met Gly Phe Ile Gly Lys Gln Glu Gly Leu Leu Val Gln Ala His 385 390 395 400

Val Ser Met Arg Tyr Lys Gln Lys Leu 405 : (2) INFORMATION FOR SEQ ID NO:144: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 amino acids

YAA

(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori ) (ix) FEATURE: (A) NAME/ KEY: misc_feature (B) LOCATION 1...270 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144:

Met Lys Lys Phe Val Ala Leu Gly Leu Leu Ser Ala Val Leu Ser Ser 1 5 10 15

Ser Leu Leu Ala Glu Gly Asp Gly 1 Tyr Ile Gly Thr Asn Tyr Gln 20 25 30

Leu Gly Gln Ala Arg Leu Asn Ser Asn Ile Tyr Asn Thr Gly Asp Cys 35 40 45

Thr Gly Ser Val Val Gly Cys Pro Pro Gly Leu Thr Ala Asn Lys His 50 55 60

Asn Pro Gly Gly Thr Asn Ile Asn Trp His Ser Lys Tyr Ala Asn Gly 65 70 75 80

Ala Leu Asn Gly Phe Gly Leu Asn Val Gly Tyr Lys Lys Phe Phe Gln 85 90 95

Phe Lys Ser Leu Asp Met Thr Ser Lys Trp Phe Gly Phe Arg Val Tyr 100 105 110

Gly Leu Phe Asp Tyr Gly His Ala Asp Leu Gly Lys Gln Val Tyr Ala 115 120 125

Pro Asn Lys Ile Gln Leu Asp Met Val Ser Trp Gly Val Gly Ser Asp 130 135 140

Leu Leu Ala Asp Ile Ile Asp Lys Asp Asn Ala Ser Phe Gly Ile Phe 145 150 155 160

Gly Gly Val Ala Ile Gly Gly Asn Thr Trp Lys Ser Ser Ala Ala Asn 165 170 175

Tyr Trp Lys Glu Gln Ile Ile Glu Ala Lys Gly Pro Asp Val Cys Thr 180 185 190

Pro Thr Tyr Cys Asn Pro Asn Ala Pro Tyr Ser Thr Asn Thr Ser Thr 135 200 205

Val Ala Phe Gln Val Trp Leu Asn Phe Gly 731 Arg Ala Asn Ile Tyr 210 215 220

Lys His Asn Gly Val Glu Phe Gly Val Arg Val Pro Leu Leu Ile Asn 225 230 235 240

Lys Phe Leu Ser Ala Gly Pro Asn Ala Thr Asn Leu Tyr His Leu 245 250 255 , Lys Arg Asp Tyr Ser Leu Tyr Leu Gly Tyr Asn Tyr Thr Phe 260 265 270 (2) INFORMATION FOR SEQ ID NO:145: (1) ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 438 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein

YAA

(iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...438 , (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

Met Ala Tyr Lys Pro Asn Lys Lys Lys Leu Lys Glu Leu Arg Glu Gln 1 5 10 15

Pro Asn Leu Phe Ser Ile Leu Asp Lys Gly Asp Val Ala Thr Asn Asn

Pro Val Glu Glu Ser Asp Lys Ala Asn Lys Ile Gln Glu Pro Leu Pro

Tyr Val Val Lys Thr Gln Ile Asn Lys Ala Ser Met Ile Ser Arg Asp 20 50 55 60

Pro Ile Glu Trp Ala Lys Tyr Leu Ser Phe Glu Lys Arg Val Tyr Lys 65 70 75 80

Asp Asn Ser Lys Glu Asp Val Asn Phe Phe Ala Asn Gly Glu Ile Lys 85 90 95 25 Glu Ser Ser Arg Val Tyr Glu Ala Asn Lys Glu Gly Phe Glu Arg Arg 100 105 110

Ile Thr Lys Arg Tyr Asp Leu Ile Asp Arg Asn Ile Asp Arg Asn Arg 115 120 125

Glu Phe Phe Ile Lys Glu Ile Glu Ile Leu Thr His Thr Asn Ser Leu 30 130 135 140

Lys Glu Leu Lys Glu Gln Gly Leu Glu Ile Gln Leu Thr His His Asn 145 150 155 160

Glu Thr His Lys Lys Ala Leu Glu Asn Gly Asn Glu Ile 1 Lys Glu : 165 170 175 35 Tyr Asp His Leu Lys Asp Ile Tyr Gln Glu Val Glu Arg Thr Lys Asp 180 185 190

Gly Gly Leu Val Arg Glu Ile Ile Pro Ser Ile Ser Ser Ala Glu Tyr 195 200 205

Phe Lys Leu Tyr Asn Lys Leu Pro Phe Glu Ser Ile Asn Asn Glu Asn 40 210 215 220

Thr Lys Leu Asn Thr Asn Asp Asn Glu Glu Val Lys Lys Leu Glu Phe 225 230 235 240

Glu Leu Ala Lys Glu Val His Ile Leu Ile Leu Glu Gln Gln Leu Leu 245 250 255 45 Ser Ala Thr Asn Tyr Tyr Ser Trp Ile Asp Lys Asp Asp Asn Ala Asn 260 265 270

Phe Ala Trp Lys Met His Arg Leu Ile Asn Glu Asn Lys Leu Lys Glu 225 280 285

Asn His Leu Ser Ala Asn Asn Ala Asn Lys Ile Lys Gln Phe Phe Phe 290 295 300

Asn Asn Gly Ser Ile Leu Gly Trp Thr Lys Glu Glu Gln Ser Ala Ile 305 310 315 320

Gln Glu Asn Arg Asp Tyr Ser Leu Arg Ser Ala Leu Leu Ser Leu Glu 325 330 335

Glu Ile ala Gln Ala Lys Ile Glu Leu Gla Lys Tyr Tyr Glu Ser Val 340 345 350

Tyr Val Asn Gly Asp Gly Asn Lys Arg Glu Ile Lys Pro Phe Lys Glu 355 360 365

Ile Leu Arg Asp Thr Asn Asn Phe Glu Lys Ala Tyr Lys Glu Arg Tyr

Ya. 370 375 380

Asp Lys Leu Val Ser Leu Ser Ala Ala Ile Ile Gln Ala Lys Glu Gly 385 390 395 400

Gly Asn Glu Arg Pro Asn Ser Ser Ala Asn Asn Asn Asn Pro Ile Lys 405 410 415

Asn Thr Ile Glu Thr Asn Thr Ser Asn Asn Ile Ile Gln Asn Asn Asp 420 425 430

Asn Ile Ile Ile Gln Ile 435 (2) INFORMATION FOR SEQ ID NO:146: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 215 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE : protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...215 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146:

Met Gln Ala Leu Lys Ser Leu Leu Glu Val Ile Thr Lys Leu Gln Asn 1 5 10 15

Leu Gly Gly Tyr Leu Met His Ile Ala Ile Phe Ile Ile Phe Ile Trp 20 25 30

Ile Gly Gly Leu Lys Phe Val Pro Tyr Glu Ala Glu Gly Ile Ala Pro 35 40 45

Phe Val Ala Asn Ser Pro Phe Phe Ser Phe Met Tyr Lys Phe Glu Lys 50 55 60

Pro Ala Tyr Lys Gln His Lys Met Ser Glu Ser Gln Ser Met Gln Glues 70 75 80

Glu Met Gln Asp Asn Pro Lys Ile Val Glu Asn Lys Glu Trp His Lys 85 90 95

Glu Asn Arg Thr Tyr Leu Val Ala Glu Gly Leu Gly Ile Thr Ile Met 100 105 110

Ile Leu Gly Ile Leu Val Leu Leu Gly Leu Trp Met Pro Leu Met Gly 115 120 125

Val Val Gly Gly Leu Leu Val Ala Gly Met Thr Ile Thr Thr Leu Ser 130 135 140 : Phe Leu Phe Thr Thr Pro Glu Val Phe Val Asn Gln His Phe Pro Trp 5 150 155 160

Leu Ser Gly Ala Gly Arg Leu Val Val Lys Asp Leu Ala Leu Phe 218 165 170 175

Gly Gly Leu Phe Val Ala Gly Phe Asp Ala Lys Arg Tyr Leu Glu Gly 180 185 190 ’

Lys Gly Phe Cys Leu Met Asp Arg Ser Ser Val Gly Ile Lys Thr Lys 195 200 205

Cys Ser Ser Gly Cys Cys Ser 210 215

Ya\{2) INFORMATION FOR SEQ ID NO:147: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) : ' (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE:- NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...20 (x1) SEQUENCE DESCRIPTION: SEQ ID NO: 147:

TATACCATGG TGGGCGCTAA 20 (2) INFORMATION FOR SEQ ID NO:148: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...23 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148: ! ATGAATTCGA GTAAGGATTT TTG 23 (2) INFORMATION FOR SEQ ID NO:149: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

Yay: (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SQURCE: : (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ' (B) LOCATION 1. ..22(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:1

TTAACCATGG TGAAAAGCGA TA 22 (2) INFORMATION FOR SEQ ID NO:150: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...23 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

TAGRAATTCGC ATAACGATCA ATC 23 (2) INFORMATION FOR SEQ ID NO:151: (i) SEQUENCE CHARACTERISTICS: (2) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double . (D) TOPOLOGY: circular ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO / (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE:

YAY

(A) NAME/KEY: misc_feature (B) LOCATION 1...22 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

ATATCCATGG TGAGTTTGAT GA 22 (2) INFORMATION FOR SEQ ID NO:152: (i) SEQUENCE CHARACTERISTICS: 1 (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO {vi} ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 1...25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

ATGAATTCAA TTITTTATTT TGCCA 25 (2) INFORMATION FOR SEQ ID NO:153: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular {ii ) MOLECULE TYPE: DNA (genomic) {iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: , (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 1...21 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

AATTCCATGG TGGGGGCTAT G 21 (2) INFORMATION FOR SEQ ID NO:154:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid {C) STRANDEDNESS: double (D) TOPOLOGY: circular 5 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO ' 10 (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...23 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154: 20 ATGAATTCTC GATAGCCARA ATC 23 INFORMATION FOR SEQ ID NO:155: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 30 (ii) MOLECULE TYPE : DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...25 ' (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155: 45 AATTCCATGG TGCATAACTT CCATT 25 1 (2) INFORMATION FOR SEQ ID NO:156:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 55 (ii) MOLECULE TYPE : DNA (genomic) (iii) HYPOTHETICAL: NO

Yao (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (BR) LOCATION 1...25 1 (xi) SEQUENCE DESCRIPTION : SEQ ID NO: 156:

AAGAATTCTC TAGCATCCAA ATGGA 25 (2) INFORMATION FOR SEQ ID NO:157: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO {vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...24 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

ATTTCCATGG TCATGTCTCA TATT 24 (2) INFORMATION FOR SEQ ID NO:158: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular ; (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori {ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...23

Yau (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

ATGAATTCCA TCTTTTATTC CAC 23 (2) INFORMATION FOR SEQ ID NO:159: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid ' (C) STRANDEDNESS: double (D) TOPOLOGY: circular ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...27 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

ARCCATGGTG ATTTTAAGCA TTGAAAG 27 (2) INFORMATION FOR SEQ ID NO:160: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori , (ix) FEATURE: : (A) NAME/KEY: misc_feature (B) LOCATION 1...28 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160:

AAGAATTCCA CTCAAAATTT TTTAACAG 28 (2) INFORMATION FOR SEQ ID NO:161: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs

O (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 5 (iii) HYPOTHETICAL: NO (iv ) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 15 (B) LOCATION 1...25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161: GATCATCCAT ATGTTATCTT CTAAT 25 20 INFORMATION FOR SEQ ID NO:162: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs 25 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (1i) MOLECULE TYPE: DNA (genomic) 30 (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature 40 (B) LOCATION 1...23 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162: 23 W TGRBATTCAAC CATTTTAACC 45 INFORMATION FOR SEQ ID NO:163: (2) (i) SEQUENCE CHARACTERISTICS : ! (A) LENGTH: 27 base pairs 50 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 55 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

Y4A (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEZY: misc_feature: (B) LOCATION 1...27 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

TATACCATGG TGAAATTTTT TCTTTTA 27 (2) INFORMATION FOR SEQ ID NO:164: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double . (i) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

AGAATTCAAT TGCGTCTTGT AAAAG 25 (2) INFORMATION FOR SEQ ID NO:165: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (11) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...24 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16S:

Yad

TATACCATGG TGATGGACAA ACTC 24 (2) INFORMATION FOR SEQ ID NO:166: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 1 ( ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 0 (ix) FEATURE: {A) NAME/KZY: misc_feature (B) LOCATION 1...23 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166:

ATGAATTCCC ACTTGGGGCG ATA 23 (2) INFORMATION FOR SEQ ID NO:167: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO } (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: : (A) NAME/KEY: misc_feature (B) LOCATION 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

TTATGGATCC AAACCAATTA DMAH 25 (2) INFORMATION FOR SEQ ID NO:168: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double

L. (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO 5 (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori .10 (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168: TATCTCGAGT TATAGAGAAG GGC 23 INFORMATION FOR SEQ ID NO:169: (2) 20 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double 25 (D) TOPOLOGY: (ii) MOLECULE TYPE: DNA (genomic circular) (iii) HYPOTHETICAL: NO 30 (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori 35 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1 ...22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169: TTAACCATGG TGAAAAGCGA TA 22 INFORMATION FOR SEQ ID NO:170: (2) 45 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double 50' (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO 55 (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...24 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO :170: TAGAATTCGC CTCTAAAACT TTAG 24 . 10 INFORMATION FOR SEQ ID NO:171: , (2) (i) SEQUENCE CHARACTERISTICS: : (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid 15 (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: 25 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY : misc_feature (B) LOCATION 1...22 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171: TTAACCATGG TGAAAAAGCGA TA 22

INFORMATION FOR SEQ ID NO:172: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid 40 (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO {iv} ANTI-SENSE: NO , (vi) ORIGINAL SOURCE: 50 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/ KEY: misc_feature (B) LOCATION 1...23 55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172: TAGRATTCGC ATAACGATCA ATC 23

909.1 (2) INFORMATION FOR SEQ ID NO:173: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...22 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173:

ATATCCATGG TGAGTTTGAT GA 22 (2) INFORMATION FOR SEQ ID NO:174: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...25: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174:

ATGAATTCAA TTTTTTATTT TGCCA 25 (2) INFORMATION FOR SEQ ID NO:175: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: , (A) NAME/KEY: misc feature (B) LOCATION 1...23 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175:

AATTCCATGG CTATCCAAAT CCG 23 (2) INFORMATION FOR SEQ ID NO:176: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

ATGAATTCGC CAAAATCGTA GTATT 25 (2) INFORMATION FOR SEQ ID NO:177: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B}) TYPE: nucleic acid (C) STRANDEDNESS: double ' (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

9p. (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...24 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177: 5 GATACCATGG AATTTATGAA AAAG 24 INFORMATION FOR SEQ ID NO:178: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs : (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 15 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178: 30 TGAATTCGAA AAAGTGTAGT TATAC 25 INFORMATION FOR SEQ ID NO:179: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 40 (ii) MOLECULE TYPE : DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: : (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...19~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179: 55 CCCTTCATTT TAGARAATCG 19 INFORMATION FOR SEQ ID NO:180: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO ( iv) ANTI-SENSE:.NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

ATTTCAACCA ATTCRAATGCG 20 (2) INFORMATION FOR SEQ ID NO:181: : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature ( B) LOCATION 1...20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181: li GCCCCTTTTG ATTTGAAGCT 20 (2) INFORMATION FOR SEQ ID NO:182: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs ( B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

p. (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO {vi} ORIGINAL SOURCE: 5 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/ KEY: misc feature ' (B) LOCATION 1...22 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182: TCGCTCCAAG ATACCARAGAA GT 22

INFORMATION FOR SEQ ID NO:183: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid 20 (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: 30 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY : misc_feature (B) LOCATION 1...22 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183: CTTGAATTAG GGGCAAAGAT CG 22

INFORMATION FOR SEQ ID NO:184: (2) (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid 45 (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) 1

(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: 55 (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY : misc_feature

Y.v (B) LOCATION 1...22 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184: 2700077777 ACCCAAAGAA GT 22 (2) INFORMATION FOR SEQ ID NO:185: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...22 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

ATAACGCCAC TTCCTTATTG GT 22 (2) INFORMATION FOR SEQ ID NO:186: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...19 {xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186:

CTTTGGGTAA AAACGCATC 19 (2) INFORMATION FOR SEQ ID NO:187: (i) SEQUENCE CHARACTERISTICS:

Y.A (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE : NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

CGATCTTTGA TCCTAATTCA 20 (2) INFORMATION FOR SEQ ID NO:188: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...19 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188:

ATCAAGTTGC CTATGCTGA 19 0 (2) INFORMATION FOR SEQ ID NO:189: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

H (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...22 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189: 10 TTGAACACTT TTGATTATGC GG 22 INFORMATION FOR SEQ ID NO:190: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 20 (ii) MOLECULE TYPE : DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...23 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190: 35 GGATTATGCG ATTGTTTTAC AAG 23 INFORMATION FOR SEQ ID NO:191: (2)

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 45 (ii) MOLECULE TYPE : DNA (genomic) } 7 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...21

AA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

GTCTTTAGCA AAAATGGCGT C 21 (2) INFORMATION FOR SEQ ID NO:192: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) ) LOCATION 1...21 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

AATGAGCGTA AGAGAGCCTT C 21 (2) INFORMATION FOR SEQ ID NO:193: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: : (A) NAME/KEY: misc feature (B) LOCATION 1...18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 193:

CTTATGGGGG TATTGTCA/18 (2) INFORMATION FOR SEQ ID NO:194: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid

11 (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

AGCATGTGGGG TATCCAGC 18 (2) INFORMATION FOR SEQ ID NO:195: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) ) LOCATION 1...19 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195:

AGGTTGTTGC CTAAAGACT 19 (2) INFORMATION FOR SEQ ID NO:196: ! (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO ( iv) ANTI-SENSE: NO

A

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

CTGCCTCCAC CTTTGATC 1 18 (2) INFORMATION FOR SEQ ID NO:197: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO R (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 9 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

ACCAATATCA ATTGGCACT 19 (2) INFORMATION FOR SEQ ID NO:198: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO ? 1 (iv) ANTI-SENSE: NO : (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO0O:198:

YAY

ACTTGGAAAL GCCTTGCA 18 (2) INFORMATION FOR SEQ ID NO:199: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B} TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular 1 (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature ( B) LOCATION 1...19 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199:

CTTGCTTGTC ATATCTAGC 19 (2) INFORMATION FOR SEQ ID NO:200: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (1ii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) ) LOCATION 1...18 } (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 200:

GTTGAAGTGT TGGTGCTA 18 (2) INFORMATION FOR SEQ ID NO:201: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular

AR} (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori } (ix) FEATURE: (A) NAME/ KEY: misc feature (B) LOCATION 1...22 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 201:

CAAGCAAGTG GTTTGGTTTT AG 22 (2) INFORMATION FOR SEQ ID NO:202: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature ( B) LOCATION 1...22 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 202:

TGGAAAGAGC AAATCATTGA AG 22 (2) INFORMATION FOR SEQ ID NO:203: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs ! (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO {iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: ( A) ORGANISM: Helicobacter pylori

Yio (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...21 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

GCCCATAATC AAAAAGCCCA T 21 (2) INFORMATION FOR SEQ ID NO:204: ' (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid A 15 (C) STRANDEDNESS: double (D ) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME /KEY: misc_feature (B) LOCATION 1...24 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

CTAAAACCAA ACCACTTGCT TGTC 24 (2) INFORMATION FOR SEQ ID NO:205: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (11) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO ? (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION 1...16 (x1) SEQUENCE DESCRIPTION: SEQ ID NO:205:

GTAAAACGAC GGCCAG 16 vi (2) INFORMATION FOR SEQ ID NO:206: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc feature ( B) LOCATION 1...17 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

CAGGARAACAG CTATGAC 17 (2) INFORMATION FOR SEQ ID NO:207: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (1ii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION 1...21 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 207:

ATCTTACCTA TCACCTCAAA T 21 (2) INFORMATION FOR SEQ ID NO:208: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME/KEY: misc_feature '10 (B) LOCATION 1...21 (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:208: ‎ acacacecaac aTerTTGTGA A 21 15

Claims (1)

Y\A Protections 1-1 isolated nucleic acid containing a nucleotide sequence encoding a polypeptide of Bacteria "117102" homosynthetic bo 10 at least 7/10 to a selected amino acid sequence 1 ?- isolated nucleic acid including a nucleotide sequence encoding a bacterial polypeptide 7 for numbers | For reference from I selected from the set of sequences with H.Pylori Y Av dy 1- An isolated nucleic acid encoding a polypeptide of H. pylori, including sequences “A nucleotide is structurally identical to at least .71 per cent of a nucleotide sequence selected from the set |to consist of sequences 93 I & | of reference numbers from/to or a complement of 3 of these sequences. 1? - nucleic acid isolated according to element 1; containing a selected nucleotide sequence Y from group | to be composed of f of [St lsd] sequences except as a  J of reference from A I to VY: or a complement thereof. 901 - An isolated gos-acid molecule encoding a polypeptide of Bacterium 11.7107, containing a “nucleotide sequence that hybridizes under strict hybridization conditions to a toui-acid molecule containing* the nucleotide sequence selected from the set of ia-numbered sequences, or a complement thereof. AY for a retrograde starting from \ to |3 nucleotide |tv| of length A isolate containing a nucleotide sequence of at least 1-1 SI acid, where the sequence hybridizes under a strict acid-to-acid hybridization run. Nuclear content Y A nucleotide sequence selected from the set of sequences with numbers le YF Or a complement thereof VY to reference 1 3 Cell envelope Sala Including a nucleotide sequence encoding Poe le J acid acid Attributable nuclear - 1 \ to mentioned selected from I be | of nucleic acid Ea ia or part of H.Pylori bacteria 7 3 Yo < ¢ 0 \ . < 1 ' b ¢ Yo I1 Y For sequences with J numbers, the group consisting of Ve, Shr, Cre, AN, NEC, EY, (VN, NEC, YL, YL, YY, VN, YY ¢, or a complement thereof 10 1 0 where U is a cell envelope peptide 0 7 and according to the element Jd acid | H.Pylori inner membrane of the aforementioned data He Lia bacteria or part of the H.Pylori Y bacteria consisting of | for sequences t {de from | for a rir rly group encoded by nucleic acid ia or its Y fragment. or its complement, EAL YO 7; with reference numbers where cell envelope polypeptide V is the nucleic acid isolated according to the element - 11 or HPylor or part thereof outer membrane polypeptide from H.Pylori bacteria Y part of it is encoded by a nucleic acid selected from the set of sequences ¥ P OY YL YAN ANA its seal 1. VL with reference numbers ¢ YY. . or a complement thereof VY 110 NEL EYL A 0A, TH 0 nucleic acid isolated according to spline 4 ;, wherein is membrane polypeptide -011 H.Pylori bacteria dha, polyia or the outer part of H.Pylori bacteria containing a terminal phenylalanine residue; And on the F terminal tyrosine group, a nucleic acid selected from the EN-containing group is part of it; sl C-3 encoder. Its complement is PRL PELE 146 2 e sequences with reference numbers where the transmembrane polypeptide, A of the element lay the isolated nucleic acid - 11 1 HPYlori mentioned or part thereof is the outer polypeptide of bacteria HPylori of a bacterium "containing a residue of terminal phenylalanine or part thereof encoded by acid YF «Yo. fo. MN of reference I of digit 1 made up of sequences with a nuclear I selected from group 2. ; or complement thereof 00 030 04007 YL MMMM RAW YALL VL YY 0 Tooi acid isolate including a nucleotide sequence encoding a cell envelope polypeptide-0/or part thereof selected from the set of HPylori-protein sequences of Bacterium Y CAV line to CAE line to CAE AYA AYV line to Fmkl ¢ 6 0 ; wherein the cell envelope polypeptide 11 of the isolated nucleic acid according to element - 11'1 H.Pylori bacteria das dou membrane peptide mentioned or part thereof H Pylori bacteria Y aA « 74 RT Numbers | To reference lod, select it from | for the set of } of IRE sequences or AYN. Where VY cell envelope polypeptide is the nucleic acid isolated according to element - 16-1 or H.Pylori fragment attached to an outer membrane peptide of ia bacteria or H.Pylori bacterium fragment 3 | For the reference of the line, Id is selected from the group consisting of the sequences Cia y CAV ALA AY AYA ATV AN AYA AL MYL VLA 6 ATL AL KAV NT M Where the polypeptide membrane VE is the nucleic acid isolated according to element - 101 A content of H.Pylori bacterium dae LIP or H.Pylori outer fragment of bacterium Y; or a residue C fragment of terminal phenylalanine and a Y-terminal tyrosine group of which VE 111 was not selected from the set of referenced sequences; NEELAM. m, where is the isolated nucleic acid VE membrane polypeptide; According to item - 111 or part thereof bacteriological polypeptide 11.1011 containing HPylor exogenous to bacteria "residual phenylalanine terminal or part thereof selected from the group consisting of |" : For sequences with reference numbers J 2 yyy VAAL AS ° Mix H in both NN AY AN AYA TALK META AYA ATV LCA — la — VV \ an isolated DNA sequence containing a nucleotide sequence encoding a secreted polypeptide Y from bacteria: 11.0710 contained a part of it, where the said DNA was selected from YY 0 \Y ¢ q I'1 2 I Y ¢ 0 \ 0 YY « 77 for reference-numbered sequences I Block Y ASE ZR ATRL Capacitance for Ktktk A DIF 1 Ktkta 79 3 . or its complement 0 81 - isolated nucleic acid containing a nucleotide sequence encoding a polypeptide secreted from Y bacterium H.Pylori or part thereof, selected from the group consisting of sequences with The following reference numbers: Y VE 3 CAT AY VL VO SET NY NO TA LLA MVE CMY OMY VA E L E L E C E ALL NYY ALL TO CAL MATCH TA PATKL KA VEN 114- isolated nucleic acid containing a nucleotide sequence encoding a cellular polypeptide Y for bacteria: 11.2710 or its dead part; Where said DNA is selected from Yv « 7 < Ye < YY 3 Y 0 / 0; The set of sequences with retrograde numbers A Y . or complement thereof PR 1. 14 15 1. 0.2 1+3 1 . An isolated nucleic acid containing a nucleotide sequence encoding a cellular polypeptide 1 H.Pylori bacterium or part thereof selected from the group of sequences with yyy NEY NEY CATV ATTY ALL 48 AVL AT AY AAC reference numbers b Y BATA 2 quae - 71 1 includes sequence A nucleotide consists of at least A nucleotides | . Complement to it ST VF - 1 nm YY 1 - Recombinant embodiment carriers that include the acid Touy according to any of the elements in EL YY Y shoulder strap lac or 01 operationally attached to a regulating element Y Copy. ,. A cell containing a recombinant transembryonic vector according to the element ?? — YF 1 Ye 1 - A method for producing a polypeptide: 11.3710 involving culture of a cell of the element YY under conditions that allow the expression of the polypeptide. ,. *?- element method;? , also including polypeptide purification from cell 1: in a sample containing Helicobacter A method for detecting the presence of nucleic acid - 1 1 nv Touching a sample with nucleic acid of any of the elements from YY - 1 until a hybrid is formed between lay wall Y 893 (Helicobacter) in the sample. ; (B) The discovery of the hybrid formed in step (1), where the discovery of the hybrid indicates the presence of ° Helicobacter nucleic acid in the sample. YV \ - polypeptide bacteria H.Pylori isolate containing a homologous amino acid sequence Y of at least .71 with polypeptide bacteria 11.7101 selected from the group w= - YA \ H.pylori peptide encoded by a nucleic acid containing at least 1:7 homologous nucleotide sequence with a nucleotide sequence selected from the Y group of the A reference sequence of 1 To the sequence with Jad I for reference 1 YA 1 - Polypeptide of HPylori bacteria isolated according to the element YA wherein said polypeptide Y is encoded by a nucleotide sequence selected from the group consisting of “| sequence referenced 1 to sequence referenced VY 1 . - Ho pylori polypeptide isolate encoded by a nucleic acid that is hybridized under strict hybridization conditions to a purified touic acid from the group composed of the Y-sequence | for number | For my reference 1 | To the sequence with i of the J number of the reference VY or the complement of lia . YYo daa - TN \Peptide Bacterium :11.5710 isolate containing an amino acid sequence selected from the ensemble consisting of the reference numbered sequence to the sequence numbered NE aa lly 1 ?7- Bacteria cell envelope polypeptide 11.5710 isolate or part thereof, wherein “The mentioned polypeptide was selected from the set of sequences with reference number 816 atta-v-khl-khl-khl-khl-khl AY AYA LV YY. Vo 1 ??- Polypeptide isolated according to element FY where the polypeptide is a cell envelope “>a or part thereof endomembrane polypeptide of bacterium 11.7101 or H Pylori bacterium Y selected from the set of sequences with the reference number Hfc for ia Y where is cell envelope polypeptide FY 4? - Polypeptide isolated according to element 1 Y Bacteria 31 or part thereof Polypeptide outer membrane of HPylori bacteria or part thereof selected from the group consisting of sequences with reference numbers ¢c MYA CAY CAA ¢ HH to both CAN types especially on each CVE AYN GAYA CATV ML CAV 0 Teka CAE of course ARN 1 7 * 9 - Polypeptide isolated according to element YE, in which the outer membrane polypeptide Y of the aforementioned Ho Pylori bacteria or part thereof is a polypeptide of HPylori ¥ containing a residue of terminal phenylalanine And on the C- 3 terminal petrosine group or part thereof selected from the group consisting of sequences with [reference numbers 7-m], the polypeptide is isolated according to the “VE” element, where the membrane polypeptide is Said H.Pylori or part thereof Polypeptide of bacteria Ho Pylori exogenous to bacteria Y 1 containing residue of terminal phenylalanine or part thereof selected from the group; Consisting of sequences with transliterated numbers AS Ma Kha Kha Vi Tana Ka 0 Akh Kaht Lal SAMAR CPR PEL CIR TE 1 77- Polypeptide cell envelope of HPylor bacteria isolated or part thereof, where it is: for reference numbers i Red) | 93 for sequences | Y ¢ A M (NT SAL L M YO AK YA A H OY YL YAN NAL 08 T G A 0 AR IPI + VE 1A 0 YN A, 0. ov, 0 1 8 - Polypeptide isolated according to item 17, where the polypeptide is a cell envelope 11.5710: the aforementioned bacteria 43 or part thereof, an endomembrane polypeptide of bacteria Y yen or part of it ‎Sia encoded by ‎la qn b selected from ‎da goal J | to be made up of sequences; Those with reference numbers 4007607. 1 4 ?- The polypeptide isolated according to element 17, where the polypeptide of a bacterial cell envelope: 11.0710 mentioned or part thereof, an inner membrane polypeptide of H.Pylori 0 part of which is encoded by a protein acid selected from | geal p a consisting of sequences ol gd 3 reference numbers “A L M M C YA VL M H F A V L A . OY 1 s 0 A 0 0 No. Dar Ard Kd Hfna 1 4.2 - The isolated polypeptide according to the YA element, where it is a membrane polypeptide H.Pylori peptide bacteria Lig aforementioned 0 part H.Pylori outer bacteria A gins ¥ on a residue of terminal phenylalanine and on a terminal tyrosine group © 2 or part thereof ' encoded fo H H DNA is selected from the group consisting of ,. Only PRE sequences with reference numbers 0 1 ? - Polypeptide isolated according to element 4? , where is the transmembrane polypeptide H.Pylori peptide He mentioned or part thereof H.Pylori Ln outer Y "0 containing residue of terminal phenylalanine or part thereof encoded by 2-toic acid selected from the set of sequences J ANY for numbers | YYA??; - cellular polypeptide of Bacteria 11.0101 isolate, or part thereof; where poly1 is: said peptide selected from the set of sequences with reference numbers “CNEL VEY VEY cel all on l to 44 AV AT AY (AA AD 0 ??) - a cellular polypeptide isolated from Streptococcus 11.7101; or A part of it where the said polypeptide-1 is encoded by a nucleic acid selected from the set consisting of: “Sequences with Reference Numbers |” ia Secreted Polypeptide Isolated from Bacteria 11.0710 or Fragment — 68 0 Said polypeptide selected from the set of numbered sequences " Reference: OY Tala Nope OA Mat Ta Laka Ta Naka AT AY The Vo The Vo — Vo +6 SVEN produced to Alma maturation through a solution of Ca ANAL NY M secreted polypeptide isolated from bacterium 11.7101 or part thereof in which said poly-9-1 peptide is encoded by Selected nucleic acid from the set consisting of: “sequences with reference numbers ¥ CO n Lv count K F N H D K D D L L L ALE YL oN L L ( STACI Te M carried sisters) 1 1 - A polyalan-incorporating fusion protein from H.pylori bacteria containing an ¥ amino acid sequence selected from the set of sequences with reference numbers 0 64a-1. Functionally bound to a non-bacterial polypeptide:11.910. 1 7 - Vaccine formulation for the prevention or treatment of infection with bacteria 11.2710:1 containing “7 effective quantity of at least one polypeptide from bacteria: 11.0710 or a part thereof according to any of the elements: YL YALU YALYV. YL LA LA EE F 4901 - Vaccine formulation according to element cov that also contains a pharmaceutically acceptable vector. 1 8.20 - Vaccine formulation according to Segment 48 - also containing a pharmaceutically acceptable vector. 111 - Vaccine formulation according to item 44, where the pharmaceutically acceptable carrier includes oY 1 - Vaccine formulation according to item 9, where the acceptable carrier includes pharmacies at YY. Vaccine formulation in accordance with item 68 - where the pharmaceutically acceptable vector on the 1 oF system includes delivery (distribution). Y where the pharmaceutically acceptable vector on the system includes , 0. Vaccine formulation according to element - 161. Y delivery. ; The distribution system includes a live vector of - formulation of vaccine according to item 1 005 . Formulate a vaccine according to the era; ;, where the delivery system includes a live vector 5 + 1 #e - formulation of a vaccine according to its component”, where the live vector is a bacterium (germ) or 1 virus. ,. Bacteria or Virus all Vaccine formulation according to item 06 , where the carrier is - #8 1 where the acceptable vector includes pharmacies of OF the formulation of a vaccine according to item - 1 e urges the pharmaceutically acceptable vector includes - of Vaccine formulation according to ingredient - 1.1 YT method to treat or reduce the risk of infection with Streptococcus 11.7101 in a person “includes - 11 1 giving the person a vaccine formulation according to the element; , so that treatment or reduction of the risk of Y. H.Pylori infection 7 in a person, HPylori includes a method to treat or reduce the risk of infection with H.Pylori -17 1 such that treatment or reduction of risk of EA occurs Giving the person a vaccine formulation according to the component “H.Pylori” . Bacteria Lila!7 comprising: Fusion of at least one isolated polypeptide 0 method for producing a vaccine formulation v = 1 selected from the set of sequences with Lia of 11.071011 bacteria or Y fragment with a pharmaceutically acceptable vector to be Thus forming a formulation VEU JIVE Reference numbers from YF Vaccine.: A method for producing a vaccine formulation containing 1-16 or part thereof; at least one H.Pylori isolated from dass bacteria. poly 0).156-176 selected from the set of reference-numbered sequences of |" (b) Incorporation of said single polypeptide from bacterium 11.271011 or part thereof with vector 6 . pharmacologically to form a formulation of the Josie 0 vaccine \ We have a method for producing a vaccine formulation that includes: (Y) cell culture under a condition that allows the expression of HPylor polypeptide or its Y part selected from the set of sequences with reference numbers from 156-176. ; (B) die polypeptide bacteria 11.091011 mentioned about the mentioned cell. © (c) Mixing of at least one polypeptide isolated from said 11.59710:1 bacteria or part 7 thereof with a pharmaceutically acceptable vector to form a vaccine formulation.